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Abstract 
 
 
“Exploring the role of mu opioid receptor (OPRM1) and CYP2B6 gene variations 
for methadone pharmacogenomics. Can these variations be used to advance 
toxicological interpretation post-mortem?” 
 
Hannah Bunten 
 
Methadone is increasingly involved in drug overdose cases and the molecular actions 
of the drug in vivo are largely unknown requiring elucidation. This study set out to 
examine the relationship between methadone toxicity and CYP2B6 and mu (µ) opioid 
receptor (OPRM1) single nucleotide polymorphisms (SNPs).  
 
Using SNP genotyping, the association between OPRM1 A118G and CYP2B6 T750C, 
G516T, and A785G variations and post-mortem methadone concentrations were 
investigated. The allele frequencies of OPRM1 and CYP2B6 variants were then 
studied in a control population of live non-methadone using subjects, to determine the 
prevalence and distribution of specific variations in post-mortem and living subjects. 
Further in vitro study was conducted to assist in interpreting the association between 
OPRM1 and CYP2B6 variations and individual susceptibility to methadone. Cloning 
strategies were designed for the studies of promoter activities affected by the T750C 
promoter SNP on CYP2B6 expression, and the role of the OPRM1 A118G variation 
for receptor internalisation following methadone treatment was investigated. 
 
A significant association was identified between high post-mortem methadone 
concentrations and G561T and A785G (CYP2B6*6) variations reflecting poor 
methadone metabolism. Furthermore, the OPRM1 A118G SNP significantly 
correlated with higher post-mortem methadone concentrations and the in vitro 
analysis of A118G indicated that this could be due to a reduction in receptor 
internalisation in 118 AG subjects. 
 
The findings from the research contribute to pre-determining, in part, individual 
susceptibility to methadone accumulation and toxicity. Specific screening to identify 
CYP2B6*6 and OPRM1 A118G carriers prior to addiction treatment could therefore 
be valuable as part of a cost-effective risk management strategy. Furthermore, 
CYP2B6*6 and A118G could be used to interpret toxicology results identifying 
subjects with poor metabolism. 
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1.1 Background 
 
Methadone is a medication valued for its effectiveness in reducing the mortality 
associated with heroin addiction as well as reducing anxieties commonly associated 
with drug addiction. It is a potent drug associated with many fatal poisonings each 
year (Corkery et al. 2004; Shields et al. 2007; Modesto-Lowe et al. 2010). Amongst 
patients in addiction treatment, the largest proportion of methadone associated deaths 
occur during the drugs induction phase, when either drug tolerance is overestimated 
or other drugs are also used (Heinemann et al. 2000; Buster et al. 2002; Maxwell et 
al. 2005; Modesto-Lowe et al. 2010).  
 
It is postulated that significant inter-individual variability in blood methadone 
concentrations and individual susceptibility to methadone toxicity may be explained 
through genetic variations of the genes encoding metabolism enzymes. Methadone is 
metabolised by CYP2B6, CYP3A4, and to a lesser extent CYP2D6. CYP2B6 is 
highly polymorphic with a number of different genotypes identified (Lang et al. 2001). 
Furthermore live patient studies demonstrated that the CYP2B6*6 allele (resulting 
from a combination of the exon 4 G516T and exon 5 A785G polymorphisms) is 
linked with poor drug metabolism (Eap et al. 2007). The influence of CYP2B6 
variations on methadone toxicity post-mortem however has not yet been examined.  
 
The mu (µ) opioid receptor OPRM1 is the preferential binding target for many opioids 
including methadone and morphine, OPRM1 gene variants are therefore likely to 
influence methadone action in vivo. There has been an exponential increase in the 
number of studies examining morphine pharmacogenomics due its clinical importance, 
and significant variability in inter-individual drug response (Ross et al. 2005; Paice, 
 3 
2007; Ishani et al. 2010). In comparison few studies have examined the association 
between the µ opioid receptor and methadone response despite reports of significant 
variability in individual methadone blood concentrations. Methadone is often 
concomitantly prescribed or abused together with benzodiazepines, and many deaths 
attributed to methadone also involve benzodiazepines (Caplehorn & Drummer, 2002; 
Corkery et al. 2004; Shields et al. 2007). It has been well documented that these two 
drugs in combination induce lethal respiratory depression (McCormick et al. 1984; 
Borron et al. 2002; Lintzeris et al. 2007; Poisnel et al. 2009; Lintzeris & Nielsen, 
2010) however the molecular mechanisms responsible for this remain obscure.   
 
Methadone is a chiral drug, with two enatiomers (R)-methadone and (S)-methadone 
that demonstrate stereoselectivity. Until recently the pharmacogenomic importance of 
this has received little attention, which may in part be a reflection of the 
pharmacological inactivity of the (S)-methadone enantiomer. Although it was 
suggested that a link between (S)-methadone and cardiotoxicity may influence 
individual susceptibility to methadone (Eap et al. 2007).  Methadone is known to 
induce a condition termed “torsades de pointes”, which involves a prolongation of the 
QT interval resulting in arrhythmia and sudden cardiac death (Krantz et al., 2002).  It 
is postulated that differences in enantiomer distribution is demonstrative of a key 
stereoselective relationship that could explain occurrences of sudden cardiac death 
following methadone exposure. Additionally it was also hypothesised that OPRM1 
and CYP2B6 variations could be associated with this, particularly variations located in 
areas linked with gene expression (promoter regions). Of particular significance are 
the T750C polymorphism in the promoter region of the CYP2B6 gene and the 
OPRM1 A118G variation located in exon 1. A118G is located in the receptor binding 
pocket and has been linked with reductions in β-endorphin binding but not morphine 
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or racemic methadone (Bond et al. 1998). The influence on (R)-methadone and (S)-
methadone separately has not yet been examined.  
 
1.1.1 Study Aim & Objectives 
 
 
The purpose of this project was to examine whether pharmacogenomics can be used 
to predict whether methadone programme participants are at higher risk of methadone 
related-death, whilst advancing current toxicological interpretation of post-mortem 
methadone concentrations. This aim will be addressed by examining two genes 
intimately linked with methadone metabolism and response, the gene encoding the 
cytochrome P450 enzyme CYP2B6 and the µ opioid receptor gene (OPRM1). 
Methodologies to amplify and genotype CYP2B6 T750C, G516T and A785G, and 
OPRM1 A118G polymorphisms will be developed and optimised (Chapter 2). The 
results from this will then be analysed and discussed in Chapter 3. The association 
between CYP2B6 (G516 T, A785G, T750C) and OPRM1 (A118G) gene variations 
and blood methadone concentrations in fatalities attributed to methadone will be 
examined to determine whether high blood methadone concentrations are linked with 
OPRM1 and CYP2B6 gene variations (Chapters 4 and 5). After this, the post-mortem 
allele frequencies will be compared against a healthy control population to identify 
drug susceptibility gene markers (Discussed in Chapter 6). 
 
This study will also conduct in vitro studies to explore the effects of CYP2B6 and 
OPRM1 polymorphisms in a controlled environment, to provide a theoretical concept 
to clarify OPRM1 and CYP2B6 gene effects in vivo. This concept could then be used 
to elucidate the molecular actions of methadone. This will involve the molecular 
cloning of the CYP2B6 promoter region to create 750 TT, and 750 TC, reporter 
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constructs (Chapter 7). Finally this study will explore the effects of methadone on µ-
receptor internalisation using CLL cells, to develop a method to examine OPRM1 
A118G effects on receptor internalisation (Chapter 8). The overall conclusions and 
suggestions for further research will be discussed in Chapter 9.  
 
1.2 Methadone pharmacology and mechanisms of action 
 
Methadone is a synthetic opioid originally created as a substitute for morphine during 
World War II (Crettol et al. 2008). Approved as an analgesic by the Food and Drug 
Administration (FDA) in 1947, methadone is now routinely used for the treatment of 
opioid addiction and dependence worldwide, leading to significant reductions in 
heroin use and mortalities associated with heroin addiction (Centre for Substance 
Abuse Treatment, (CSAT), 2004). A substance abuse and mental health services 
administration (SAMHSA) report in 2000 documented that over 3 million persons in 
the US had used heroin at some point, with an estimated number of 0.8 to 1.2 million 
individuals addicted to the drug (SAMHSA, 2000). In the UK methadone prescription 
increased sevenfold between 1993 and 2000 and current UK statistics report that 
147,000 individuals are enrolled in drug maintenance programmes, with methadone 
prescription accounting for a significant percentage of this. The 2008 SAMHSA 
report examined drug use between 2006 and 2007, noting a reduction in the number 
of current heroin users from 338,000 (0.14%) in 2006 and 153,000 (0.06%) in 2007 
(SAMHSA, 2008).   
  Prescribed orally, methadone is a liposoluble basic drug with a pKa of 
9.2, available as a solid tablet, a rapidly dissolving wafer or as a premixed liquid 
(Garrido & Troćoniz, 1999; Baselt, 2004). Administered in a racemic mixture, oral 
methadone has a long plasma elimination half-life and high oral bioavailability (70-
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90%), appearing in the blood 30 minutes following administration, the unique 
pharmacological properties that make it an appropriate choice for the treatment of 
opioid addiction and pain relief (Wolff et al. 1997; Foster et al. 1999; Corkery et al. 
2004; Nettleton et al. 2007). Extensively metabolised in the liver (Figure 1), 
methadone is converted into its primary metabolites 2-ethylidene-1, 5-dimethyl-3, 3-
diphenylpyrrolidine (EDDP) and 2-ethyl-5-methyl-3, 3-diphenyl-1-pyrrolidine 
(EMDP) by the cytochrome P450 enzymes CYP3A4, CYP2B6 and to a lesser extent 
CYP2D6 (Sullivan & Due, 1973; Eap et al. 2007; Pimentel & Mayo, 2008). The two 
metabolites are widely considered pharmacologically inactive and are eliminated from 
the body in the faeces and urine together with any unchanged methadone (Corkery et 
al. 2004). 
 
 
 
Figure 1: Main metabolic pathway of methadone (asterisk (*) denotes chiral centre).  
 
The percentage of free (unbound) pharmacologically active drug is very low at 
6-14% (Wolff, 2003). Drug metabolism can be affected by other drugs through 
enzymatic inhibition or induction (Table 1), affecting the elimination half life and 
plasma concentrations (Shields et al. 2007). Typically the elimination half life for 
methadone averages 24-36 hours at steady state, but this can vary from anywhere 
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between 4 and 91 hours (Ayonrinde & Bridge, 2000). This variability complicates 
patient steady-state blood levels by affecting the equilibrium between drug 
elimination and the amount of active drug remaining in the body. During treatment 
induction this balance usually takes between 4 and 5 days to achieve, however for 
some individuals this can take a significantly longer time (CSAT, 2004). Extensive 
(17-fold) inter-individual variability has been documented for blood methadone 
concentrations, and the prevalence of methadone toxicity following inappropriately 
short dosing intervals has increased in frequency (Foster et al. 2005). 
Methadone is a chiral drug (Figures 1 & 2 demonstrate the chiral center) with 
two enantiomeric forms (R)-methadone (which is thought to account for most of the 
drugs pharmacological activity) and (S)-methadone (often described as being 
pharmacologically inactive) that may be an important determinant in the adverse 
responses reported for methadone (Eap et al., 2002; Megarbane et al., 2007). A 25-50 
fold difference between the analgesic potency of (R)-methadone and (S)-methadone 
has been described (Pham-Huy et al., 1997). 
 
  
Figure 2: The chemical structure of r-(-)-methadone and s-(+)-methadone (asterisk (*) 
denotes chiral centre). 
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Pharmacological activity is induced through selective binding of methadone at 
the opioid receptors, which include the µ-opioid receptor, the delta (δ)-opioid receptor 
and the kappa (κ)-opioid receptor. The µ-opioid receptor is the preferential binding 
target for methadone with a recorded Ki value of 3.7 ± 0.03 (nM) (Mestek et al. 1995). 
This receptor is a member of the G-protein coupled receptor (GPCR) family and 
ligand-receptor binding induces signal transduction cascades affecting analgesia, 
respiratory activity, protein phosphorylation, neurotransmitter release, and OPRM1 
gene expression (Mestek et al. 1995; Chartuvedi et al. 2000). Methadone also binds 
with low affinity to N-methyl-D-aspartic acid (NMDA) receptors, which may result in 
alterations to the development of drug tolerance (Lewanowitsch et al. 2004). 
 
 
Table 1: Inhibitors and inducers of CYP3A4 and CYP2B6, methadone‟s primary 
metabolising enzymes. 
 
 
Inducers 
 
Inhibitors 
CYP3A4  
Phenobarbital (Runge et al. 2000) Itraconazole (Raaska & Neuvonen, 1998) 
Carbamazepine (Magnusson et al. 2008) Ritonavir (Eagling et al. 1997) 
Phenytoin (Tomlinson et al. 1996) Nelfinavir (Lillibridge et al. 1998) 
Dexamethasone (LeCluyse et al. 2000) Verapamil (Kantola et al. 1998) 
Nevirapine (Lamson et al. 1999) Erythromycin (Funderburg et al. 1994) 
Topiramate (Nallani et al. 2003) Ketoconazole (Baldwin et al. 1995) 
Rifampicin (Lehmann et al. 1998) Fluconazole (Ahonen et al. 1997) 
Efavirenz (Clarke et al. 2001) Clarithromycin (Quinney et al. 2008) 
  
CYP2B6  
Phenytoin (Wang et al. 2004) Nelfinavir (Hesse et al. 2001) 
Carbamazepine (Ketter et al. 1995) Ticlopidine (Turpeinen et al. 2004) 
Rifampin (Ribera et al. 2001) Clopidogrel (Richter et al. 2004) 
Efavirenz (Robertson et al. 2008) Paroxetine (Walsky et al. 2006) 
Phenobarbital (Rencurel et al. 2005) Sertraline (Walsky et al. 2006) 
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1.3 Methadone safety profile (adverse drug reactions) 
 
Opiate addicts are at increased risk of accidental death, principally through drug 
overdose. Substitution with methadone has been used in the treatment of opioid 
addiction for a number of years and it has been well documented that methadone 
prescription reduces heroin use and the related crime and health problems improving 
overall survival rates (Bertschy, 1995; Neeleman & Farrell, 1997; Esteban et al. 2003). 
The prevalence of communicable diseases such as human immunodeficiency virus 
(HIV) and hepatitis C are high in injecting drug users (IDU‟S) and participation in 
methadone maintenance programmes has significantly reduced disease prevalence 
(Harding-Pink, 1993; Caplehorn & Ross, 1995; Broers et al. 1998; Wong et al. 2003; 
Gowing et al. 2006; Tross et al. 2008; Wilson et al. 2010). 
Initially, UK treatment practises implemented general controls for drug 
prescription in place of regimented protocols which impacted individual prescription 
periods (two weeks through to unlimited duration) and encouraged illicit drug abuse 
(Gossop et al. 2001). Increased supervision of maintenance programmes and reduced 
prescription of methadone tablets significantly improved methadone‟s safety profile 
(Zador et al. 2006). A relevant proportion of heroin users who start methadone 
maintenance will however continue concomitant heroin use at least intermittently for 
some time (Heinemann et al. 2000).  
Clinical research demonstrated that methadone maintenance reduces the 
mortality associated with heroin use. However methadone is also dangerous in 
overdose and increased numbers of methadone-associated deaths suggest stricter 
reviewing of maintenance practises (Neeleman & Farrell, 1997; CSAT, 2004). 
Overdose risk during the drug induction period is central to this and prescriptions that 
exceed the recommended daily doses of 20-40 mg should be monitored (Heinemann 
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et al. 2000). The UK Department of Health recommended an initial daily dose of 10-
40 mg and for drug tolerant patients 25-40 mg (Department of Health, 1999). More 
recently, a study reported the mean methadone daily dosage across 157 methadone 
treatment practises to be 47 mg (Joseph & Moselhy, 2005). 
Caplehorn, (2000) documented that only 14 % of clinic staff in the US (a 
study group of 149 individuals) were aware that the risk of methadone-associated 
death is significantly increased during the first two weeks of treatment. Furthermore, 
only 15% of staff understood that prescription of daily dose‟s of 30-40 mg were 
unsafe for methadone naïve patients. A 2009 CSAT report noted that adverse events 
during methadones induction phase are due to an overestimation of drug tolerance by 
clinic staff. Reports of this nature suggest education is critical to improve 
methadone‟s safety profile with particular emphasis on the dangers of the drug 
induction phase. 
 
1.4 Methadone-related deaths 
 
Large doses of methadone, concomitant use with other substances and accidental 
ingestion by intolerant persons can all result in toxic reactions and overdose fatalities 
(Laberke & Bartsch, 2010; Modesto-Lowe et al. 2010; Romelsjö et al. 2010). 
Amongst the more common adverse effects of methadone are nausea, vomiting, 
dizziness, clouding of consciousness, anorexia, dry mouth and excessive sweating. 
Indicators of drug overdose include respiratory depression, pinpoint pupils, 
hypotension, pulmonary oedema and coma (Davis & Walsh, 2001; Corkery et al. 
2004). Deaths typically occur during the induction phase of treatment when drug 
tolerance is overestimated or during maintenance when several days‟ doses are 
combined (Harding-Pink, 1993; Heinemann et al. 2000). Maxwell et al. (2005) 
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reported a total of 766 patients in methadone maintenance to have died in Texas 
between 1994 and 2002, the causes of death ranged from cardiovascular and 
respiratory disease through to drug overdose. At least three-fifths of deaths associated 
with methadone in England and Wales are due to illicit methadone use (Ghodse et al. 
2003). In the UK between 1993 and 2002 there were 3604 deaths where methadone 
was noted on the death certificate (Corkery et al. 2004), it is therefore important to 
identify why these deaths are occurring. Typically there are three possible scenarios 
for methadone related fatalities all of which can lead to cardio-toxicity and respiratory 
depression. Illicitly obtained methadone used in excessive doses to experience drug 
induced euphoria; concomitant use of methadone with other prescription medications 
such as benzodiazepines; and toxic drug accumulation during the induction period of 
methadone maintenance (CSAT, 2004). 
 
1.4.1 Cardio-toxicity  
There is a clear association between methadone use and cardiotoxicity and it is 
postulated that this is a result of (S)-methadone. Several studies have documented an 
association between methadone treatment and QT interval prolongation, leading to 
cardio-toxicity and fatal ventricular arrhythmias (Kornick et al. 2003; Routhier et al. 
2006, Eap et al. 2007; Chugh et al. 2008). The QT interval is a measurement of 
cardiac repolarisation. The normal upper limits of the QT interval are < 430 
milliseconds (ms) in males and < 450 ms in females, QT intervals greater than 440 ms 
and 460 ms are classed as being prolonged (Hancox et al. 2008). QT prolongation has 
been associated with congenital long-QT syndrome as a result of gene mutations, 
ionic disorders, and drug administration (Fonseca et al. 2009). High doses of 
methadone prolong the QT interval by blocking the cardiac potassium channel 
expressed by the human ether-a-go-go gene (hERG or KCNH2), as demonstrated in 
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vitro in human cell lines (Katchman et al. 2002). This induces polymorphic 
ventricular tachycardia (an electrophysiological disorder of the heart occuring in 
genetically predisposed individuals), a condition termed Torsades de Pointes (TdP), 
which if uncorrected can result in sudden cardiac death (Kornick et al. 2003; Eap et al. 
2007).  
A number of studies have reported methadone induced TdP (Krantz et al. 
2002; Gil et al. 2003; Kornick et al. 2003; Walker et al. 2003; Martell et al. 2005; 
Sánchez Hernández et al. 2005; Skverjold et al. 2006; Fanoe et al. 2007; Routhier et 
al. 2006; Pimentel & Mayo, 2008) with several reporting sudden cardiac death as a 
consequence of methadone treatment (Kornick et al. 2003; Pearson & Woosley, 2005; 
Ehret et al. 2006; Gupta et al. 2007; Chugh et al. 2008; Darke et al. 2010). Krantz et 
al. (2002) reported 17 cases of TdP in patients in methadone treatment, the individual 
doses for these cases were significantly higher than average ranging from 65 to 1000 
mg/day. Martel et al. (2005) examined 132 patients during the induction phase of 
methadone treatment reporting a significant prolongation in individual QT intervals. 
Skverjold et al. (2006) found that high concentrations of (R)-methadone correlated 
with QTc values in the upper range, this result was not repeated for (S)-methadone 
and racemic methadone. Chugh et al. (2008) examined sudden cardiac death cases in 
the presence and absence of methadone, reporting a significantly lower prevalence of 
cardiac abnormalities in the cases where methadone was present, implying methadone 
as the factor responsible for sudden death. Darke et al. (2010) reported higher levels 
of heart disease in methadone associated fatalities when examined against heroin 
associated fatalities. Increased frequencies of myocardial fibrosis, cardiomyopathy 
and myocarditus were documented for the methadone deaths. Darke et al. (2010) 
emphasised that these findings should not be taken to imply that enrolment in 
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methadone treatment will result in organ damage however the predisposition to 
methadone induced cardio-toxicity may be explained by these findings.  
Therefore, chronic opioid use could have a detrimental effect on the 
physiology and functionality of the cardiac network. Kienbaum et al. (2002) noted 
that humans addicted to opioids for a number of years (10 years) displayed reductions 
in central nervous system (CNS) responses to arterial hypotension (where the heart 
pumps insufficient quantity of blood) as a result of chronic µ-opioid receptor 
stimulation. Experimental studies have demonstrated that stimulation of the opioid 
receptors is a predisposing factor in TdP due to a decreased heart rate (Sánchez 
Hernández et al. 2005). The precise role of opioid receptors for cardio-toxicity is still 
however unclear. 
Although methadone has been used for over 40 years TdP has only recently 
been recognised as a factor in methadone associated deaths (Justo et al. 2006; Zünkler 
& Wos-Maganga, 2010). Therefore it is possible that many cases of TdP during 
methadone treatment have been misdiagnosed as respiratory in nature. 
 
1.4.2 Respiratory depression  
Respiratory depression is the leading cause of death in cases of methadone overdose 
following the activation of the opioid system. Harding-Pink, (1993) stated that the 
foremost toxic effect of methadone is respiratory depression with pulmonary oedema 
and aspiration pneumonia.  Respiration is largely an involuntary activity induced by 
nervous stimulation of the diaphragm and intercostal muscles (Francisco, 2007). 
Respiratory depression is generally manifested as a dose-dependent reduction in tidal 
volume and the slowing of the respiratory rate.  This is primarily mediated through 
the central nervous system. However peripheral chemosensors are also thought to be 
involved (McDonald, 1981; Francisco, 2007; Chevillard et al. 2009). Chevillard et al. 
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(2009) discussed two central sites for opioid induced respiratory depression, the 
brainstem which integrates sensory signals and controls the switch between 
inspiration and expiration and the pre-Bötzinger complex which is located in the 
medulla and represents the active component of inspiration. The medulla determines 
the need to breathe through partial pressure levels of carbon dioxide (pCO2) detected 
by chemosensors in the carotid arteries. An accumulation of pCO2 will induce the 
medulla to stimulate the diaphragm and intercostals to breathe deeper, quicker and 
more rhythmically increasing oxygen intake (Francisco, 2007). Opioid exposure 
desensitises the medulla resulting in hypoventilation and hypoxemia, occurring 12-14 
hours after methadone ingestion (Kreek, 1978; White & Irvine, 1999; Eilers & 
Schumacher, 2004; Lötsch et al. 2005). 
The depressive properties of methadone are generally attributed to the (R)-
enantiomer, however S-methadone may also be involved. Silverman et al. (2009) 
documented that in the neonatal guinea pig (R)-methadone caused significantly 
reduced respiratory depression compared with that of racemic methadone. This result 
suggests a synergistic role for (S)-methadone in opioid induced respiratory depression. 
It should however be cautioned that this result could reflect developmental changes in 
the neonate, with no influential role on respiratory function after maturation. 
Animal models indicate that on a molecular level the mechanism responsible 
for opioid-induced respiratory depression involves µ-opioid receptor blockade of 
specialised respiratory neurons in the brainstem (Takeda et al. 2001; Lalley, 2003; 
Eilers & Schumacher, 2004; Mutolo et al. 2007). A study on the effects of fentanyl on 
the cat respiratory network documented that blockade of the dopamine D1 receptor 
increased the effects of µ-opioid receptor activation and as a consequence increased 
fentanyl induced respiratory depression in addition to lengthening the duration of 
action (Lalley, 2005). Therefore, cross talk between different neural modulatory 
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systems seemed likely to be an influencing factor in opioid induced respiratory 
depression.  
The prevalence of opioid respiratory complications is high, an analysis of 
postoperative respiratory depression following opioid treatment revealed that out of 
20, 000 patients, 17% (3,400) experienced depressive effects (Lötsch et al. 2005). 
Furthermore, earlier studies showed that chronic drug exposure like methadone 
maintenance treatment can cause respiration to remain depressed even after the 
development of drug tolerance (Santiago et al. 1977; Dyer et al. 1999). Because of 
methadone‟s long elimination half-life the effects of respiratory depression were 
observed for more than 24 hours after a dose has been administered (Maxwell et al. 
2005). This potential for delayed toxicity sets methadone apart from other opioids, it 
stays in the body for increased periods of time causing plasma levels to rise quicker 
than realised in many cases (Wolff, 2002; Corkery et al. 2004). Interestingly, opioid-
induced respiratory depression does not occur in subjects experiencing pain as the 
pain acts as a physiological antidote to the depressive effects of the administered drug. 
The mechanisms responsible for this remain obscure however this could simply 
reflect the lower drug levels required for sufficient analgesia compared with that 
required to induce respiratory depression (Francisco et al. 2007). Alternatively, this 
could reflect differences in cellular signalling. Kieffer et al. (2009) documented that 
for opioids it is likely that separate signalling pathways exist and the pathways 
leading to respiratory depression and drug addiction are different from those that 
inhibit pain. 
 
1.4.3 Influence of drug-drug interactions 
Polydrug use is an important factor in methadone-attributed deaths. Deaths involving 
methadone are more likely to occur when methadone is used in combination with 
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other drugs, particularly benzodiazepines and alcohol (Corkery et al. 2004; Shields et 
al. 2007; Poisnel et al. 2009). It has been well documented that the co-administration 
of methadone and benzodiazepines can result in lethal respiratory depression with 
benzodiazepines found in over 50 % of cases of death through overdose (Reynaud et 
al. 1998; Caplehorn & Drummer, 2002). This relationship may not be a result of 
pharmacokinetic interactions, as plasma drug concentrations following administration 
of methadone and benzodiazepines do not significantly differ from concentrations 
following the administration of either drug alone (Preston et al. 1986).  
Methadone and alcohol in combination will also affect individual drug 
susceptibility. Donnelly et al. (1983) reported an enhanced CNS depressant effect 
when methadone and alcohol were administered together. Joseph & Appel, (1985) 
reported that alcohol dependence and alcohol related factors are a leading cause of 
death in methadone associated fatalities accounting for up to 60% of all mortalities. 
Co-adminstration of methadone and CNS depressants like alcohol can result in 
methadone concentrations below the fatal threshold inducing death. Worm et al. 
(1993) documented that in post-mortem cases where alcohol and methadone were 
identified together the concentration of methadone required to cause death (0.25 mg/L 
mean) was significantly lower than methadone alone (0.43 mg/L). As approximately 
20-50% of patients in methadone maintenance programmes have alcohol related 
problems (Dobler-Mikola et al. 2005), this interaction requires further investigation.  
Other drugs that have been linked with methadone toxicity include fluoxetine, 
rifampcin, and cocaine. Serotonin-selective re-uptake inhibitors (SSRIs) such as 
fluoxetine influence the activity of CYP3A4. Co-administration of SSRI agents with 
methadone will increase methadone serum levels resulting in toxicity and respiratory 
arrest (Davis & Walsh, 2001). Rifampcin is a CYP3A4 inducer prescribed to treat 
tuberculosis, a common condition in the AIDS population. The combination of 
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methadone and rifampcin can result in opioid withdrawal as a consequence of 
CYP3A4 induction. Cocaine administration can lead to an up regulation of opioid 
receptors altering methadone‟s efficacy (Unterwald et al. 1992). 
 
1.4.4 Drug Tolerance 
Drug tolerance is where a subject‟s response to a drug decreases over time resulting in 
larger drug dose requirements in order to achieve the same effects and is a significant 
factor in methadone toxicity and death.  Tolerance should not be confused with drug 
dependence (where a subject requires a drug in order to function normally) or drug 
addiction (the overpowering desire or need (compulsion) to continue taking a drug). A 
drug tolerant individual will experience less susceptibility to the effects of a drug as a 
consequence of its prior administration resulting in increased drug requirements 
(Shields et al., 2007; Bayerer et al., 2007). Acute tolerance develops in response to a 
single dose or following repeated doses over a very short period of time. Chronic 
tolerance is conferred over a longer period of exposure, eventually promoting a 
reduction in drug effects. Methadone maintenance leads to chronic drug tolerance 
with some individuals requiring significantly elevated drug doses. For example a fatal 
dose for an opioid naïve individual may be the same or lower than a daily dose for a 
methadone maintenance patient (Harding-Pink, 1993). Worm et al. (1993) examined 
41 methadone fatalities from 1981 and 1989 reporting lower mean and median post-
mortem blood methadone concentrations in opioid naïve individuals (median 0.22 
mg/L; mean 0.27 mg/L) when compared with subjects who had been enrolled in 
maintenance programmes (median 0.43 mg/L; 0.47 mg/L).  
On a cellular level drug tolerance has been linked with the desensitisation and 
internalisation of opioid receptors following chronic drug exposure (Koch et al. 1998). 
This reduces agonist response due to a decrease in the number of signalling receptors 
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(Koch et al. 2005). Receptor phosphorylation has been postulated as a key influential 
factor in acute receptor desensitisation. After desensitisation the recruitment of β-
arrestins to the plasma membrane facilitates the uncoupling of the receptor from the 
G-protein causing internalisation (Ferguson et al. 1996). von Zastrow et al. (2003) 
suggested that internalisation acts to sort receptors into either a degradative pathway 
for destruction or to a recycling pathway returning the receptors back to the cell 
surface in an activated state. Contrary to this, some argued that receptor 
internalisation acts to reduce opioid-induced tolerance (Koch et al. 1998; Whistler & 
von Zastrow, 1999; Law et al. 2000; Grecksch et al. 2006). One theory is that rapid 
receptor internalisation is an important mechanism to ensure that desensitised 
receptors are recycled back to the cell surface in an activated state as quickly as 
possible (Koch et al. 1998). This will maintain receptor signalling thus reducing the 
development of drug tolerance (Zhang et al. 1998).  A second theory suggests that 
receptor internalisation terminates signalling processes retarding the development of 
adaptive changes normally triggered by prolonged opioid exposure (Koch et al. 2008). 
Clearly the specific cellular mechanisms responsible for opioid induced tolerance 
remain controversial; however it seems probable that this is largely influenced by 
receptor signalling processes. 
 
1.5 Toxicological interpretation of methadone cases 
 
The toxicological interpretation of methadone-attributed deaths is a complex process 
complicated further by the acquisition of drug tolerance. Assessing tolerance in drug 
users is difficult requiring the complete documentation of an individual‟s drug history 
(Shields et al., 2007). Tagliaro & De Battisti, (1999) commented on the difficulties 
faced with drug overdose cases when drug habits, tolerance acquisition and drug 
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history are unknown. Interpretation of toxicology results in such situations is limited. 
Another point for consideration is that drug concentrations identified in overdose 
cases are often significantly lower than those found in living and active users, 
suggesting a period of abstinence from drug use during the months prior to the fatal 
incident. Epidemiological data supported this by demonstrating higher incidence of 
overdose cases in subjects recently released from jail (Binswanger et al. 2007; Shields 
et al. 2007; Wakeman et al. 2009). The molecular mechanisms responsible for the 
acquisition and subsequent loss of tolerance are controversial and remain unclear 
(Figure 3). 
 
 
Figure 3: Loss of Tolerance Following Methadone Abstinence. 
 
The loss of tolerance can result in fatalities if previous dosage concentrations are resumed following a 
period of abstinence. 
 
 
1.5.1 Post-mortem redistribution 
In post-mortem cases particularly where the body has been exhumed toxicological 
interpretation can be further affected by post-mortem change and redistribution, 
putrefaction, decomposition and the extent and location of tissues left for sampling 
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(Prouty & Anderson, 1990). Since methadone is a lipophillic drug with a high volume 
of distribution the likelihood of post-mortem redistribution is increased, thereby, 
affecting toxicological interpretation.  Detection of a drug and its glucuronide 
metabolites is of great importance in interpretive forensic and clinical toxicology of a 
drug. The ability to estimate metabolite/drug ratios may provide information about 
methadones route, dose and time of exposure (Kaushik et al., 2006). However it is not 
possible to definitively identify whether the concentrations identified truly reflect the 
drug concentrations administered. Drug concentrations in the blood of corpses are 
often site-dependent following post-mortem redistribution and diffusion (Pounder & 
Jones, 1990; Cook et al. 2000; Kennedy, 2010). Even in femoral venous blood, which 
is generally believed to be spared post-mortem factors, and in corpses with little 
putrefaction, drug concentration can change greatly within hour‟s following death 
(Moriya & Hashimoto, 1999; Ferner, 2008; Butzbach, 2010; Kennedy, 2010).  
 
1.5.2 Individual differences in drug metabolism 
In addition to post-mortem redistribution and drug tolerance complicating 
toxicological interpretation, inter-individual differences in drug metabolism can affect 
blood methadone concentrations post-mortem. This can be examined through gene 
analysis of the enzymes responsible for methadone metabolism. The science of 
attributing genome variations to alterations in drug metabolism and response is 
termed pharmacogenomics. 
 
1.6 Pharmacogenomics  
 
Pharmacogenetics focuses on individual traits with respect to one compound or drug, 
and pharmacogenomics focuses on the differences between several compounds and 
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whole genome responses through the examination of drug modifications on gene 
expression (White & Wong, 2005). One of the key principles of pharmacogenomics is 
that the correct drug dose for one individual may not be an appropriate dose or even 
the most suitable drug for another, due to differences in each individual‟s genetic 
makeup. The determination of what is the appropriate dose and, in some cases, what 
is even the best drug for a given individual constitutes the reasons for the 
development of the sciences of pharmacogenetics and pharmacogenomics (White & 
Wong, 2005). In both forensic and clinical practice inter-individual variation in drug 
response are frequently identified, however the precise mechanisms responsible 
remain unclear. Clarity may be achieved through the examination of molecular 
processes in tandem with the continuing advancement of genome research.  
Routine application of pharmacogenetics and pharmacogenomics is still in its 
infancy, however the concept has been in existence for thousands of years, stretching 
as far back as 510 B.C. when Pythagoras noted that the ingestion of fava beans resulted 
in a potentially fatal reaction in some, but not all, individuals (Nerbert, 1999). Wider 
recognition of inter-individual drug sensitivity has since developed. Multiple 
definitions for pharmacogenetics and pharmacogenomics can be found within the 
contemporary literatures (Pirmohamed, 2001; Kupiec et al. 2006; Catania, 2006). 
Pirmohamed, (2001) described pharmacogenetics as the study of variability in drug 
response due to heredity, applicable to genes determining drug metabolism whilst 
pharmacogenomics encompasses all genes in the genome that may determine drug 
response. Kupiec et al. (2006) stated that pharmacogenetics defines the spectrum of 
inherited differences in drug metabolism and disposition, whereas pharmacogenomics 
refers to all the genes that determine drug behaviour and sensitivity.  Multiple 
definitions can be confusing as the distinction between the two is somewhat tenuous, 
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and the terms are often used interchangeably (Vesell, 2000; Kupiec et al. 2006). 
Therefore, care must be taken when reviewing this subject area. 
For the purpose of this review the following definition for pharmacogenomics 
will be used, to clarify the molecular actions of methadone with clarity: 
pharmacogenomics combines the study of two scientific fields  ‘pharmacology and 
genomics’ and can be defined as the study of how genetic variation between 
individuals (genomics) influences drug response and susceptibility to adverse drug 
reactions (pharmacology) (Catania, 2006).  
 
1.6.1 Toxicological interpretation and pharmacogenomics 
Following the publication of the draft sequence of the human genome project in 2001, 
research examining the association between individual genetic variability and 
susceptibility to disease, clinical symptoms or treatment responses has increased 
exponentially heralding a new era in genomics (Skorpen & Laugsand, 2008; Bhathena 
& Spear, 2008; Harkcom & Abbott, 2010; Savas, 2010). A key topic in innumerable 
science reports, medical reviews and articles in the lay press, the process of linking 
basic inheritance to drug discoveries and therapeutics is progressing. The concept that 
an individual‟s DNA sequence could be an integral determinant of drug therapy has 
not yet become a standard notion of clinical medicine, however it is now certainly 
more than a mere consideration (Giacomini et al. 2007). 
Clinical discoveries can in turn be utilised to advance scientific progresses 
within the forensic field particularly with regards to the interpretation of toxicological 
data. Research conducted by Wong et al. (2003) demonstrates that pharmacogenomic 
studies can be used to identify gene variations for molecular autopsy aiding the 
interpretation of toxicology results (Wong et al. 2003). Current advancements in 
molecular technologies (such as real-time PCR and DNA chip technology) will situate 
 23 
pharmacogenomic testing alongside the traditional immunodiagnostics and analytical 
toxicological tests used currently to correlate in vivo drug levels with specific 
responses.  
Toxicological interpretation of biological fluids from either antemortem or 
postmortem samples is complex. Linking a specific reaction or behaviour to a drug 
concentration is hindered by many factors including inter-individual differences, 
development of tolerance, and ambient environment. As discussed previously, this is 
complicated further in post-mortem samples due to post-mortem redistribution, tissue 
degradation and the lack of antemortem samples as a means of comparison. Wong et 
al. (2003) proposed that pharmacogenomics may greatly aid in the interpretation of 
drug toxicity. Pharmaceutical agents are frequently associated with adverse drug 
responses, and can often be linked with significant morbidity and mortality as 
discussed in Section 1.4 Methadone –Related Deaths. A significant proportion of 
pharmacogenomic research is clinical and extrapolation from clinical to forensic 
research may assist in predicting individual susceptibility to methadone in addition to 
aiding the interpretation of toxicology results in methadone-attributed fatalities. 
Clinical research demonstrates that variations in single genes can be linked 
with unpredictability in the response to drug use. As such single genes are a 
significant area to concentrate on for the progression of forensic pharmacogenomics, 
establishing the cause and manner of death can be extremely challenging, especially 
in unidentified causes of death. Diagnosis of drug toxicity should be made in 
conjunction with autopsy findings, medical history and gene analysis. Cognizance of 
variables likely to affect pharmacokinetic and pharmacodynamic parameters would 
assist with this (Kupiec et al. 2006; Weschules et al. 2008; Phillips & Mallal, 2010). 
Genes involved in pharmacokinetic (genes controlling drug metabolism and drug 
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transport) and pharmacodynamic pathways (genes linked with disease susceptibility 
or drug targets) should therefore aid toxicological interpretation.   
Drug metabolism is a critical component of the final clinical effect of a drug 
and as such, genes that influence drug pharmacokinetics have become the focus of 
extensive research. It has been well documented that the genes encoding metabolising 
enzymes are highly polymorphic (Guttmacher & Collins, 2003; Bhathena & Spear, 
2008; Eckhart et al. 2009). Alterations to the function of a cytochrome P450 (CYP) 
enzyme would significantly affect drug efficacy, accounting for inter-individual 
variations. An individual phenotyped as a poor metaboliser would be expected to 
exhibit slower drug metabolism resulting in drug accumulation which could lead to 
drug toxicity (Kupiec et al. 2006). Similarly an alteration to the function of a 
transporter responsible for conveying drugs across the blood brain barrier would have 
a profound effect on the expected drug response.  
Pharmacodynamic pathways are another significant route in which to direct 
research. It has become increasingly clear over the years that drug receptors are highly 
polymorphic. It is logical therefore to propose that polymorphisms located in these 
regions may underlie the target of treatment resistance and super-responders (Kerwin, 
1999). The interpretation of post-mortem drug concentrations should therefore be 
guided by with knowledge of possible pharmacogenomic influences on drug 
metabolism and drug response. The introduction of alterations at the molecular level 
can result in significant changes with regards to drug processing and response.  
 
1.6.2 Pharmacogenomic influences on methadone metabolism 
Methadone is primarily metabolised in the liver, where it undergoes N-demethlyation 
by CYP3A4 and CYP2B6 (with a minor contribution from CYP2D6) forming the 
metabolites 2-ethylidene-1, 5-dimethyl-3, 3-diphenylpyrrolidine (EDDP) and 2-ethyl-
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5-methyl-3, 3-diphenyl-1-pyrrolidine (EMDP) (Sullivan & Due, 1973; Eap et al. 
2007). As discussed earlier these enzymes are critical for drug metabolism and the 
correlation between CYP variations and drug response has been well published for 
many classes of drugs (de Vos et al. 2010; Roberts et al. 2005; Lee et al. 2010; 
Suzuki et al. 2010). The human genome has 57 different CYP genes (most of which 
are polymorphic). Only four (CYP2A6, CYP2C9, CYP2C19, and CYP2D6) were 
considered to have “real pharmacogenomic relevance” (Vesell, 2000), however since 
then a number of pharmacogenomic studies have focused on other CYP genes 
(Bergmann et al. 2010; Li et al. 2010; Sagrieya et al. 2010; Wang et al. 2010)  
CYP2D6 has been associated with alterations to drug metabolism. Eap et al. 
(2001) examined the impact of CYP2D6 on drug metabolism, establishing three 
metaboliser groupings: poor metaboliser (having a non-functional gene), extensive 
metaboliser (possessing one or two functional genes) and ultra-rapid metaboliser 
(having three or more functional genes), supporting the concept of pharmacogenomic 
relevance.  Wong et al. (2003) examined whether methadone fatalities could be 
attributed to CYP2D6 mutations. The group reviewed case histories for methadone 
associated deaths from the Milwaukee County Medical Examiner‟s Office between 
1998 and 2000, using real-time PCR to genotype for CYP2D6 variations.  The 
genotyping data suggested that CYP2D6*3(2549 deleted A), *4(C100T, C974A, 
A984G, & G4180C), and *5 ( CYP2D6 deletion) alleles may assist in molecular 
autopsy potentially aiding death certification. However the results from this study 
were not statistically significant and it was noted that futher works with larger sample 
sizes are essential to truly identify a role for CYP2D6 screening (Wong et al. 2003). 
In addition, the significance of such work is limited, as CYP2D6 only has a minor role 
in methadone metabolism.  
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For pharmacogenomic studies on methadone it would be logical to concentrate 
on the primary metabolising enzyme CYP3A4 and CYP2B6. However due to a 
significant lack of literary information on methadone metabolism especially for 
CYP3A4, the toxicity of other substrates in relation to variations of CYP3A4 may be 
extrapolated to that of methadone, in order to bridge the knowledge gaps at the 
molecular level. Today increasing advancements in molecular studies have allowed a 
number of CYP3A4 variants to be identified. As CYP3A4 gene expression levels are 
often reported to have considerable inter individual variations (40-fold), it is logical to 
postulate that some of the variability identified in drug metabolism could be explained 
by these variations (Dai et al. 2001; Plant, 2007). Rebbeck et al. (1998) reported the 
discovery of a SNP in the 5‟regulatory region of CYP3A4 when examining the 
relevance of the gene in prostate cancer. They reported that the A290G (CYP3A4*1B 
allele) polmorphism is located in a transcriptional regulatory element and as a 
consequence may be responsible for alterations in gene expression. Westlind et al. 
(2001) sequenced the gene promoter and 5‟regulatory region of CYP3A4 in a group of 
Swedish individuals. The gene promoter region was highly conserved with no other 
variations identified, it was also concluded that the A290G SNP did not significantly 
affect the catalytic activity of CYP3A4. Dai et al. (2001) also examined CYP3A4 
molecular relevance by screening for polymorphisms in 72 individuals from three 
ethnic groups (Caucasians, African-Americans, and Asians (Taiwanese, Chinese, 
Melanesian, Indo-Pakistani, Cambodian, and Japanese)) identifying 28 SNPs in total, 
four of which were novel non synonymous polymorphisms leading to changes of 
R162Q, F189S, L293P, and P467S. L293P (2% frequency) and P467S (12.5% 
frequency) were only identified in Asians, where as R162Q only occurred in African-
Americans, implicating ethnic relevance in the SNP distributions.  Testosterone and 
the insecticide Chlopyrifos were used to test the effects of the mutations on 
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metabolism. The F189S allele attributed significantly lower enzyme activity for both 
substrates whilst L293P increased enzyme activity, this evidenced that the CYP3A4 
variation could be responsible for inter-individual differences in substrate metabolism 
(Dai et al. 2001).   
Despite these studies the biological significance of the variants remains 
questionable and it is clear further work is required. The reported variability in 
metabolism is likely to be due to the inducibility and inhibition of CYP3A4 by other 
drugs (Table 1). Therefore, drug-drug interactions must be taken into account when 
conducting pharmacogenomic studies to ensure that any relationships identified are 
truly representative of gene variants and are not otherwise hidden consequences of co-
medications. 
 CYP2B6 has been studied more frequently and several CYP2B6 SNPs have 
been correlated with enzyme efficiency or gene expression levels. Lang et al. (2001) 
screened 35 Caucasian individuals for CYP2B6 variations. Nine SNPs were identified, 
five of which were non-synonymous.  The C1459T variant was of particular interest, 
since it causes an amino acid change from arginine to cysteine at position 487. 
Individuals homozygous for the „T‟ allele demonstrated an 8 fold decrease in 
enzymatic activity compared to wild type individuals. However „T‟ allele frequency 
(14%) within this population could not explain the total extent of metabolism 
variability identified for this gene. Lamba et al. (2003) examined the relationship 
between CYP2B6 expression and the transcription factor constitutive androstane 
receptor (CAR) expression, noting the effects of SNPs located in exonic, intronic and 
5‟ flanking regions on overall gene expression in Caucasian, African and Hispanic 
American populations. Alternative splicing by resequencing mRNA from liver 
samples was conducted using TaqMan® flurogenic probes. Sequencing information 
for both forward and reverse primers was examined noting the presence of base 
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substitutions. In agreement with Lang et al. (2001), the C1459T SNP was associated 
with a decrease in expression; however this relationship was only identified in 
females. Another gender trend SNP is located in intron 3 (C15582T). The promoter 
region (T2320C) also correlated with expression differences in female subjects. 
Higher mRNA levels of the transcription factor CAR were observed in female 
subjects, which could perhaps explain the observed gender differences by Lamba et al. 
(2003). The study identified several splicing transcripts, SV1 (the main splice variant, 
SV) was found in many of the samples examined. This SV lacks sequencing 
information for exons, 4, 5 and 6. Furthermore, SNPs in exon 4 (G516T) and intron 3 
were found to correlate with SV1 presence.  Despite positive associations between 
SNP presence and CYP2B6 expression Lamba et al. (2003) concluded that the 
identification of functionally important CYP2B6 genotypes was complicated. Many of 
the SNPs analysed were found to be in linkage disequilibrium (the non-random 
association of SNPs at two or more loci but not necessarily on the same chromosome) 
and therefore associated with different haplotypes. The importance of gender and 
ethnic difference was noted with the suggestion that future studies should not be 
limited by focusing on markers of CYP2B6 phenotype but should instead examine 
which variants are associated with gender and ethnic differences (Lamba et al. 2003). 
Hoffman et al. (2008) examined the relevance of the CYP2B6*6 allele (G516T and 
A785G SNP) by constructing CYP2B6 minigenes and transfecting them into COS-1 
and Huh7 cells. CYP2B6 genotyping was also conducted on a number of liver samples, 
with the aim of identifying the molecular mechanism responsible for CYP2B6*6 
decreased protein expression and as a consequence protein activity (slow metaboliser 
phenotype). The study reported the exon 4 SNP (G516T) as being the causal mutation 
linked to gene function reduction, additionally this mutation was responsible for 
aberrant splicing resulting in a major splice variant lacking exons 4, 6 and the intronic 
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regions between. This resulted in the reduction of mRNA transcript length, and total 
enzyme activity (Hoffman et al. 2008). The group also examined the effects of the 
promoter region SNP (T750C) on expression levels as this SNP is found in tandem 
with the CYP2B6*6 allele (Hesse et al. 2004). No significant relationship was 
identified despite a large sample size (235 samples) leading the group to have 
assumed that the T750C promoter mutation has little effect on transcription. Contrary 
to Lamba et al. (2003) the group were not able to establish a relationship between 
C15582T (intron 3), hepatic phenotype, and the splice variant SV1. The RT-PCR data 
did however reveal a significant relationship between the CYP2B6*1/*1 genotype and 
the CYP2B6*6/*6 genotype. For the *1/*1 (T2320C) samples the major transcript 
detected was the “normal” splice product, for the *6/*6 samples the SV1 transcript 
was identified. Hoffman et al. (2008) concluded that the G516T mutation can be 
recognised as a causal indicator of expression variability, for predicting inter-
individual sensitivity in drug response. The above examples are not specific to 
methadone, however we postulate that the results from these studies can be used to 
create a strategy for examining CYP2B6 effects on methadone metabolism. Further 
work focusing on methadone metabolism is required to determine the contribution of 
the CYP2B6*6 allele for drug metabolism and adverse drug responses. 
 Methadone stereoselectivity has been associated with many genes including 
CYP2D6, CYP2B6, ABCB1, KCNH2 (hERG) (Gerber et al. 2004; Wang et al. 2004; 
Crettol et al. 2005; Crettol et al. 2006; Eap et al. 2007). The stereoselective 
relationship identified between CYP2B6 and methadone‟s enantiomers is of particular 
interest (Figure 2). Preferential targeting of the (R)-enantiomer by CYP2B6 had been 
widely demonstrated (Bertschy et al. 1994; Eap et al. 1997). In addition Gerber et al. 
(2004) identified a stereoselective relationship between CYP2B6 and (S)-methadone, 
with significantly higher (S)-methadone metabolism compared to (R)-methadone. The 
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group also documented that the steady state of (R)/(S) methadone concentrations in 
plasma can be controlled by the relative expression of CYP2B6. Therefore changes in 
CYP2B6 expression could result in greater effects in one enantiomer ((S)-methadone) 
than the other ((R)-methadone), complicating the interpretation of toxicology results. 
Eap et al. (2007) examined CYP2B6 and hERG (human ether-a-gogo related gene) 
stereoselectivity. As discussed previously the human heart is mediated by voltage-
gated potassium channels, one of which is the hERG channel. It is known that a 
number of drugs including methadone can block hERG resulting in malignant 
ventricular arrhythmias (“torsades de pointes”) and sudden death (Katchman et al. 
2002; Kornick et al. 2003). Using genotyping assays and whole-cell patch-clamp 
experiments with HEK293 cells Eap et al. (2007) identified a stereoselective 
relationship between (S)-methadone and the hERG channel, with (S)-methadone 
reducing IhERG by ~ 65% compared to (R)-methadone which reduced IhERG by ~ 40%. 
Furthermore, the group noted a correlation between the CYP2B6 *6 genotype (slow 
metaboliser) and increases in (S)-methadone plasma concentrations supporting the 
relationship identified by Gerber et al. (2004). This study suggested a cardiotoxic role 
for (S)-methadone particularly in individuals with the CYP2B6*6 genotype where (S)-
methadone concentration levels will be significantly higher than wild type individuals. 
It should be considered however that this conclusion was based on in vitro data, and 
may not be a true representation of the complexity of the in vivo system. Furthermore, 
Kienbaum et al. (2002) noted a relationship between chronic µ receptor stimulation 
by methadone and the subsequent depression of muscle sympathetic activity in the 
heart, demonstrating the potential importance of opioid agonists to cardiac response. 
Nonetheless this is certainly an important aspect that requires further investigation, 
especially when it is taken into account that CYP2B6 is expressed in the human heart 
(Park, 2000).  
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 The importance of studies focused on CYP2B6 is directly proportional to the 
increasing incidence of methadone-attributed deaths. Rising occurrences of 
cardiotoxicity and respiratory depression highlight the significance of methadone 
pharmacogenomic research, especially when the current data deficiency is considered 
(Corkery et al. 2004; Pimentel & Mayo, 2008). Concentrating pharmacogenomic 
studies in this area will advance toxicological interpretation and assist in the 
development of screening methods to identify methadone susceptible individuals.   
 
1.6.3 Pharmacogenomic influences on methadone-receptor binding and response 
The µ opioid receptor represents the principle molecular target for methadone binding 
in vivo, with reported Ki values of 3.7 ± 0.3 (nM) (Mestek et al. 1995; Wendel & 
Hoehe, 1998). Despite frequent usage and increasingly reported adverse effects, the 
studies focusing on methadone actions and OPRM1 variability has been significantly 
less than that on morphine. This perhaps reflects the importance of morphine within 
the clinical environment where most of the studies discussed so far have been 
conducted. Additionally, the studies that have considered methadone from a 
pharmacogenomic perspective have done so from a drug metabolism perspective. 
Only one study examining the relationship between methadone and OPRM1 
variability was found during this study and it was conducted in conjunction with drug 
metabolism and transport genes. Lötsch et al. (2006) examined the effects of 
levomethadone (r-methadone) on drug response using miosis as an indicator. The 
group selected not only the genes critical to methadone metabolism and transport 
namely, CYP2B6, 2D6, 3A, 1A2, 2C8, 2C9, and 2C19, p-glycoprotein ABCB1, but 
also the receptor gene OPRM1. Of the genes studied the OPRM1 A118G 
poymorphism was considered to be the most important factor affecting drug response. 
Individuals with the 118G allele demonstrated a 1.74 times lower miotic potency 
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compared to wild type subjects. Despite this association no further work had been 
conducted since. Contrastingly, studies on OPRM1 sequence structure, heroin 
addiction and morphine variability have been extensive. Therefore these studies will 
be discussed to predict the potential role of OPRM1 in methadone toxicity. 
Wendel & Hoehe, (1996) examined the 5‟regulatory and intronic sequence 
information for OPRM1 to identify potential transcription sites. The group noted a 
40% homology between the human OPRM1 5‟ regulatory region and the rat OPRM1 
gene suggesting that this is a homologous region between species (Mestek et al. 1995). 
The absence of classical TATA and CCAAT regions was interesting since it is usually 
the “housekeeping” genes that lack these regions for the constitutive expression 
requirements. Tissue specific expression of OPRM1 gene might be another 
explanation. Wendel & Hoehe, (1998) identified 2408 base pairs (bp) of the 5‟ 
regulatory region and discovered transcription initiation sites in addition to potential 
binding sites for transcription regulators. This was a significant contribution to 
molecular research and extended the known OPRM1 sequence information to a total 
of 6968 bp (Wendel & Hoehe, 1998). Such sequence analyses have provided the 
necessary foundations required for the progression of pharmacogenomic research, 
assisting in the development of drug – gene orientated studies. 
Initially studies on OPRM1 explored basic drug dependence and addiction, 
later progressing into genotyping and expression studies. For example Tsuang et al. 
(1998) surveyed drug dependence, examining the probability of drug abuse in 3372 
twin males. The Diagnostic Interview Schedule, revision 3 (DIS-III-R) was used to 
assess abuse and dependence, correlating phenotype (drug use) with the probability of 
dependence, monitoring gene differences between siblings (Tsuang et al. 1998). The 
group noted that heroin abuse revealed the largest amount of unique genetic variance 
(38 %) suggesting a key area for phamacogenomic research. Bond et al. (1998) also 
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examined drug abuse and dependence association however this group applied a 
molecular examination of OPRM1 as opposed to the model approach used by Tsuang 
et al. (1998). The study characterised OPRM1 SNPs in former and current heroin 
addicts, examining their influence on receptor function. The group studied the 
OPRM1 coding regions and identified the following gene variants A118G, C17T, 
G24A, G779A and G942A, of these only A118G and C17T had previously been 
identified by Berrettini et al. (1997) and Bergen et al. (1997). Allele frequencies for 
African-American, Caucasian and Hispanic ethnic groupings were statistically 
significant for both A118G (P value of 0.028) and C17T (P value of 0.000002) (Bond 
et al. 1998). Additionally within the Hispanic group it was noted that the 118G allele 
was present in a higher proportion of non-opioid dependent subjects, although this 
result was not significant. The group stated that this could be a possible artefact of 
population admixture, with 118G conferring protection against opioid dependence in 
a larger sample size (Bond et al. 1998). Bond et al. (1998) also examined binding 
affinity in response to A118G by introducing mutant receptors into AV-12 cells and 
conducting radioligand binding assays. Located in the N-terminal region of the 
receptor N40D is postulated to induce the loss of a potential glycosylation site (Lötsch 
& Geisslinger, 2005), resulting in protein modifications (Befort et al. 2001). A 
substantial difference in β-endorphin binding (approximately three fold) was noted 
between wild type and variant receptors. This was not reciprocated for morphine, 
methadone, and fentanyl binding, which was not unexpected as a single amino 
substitution in the N-terminal region is unlikely to affect the tertiary structure of the 
receptor (Bond et al. 1998).  
Befort et al. (2001) also examined OPRM1, screening for genetic variations 
that could be linked with inter-individual differences in opiate response, and opioid-
associated pathophysiology. Similarly to Bond et al. (1998), Befort et al. (2001) 
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examined the effects of OPRM1 mutants (N40D, N152D, R265H, and S268P) on 
receptor functionality through site directed mutagenesis and transfection of the COS 
cells. Binding affinity profiles for morphine, [D-Ala
2
, N-MePhe
4
, Gly-ol]-enkephalin 
(DAMGO), diprenorphine, [D-Phe-Cys-Tyr-Orn-Thr-Pen-Thr-NH2] CTOP, 
[Met]enkephalin, β-endorphin, and dynorphin A were analysed for each of the 
variants. At the amino acid level the A118G DNA polymorphism is N40D, and 
induces an amino acid change from asparagine to aspartic acid, with an allelic 
frequency of 10-20%. No significant difference between N40D and wild type receptor 
densities was observed. N152D and R265H both represent rare mutations with N152D 
being described for the first time in this study. The relevance of these mutations to 
opioid pharmacogenomics is therefore limited. S268P was also rare, identified in only 
1 subject out of a total of 250 Caucasian subjects. The group however noted that 
S268P significantly impaired receptor signalling and it was postulated that this 
represented a functional change in receptor conformation by the proline residue by 
disrupting the tertiary loop structure, compromising G protein coupling (Koch et al. 
1997; Befort et al. 2001). It was concluded that the degree of receptor signalling 
impairment warranted further investigation in larger sample groups. 
Lötsch et al. (2002) studied the effects of the A118G polymorphism on 
morphine-6-glucuronide toxicity (M6G). The morphine metabolite M6G has a 
binding affinity similar to that of its parent, a higher analgesic potency and has been 
reported to accumulate in tissues resulting in drug toxicity (Ashby et al. 1997). 
Therefore gene variations likely to affect this metabolite in vivo are of critical 
importance.  Two clinical case studies (patients experiencing unwanted clinical 
effects) were used to determine the effects of A118G on M6G response. The group 
noted a decreased M6G potency in carriers of the 118G allele, leading to the 
hypothesis that A118G confers protection against M6G toxicity (Lötsch et al. 2002). 
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Despite the positive association demonstrated in this study the sample size was too 
small for this result to be representative of a population trend. Klepstad et al. (2004) 
continued to work in this area noting a correlation between 118G and increased 
morphine requirements. The study also examined the response to morphine by several 
other OPRM1 SNPs (G1727, A118G, IVS2 + G31A, and IVS2 + G691C) located in 
both exonic and intronic domains. A total of 207 palliative care patients receiving 
chronic morphine treatment were genotyped and it was noted that subjects 
homozygous for 118G required significantly more morphine than heterozygous and 
wild type individuals (Klepstad et al. 2004). Combining the works of Lötsch et al. 
(2002) the 118G reflected inter-individual differences in M6G efficacy. However the 
relevance of such results was limited by a small sample size with only four subjects 
found to be 118G homozygous. Romberg et al. (2005) searched for a link between 
A118G and respiratory depression, with the hypothesis of Lötsch et al. (2002) that 
this mutation conferred some protection against M6G induced respiratory depression. 
However, Romberg et al. (2005) did not find a significant relationship between 
A118G and respiratory depression. An association was however noticed between 
A118G and a reduction in analgesic efficiency. The relevance of such results is 
somewhat contentious as the study sampled only 16 individuals with no 118G 
homozygous individuals identified. In comparison Lötch et al. (2002) examined 207 
subjects finding 4 individuals homozygous for 118G, and yet this was considered to 
be a limiting sample size. Therefore the study conducted by Romberg et al. (2005) 
was severely hindered by sample size. 
Bart et al. (2004) re-examined the A118G variant from a different perspective 
searching for a link between this SNP and drug addiction in a cohort of Swedish 
heroin addicts. A118G distribution was found to be in Hardy-Weinberg equilibrium 
for all of the subgroups with an allelic frequency of 11%. The group discovered a 
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significant odds ratio between the 118G allele and increased heroin addiction, with 
the results indicating a 21% risk of heroin addiction mediated by the 118G allele, 
contrasting with the works of Bond et al. (1998). The group also examined A118G 
relevance in drug addiction and alcohol dependence (Bart et al., 2005). 
Zhang et al. (2005) conducted a study to elucidate the contribution of A118G 
to allelic-specific expression. Genomic DNA and total RNA were extracted from 
post-mortem brain tissue samples to measure allelic imbalance in mRNA expression. 
The study documented a significant difference in mRNA expression in brain tissues 
and transfected cells as a result of the A118G polymorphism. Allele-specific 
expression analysis demonstrated a 2-fold increase in the expression of 118 AA (wild-
type) compared with 118 AG heterozygous individuals, potentially explained by the 
existence of a cis-acting factor (Zhang et al. 2005). 118 AA yielded 10-fold more 
binding sites than 118 AG. It was postulated that 118G substitutions may affect 
translation, post translational processing, or OPRM1 protein turnover and further 
work was required to definitively identify the contribution of A118G for opioid 
response. As yet the role of A118G in translation and post translational processing 
remains undetermined. 
Ross et al. (2005) conducted a similar study to that of Lötsch et al. (2002) and 
Klepstad et al. (2004) focusing on patients who demonstrated morphine intolerance. 
Two groups were assigned, the first group comprised 138 people as controls that had 
been using morphine for over a month with clinical benefit, and the second group 
consisted of 48 switchers that had not achieved analgesic control instead experiencing 
intolerable side effects. Four genes pertinent to morphine action in vivo were 
examined by the group. They were UGT2B7, OPRM1, βarrestin2, and stat6. Since the 
βarrestin2 gene was involved in the signalling process for µ receptor desensitisation 
(Bohn et al. 2002) it was also included to the study. The transcription factor stat6 is 
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known to be involved in OPRM1 expression (Kraus et al. 2001). Ross et al. (2005) 
were the first group for the identification of a significant correlation between 
βarrestin2 and analgesic response in humans. There was a higher prevelance of 
T8622C in subjects unresponsive to morphine treatment, indicating that T8622C may 
be a susceptibility polymorphism. This variation is a synonymous SNP (located in 
exon 11) so such a functional response was unexpected. However, it was postulated 
that T8622C could be in acting in combination with a non synonymous SNP within 
the OPRM1 gene. In disagreement with Lötsch et al. (2002), no significant 
relationship between morphine response and the A118G SNP was identified by Ross 
et al. (2005). Indicating that A118G contribution to drug response is highly 
controversial. For five of the studies described here A118G had associated with 
addiction, increased morphine requirements, OPRM1 expression modifications and 
protection from M6G toxicity (Lötsch et al. 2002; Klepstad et al. 2004; Zhang et al. 
2005). However, it had also been reported that OPRM1 receptor densities as a result 
of A118G were not significantly different in subjects unresponsive to morphine 
treatment (Befort et al. 2001; Ross et al. 2005).  
In the same year however Ide et al. (2005) moved away from the A118G 
variant focusing instead on the 3‟ untranslated region of the OPRM1 gene. In humans 
more than 50 polymorphisms have been discovered within the 3‟downstream region, 
and Ide et al. (2005) noted that many of these are in significant linkage disequilibrium, 
effectively making it possible to group humans according to their polymorphic 
patterns. The group continued to examine OPRM1 for an association between gene 
polymorphisms and methamfetamine dependence and psychosis in 2006 (Ide et al. 
2006). However no significant link could be established between A118G and 
methamfetamine dependence, contrastingly a significant association between the 
1VS2 + G691C SNP in intron 2 and methamfetamine dependence was noted by the 
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group (Ide et al. 2006). Further research on polymorphisms located in intronic and the 
3‟ untranslated region of the OPRM1 gene is required. 
Similarly to the work of Zhang et al. (2005) Bayerer et al. (2005) examined 
the effects of cis-acting elements on OPRM1 promoter activity. Cis-acting elements 
are involved with transcription factor binding and gene promoter activity. The 
OPRM1 promoter region possesses binding sites for a host of cis acting elements 
NFkB, STAT6, SP1, AP1, GRE and CRE, and variations close to or within the site 
for one of these elements were postulated to alter promoter activity (Wendel & Hoehe, 
1998; Kraus et al. 2001, 2003). Bayerer et al. (2005) used in vitro mutagenesis to 
examine the effects of 8 promoter mutations at positions -172, -236, -554, -995, -1045, 
-1320, -1699, and -1748 on gene expression regulation using the luciferase assay. In 
addition to this in vitro work the group also genotyped 700 Caucasian individuals for -
554 and -1320 to characterise variation presence within the population. The G554A 
polymorphism was found to exist within a cis-acting element significantly reducing 
promoter activity. The polymorphism was not however identified within the 
Caucasian population genotyped. The A1320G variant also showed a significant 
change in promoter activity, however it is not known whether this polymorphism is 
located in, or near, a transcription factor binding site. The genotyping results showed 
one individual to be homozygous for 1320G with another individual demonstrating 
heterozygocity. The group concluded that out of the eight SNPs studied, two (G554A 
& A1320G) are likely to affect transcriptional regulation and therefore the OPRM1 
expression. Individuals with these mutations may therefore react differently to opioid 
administration (Bayerer et al. 2005).  
Reyes-Gibby et al. (2007) continued with the work started by Lötsch et al. 
(2002) and Klepstad et al. (2004) by examining the effect of genetic variability on 
morphine efficiacy. The data used was from the study conducted by Klepstad et al. 
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(2004) with genotyping information recorded for a total of 207 patients undergoing 
morphine therapy for cancer pain. Reyes-Gibby et al. (2007) explored the joint effects 
of OPRM1 and COMT (catechol-O-methyl transferase) variations on morphine 
response. COMT is responsible for metabolising the catecholamines including, 
dopamine, epinephrine and norepinephrine and is known to display wide variations in 
enzymatic activity that could be underlined by the Val158Met functional 
polymorphism (Klepstad et al. 2005). This particular variation can alter enzymatic 
activity by up to four-fold difference (Montagna, 2007). Additionally when Rakvag et 
al. (2005) studied this variation in a group of cancer patients being treated with 
morphine it was noticed that patients homozygous for valine at 58 required higher 
doses of morphine compared to heterozygous and homozygous methionine. Reyes-
Gibby et al. (2007) demonstrated a key relationship between OPRM1 and COMT with 
regards to morphine efficacy noting that patients homozygous for Met/Met (or AA 
genotype) at 58 in the COMT gene and OPRM1 respectively required lower morphine 
doses for optimal analgesia (Reyes-Gibby et al. 2007). This finding demonstrates the 
importance of gene-gene interactions as the nature of pharmacogenomic research 
heralds a new dimension in the studies of genetic linked analgesia. 
More recently Yamamoto et al. (2008) examined the relationship between 
OPRM1 expression and bone cancer pain. The group used a murine model to examine 
the effects of chronic morphine exposure on OPRM1 expression and distribution in 
response to bone cancer pain, revealing that differences in morphine sensitivity 
correlated with changes in OPRM1 expression. Additionally reductions in OPRM1 
expression correlated with the sarcoma-implanted mice (Befort et al. 2001; Zhang et 
al. 2005; Bayerer et al. 2005). SNPs affecting gene expression are therefore critical to 
the final clinical effect of a drug such as morphine. 
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In viewing all the research on OPRM1 to date, it is clear that further 
examination of A118G relevance to morphine and other illicit drugs is necessary, 
especially from a forensic context. Additionally joint-effects such as the relationship 
between OPRM1 and COMT highlighted by Reyes-Gibby et al. (2007) may be 
important. 
 
 
1.7 Summary  
 
 
The aim of this review was to explore methadone pharmacogenomics identifying how 
this information can be used to advance toxicological interpretation. Of the studies 
reviewed here, only one was conducted from a forensic perspective demonstrating the 
need for progression in this field. Wong et al. 2003 have begun to explore 
pharmacogenomic relevance for forensic toxicology however there is still much more 
work required. Areas that required future research have been identified, namely the 
association between CYP2B6 and OPRM1 variations for methadone action and this 
study will explore this further. Existing knowledge on methadone-related overdoses is 
mostly based on quantitative data collected retrospectively from coroners‟ records and 
drug death statistics (Shields et al. 2007). Whilst reports of this nature provide crucial 
insights into the incidence of methadone-attributed fatalities, the research is less 
amenable to exploring how, why, and in which situations individual drug users die 
because of consuming methadone (Shields et al. 2007). 
 Studies on methadone pharmacogenomics have mainly concentrated on 
metabolising enzymes instead of exploring the role of opioid receptor variations for 
methadone. The role of the A118G variant for methadone action remains unclear and 
requires clarification. Studies that have examined the impacts of CYP2B6 metaboliser 
status have done so in living subjects. The role of CYP2B6 in methadone 
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susceptibility needs to be determined and this can be achieved by examining SNP 
prevalence in methadone-attributed deaths. This would identify target variations that 
can be used as molecular autopsy to aid toxicological interpretations. This will benefit 
many aspects of forensic casework, for example, individuals driving under the 
influence of drugs (DUID) or for the interpretation of post-mortem drug 
concentrations. It is hoped that screening protocols for methadone maintenance users 
could be implemented as a risk management tool to identify susceptible individuals 
prior to treatment. 
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CHAPTER 2 
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2.1 Method Optimisation 
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2.1.1 DNA Collection and Extraction 
 
2.1.1.1 DNA extraction from buccal swabs 
Genomic DNA was collected by rubbing each of the three swabs against the buccal 
(cheek) surface of six different subjects. Following collection the DNA was extracted 
in 220µl of MasterAmp™ buccal extraction fluid (Epicentre Biotechnologies, USA) 
following the manufacturers protocol. Each of the swabs were thoroughly submersed 
and mixed with the extraction fluid to remove the DNA from the swab to the fluid. 
The samples were vortexed before incubation at 65ºC for two minutes. Following this 
the samples were vortexed again before being incubated at 98ºC for three minutes. A 
final vortex step completed the extraction process. The samples were left to cool at 
room temperature before being stored at -20ºC. 
 
Table 2: DNA sample identification for the buccal extractions. 
 
Samples 
 
Isohelix SK-1 Catch-All Swab MasterAmp™ Brush 
E E1 E2 E3 
L L1 L2 L3 
P P1 P2 P3 
A A1 A2 A3 
Ky Ky1 Ky2 Ky3 
R R1 R2 R3 
 
 
2.1.1.1.1 Buccal DNA quantification 
To determine which of the three collection swabs was the most suitable for use in this 
project the extracted DNA samples were quantified. This was conducted using the 
Human Quantifiler® Kit (Applied Biosystems, UK) and the StepOne™ real-time 
PCR machine (Applied Biosystems, UK). The buccal samples were run twice to 
ensure experimental reproducibility. 
 
 45 
2.1.1.1.2 Quantifiler® Software Setup 
The human Quantifiler® kit quantifies the amount of amplifiable human DNA that is 
present in a sample from 0.023 ng/L to >50 ng/L. The gene target for the human 
Quantifiler® kit is the human telomerase reverse transcriptase gene (hTERT). A 
Quantifiler® programme “buccal extraction run 1” was created using the StepOne 
Experiment Wizard according to the manufacturer‟s instructions for the following 
samples:  
E1, E2, E3, L1, L2, L3, P1, P2, and P3. 
 
A Quantifiler® programme “buccal extraction run 2” was created using the StepOne 
Experiment Wizard for the following samples:  
A1, A2, A3, Ky1, Ky2, Ky3, R1, R2 and R3. 
 
The standard curve quantitation parameter for genomic DNA (gDNA) was selected. A 
2 hour run time (standard) was selected for both experimental runs. Each of the 
samples was run in triplicate, with the Quantifiler® standards run in duplicate in a 
total well volume of 10µl.  
 
2.1.1.1.3 Sample Preparation 
A standard dilution series for the experiment was conducted (Table 3), using the 200 
ng purified DNA standard provided. The dilutions were prepared with a 3:1 serial 
factor. A sample at the lowest concentration contains about 14 to 16 copies of a 
diploid single-copy locus and 7 to 8 copies of a haploid single-copy locus. 
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Table 3: Standard dilution series of the 200 ng purified DNA standard for quantification.  
 
Dilution 
Point 
Source Source 
Volume 
(µl) 
Diluent 
Volume 
T10E0.1 (µl) 
Total 
Volume 
(µl) 
Standard 
Concentration 
(ng/µl) 
1  Stock 2.5 7.5 10.0 50.00 
2  Dilution 1 3.34 6.66 10.0 16.7 
3  Dilution 2 3.34 6.66 10.0 5.56 
4  Dilution 3 3.34 6.66 10.0 1.85 
5  Dilution 4 3.34 6.66 10.0 0.62 
6  Dilution 5 3.34 6.66 10.0 0.21 
7  Dilution 6 3.34 6.66 10.0 0.068 
8  Dilution 7 3.34 6.66 10.0 0.023 
 
Table 4: Quantifiler® Reaction Mix Components. 
 
Components Per well (µl) 
Quantifiler Reaction mix 5.0 
Quantifiler Primer mix 4.2 
Samples (0.1ng/µl)/Standards 0.8 
Total reaction volume 10 
 
 
The required Quantifiler® reaction mix and Quantifiler® primer mix (Table 4) for 
each experimental run (including an extra 10% for excess) was calculated and a 
master mix created.  Then 9.2µl of the prepared master mix was added to each well of 
a 48-well optical plate. For the negative controls 10µl of reaction mix was added. 
Following the plate layout (generated when setting up the StepOne™ quantification 
experiment) 0.8µl of the appropriate samples/standards were added to each well. For 
results see section 3.1.1.1 DNA extraction from buccal swabs. 
 
2.1.1.2 DNA extraction from whole blood 
Two commercial DNA extraction kits were tested to determine which should be used 
for the extraction of DNA from post-mortem whole blood samples. The Promega 
Wizard Purification Kit routinely used for DNA extraction (Wang et al. 2007) and the 
Qiagen DNeasy Blood and Tissue Kit. In addition to determining the optimum kit for 
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experimental use, the effects of three commonly used preservatives lithium heparin, 
EDTA, and potassium oxalate on DNA yield were examined during each extraction. 
 
2.1.1.2.1 DNA extraction using the Promega Wizard Purification Kit  
Samples of whole blood preserved in EDTA, lithium heparin and potassium oxalate 
were extracted using the Promega Wizard Purification Kit as per the manufacturers 
instructions (Table 5). Each sample was extracted in triplicate to ensure experimental 
efficiency and reproducibility. 
 
Table 5: Promega Wizard Purification Extraction components and volumes. 
 
 
 
2.1.1.2.2 DNA extraction using the Qiagen DNeasy Blood and Tissue kit 
 
Samples of whole blood preserved in EDTA, lithium heparin, and potassium oxalate 
were extracted using the DNeasy Blood Extraction Kit as per the manufacturer‟s 
instructions (Table 6). This method utilises spin column technology to selectively 
bind the DNA to a silica membrane. Each sample was extracted in triplicate to check 
method efficiency and reproducibility. 
 
Table 6: Qiagen DNeasy Extraction Components and Volumes. 
 
Sample 
size 
Proteinase 
K 
PBS 
(7.2 pH) 
Buffer 
AL 
Ethanol 
(100%) 
Buffer 
AW1 
Buffer 
AW2 
Buffer 
AE 
100 µl 20 µl 100 µl 200 µl 200 µl 500 µl 500 µl 200 µl 
 
 
 
 
Sample 
size 
Cell 
lysis 
solution 
Nuclei 
lysis 
solution 
Protein 
precipitation 
solution 
Isopropanol Ethanol 
(70%) 
DNA 
rehydration 
solution 
300 µl 900 µl 300 µl 100 µl 300 µl 300 µl 100 µl 
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2.1.1.2.3 Quantification of DNA from whole blood 
The samples extracted for both the Promega Wizard Purification Kit and the Qiagen 
DNeasy Blood and Tissue Kit were quantified using the Human Quantifiler® Kit 
(Applied Biosystems, UK) on the StepOne™ real-time machine (Applied Biosystems, 
UK). Programmes were titled “Quantification of Promega Samples” and “Qiagen 
Extraction Run”. Each programme used the standard curve quantitation setting for 
gDNA. The experiment run time was 2 hours and the samples (9 total for each 
extraction) were run in triplicate with the quantifiler® standards run in duplicate. 
The reaction plate was set up as described in section 2.1.1.1.3 Sample preparation. 
For results see section 3.1.1.2 DNA extraction from whole blood. 
 
2.1.2 PCR Amplification of SNP regions of OPRM1 gene 
 
The µ opioid receptor gene (OPRM1) is one of the molecular targets for this research 
project. Amplification of specific gene regions (promoter, exon 1, exon 2, and exon 3) 
through the polymerase chain reaction (PCR) will identify gene variations (SNPs). 
These can then be used as positive controls for the real-time SNP genotyping assays 
conducted on the StepOne™ real-time machine. Complementary oligonucleotide 
primers were designed using the flanking sequence regions in order to effectively 
amplify these target regions. 
 
2.1.2.1 Primer design and Rehydration 
Sequences from the promoter and coding regions of the human OPRM1 gene were 
used to design primers for use in PCR amplification (see appendix). PCR primers 
were synthesised for three of the four coding regions of the gene, exons 1, 2 and 3 
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(see appendix). PCR primers were also synthesised for the proximal promoter region 
of the gene. The following primers PRO554_HB, PRO995_HB, EX1_HB, EX2_HB 
and EX3_HB were hydrated with T10 buffer according to their molecular weight 
(Table 7; see Table 8 for primer sequence information). Primers were left for 20 
minutes at room temperature to dissolve before being stored at –20C until used. 
 
 
Table 7: OPRM1 Primer rehydration volumes. 
 
 
PRIMERS Volume of T10 required for a 
concentration of 100 pmol/L. 
PRO995F_HB 186 L 
PRO995R_HB 222 L 
PRO554F_HB 210 L 
PRO554R_HB 224 L 
EX1F_HB 214 L 
EX1R_HB 208 L 
EX2F_HB 215 L 
EX2R_HB 250 L 
EX3F_HB 209 L 
EX3R_HB 194 L 
 
 
 
2.1.2.2 Primer validation 
The proximal promoter region including –1045A > G, –995C > A, and –554G > A, 
the region of exon 1 including –118A >G, and –17C > T, the region of exon 2 
including –440C > G, and –454A > G, and the region of exon 3 including –779G > A, 
–793C > T, –820G > A, –877G > A, and –942G > A were amplified by PCR. The 
primers used were 19-24 mer oligonucleotides (Table 8). These were synthesised by 
COGENICS The Sequencing Company (Essex, UK). The sequence of each primer 
pair, the position in the OPRM1 gene, and the size of each of the amplicons amplified 
with PCR are shown in Table 8. 
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Table 8: OPRM1 primer sequence information. 
 
 
Gene and 
Polymorphism 
Amplified 
Region 
Primer sequence Annealing 
temperature 
°C 
Amplicon  
size (bp) 
OPRM1  A1045G Promoter region Forward TAGAAGCACTGGACTTAG 59.5 350 
  Reverse CCTACCCACTGAAACAAAATC   
OPRM1  C995A Promoter region Forward TAGAAGCACTGGACTTAG 59.5 350 
  Reverse CCTACCCACTGAAACAAAATC   
OPRM1 G554A Promoter region Forward  CTGCACAAAAGTTTATTTGTTTCTC 59.5 338 
  Reverse CACTGCTACCAAAGACTAACT   
OPRM1 A118G Exon 1 Forward ATGCCTTGGCGTACTCAAGTTG 65.3 333 
  Reverse CTAACTCCCAAGGCTCAATGTTG   
OPRM1 C17T Exon 1 Forward ATGCCTTGGCGTACTCAAGTTG 65.3 333 
  Reverse CTAACTCCCAAGGCTCAATGTTG   
OPRM1 C440G Exon 2 Forward TCCAGAGTGAATTACCTAATG 63.2 287 
  Reverse CAAGGTGAGTGATGTTACCAG   
OPRM1 A454G Exon 2 Forward TCCAGAGTGAATTACCTAATG 63.2 287 
  Reverse CAAGGTGAGTGATGTTACCAG   
OPRM1 G779A Exon 3 Forward ATTCTCTCATCCAACCTGGTAC 64.7 353 
  Reverse CTCAACCCAGTCCTTTATGCAT   
OPRM1 C793T Exon 3 Forward ATTCTCTCATCCAACCTGGTAC 64.7 353 
  Reverse CTCAACCCAGTCCTTTATGCAT   
OPRM1 G820A Exon 3 Forward ATTCTCTCATCCAACCTGGTAC 64.7 353 
  Reverse CTCAACCCAGTCCTTTATGCAT   
OPRM1 G877A Exon 3 Forward ATTCTCTCATCCAACCTGGTAC 64.7 353 
  Reverse CTCAACCCAGTCCTTTATGCAT   
OPRM1 G942A Exon 3 Forward ATTCTCTCATCCAACCTGGTAC 64.7 353 
    Reverse CTCAACCCAGTCCTTTATGCAT     
 
 
PCRs were performed with a reaction volume of 50 l, including 27 l PCR grade 
water (Sigma), 10 l of 5x GoTaq ™ buffer (Promega, UK), 2 l MgCl2, 5 l of 2.5 
mM deoxynucleoside triphosphates (dNTPs) (Roche, UK) (final concentration of 0.25 
mM), 1 l Forward and Reverse primers, 3 l DNA and 0.3 l GoTaq ™ DNA 
polymerase (Promega, UK). The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
annealing at 60-62C for 30 seconds; primer extension at 72C for 2 minutes, 
repeated for 30 cycles, followed by final extension at 72C for 5 minutes. The PCR 
products were confirmed by electrophoresis with a 2 % Cyber Green-agarose gel on 
blue light.  PCR reactions were performed with a Primus 96 advanced machine 
(Alpha Laboratories, UK).  
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2.1.2.3 PCR Development 
 
2.1.2.3.1 MgCl2 
Different MgCl2 concentrations were tested in an effort to determine the most 
effective concentration required to produce optimal DNA amplification. The primer 
set PRO554_HB was used. The reaction volume was 50 l (Table 9). The cycling 
conditions were as follows: initial denaturation at 95C for 5 minutes; subsequent 
denaturation at 95C for 1 minute; annealing at 62C for 30 seconds; primer extension 
at 72C for 2 minutes, repeated for 30 cycles, followed by final extension at 72 C for 
5 minutes. The PCR products were confirmed by electrophoresis with a 2 % Cyber 
Green-agarose gel on blue light.  PCR reactions were performed with a Primus 96  
advanced machine (Alpha Laboratories). For results see section 3.1.2.1 MgCl2. 
 
Table 9: Reaction components for MgCl2 optimisation. 
 
Reaction 
components 
 1 l 
MgCl2 
1.5 l 
MgCl2 
2 l 
MgCl2 
2.5 l 
MgCl2 
3 l 
MgCl2 
3.5 l 
MgCl2 
4 l 
MgCl2 
H2O 28 l 27.5 l 27 l 26.5 l 26 l 25.5 l 25 l 
5x GoTaq ™ 
Flexi Buffer 
10 l 10 l 10 l 10 l 10 l 10 l 10 l 
MgCl2 1 l 1.5 l 2 l 2.5 l 3 l 3.5 l 4 l 
dNTPs 
(2.5mM) 
5 l 5 l 5 l 5 l 5 l 5 l 5 l 
Forward primer 1 l 1 l 1 l 1 l 1 l 1 l 1 l 
Reverse primer 1 l 1 l 1 l 1 l 1 l 1 l 1 l 
DNA 3 l 3 l 3 l 3 l 3 l 3 l 3 l 
GoTaq ™ 
polymerase 
0.3 l 0.3 l 0.3 l 0.3 l 0.3 l 0.3 l 0.3 l 
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2.1.2.3.2 Temperature 
Temperature gradients 
Temperature gradient reactions were conducted to determine optimal primer 
annealing temperatures. Primer sets PRO995_HB and PRO554_HB were used. The 
reaction volume was 50 l including 27 l PCR grade water, 10 l of 5x GoTaq ™ 
buffer, 2 l MgCl2, 5 l of 2.5 mM dNTPs (final concentration of 0.25 mM), 1 l 
Forward and Reverse primers, 3 l DNA and 0.3 l GoTaq ™ DNA polymerase. The 
cycling conditions were as follows: initial denaturation at 95C for 5 minutes; 
subsequent denaturation at 95C for 1 minute; temperature gradient set at 62C  3C 
for 30 seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, 
followed by final extension at 72C for 5 minutes. The median temperature point was 
set at the calculated annealing temperature of 62C for the primer sets. The PCR 
products were visualised by electrophoresis with a 2 % Cyber Green-agarose gel on 
blue light.  PCR reactions were performed with a Primus 96 advanced machine 
(Alpha Laboratories). For results see section 3.1.2.2 Temperature.  
Temperatures selected from gradient PCR reactions 
Three temperatures were selected from the gradient reaction to test with PRO554_HB 
and PRO995_HB. The reaction volume was maintained at 50 l and included 28.5 l 
PCR grade water, 10 l of 5x GoTaq ™ Flexi Buffer, 5 l of MgCl2, 1 l of 10mM 
dNTPs (final concentration of 0.25mM), 1 l of forward and reverse primers, 3 l 
DNA, and 0.5 l GoTaq ™ DNA polymerase. The cycling conditions were as 
follows: initial denaturation at 95C for 5 minutes; subsequent denaturation at 95C 
for 1 minute; annealing temperature points of 60.1C, 61.2 C, and 62.2C for 30 
seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, followed by 
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final extension at 72C for 5 minutes. The median temperature point was set at the 
calculated annealing temperature of 62C for the primer sets. The PCR products were 
confirmed by electrophoresis with a 2 % Cyber Green-agarose gel on blue light.  PCR 
reactions were performed with a Primus 96 Advanced machine (Alpha Laboratories). 
For results see section 3.1.2.2 Temperature. 
Temperature alterations to increase specificity 
The annealing temperatures for PRO554_HB, PRO995_HB, EX1_HB, and EX2_HH 
were decreased to increase banding specificity and decrease DNA smearing. The 
annealing temperature for EX3_HB was increased from 64.4C to 64.7 C and to 
65.3C. The reaction volume was 50 l and included 29.5 l PCR grade water, 10 l 
of 5x GoTaq ™ Flexi Buffer, 4 l of MgCl2, 1 l of 10mM dNTPs (final 
concentration of 0.25mM), 1 l of forward and reverse primers, 3 l DNA, and 0.5 l 
GoTaq ™ DNA polymerase. The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
temperature gradient set at 62.2C  4C for 30 seconds; primer extension at 72C for 
2 minutes, repeated for 30 cycles, followed by final extension at 72C for 5 minutes. 
The median temperature point was set at the calculated annealing temperature of 62C 
for the primer sets. The PCR products were processed by electrophoresis with a 2 % 
cyber green-agarose gel, and amplification by PCR was confirmed.  PCR reactions 
were performed with a Primus 96 Advanced (Alpha Laboratories) machine. For 
results see section 3.1.2.2 Temperature. 
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2.1.2.4 PCR Validation 
The results for the PCR reactions were validated through DNA sequencing, 
examining the sequencing results obtained against the consensus OPRM1 sequence 
(see appendix). For this target PCR products were purified using the QIAquick PCR 
Purification Kit (Qiagen, UK) according to the manufacturer‟s protocol. The purified 
PCR products were then sent to COGENICS to be sequenced. For results see section 
3.1.2.2.4 SNPs revealed by DNA sequencing results. 
 
2.1.2.5 A118G identification 
Of the OPRM1 regions studied only one yielded a SNP with possible significance for 
methadone susceptibility, the exon 1 A118G SNP. A positive control was required for 
SNP genotyping so using EX1_HB this region was amplified for 20 control subjects. 
PCRs were performed with a reaction volume of 50 l, including 27.5 l PCR grade 
water, 10 l of 5x GoTaq ™ buffer, 6 l MgCl2, 1 l of 10 mM deoxynucleoside 
triphosphates (dNTPs) (final concentration of 0.25 mM), 1 l Forward and Reverse 
primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. The cycling conditions 
were as follows: initial denaturation at 95C for 5 minutes; subsequent denaturation at 
95C for 1 minute; annealing at 65.3C for 30 seconds; primer extension at 72C for 2 
minutes, repeated for 30 cycles, followed by final extension at 72C for 5 minutes. 
The PCR products were visualised by electrophoresis with a 2 % Cyber Green-
agarose gel on blue light. PCR reactions were performed with a Primus 96 advanced 
machine (Alpha Laboratories, UK). The PCR products were purified using the 
QIAquick PCR Purification Kit (Qiagen, UK) and sequencing was conducted by 
COGENICS. For results see section 3.1.2.3 A118G identification and for a discussion 
of the results see chapters 4, 5 and 6. 
 55 
2.1.3 PCR Amplification of SNP regions of CYP2B6 gene 
 
 
CYP2B6 is responsible for methadone metabolism and together with OPRM1 is the 
focus of this study. Amplification of specific gene regions (promoter, exon 4 and exon 
5) through PCR will identify CYP2B6 SNPs. These can then be used as positive 
controls for the real-time SNP genotyping assays conducted on the StepOne™ real-
time machine.  
 
2.1.3.1 Primer design and Rehydration 
Sequences from the promoter and coding regions of the human CYP2B6 gene were 
used to design primers for use in PCR amplification. PCR primers were synthesised 
for two of the nine coding regions of the gene, exons 4 and 5 (see appendix CYP2B6 
Sequence Information). PCR primers were also synthesised for the proximal promoter 
region of the gene (Table 10).The following primers C2B6E4, C2B6E5 and C2B6Pr 
(see Table 11 for primer sequence information) were hydrated in T10 buffer according 
to their molecular weight (Table 10). Primers were left for 20 minutes at room 
temperature to dissolve before being stored at –20C until used. 
 
Table 10: CYP2B6 Primer rehydration volumes. 
 
 
PRIMERS Volume of T10 required for a 
concentration of 100 pmol/L. 
C2B6E4F 172 L 
C2B6E4R 152 L 
C2B6E5F 130 L 
C2B6E5R 180 L 
C2B6PrF 206 L 
C2B6PrR 169 L 
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2.1.3.2  Primer validation 
The CYP2B6 primers target 750 T > C in the proximal promoter region, 516 G > T in 
exon 4 and 785 A > G in exon 5. Each SNP has been implicated with modifications to 
enzyme efficiency, with 516 G > T resulting in a reduction of enzymatic efficiency in 
vivo, 785 A > G increasing enzyme efficiency in vivo and 750 T > C affecting overall 
gene expression. The sequence of each primer pair, the position in the CYP2B6 gene, 
and the size of each of the amplicons amplified with PCR are shown in Table 11. 
 
Table 11: CYP2B6 primer sequence information. 
 
Gene and 
Polymorphism 
Amplified 
Region 
Primer sequence Annealing 
temperature 
°C 
Amplicon  
size (bp) 
 
CYP2B6 T750C 
 
Promoter region 
 
C2B6PrF CAGGTTCAAGTGATTCTCTTG 
 
59.5 
 
229 
  C2B6PrR CATGTTCAAAACTGAGAGGCT   
CYP2B6 G516T Exon 4 C2B6E4F GTACATAATTAGCTGTTACGG 59.5 268 
  C2B6E4R AAGTCTGGTAGAACAAGTTCA   
CYP2B6 A785G Exon 5 C2B6E5F AGGAGATATAGAGTCAGTGAG 62.3 536 
  C2B6E5R AGTTCCTCCTCCCTATTTTCT   
 
 
 
PCRs were performed with a reaction volume of 50 l, including 27.5 l PCR grade 
water (Sigma), 10 l of 5x GoTaq ™ buffer (Promega, UK), 6 l MgCl2, 1l of 10 
mM deoxynucleoside triphosphates (dNTPs) (Roche, UK) (final concentration of 0.25 
mM), 1 l Forward and Reverse primers, 3 l DNA and 0.5 l GoTaq ™ DNA 
polymerase (Promega, UK). The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
annealing at 56-62.5C for 30 seconds; primer extension at 72C for 2 minutes, 
repeated for 30 cycles, followed by final extension at 72C for 5 minutes. The PCR 
products were confirmed by electrophoresis with a 2 % Cyber Green-agarose gel on 
blue light.  PCR reactions were performed with a Primus 96 advanced machine 
(Alpha Laboratories, UK). For results see section 3.1.3.1 Primer Validation. 
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2.1.3.3 T750C PCR Validation 
2.1.3.3.1 Temperature 
Temperature gradient reactions were conducted to determine optimal primer 
annealing temperatures. The reaction volume was 50 l including 27 l PCR grade 
water, 10 l of 5x GoTaq ™ buffer, 6 l MgCl2, 1 l of 10 mM dNTPs (final 
concentration of 0.25 mM), 1 l Forward and Reverse primers, 3 l DNA and 0.5 l 
GoTaq ™ DNA polymerase. The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
temperature gradient set at 62C  3C for 30 seconds; primer extension at 72C for 2 
minutes, repeated for 30 cycles, followed by final extension at 72C for 5 minutes. 
The median temperature point was set at the calculated annealing temperature for the 
primer sets (62C). The PCR products were visualised by electrophoresis with a 2 % 
Cyber Green-agarose gel on blue light.  PCR reactions were performed with a Primus 
96 advanced machine (Alpha Laboratories). For results see section 3.1.3.2.1 
Temperature. 
 
 
2.1.3.3.2 MgCl2 
 
A reduction in MgCl2 concentration was tested in an effort to determine the optimal 
concentration required for efficient DNA amplification. The reaction volume was 50 
l including 29.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 4 l MgCl2, 1 l 
of 10 mM dNTPs (final concentration of 0.25 mM), 1 l Forward and Reverse 
primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. The cycling conditions 
were as follows: initial denaturation at 95C for 5 minutes; subsequent denaturation at 
95C for 1 minute; annealing at 62.1C for 30 seconds; primer extension at 72C for 2 
minutes, repeated for 30 cycles, followed by final extension at 72 C for 5 minutes. 
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The PCR products were confirmed by electrophoresis with a 2 % Cyber Green-
agarose gel on blue light.  PCR reactions were performed with a Primus 96  
advanced machine (Alpha Laboratories). For results see section 3.1.3.2.2 MgCl2. 
 
2.1.3.4 T750C Identification 
Following method optimisation for T750C amplification PCRs were performed to 
identify positive controls for SNP genotyping. The PCR volume was 50 l, including 
29.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 4 l MgCl2, 1 l of 10 mM 
deoxynucleoside triphosphates (dNTPs) (final concentration of 0.25 mM), 1 l 
Forward and Reverse primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. The 
cycling conditions were as follows: initial denaturation at 95C for 5 minutes; 
subsequent denaturation at 95C for 1 minute; annealing at 65.0C for 30 seconds; 
primer extension at 72C for 2 minutes, repeated for 30 cycles, followed by final 
extension at 72C for 5 minutes. The PCR products were visualised by electrophoresis 
with a 2 % Cyber Green-agarose gel on blue light. PCR reactions were performed 
with a Primus 96 advanced machine (Alpha Laboratories, UK). The PCR products 
were purified using the QIAquick PCR Purification Kit (Qiagen, UK) and sequencing 
was conducted by COGENICS. For results see section 3.1.3.3.1 T750C Sequencing 
Results. 
 
 
2.1.3.5 G516T PCR Validation 
 
2.1.3.5.1 Temperature 
Temperature Gradients 
A temperature gradient reaction was conducted to determine optimal C2B6E4 primer 
annealing temperature. The temperatures tested were as follows: 58.0 ºC, 58.8 ºC, 
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59.5 ºC, 60.2 ºC, 61.0 ºC, 61.7 ºC, 62.3 ºC, 63.0 ºC, 63.8 ºC, X ºC, and 65.2 ºC. The 
reaction volume was 50 l including 27.5 l PCR grade water, 10 l of 5x GoTaq ™ 
buffer, 6 l MgCl2, 1 l of 10 mM dNTPs (final concentration of 0.25 mM), 1 l 
Forward and Reverse primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. The 
cycling conditions were as follows: initial denaturation at 95C for 5 minutes; 
subsequent denaturation at 95C for 1 minute; temperature gradient set at 62C  4C 
for 30 seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, 
followed by final extension at 72C for 5 minutes. The PCR products were visualised 
by electrophoresis with a 2 % Cyber Green-agarose gel on blue light.  PCR reactions 
were performed with a Primus 96 advanced machine (Alpha Laboratories). For results 
see section 3.1.3.4.1 Temperature. 
 
Temperatures selected from gradient PCR reactions 
The gradient reaction demonstrated that the lower annealing temperatures yielded the 
most specific DNA bands. From this a further gradient reaction was conducted 
focusing on lower annealing temperatures: 56.0 ºC, 56.8 ºC, 57.5 ºC, 58.2 ºC and 59.0 
ºC. The reaction volume was 50 l including 27.5 l PCR grade water, 10 l of 5x 
GoTaq ™ buffer, 6 l MgCl2, 1 l of 10 mM dNTPs (final concentration of 0.25 mM), 
1 l Forward and Reverse primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. 
The cycling conditions were as follows: initial denaturation at 95C for 5 minutes; 
subsequent denaturation at 95C for 1 minute; temperature gradient set at 60C  4C 
for 30 seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, 
followed by final extension at 72C for 5 minutes. The PCR products were visualised 
by electrophoresis with a 2 % Cyber Green-agarose gel on blue light.  PCR reactions 
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were performed with a Primus 96 advanced machine (Alpha Laboratories). For results 
see section 3.1.3.4.1 Temperature. 
 
2.1.3.5.2 MgCl2 
Different MgCl2 concentrations were tested in an effort to determine the most 
effective concentration required to produce optimal DNA amplification. The reaction 
volume was 50 l (Table 12). The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
annealing at 59.5C for 30 seconds; primer extension at 72C for 2 minutes, repeated 
for 30 cycles, followed by final extension at 72 C for 5 minutes. The PCR products 
were confirmed by electrophoresis with a 2 % Cyber Green-agarose gel on blue light.  
PCR reactions were performed with a Primus 96 advanced machine (Alpha 
Laboratories). For results see section 3.1.3.4.2 MgCl2. 
 
Table 12: Reaction components for MgCl2 optimisation protocol. 
 
 
Reaction 
components 
 4 l 
MgCl2 
5 l 
 MgCl2 
6 l 
MgCl2 
7 l 
 MgCl2 
8 l 
MgCl2 
9 l 
MgCl2 
H2O              29.5 l 28.5 l 27.5 l 26.5 l 25.5 l 24.5 l 
5x GoTaq ™ 
Flexi Buffer 
10 l 10 l 10 l 10 l 10 l 10 l 
MgCl2 4 l 5 l 6 l 7 l 8 l 9 l 
dNTPs (10mM) 1 l 1 l 1 l 1 l 1 l 1 l 
Forward primer 1 l 1 l 1 l 1 l 1 l 1 l 
Reverse primer 1 l 1 l 1 l 1 l 1 l 1 l 
DNA 3 l 3 l 3 l 3 l 3 l 3 l 
GoTaq ™ 
polymerase 
0.5 l 0.5 l 0.5 l 0.5 l 0.5 l 0.5 l 
 
2.1.3.6 G516T Identification 
Following method optimisation for G516T amplification PCRs were performed to 
identify positive controls for SNP genotyping. The PCR volume was 50 l, including 
27.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 7 l MgCl2, 1 l of 10 mM 
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deoxynucleoside triphosphates (dNTPs) (final concentration of 0.25 mM), 1 l 
Forward and Reverse primers, 2 l DNA and 0.5 l GoTaq ™ DNA polymerase. The 
cycling conditions were as follows: initial denaturation at 95C for 5 minutes; 
subsequent denaturation at 95C for 1 minute; annealing at 59.5C for 30 seconds; 
primer extension at 72C for 2 minutes, repeated for 30 cycles, followed by final 
extension at 72C for 5 minutes. The PCR products were visualised by electrophoresis 
with a 2 % Cyber Green-agarose gel on blue light. PCR reactions were performed 
with a Primus 96 advanced machine (Alpha Laboratories, UK). The PCR products 
were purified using the QIAquick PCR Purification Kit (Qiagen, UK) according to the 
manufacturer‟s protocol. The purified PCR products were then sent to COGENICS to 
be sequenced. For results see section 3.1.3.5 G516T Identification. 
 
2.1.3.7 A785G PCR Validation 
2.1.3.7.1 Temperature 
The banding yielded during C2B6E5 primer validation (Section 2.1.3.2 Primer 
validation) was unselective with possible non-specific amplification. To improve this 
result an increase in annealing temperature was conducted. The annealing 
temperatures from the preliminary reaction were: 58.0 ºC, 59.5 ºC and 61.0 ºC. These 
temperatures were increased to 61.5 ºC, 62.1ºC, and 63.2ºC. The reaction volume was 
50 l including 27.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 6 l MgCl2, 1 
l of 10 mM dNTPs (final concentration of 0.25 mM), 1 l Forward and Reverse 
primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. The cycling conditions 
were as follows: initial denaturation at 95C for 5 minutes; subsequent denaturation at 
95C for 1 minute; temperature gradient set at 64.5C  3C for 30 seconds; primer 
extension at 72C for 4 minutes, repeated for 30 cycles, followed by final extension at 
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72C for 5 minutes. The PCR products were visualised by electrophoresis with a 2 % 
Cyber Green-agarose gel on blue light.  PCR reactions were performed with a Primus 
96 advanced machine (Alpha Laboratories). For results see section 3.1.3.6.1 
Temperature. 
 
2.1.3.8 A785G Identification 
Following method optimisation for A785G amplification PCRs were performed to 
identify positive controls for SNP genotyping. The PCR volume was 50 l, including 
27.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 6 l MgCl2, 1 l of 10 mM 
deoxynucleoside triphosphates (dNTPs) (final concentration of 0.25 mM), 1 l 
Forward and Reverse primers, 3 l DNA and 0.5 l GoTaq ™ DNA polymerase. The 
cycling conditions were as follows: initial denaturation at 95C for 5 minutes; 
subsequent denaturation at 95C for 1 minute; annealing at 62.1C for 30 seconds; 
primer extension at 72C for 4 minutes, repeated for 30 cycles, followed by final 
extension at 72C for 5 minutes. The PCR products were visualised by electrophoresis 
with a 2 % Cyber Green-agarose gel on blue light. PCR reactions were performed 
with a Primus 96 advanced machine (Alpha Laboratories, UK). The PCR products 
were purified using the QIAquick PCR Purification Kit (Qiagen, UK) according to the 
manufacturer‟s protocol. The purified PCR products were then sent to COGENICS to 
be sequenced. For results see section 3.1.3.7 A785G Identification. 
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2.2 Post-mortem Sample Examination 
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2.2.1 DNA extraction from whole blood 
 
DNA was extracted from whole blood samples for 84 subjects whose deaths were 
associated with methadone (Tayside, Fife and Central regions of Scotland). The 
samples were preserved in fluoride/oxalate. The extraction was performed using the 
DNeasy Blood and Tissue Kit as described above in section 2.1.1.2.2 DNA extraction 
using the Qiagen DNeasy Blood and Tissue kit. 
 
2.2.2 Quantification of DNA from post-mortem blood 
 
The post-mortem DNA samples were quantified using the Quantifiler® Kit (Applied 
Biosystems, UK) on the StepOne™ real-time machine (Applied Biosystems, UK). 
Programmes were titled Dundee Run 1, Dundee Run 2, and Dundee Run 3. Each 
programme used the standard curve quantitation setting for gDNA. The experiment 
run time was standard (2 hours) and the quantifiler® standards run in duplicate. The 
reaction plate was set up as described in section 2.1.1.1.3 Sample preparation. For 
results see section 3.2.1.1 Quantification of DNA from post-mortem blood. 
 
2.2.3 A118G SNP Genotyping 
 
After DNA quantification the samples were genotyped for the OPRM1 A118G 
variation using the validated Taqman™ assay (product no. 4351379, Applied 
Biosystems, UK).  
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2.2.3.1 Software set-up 
A Taqman™ SNP genotyping programme “A118G typing Dundee 1” was created 
using the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “A118G typing Dundee 2” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples:  
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “A118G typing Dundee 3” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples:  
 
DC41, DC41, DC42, DC42, DC43, DC43, DC44, DC44, DC45, DC45, DC46, DC46, 
DC47, DC47, DC48, DC48, DC49, DC49, DC50, DC50, DC51, DC51, DC52, DC52, 
DC53, DC53, DC54, DC54, DC55, DC55. 
 
 
A Taqman™ SNP genotyping programme “A118G typing Dundee 4” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples:  
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DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84. 
 
A Taqman™ SNP genotyping programme “A118G typing Dundee 5” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84. 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
Allele1/ Allele 1 (AA) DC1 
Allele 1/ Allele 2 (AG) DC19 
Allele 2/ Allele 2 (GG) DC15 
 
For all controls and samples a total well volume of 10µl was used.  
 
2.2.3.2 Sample preparation 
 
The Taqman™ mastermix, SNP assay mix, and DNAse free H2O (Table 13) for each 
experimental run (including an extra 10% for excess) was calculated and a mastermix 
created. Then 9µl of the prepared master mix was added into each well of a 48-well 
optical plate. For the negative control wells 10µl of reaction mix was added. Finally 
1µl of the appropriate samples/positive controls were added to each well; following 
the plate layout generated when setting up the StepOne™ quantification experiment. 
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For results see section 3.2.1.2 A118G SNP Genotyping, for a discussion of the results 
see Chapters 4, 5, & 6. 
 
Table 13: Taqman™ SNP Genotyping Reaction Mix Components. 
 
Components Per well (µl) 
Taqman™ mastermix 5µl 
SNP Assay mix (x20) 0.5µl 
H20, DNase-free 3.5µl 
DNA (0.1ng/µl)/Controls 1µl 
Total reaction volume 10µl 
 
 
 
 
2.2.4 T750C SNP Genotyping 
 
 
The post-mortem samples were genotyped for the CYP2B6 T750C variation using a 
validated Taqman™ assay (product no. 4362691, Applied Biosystems, UK).   
 
2.2.4.1. Software set-up 
A Taqman™ SNP genotyping programme “T750C SNP 1” was created using the 
StepOne Advanced Experiment Design programme according to the manufacturer‟s 
instructions for the following samples:  
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “T750C SNP 2” was created using the 
StepOne Advanced Experiment Design programme for the repeat SNP genotyping of: 
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
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DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “T750C SNP 3” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC41, DC41, DC42, DC42, DC43, DC43, DC44, DC44, DC45, DC45, DC46, DC46, 
DC47, DC47, DC48, DC48, DC49, DC49, DC50, DC50, DC51, DC51, DC52, DC52, 
DC53, DC53, DC54, DC54, DC55, DC55 
 
A Taqman™ SNP genotyping programme “T750C SNP 4” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84 
 
A Taqman™ SNP genotyping programme “T750C SNP 5” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (TT) DC2 
Allele 1/ Allele 2 (TC) DC1 
Allele 2/ Allele 2 (CC) DC13 
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For all controls and samples a total well volume of 10µl was used. 
 
2.2.4.2 Sample preparation 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.2.1.3 T750C SNP Genotyping, for a discussion of the results see Chapters 4, 5, & 6. 
 
2.2.5 G516T SNP Genotyping 
 
The post-mortem samples were genotyped for the CYP2B6 G516T variation using a 
validated Taqman™ assay (product no. 4362691, Applied Biosystems, UK).  
 
2.2.5.1 Software set-up 
A Taqman™ SNP genotyping programme “G516T SNP 1” was created using the 
StepOne Advanced Experiment Design programme according to the manufacturer‟s 
instructions for the following samples:  
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
A Taqman™ SNP genotyping programme “G516T SNP 2” was created using the 
StepOne Advanced Experiment Design programme for the repeat SNP genotyping of: 
 
 DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “G516T SNP 3” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
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DC41, DC41, DC42, DC42, DC43, DC43, DC44, DC44, DC45, DC45, DC46, DC46, 
DC47, DC47, DC48, DC48, DC49, DC49, DC50, DC50, DC51, DC51, DC52, DC52, 
DC53, DC53, DC54, DC54, DC55, DC55. 
 
A Taqman™ SNP genotyping programme “G516T SNP 4” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84 
 
A Taqman™ SNP genotyping programme “G516T SNP 5” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (GG) DC13 
Allele 1/ Allele 2 (GT) DC1 
Allele 2/ Allele 2 (TT) DC38 
 
For all controls and samples a total well volume of 10µl was used. 
 
 
 
 
 71 
2.2.5.2 Sample preparation 
 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.2.1.4 G516T SNP Genotyping, for a discussion of the results see Chapters 4, 5, & 6.  
 
2.2.6 A785G SNP Genotyping 
 
The post-mortem samples were genotyped for the CYP2B6 A785G variation using a 
custom-designed Taqman™ assay (product no. 4331349, Applied Biosystems, UK).  
 
2.2.6.1 Software set-up 
A Taqman™ SNP genotyping programme “A785G SNP 1” was created using the 
StepOne Advanced Experiment Design programme according to the manufacturer‟s 
instructions for the following samples:  
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “A785G SNP 2” was created using the 
StepOne Advanced Experiment Design programme for the repeat SNP genotyping of: 
 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10, DC11, DC12, DC13, 
DC14, DC15, DC16, DC17, DC18, DC19, DC20, DC21, DC22, DC23, DC24, DC25, 
DC26, DC27, DC28, DC29, DC30, DC31, DC32, DC33, DC34, DC35, DC36, DC37, 
DC38, DC39, DC40. 
 
 
A Taqman™ SNP genotyping programme “A785G SNP 3” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
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DC41, DC41, DC42, DC42, DC43, DC43, DC44, DC44, DC45, DC45, DC46, DC46, 
DC47, DC47, DC48, DC48, DC49, DC49, DC50, DC50, DC51, DC51, DC52, DC52, 
DC53, DC53, DC54, DC54, DC55, DC55. 
 
A Taqman™ SNP genotyping programme “A785G SNP 4” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84 
 
A Taqman™ SNP genotyping programme “A785G SNP 5” was created using the 
StepOne Advanced Experiment Design programme for the following samples:  
 
DC56, DC57, DC58, DC59, DC60, DC61, DC62, DC63, DC64, DC65, DC66, DC67, 
DC68, DC69, DC70, DC71, DC72, DC73, DC74, DC75, DC76, DC77, DC78, DC79, 
DC80, DC81, DC82, DC83, DC84 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (AA) DC5 
Allele 1/ Allele 2 (AG) DC15 
Allele 2/ Allele 2 (GG) DC38 
 
For all controls and samples a total well volume of 10µl was used.  
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2.2.6.2 Sample preparation 
 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.2.1.5 A785G SNP Genotyping, for a discussion of the results see Chapters 4, 5 & 6.  
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2.3 Control Sample Examination 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 75 
2.3.1 DNA Extraction from buccal swabs 
 
A non-methadone using control population of staff and student volunteers from 
Bournemouth University was sampled. This consisted of 45 men and 55 women. The 
mean age was 24 ± 0.72 (18-55 range). DNA was extracted from 100 buccal samples. 
The extraction was performed using 150 µl of MasterAmp™ buccal extraction fluid 
(Epicentre Biotechnologies, USA) as described in section 2.1.1.1 DNA extraction 
from buccal swabs. 
 
2.3.2 Buccal DNA Quantification 
 
The control samples extracted were quantified using the Quantifiler® Kit (Applied 
Biosystems, UK) on the StepOne™ real-time machine (Applied Biosystems, UK). 
Programmes were titled Control Run 1, Control Run 2, Control Run 3, and Control 
Run 4. Each programme used the standard curve quantitation setting for gDNA. The 
experiment run time was standard (2 hours) and the quantifiler® standards run in 
duplicate. The reaction plate was set up as described in section 2.1.1.1.3 Sample 
preparation. For results see section 3.3.2 Buccal DNA Quantification and for a 
discussion of the results see Chapter 5. 
 
2.3.3 A118G Genotyping 
 
Following DNA quantification the 100 control samples were genotyped for the 
OPRM1 A118G variation using the validated Taqman™ assay (product no. 4351379, 
Applied Biosystems, UK).  
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2.3.3.1 Software set-up 
A Taqman™ SNP genotyping programme “A118G Control SNP 1” was created using 
the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
A Taqman™ SNP genotyping programme “A118G Control SNP 2” was created using 
the StepOne Advanced Experiment Design programme for the repeat SNP genotyping 
of: 
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
 
A Taqman™ SNP genotyping programme “A118G Control SNP 3” was created using 
the StepOne Advanced Experiment Design programme for the following samples:  
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
 
 
A Taqman ™ SNP genotyping programme “A118G Control SNP 4” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples: 
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
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A Taqman ™ SNP genotyping programme “A118G Control SNP 5” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples: 
 
CC88, CC88, CC89, CC89, CC90, CC90, CC91, CC91, CC92, CC92, CC93, CC93, 
CC94, CC94, CC95, CC95, CC96, CC96, CC97, CC97, CC98, CC98, CC99, CC99, 
CC100, CC100 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (AA) DC1 
Allele 1/ Allele 2 (AG) DC19 
Allele 2/ Allele 2 (GG) DC15 
 
For all controls and samples a total well volume of 10µl was used.  
 
2.3.3.2 Sample preparation 
 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.3.3 A118G SNP Genotyping, for a discussion of the results see Chapter 6. 
 
2.3.4 T750C Genotyping 
 
Following DNA quantification the 100 control samples were genotyped for the 
CYP2B6 T750C variation using the validated Taqman™ assay (product no. 4362691, 
Applied Biosystems, UK).  
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2.3.4.1 Software set-up 
A Taqman™ SNP genotyping programme “T750C Control SNP 1” was created using 
the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
 
A Taqman™ SNP genotyping programme “T750C Control SNP 2” was created using 
the StepOne Advanced Experiment Design programme for the repeat SNP genotyping 
of: 
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
 
A Taqman™ SNP genotyping programme “T750C Control SNP 3” was created using 
the StepOne Advanced Experiment Design programme for the following samples:  
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
 
A Taqman ™ SNP genotyping programme “T750C Control SNP 4” was created using 
the StepOne Advanced Experiment Design programme for the following samples: 
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
 
A Taqman ™ SNP genotyping programme “T750C Control SNP 5” was created using 
the StepOne Advanced Experiment Design programme for the following samples: 
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CC88, CC88, CC89, CC89, CC90, CC90, CC91, CC91, CC92, CC92, CC93, CC93, 
CC94, CC94, CC95, CC95, CC96, CC96, CC97, CC97, CC98, CC98, CC99, CC99, 
CC100, CC100 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (TT) DC2 
Allele 1/ Allele 2 (TC) DC1 
Allele 2/ Allele 2 (CC) DC13 
 
For all controls and samples a total well volume of 10µl was used. 
 
2.3.4.2 Sample preparation 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.3.4 T750C SNP Genotyping, for a discussion of the results see Chapter 6. 
 
2.3.5 G516T Genotyping 
 
Following DNA quantification the 100 control samples were genotyped for the 
CYP2B6 G516T variation using the custom designed Taqman™ assay (product no. 
4362691, Applied Biosystems, UK).  
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2.3.5.1 Software set-up 
A Taqman™ SNP genotyping programme “G516T Control SNP 1” was created using 
the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
 
A Taqman™ SNP genotyping programme “G516T Control SNP 2” was created using 
the StepOne Advanced Experiment Design programme for the repeat SNP genotyping 
of: 
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
 
A Taqman™ SNP genotyping programme “G516T Control SNP 3” was created using 
the StepOne Advanced Experiment Design programme for the following samples:  
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
 
A Taqman ™ SNP genotyping programme “G516T Control SNP 4” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples: 
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
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A Taqman ™ SNP genotyping programme “G516T Control SNP 5” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples: 
 
CC88, CC88, CC89, CC89, CC90, CC90, CC91, CC91, CC92, CC92, CC93, CC93, 
CC94, CC94, CC95, CC95, CC96, CC96, CC97, CC97, CC98, CC98, CC99, CC99, 
CC100, CC100 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (GG) DC13 
Allele 1/ Allele 2 (GT) DC1 
Allele 2/ Allele 2 (TT) DC38 
 
For all controls and samples a total well volume of 10µl was used. 
 
 
2.3.5.2 Sample preparation 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.3.5 G516T SNP Genotyping, for a discussion of the results see Chapter 6. 
 
2.3.6 A785G Genotyping 
 
Following DNA quantification the 100 control samples were genotyped for the 
CYP2B6 A785G variation using the validated Taqman™ assay (product no. 4331349, 
Applied Biosystems, UK).  
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2.3.6.1 Software set-up 
A Taqman™ SNP genotyping programme “A785G Control SNP 1” was created using 
the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
 
A Taqman™ SNP genotyping programme “A785G Control SNP 2” was created using 
the StepOne Advanced Experiment Design programme for the repeat SNP genotyping 
of: 
 
CC1, CC2, CC3, CC4, CC5, CC6, CC7, CC8, CC9, CC10, CC11, CC12, CC13, 
CC14, CC15, CC16, CC17, CC18, CC19, CC20, CC21, CC22, CC23, CC24, CC25, 
CC26, CC27, CC28, CC29, CC30, CC31, CC32, CC33, CC34, CC35, CC36, CC37, 
CC38, CC39, CC40, CC41, CC42, CC43. 
 
A Taqman™ SNP genotyping programme “A785G Control SNP 3” was created using 
the StepOne Advanced Experiment Design programme for the following samples:  
 
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
 
A Taqman ™ SNP genotyping programme “A758G Control SNP 4” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples: 
 
CC44, CC45, CC46, CC47, CC48, CC49, CC50, CC51, CC52, CC53, CC54, CC55, 
CC56, CC57, CC58, CC59, CC60, CC61, CC62, CC63, CC64, CC65, CC66, CC67, 
CC68, CC69, CC70, CC71, CC72, CC73, CC74, CC75, CC76, CC77, CC78, CC79, 
CC80, CC81, CC82, CC83, CC84, CC85, CC86, CC87. 
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A Taqman ™ SNP genotyping programme “A758G Control SNP 5” was created 
using the StepOne Advanced Experiment Design programme for the following 
samples: 
 
CC88, CC88, CC89, CC89, CC90, CC90, CC91, CC91, CC92, CC92, CC93, CC93, 
CC94, CC94, CC95, CC95, CC96, CC96, CC97, CC97, CC98, CC98, CC99, CC99, 
CC100, CC100 
 
 
The standard run time (2 hours) was selected for all of the experimental runs, with 50 
cycles of 92 ºC for 30 seconds and 65º for 1.30 minutes. Two negative controls and 
three positive controls were run for all experiments. Positive controls were allocated 
accordingly: 
 
Allele1/ Allele 1 (AA) DC5 
Allele 1/ Allele 2 (AG) DC15 
Allele 2/ Allele 2 (GG) DC38 
 
For all controls and samples a total well volume of 10µl was used. 
 
2.3.6.2 Sample preparation 
 
Sample preparation was as described above (section 2.2.3.2). For results see section 
3.3.6 A785G SNP Genotyping, for a discussion of the results see Chapter 6. 
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2.4 CYP2B6 cloning 
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2.4.1 Primary Cloning strategy 
The sequence information for the CYP2B6 promoter regions was analysed, identifying 
the stages of cloning using Redasoft software. The cloning strategies are highlighted 
in Figure 4.  
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Figure 4: Molecular cloning strategy for CYP2B6 promoter region. 
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2.4.2 Plasmid DNA preparation 
E. coli strains harbouring the hSVC2 and EGFP plasmids were cultured on LB 
ampicillin agar plates overnight at 37º C. Plasmid DNA was extracted using the 
Quicklyse Miniprep kit (Qiagen, UK) according to the manufacturer‟s protocol. 
 
2.4.3 HindIII & XbaI digest 
Restriction digests for the hSVCT2 and EFGP plasmid DNA were conducted using 
the HindIII, BamHI, and XbaI restriction enzymes. The digests were conducted with a 
total volume of 50l, including 37.5l PCR grade water, 5l buffer 2 (x10) (New 
England Biolabs), 5l DNA, 1l BSA (New England Biolabs), 0.5l HindIII, 0.5l 
BamHI and 0.5l XbaI (New England Biolabs). The samples were left to incubate for 
3 hours at 37º C before the reaction was terminated with 10l 6x blue dye (New 
England Biolabs). The results were confirmed by gel electrophoresis (1.6 % Agarose 
& Cyber Green gel) and visualised using blue light (Figure 50). Uncut DNA (1l) 
with 4l TE buffer and 6 x blue dye was used as a control. For results see section 
3.4.1.1 Examination of the plasmid by HindIII & XbaI Digest. 
 
 2.4.4 Gel Extraction of EGFP Gene 
 
The EGFP inserts were cut from the gel and extracted using the QIAquick gel 
extraction kit (Qiagen, UK) in accordance with the manufacturer‟s instructions. The 
extraction was confirmed by gel electrophoresis (2 % Agarose & Cyber Green gel) 
and visualised under blue light (Figures 51, 52). 
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2.4.5 Gel Extraction of hSVCT2 Gene 
 
The hSVCT2 inserts were cut from the gel and extracted using the QIAquick gel 
extraction kit (Qiagen, UK) in accordance with the manufacturer‟s instructions. The 
extraction was confirmed by gel electrophoresis (2 % Agarose & Cyber Green gel) 
and visualised under blue light (Figures 53, 54). 
 
 
2.4.6 DNA ligation of EGFP into hSVCT2 vector 
 
A 1:1 ratio between the hSVCT2 vector and the EGFP insert was determined, equal to 
1µl of hSVCT2: 8µl of EGFP. A series of different vector: insert ratios was tested 
(Table 14) to determine the optimal ligation ratio for transformation. Reactions A 
(0/1) and G (1/0) acted as negative controls to test enzymatic efficiency. Additionally, 
a single cut vector was used in the reaction both with DNA ligase (DDL) and without 
DNA ligase (DDM) to test reaction efficiency. Finally a positive control (LDH) for 
the ligation was conducted using a Lamda-HindIII control sample (New England 
Biolabs, UK). 
 
Table 14: Reaction components for the DNA ligation of EGFP into the hSVCT2 vector. 
  
    
Reaction 
components 
A 
0/1 
B    
1/3 
C  
1/2 
D 
1/1 
E 
2/1 
F  
3/1 
G   
1/0 
DDL DDM LHD 
Water   (µl) 8.5 1.5 0 7.5 6.5 5.5 15.5 15.5 16 14.5 
Vector  (µl) 0 1 1 1 2 3 1 1 1 2 
Insert    (µl) 8 24 16 8 8 8 0 0 0 0 
Buffer   (µl) 3 3 3 3 3 3 3 3 3 3 
T4 DNA 
ligase    (µl) 
0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0 0.5 
           
Final     (µl) 
Volume  
20 30 20.5 20 20 20 20 20 20 20 
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The reactions were set up according to the manufacturer‟s instructions (Table 14) and 
left to incubate at room temperature for 30 minutes. The ligation was confirmed by 
gel electrophoresis (2 % Agarose & Cyber Green gel) of LDH and visualisation under 
blue light (Figure 55). 
 
 
2.4.7 Transformation of EGFP clone into JM109 cells 
 
The ligated hSVCT2-EGFP vector was transformed into JM109 competent cells 
(Promega, UK) according to the manufacturer‟s instructions. Briefly, on ice, 5µl of 
ligated product was added to 100µl of competent cells and incubated for ten minutes. 
The reactions were heated at 42 ºC for 45 seconds before being returned to ice for two 
minutes. After this 900µl of SOC media was added and the reactions were incubated 
at 37 ºC for 6 minutes before being streaked onto LB-ampicillin plates. The plates 
were incubated at 37 ºC for 15 hours. The resulting colonies were verified by 
conducting NdeI restriction digests (Figures 56, 57, 58, 59). 
 
2.4.8 PCR amplification of CYP2B6 promoter region  
2.4.8.1 Primer design and Rehydration 
CYP2B6 promoter sequence information was used to design three sets of primers for 
the amplification of the gene promoter region for the cloning experiment (Table 15). 
The following primers C2B6F1 BglII, C2B6F2, CSB6F3, C2B6R1 HindIII, C2B6R2, 
and C2B6R3 were hydrated with appropriate amounts of T10 buffer according to their 
molecular weight (Table 16). Primers were left for 20 minutes at room temperature to 
dissolve before being stored at –20C until used. 
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Table 15: CYP2B6 promoter primer sequences. 
 
Primer CYP2B6 
Amplified 
Region 
Primer sequence  Annealing 
temperature 
°C 
C2B6F1 BglII * Promoter region ataAGATCTTTCTGGTTTTACGGCTCAG 62.2 
C2B6F2 Promoter region GTTACTGTGTGTAAAGCACTT             54.0  
C2B6F3 Promoter region GCTATGCTACAAAGGCAGT 54.5 
C2B6R1 HindIII ** Promoter region attAAGCTTCATCATCCAGGAGCATTAGCTT 61.9 
C2B6R2 Promoter region ACTGCCTTTGTAGCATAGC 54.4 
C2B6R3 Promoter region AAGTGCTTTACACACAGTAAC 54.0 
* F denotes forward primer ** R denotes reverse primer 
 
 
 
Table 16: CYP2B6 promoter primer rehydration volumes. 
 
 
PRIMERS Volume of T10 required for a 
concentration of 100 pmol/l. 
C2B6F1 BglII * 232l 
C2B6F2 173l 
C2B6F3 175l 
C2B6R1 HindIII ** 187l 
C2B6R2 273l 
C2B6R3 248l 
* F denotes forward primer ** R denotes reverse primer 
 
 
 
2.4.8.2 Primer validation 
The proximal promoter region including –750 T > C was amplified by PCR. The 
primers used were 19-24 mer oligonucleotides (Table 15). These were synthesised by 
COGENICS (UK). The sequence of each primer pair, the position in the CYP2B6 
gene, and the calculated annealing temperatures are shown in Table 15. PCRs were 
performed with a reaction volume of 50 l, including 27.5 l PCR grade water 
(Sigma), 10 l of 5x GoTaq ™ buffer (Promega, UK), 6 l MgCl2, 1 l of 10 mM 
deoxynucleoside triphosphates (dNTPs) (Roche, UK) (final concentration of 0.25 
mM), 1 l Forward and Reverse primers, 3 l DNA and 0.5 l GoTaq ™ DNA 
polymerase (Promega, UK). The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
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annealing at 60-62C for 30 seconds; primer extension at 72C for 2 minutes, 
repeated for 30 cycles, followed by final extension at 72C for 5 minutes. The PCR 
products were confirmed by electrophoresis with a 2 % Cyber Green-agarose gel on 
blue light (Figure 60).  PCR reactions were performed with a Primus 96 advanced 
machine. 
 
2.4.8.3 PCR temperature development 
 
 
In order to determine the optimal annealing temperature for C2B6F1 BglI and 
C2B6R1 HindIII a gradient PCR was conducted. Additionally to reduce smearing the 
MgCl2 concentration was reduced. PCRs were performed with a reaction volume of 
50 l, including 28.5 l PCR grade water (Sigma), 10 l of 5x GoTaq ™ buffer 
(Promega, UK), 5 l MgCl2, 1 l of 10 mM deoxynucleoside triphosphates (dNTPs) 
(Roche, UK) (final concentration of 0.25 mM), 1 l Forward and Reverse primers, 3 
l DNA and 0.5 l GoTaq ™ DNA polymerase (Promega, UK). The cycling 
conditions were as follows: initial denaturation at 95C for 5 minutes; subsequent 
denaturation at 95C for 1 minute; gradient reaction for annealing 58.0-65.2ºC for 30 
seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, followed by 
final extension at 72C for 5 minutes. The PCR products were confirmed by 
electrophoresis with a 2 % Cyber Green-agarose gel on blue light (Figure 61).  PCR 
reactions were performed with a Primus 96 advanced machine (Alpha Laboratories, 
UK).  
 
2.4.8.4 Amplification of CYP2B6 promoter region. 
 
The CYP2B6 promoter regions for T750C heterozygous, homozygous wild type and 
homozygous variant subjects were amplified using the 60.2 º C annealing temperature 
parameter from the gradient reaction. PCRs were performed with a reaction volume of 
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50 l, including 28.5 l PCR grade water (Sigma), 10 l of 5x GoTaq ™ buffer 
(Promega, UK), 5 l MgCl2, 1 l of 10 mM deoxynucleoside triphosphates (dNTPs) 
(Roche, UK) (final concentration of 0.25 mM), 1 l Forward and Reverse primers, 3 
l DNA and 0.5 l GoTaq ™ DNA polymerase (Promega, UK). The cycling 
conditions were as follows: initial denaturation at 95C for 5 minutes; subsequent 
denaturation at 95C for 1 minute; gradient reaction for annealing 60.2 ºC for 30 
seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, followed by 
final extension at 72C for 5 minutes. The PCR products were confirmed by 
electrophoresis with a 2 % Cyber Green-agarose gel on blue light (Figure 62).  PCR 
reactions were performed with a Primus 96 advanced machine. 
 
2.4.8.5 Gel Extraction of CYP2B6 promoter region 
 
The CYP2B6 wild type, heterozygous and homozygous variant amplified promoters 
were cut from the gel and extracted using the QIAquick gel extraction kit (Qiagen, 
UK) in accordance with the manufacturer‟s instructions. After this a dATP extension 
was conducted to ensure (a) overhangs for ligation into the vector. For this 5 µl of 
Flexi Buffer (10 x), 1 µl of dATP and 0.5 µl of GoTaq™ was added to the gel 
extracted CYP2B6 promoters. This was followed by a 15 minute incubation at 72 ºC. 
The extraction was confirmed by gel electrophoresis (2 % Agarose & Cyber Green 
gel) and visualised under blue light. 
 
2.4.9 Alternative Cloning strategy 
The cloning strategy for inserting the CYP2B6 promoter regions into the 
pcDNA3.1/CT-GFP-TOPO® vector (Invitrogen) was conducted, using Redasoft 
software. The cloning strategies are highlighted in Figure 5.  
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Figure 5: Molecular Cloning Strategy for p2B6-GFP-HB. 
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2.4.10 CYP2B6 promoter insertion into pcDNA3.1/CT-GFP-TOPO® vector 
 
2.4.10.1 DNA ligation of CYP2B6 into pcDNA3.1/CT-GFP-TOPO® vector 
 
 
The CYP2B6 promoter regions were ligated into the pcDNA3.1/CT-GFP-TOPO® 
(Invitrogen, UK) vector according to the manufacturers instructions (Table 17).  
 
Table 17: Reaction components for the DNA ligation of CYP2B6 into the pcDNA3.1/CT-
GFP-TOPO® vector. 
 
CYP2B6 Reaction Control Reaction 
Reagent Volume  Reagent Volume  
Fresh PCR product  4 µl Control PCR product  1 µl 
Salt Solution 1µl Salt Solution 1µl 
Sterile Water 1µl Sterile Water 3µl 
TOPO Vector 1µl TOPO Vector 1µl 
Total Volume 7µl Total Volume 6µl 
 
 
In order to test ligation efficiency a control PCR reaction was also conducted. The 
samples were incubated at room temperature for 30 minutes. 
 
2.4.10.2 Transformation of p2B6-GFP-HB clones into OneShot® TOP10 E. coli  
The homozygous wild type, heterozygous and homozygous variant p2B6-GFP-HB 
clones were transformed into OneShot® TOP10 chemically competent E. coli 
following the manufacturer‟s protocol. Briefly 2 µl of each TOPO® Cloning reaction 
(including the control reaction) was added into a vial of OneShot® TOP10 chemically 
competent E. coli and mixed gently. The vials were then incubated on ice for five 
minutes. The cells were then heat-shocked at 42 ºC, before being immediately 
transferred back to ice. After this 250 µl of room temperature SOC medium was 
added and the vials were capped tightly and shook (horizontally) at 200 rpm at 37 ºC 
for 1 hour. Then 125 µl from each transformation was spread onto a prewarmed LB 
ampicillin plate. Two plates for each transformation were prepared these were then 
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incubated for 16 hours at 37 ºC. The resulting colonies were verified by conducting a 
BglII & HindIII double restriction digest and a BglII single digest to check CYP2B6 
orientation (Figures 63, 64, 65). 
 
2.4.10.3 p2B6-GFP-HB Clone Sequencing 
Each p2B6-GFP-HB clone was sent off for sequencing to COGENICS to confirm the 
successful transformation of the CYP2B6 promoter region into the TOPO® TA vector. 
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2.5 A118G Methadone Binding Study 
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2.5.1 B-Cell line DNA extraction 
 
 
A total of 44 chronic lymphoid leukaemia (CLL) primary B-cell lines were extracted 
using the DNeasy Blood Extraction Kit as per the manufacturer‟s instructions (Table 
18) to identify 118 AG/GG subjects.  
 
 
Table 18: Qiagen DNeasy Extraction Components and Volumes. 
 
 
Sample 
size 
Proteinase 
K 
PBS 
(7.2 pH) 
Buffer 
AL 
Ethanol 
(100%) 
Buffer 
AW1 
Buffer 
AW2 
Buffer 
AE 
100 µl 20 µl 200 µl 200 µl 200 µl 500 µl 500 µl 200 µl 
 
 
2.5.2 Quantification of DNA from post-mortem blood 
 
The B-cell CLL DNA samples were quantified using the Nanodrop (Thermo 
Scientific, Wilmington, USA). For results Section 3.5.1 B-cell line DNA 
Quantification. 
 
2.5.3 A118G SNP Genotyping 
 
After DNA quantification the samples were genotyped for the OPRM1 A118G 
variation using the validated Taqman™ assay (product no. 4351379, Applied 
Biosystems, UK).  
 
2.5.3.1 Software set-up 
A Taqman™ SNP genotyping programme “CLL A118G typing 1” was created using 
the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
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CL1, CL1, CL2, CL2, CL3, CL3, CL4, CL4, CL5, CL5, CL6, CL6, CL7, CL7, CL8, 
CL8, CL9, CL9, CL10, CL10, CL11, CL11, CL12, CL12, CL13, CL13, CL14, CL14, 
CL15, CL15, CL16, CL16, CL17, CL17, CL18, CL18, CL19, CL19, CL20, CL20, 
CL21, CL21, CL22, CL22. 
 
The standard run time (2 hours) was selected, with 50 cycles of 92 ºC for 30 seconds 
and 65º for 1.30 minutes. Two negative controls and two positive controls were run 
for all experiments. Positive controls were allocated accordingly: 
 
Allele1/ Allele 1 (AA) CC1 
Allele 1/ Allele 2 (AG) CC3 
 
For all controls and samples a total well volume of 10µl was used.  
 
A Taqman™ SNP genotyping programme “CLL A118G typing 2” was created using 
the StepOne Advanced Experiment Design programme according to the 
manufacturer‟s instructions for the following samples:  
 
CL23, CL23, CL24, CL24, CL25, CL25, CL26, CL26, CL27, CL27, CL28, CL28, 
CL29, CL29, CL30, CL30, CL31, CL31, CL32, CL32, CL33, CL33, CL34, CL34, 
CL35, CL35, CL36, CL36, CL37, CL37, CL38, CL38, CL39, CL39, CL40, CL40, 
CL41, CL41, CL42, CL42, CL43, CL43, CL44, CL44. 
 
The standard run time (2 hours) was selected, with 50 cycles of 92 ºC for 30 seconds 
and 65º for 1.30 minutes. Two negative controls and two positive controls were run 
for all experiments. Positive controls were allocated accordingly: 
 
Allele1/ Allele 1 (AA) CC1 
Allele 1/ Allele 2 (AG) CC3 
 
For all controls and samples a total well volume of 10µl was used.  
 99 
2.5.3.2 Sample preparation 
 
The Taqman™ mastermix, SNP assay mix, and DNAse free H2O (Table 13) for each 
experimental run (including an extra 10% for excess) was calculated and a mastermix 
created. Then 9µl of the prepared master mix was added into each well of a 48-well 
optical plate. For the negative control wells 10µl of reaction mix was added. Finally 
1µl of the appropriate samples/positive controls were added to each well; following 
the plate layout generated when setting up the StepOne™ quantification experiment. 
For results see Section 3.5.2 A118G SNP Genotyping, for a discussion of the results 
see Chapter 8. 
 
 
2.5.4 Receptor Internalisation 
 
2.5.4.1 Primary anti-µ and secondary anti-rabbit IgGFITC Optimisation 
 
 
Using a whole blood sample from a CLL subject (stored at room temperature for 4  
days) an assay was conducted to determine the optimal primary and secondary 
antibody concentrations for µ receptor binding. The rabbit monoclonal [EP1470Y] to 
µ opioid receptor (Abcam, Cambridge, UK) acted as the primary antibody and the 
goat polyclonal to rabbit IgG – H&L (Fluorescein isothiocyanate, FITC) (Abcam, 
UK) acted as the secondary antibody. For both the primary and secondary antibodies 
1:10, 1:20, and 1:50 concentrations were tested according to the strategy outlined in 
Table 19. A positive control using the kappa and lambda antibodies with the 
secondary rabbit IgG was performed. 
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Table 19: Reaction strategy 1 to determine optimal antibody concentration.  
Tube Reaction Primary antibody Secondary antibody 
1 Negative Control 1:10 anti-µ (2µl)  
2 Negative Control  1:10 anti-rabbit IgG (2µl) 
3 Positive Control anti Kappa(2µl) anti-Lambda (2µl) 1:10 anti-rabbit IgG (2µl) 
4 Test Reaction 1:10 anti-µ (2µl) 1:10 anti-rabbit IgG (2µl) 
5 Test Reaction 1:10 anti-µ (2µl) 1:20 anti-rabbit IgG (2µl) 
6 Test Reaction 1:10 anti-µ (2µl) 1:50 anti-rabbit IgG (2µl) 
7 Test Reaction 1:20 anti-µ (2µl) 1:10 anti-rabbit IgG (2µl) 
8 Test Reaction 1:20 anti-µ (2µl) 1:20 anti-rabbit IgG (2µl) 
9 Test Reaction 1:20 anti-µ (2µl) 1:50 anti-rabbit IgG (2µl) 
10 Test Reaction 1:50 anti-µ (2µl) 1:10 anti-rabbit IgG (2µl) 
11 Test Reaction 1:50 anti-µ (2µl) 1:20 anti-rabbit IgG (2µl) 
12 Test Reaction 1:50 anti-µ (2µl) 1:50 anti-rabbit IgG (2µl) 
 
A blood cell count was conducted on the whole blood sample with a white blood cell 
(WBC) cell count of 40 x 10
6
 cells/ml. For the assay a million cells per reaction was 
required = 25 µl of whole blood per reaction, which was transferred into 12 labelled 
flow tubes. Next 75µl of FACSFlow (BD Biosciences, UK) solution was added to the 
blood. Using the strategy outlined in Table 19 2 µl of the relevant primary antibody 
concentration was added to the reactions and incubated at 4ºC for 30 minutes. 
Following this the samples were washed with FACSFlow centrifuged at 13,000 rpm 
for 5 minutes. The supernatant was discarded leaving a pellet and approximately 100 
µl of solution in the flow tubes. Next 2 µl of the secondary antibody was added and 
the reactions incubated at 4ºC for 30 minutes. After incubation 1 ml of FACSLyse 
(BD Biosciences, UK) was added to the reactions and vortexed to lyse the red blood 
cells. The reactions were incubated at room temperature for 5 minutes before 
centrifugation at 13,000 rpm for 5 minutes. The supernatant was discarded and the 
pellet re-suspended in 100µl of FACSFlow. Each reaction was tested with a flow 
cytometer which was set to record 10,000 events at 700 volts. The data was analysed 
by examining forward scatter, side scatter and anti-µ + anti-rabbit IgGFITC. 
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Following gating of the lymphocyte cell population histograms were generated and 
the geometric means for each reaction were deduced. 
 
2.5.4.2 Blockage of Fc receptors to improve Antibody-Receptor Binding 
 
Using a whole blood sample from a CLL subject (collected that day) an assay was 
conducted to test the effects of human AB (HAB) serum on blocking Fc receptors 
(thought to be influencing the high baseline for the secondary antibody). A positive 
control using the kappa and lambda antibodies with the secondary rabbit IgG was 
performed. The reaction strategy used was as outlined above in Table 19. The white 
blood cell (WBC) cell count was 20 x 10
6
 cells/ml. For the assay 100 µl of HAB 
serum was added to 100 µl of whole blood and incubated at room temperature for 5 
minutes to block the interfering Fc receptors. After this the experiment was performed 
as discussed earlier. Each reaction was tested with a flow cytometer which was set to 
record 10,000 events at 700 volts. The data was analysed by examining forward 
scatter, side scatter and anti-µ + anti-rabbit IgGFITC. Following gating of the 
lymphocyte cell population histograms were generated and the geometric means for 
each reaction were deduced. 
 
2.5.4.3 Primary anti-µ and secondary anti-rabbit IgGPE Optimisation 
 
Using a whole blood sample from a CLL subject (stored at 4ºC for 2 days) an assay 
was conducted to test a new monoclonal secondary antibody. The rabbit monoclonal 
[EP1470Y] to µ opioid receptor (Abcam, Cambridge, UK) acted as the primary 
antibody and the mouse monoclonal to rabbit IgG – R-Phycoerythrin (PE) (Acris 
Antibodies, Herford, Germany) acted as the secondary antibody. 
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 A positive control using the kappa and lambda antibodies with the secondary rabbit 
IgG was performed. Additionally the polyclonal rabbit IgG-FITC (Abcam, UK) 
antibody was tested as a control for binding to the primary antibody (Table 20). 
 
Table 20: Reaction strategy 2 to determine optimal antibody concentration.  
 
Tube Reaction Primary 
antibody 
Secondary  
antibody - PE 
Secondary  
antibody - FITC 
1 Negative Control 1:20 anti-µ    
2 Negative Control  1:10 anti-rabbit IgG   
3 Test Reaction 1:10 anti-µ  1:10 anti-rabbit IgG   
4 Test Reaction 1:10 anti-µ  1:20 anti-rabbit IgG   
5 Test Reaction 1:10 anti-µ  1:50 anti-rabbit IgG   
6 Test Reaction 1:20 anti-µ  1:10 anti-rabbit IgG   
7 Test Reaction 1:20 anti-µ  1:20 anti-rabbit IgG   
8 Test Reaction 1:20 anti-µ  1:50 anti-rabbit IgG   
9 Test Reaction 1:50 anti-µ  1:10 anti-rabbit IgG   
10 Test Reaction 1:50 anti-µ  1:20 anti-rabbit IgG   
11 Test Reaction 1:50 anti-µ  1:50 anti-rabbit IgG   
12 Test Reaction   1.10 anti-rabbit IgG  
13 Test Reaction 1:20 anti-µ   1.10 anti-rabbit IgG  
14 Positive Control anti Kappa  
anti-Lambda  
1:10 anti-rabbit IgG   
 
 
The white blood cell (WBC) cell count was 20 x 10
6
 cells/ml. Using the strategy 
outlined in Table 20 the experiment was conducted as previously described. Each 
reaction was tested with a flow cytometer which was set to record 10,000 events at 
700 volts. The data was analysed by examining forward scatter, side scatter and anti-µ 
+ anti-rabbit IgG PE and anti-mu + anti-rabbit FITC. Following gating of the 
lymphocyte cell population histograms were generated and the geometric means for 
each reaction were deduced. 
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2.5.4.4 Primary anti-µ and secondary anti-rabbit IgGFITC Optimisation 
 
Using a whole blood sample from a CLL subject (stored at 4ºC for 2 days) an assay 
was conducted to determine the optimal primary and secondary antibody 
concentrations for the rabbit polyclonal to µ opioid receptor (ab10275, Abcam, 
Cambridge, UK) and the goat polyclonal to rabbit IgG – H&L (Fluorescein 
isothiocyanate, FITC) (Abcam, UK), and mouse monoclonal to rabbit IgG – R-
Phycoerythrin (PE) (Acris Antibodies, Herford, Germany) secondary antibodies. For 
both the primary and secondary antibodies 1:10, 1:100, and 1:1000 concentrations 
were tested according to the strategy outlined in Table 21. A positive control using the 
kappa and lambda antibodies with the secondary rabbit IgG was performed. 
 
Table 21: Reaction strategy 3 to determine optimal antibody concentration.  
Tube Reaction Primary 
antibody 
Secondary  
antibody - PE 
Secondary  
antibody - FITC 
1 Negative Control 1:10 anti-µ    
2 Negative Control   1:10 anti-rabbit IgG  
3 Negative Control  1:10 anti-rabbit IgG   
4 Test Reaction 1:10 anti-µ   1:10 anti-rabbit IgG  
5 Test Reaction 1:10 anti-µ   1:100 anti-rabbit IgG  
6 Test Reaction 1:10 anti-µ   1:1000 anti-rabbit IgG  
7 Test Reaction 1:100 antiµ   1:10 anti-rabbit IgG  
8 Test Reaction 1:100 anti-µ   1:100 anti-rabbit IgG  
9 Test Reaction 1:100 anti-µ   1:1000 anti-rabbit IgG  
10 Test Reaction 1:1000 anti-µ   1:10 anti-rabbit IgG  
11 Test Reaction 1:1000 anti-µ   1:100 anti-rabbit IgG  
12 Test Reaction 1:1000 anti-µ   1:1000 anti-rabbit IgG  
13 Test Reaction 1:10 anti-µ 1:10 anti-rabbit IgG   
14 Test Reaction 1:10 anti-µ  1:100 anti-rabbit IgG   
15 Test Reaction 1:10 anti-µ  1:1000 anti-rabbit IgG   
16 Test Reaction 1:100 anti-µ  1:10 anti-rabbit IgG   
17 Test Reaction 1:100 anti-µ  1:100 anti-rabbit IgG   
18 Test Reaction 1:100 anti-µ  1:1000 anti-rabbit IgG   
19 Test Reaction 1:1000 anti-µ  1:10 anti-rabbit IgG   
20 Test Reaction 1:1000 anti-µ  1:100 anti-rabbit IgG   
21 Test Reaction 1:1000 anti-µ  1:1000 anti-rabbit IgG   
22 Positive Control anti Kappa  
anti-Lambda  
1:10 anti-rabbit IgG   
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The white blood cell (WBC) cell count was 20 x 10
6
 cells/ml. Using the strategy 
outlined in Table 21 the experiment was conducted as previously described. Each 
reaction was tested with a flow cytometer which was set to record 10,000 events at 
700 volts. The data was analysed by examining forward scatter, side scatter and anti-µ 
+ anti-rabbit IgG PE and anti-µ + anti-rabbit FITC. Following gating of the 
lymphocyte cell population histograms were generated and the geometric means for 
each reaction were deduced. 
 
2.5.5 Racemic Methadone Binding Study 
 
 
2.5.5.1 The effects of cell culture incubation interval on cell apoptosis 
 
A total of 4 CLL primary B-cell lines were selected for cell culture to determine the 
effects of cell culture incubation interval on cellular apoptosis. The cells were rapidly 
thawed in a water bath at 37ºC before being resuspended in 10 ml of culture media. 
The samples were then centrifuged at 1,500 rpm for 5 minutes, the supernatant was 
discarded and the pelleted cells were resuspended in 3 ml of fresh culture media. Into 
a 4 x 6 culture plate, 500 µl of each cell sample was transferred into a total of 6 wells. 
Following this 500 µl of culture media was added and the samples were incubated at 
37ºC for 30 minutes, 1 hour, 1.3 hours, 2 hours and 2.3 hours. 
 
 
2.5.5.2 Cell apoptosis Trial 
 
To determine the effects of freezing and rapid thawing on cell survival the Annexin 
V-FITC Apoptosis Detection Kit (Sigma, Dorset, UK) was used. Following each 
incubation interval the cells were transferred into flow tubes and washed in phosphate 
buffered saline (PBS) solution by centrifuging at 13,000 rpm for 5 minutes. The 
supernatant was discarded and the cells were resuspended in 100 µl of PBS. To this 1 
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µl of Annexin V-FITC conjugate and 2 µl of propidium iodide was added and the 
samples were incubated at room temperature for 10 minutes, in the dark. Each 
reaction was tested with a flow cytometer which was set to record 10,000 events at 
700 volts. The data was analysed by examining forward scatter, side scatter, Annexin 
V-FITC, and propidium Iodide. Following gating of the lymphocyte cell population 
histograms were generated and the geometric means for each reaction were deduced. 
For Annexin V the cell sample was divided into Annexin positive and Annexin 
negative cells. For propidium iodide the cell sample was divided into live cells 
(propidium iodide negative), permeabilised cells and fragemented cells. 
 
 
2.5.5.3 Cell Culture of B-lymphocytes in methadone 
 
A total of 12 CLL primary B-cell lines were selected for cell culture including six 
homozygous for the A allele (CLL44, CLL43, CLL39, CLL38, CLL37, CLL34 ), 5 
heterozygous for the G allele and 1 homozygous for the G allele (CLL42, CLL41, 
CLL40, CLL36, CLL19, CLL18). The cells were rapidly thawed in a water bath at 37 
ºC before being resuspended in 10 ml of culture media. The samples were then 
centrifuged at 1,500 rpm for 5 minutes, the supernatant discarded and the pelleted 
cells were resuspended in 3 ml of fresh culture media. Into a 4 x 6 culture plate, 500 
µl of each cell sample was transferred into a total of 6 wells. Following the strategy 
outlined in Table 22 methadone spiked culture media (stock concentration of 200 µM) 
and unspiked culture media was added to each of the wells to ensure 6 treatments 
(Control, 100 µM, 20 µM, 10 µM, 5 µM, 1 µM methadone). The samples were then 
incubated at 37ºC for 1 hour. 
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Table 22: Reaction strategy for sample cell culture in methadone. 
 
 Control 
(µl) 
100 µM 
(µl) 
20 µM 
(µl) 
10 µM 
(µl) 
5 µM 
(µl) 
1 µM 
(µl) 
Cells 500 500 500 500 500 500 
Media 500 0 400 450 475 495 
Methadone 0 500 100 50 25 5 
 
 
2.5.5.4 Cell apoptosis Trial 
 
After incubation with methadone 500 µl of cells from each treatment were transferred 
into flow tubes and washed in phosphate buffered saline (PBS) solution by 
centrifuging at 13,000 rpm for 5 minutes. The supernatant was discarded and the cells 
were resuspended in 100 µl of PBS. To this 1 µl of Annexin V-FITC conjugate and 2 
µl of propidium iodide was added and the samples were incubated at room 
temperature for 10 minutes, in the dark. Each of the reactions was tested with a flow 
cytometer which was set to record 10,000 events at 700 volts. The data was analysed 
by examining forward scatter, side scatter, Annexin V-FITC, and propidium Iodide. 
Following gating of the lymphocyte cell population histograms were generated and 
the geometric means for each reaction were deduced. For Annexin V the cell sample 
was divided into Annexin positive and Annexin negative cells. For propidium iodide 
the cell sample was divided into live cells (propidium iodide negative), permeabilised 
cells and fragemented cells. 
 
2.5.5.5 µ receptor Internalisation 
 
 
The extent of µ-opioid receptor internalisation following methadone treatment was 
analysed using the µ opioid receptor (ab10275) primary antibody (Abcam, UK) and 
the goat polyclonal to rabbit IgG – H&L (Fluorescein isothiocyanate, FITC) (Abcam, 
UK). Having been cultured in methadone 500µl of cells for each treatment were 
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transferred into flow tubes and washed in FACSFlow by centrifuging at 13,000 rpm 
for 5 minutes. The supernatant was discarded and the cells were resuspended in 100 
µl of FACSFlow. To this 2 µl of the primary antibody in a 1:10 concentration was 
added and the samples were incubated at 4ºC for 30 minutes. Following this the 
samples were washed by adding FACSFlow and centrifuging at 13,000 rpm for 5 
minutes. The supernatant was discarded leaving a pellet and approximately 100µl of 
solution in the flow tubes. Then 2 µl of the secondary antibody (1:10) was added and 
the reactions were incubated at 4ºC for 30 minutes. The reactions were washed in 
FACSFLow through centrifugation at 13,000 rpm for 5 minutes. The supernatant was 
discarded and the pellet was re-suspended in 100µl of FACSFlow. Each reaction was 
tested with a flow cytometer which was set to record 10,000 events at 700 volts. The 
data was analysed by examining forward scatter, side scatter and anti-µ + anti-rabbit 
FITC. Following gating of the lymphocyte cell population histograms were generated 
and the geometric means for each reaction were deduced. 
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2.6 Statistical Analysis 
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2.6.1 Data Normalisation 
All data was tested for normality by conducting data frequency analysis, examining 
comparative and descriptive statistics including mean, standard error and data outliers 
using SPSS 14.0 software. 
 
2.6.2 Post-mortem drug-drug correlations 
As a number of the post-mortem subjects studied were engaged in polydrug use the 
association between methadone and other drugs identified in the toxicology screen 
was examined. The drugs found together with methadone included: 
 Opioids – morphine, dihydrocodeine, codeine.  
 Benzodiazepines – diazepam, oxazepam. 
 Ethanol. 
 Selective Serotonin Reuptake Inhibitors (SSRI‟s) – citalopram, fluoxetine. 
paroxetine, sertraline. 
 Serotonin-Norepinephrine Reuptake Inhibitors (SNRI‟s) – venlafaxine. 
 Tricyclic antidepressants – amitryptyline, dothiepin. 
 Tetracyclic antidepressants – mirtazapine. 
 Antipsychotics – quetiapine. 
 
2.6.2.1. Post-mortem drug concentrations 
Bivariate correlations using Pearson‟s two-tailed significance were used to evaluate 
the relationship between each of the drugs identified post-mortem. In addition to this 
simple scatter plots were created to identify positive or negative correlations. This 
was conducted using SPSS 14.0 software. 
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2.6.3 Independent T-test 
 
This study used the Independent T-test to identify significant associations between 
CYP2B6 and OPRM1 SNPs and post-mortem methadone concentration. The 
Independent T-test is used to test for a difference between two independent groups 
(wild type allele and variant alleles) on the means of a continuous variable (post-
mortem methadone concentration). 
 
2.6.4 Hardy Weinberg equilibrium 
The Hardy-Weinberg Equilibrium or Hardy-Weinberg Law is a concept of population 
genetics, which states that both allele and genotype frequencies in a population will 
remain constant, hence be in equilibrium, unless disturbing influences are introduced. 
These can include mutations, selection, non-random breeding, limited population‟s 
size, random genetic drift and gene flow. In nature one or more of these disturbing 
influences will always be active; therefore it is impossible to achieve Hardy-Weinberg 
Equilibrium in nature. In this study the Hardy-Weinberg Equilibrium has been used as 
a baseline that CYP2B6 and OPRM1 genetic change can be measured against for the 
post-mortem and control populations sampled. 
Hardy-Weinberg Equilibrium 
 
p
2
 + 2 pq + q
2
 = 1. 
 
Where p
2
 represents the wild type genotype, pq is the heterozygous genotype and q
2
 
stands for the homozygous variant genotype. 
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For CYP2B6, T750C, G516T, A785G and OPRM1 A118G Hardy Weinberg 
Equilibrium was tested for both the post-mortem and control populations using Chang 
Bioscience software. 
2.6.5 CYP2B6 & OPRM1 SNP-SNP Correlations 
 
Linkage between gene variants for both CYP2B6 and OPRM1 was determined using 
Pearson‟s Chi-square test and Spearman‟s rank correlation. This was conducted for 
both the post-mortem and control populations. A P value of ≤ 0.05 was considered to 
indicate statistical significance.  
 
2.6.6 Comparing the prevalence of CYP2B6 and OPRM1 variations in a post-
mortem and a control population 
 
This study examined two populations, a post-mortem population where the deaths had 
been attributed to methadone and a healthy living control population in order to 
determine whether methadone susceptibility could be identified through SNP 
prevalence. Differences in genotype frequencies for T750C, G516T, A785G, and 
A118G between populations were examined using T-Test and Fisher‟s exact test.   
 
2.6.7 The influence of Age, Gender and Involvement in Methadone Maintenance 
 
The influence of age and gender for the CYP2B6 and OPRM1 gene variations was 
examined using a binary logistic regression model. The dependent variable used was 
population, and the cofactors examined were age, gender and race. The influence of 
subject participation in methadone maintenance for methadone susceptibility was 
examined using the Independent T-test.
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3.1 Method Optimisation 
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3.1.1 DNA Extraction 
 
3.1.1.1 DNA extraction from buccal swabs 
Three different swabs were tested to identify which yielded the greatest DNA 
concentration. The swabs comprised: 
 
 The Isohelix SK-1 swab-which uses a reduced liquid absorbancy matrix 
together with a quick release surface to increase DNA uptake and yield. 
 The Epicentre Catch-All Collection swab- which utilises a porous spongy 
swab, said to increase collection due to greater DNA retention. 
 The Epicentre MasterAmp™ Buccal Swab Brush-which uses soft bristles to 
collect DNA from the buccal surface. 
 
The DNA quantification results for the three different swabs demonstrate that the 
Epicentre Catch-All Collection swab yields the highest DNA concentration with an 
average of 1.14 ng/µl (Table 23).  The lowest DNA yield was collected by the 
Isohelix SK-1 swab with an average of 0.86 ng/µl.  
 
Table 23: Mean DNA yield for the three buccal swabs. 
 
DNA Swab 
 
Mean 
(ng/µl) 
Std. deviation 
Isohelix SK-1 0.86 ± 0.89 
Epicentre Catch-All Collection swab 1.14 ± 0.49 
Epicentre MasterAmp™ Buccal Swab Brush 1.04 ± 0.19 
Significance was tested using the Kruskal Wallis test. There was no significant difference (P 0.101).  
 
The Quantifiler® standard curves are displayed below (Figures 6 & 7). The R2 value 
for buccal extraction run 1 is lower than expected perhaps reflecting poor mixing of 
the assay mix prior to use.  
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Figure 6: Standard curve for buccal extraction run 1. 
 
 
Figure 7: Standard curve for buccal extraction run 2. 
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3.1.1.2 DNA extraction from whole blood 
The DNA extractions from blood yielded a much higher concentration of DNA 
compared with the buccal swab extraction protocol. This finding is expected and has 
been well documented. The quantification study revealed that the Qiagen DNeasy 
Blood and Tissue Kit yielded significantly more DNA than the Promega Wizard 
Purification Kit (Figures 8 & 9, Table 24). Both kits have been commercially 
validated and are suitable for use in molecular research. However for the purpose of 
this study the Quantifiler® results recommend the Qiagen kit for further use.  
Additionally the effects of different preservatives on DNA yield were examined with 
EDTA yielding the highest DNA concentrations for both the Qiagen and Promega kits 
and potassium oxalate yielding the lowest DNA concentrations (Table 25). 
 
 
Table 24: Mean DNA yield for the Promega and Qiagen extraction kits examined. 
 
Whole Blood DNA Extraction Kit 
 
Mean 
(ng/µl) 
Std. deviation 
Promega Wizard Purification Kit 0.28 ± 0.25 
Qiagen Dneasy Blood and Tissue Kit 20.8 ± 12.3 
 
Significance was tested using the non parametric Mann Whitney test as the data was not normally 
distributed (P >0.001). 
 
 
 
 
Table 25: The effects of different whole blood preservatives on DNA yield. 
 
Blood preservative DNA yield 
(Mean ng/µl) 
Std. deviation 
EDTA 15.9 ± 16.8 
Lithium heparin 12.4 ± 13.5 
Potassium oxalate 3.4 ± 4.0 
 
Significance was tested using the Kruskal Wallis test as the data distribution was not normal. There 
was a significant difference between the three different blood preservatives with a P value of 0.036 
 
 
 117 
From these results it is clear that EDTA is the optimal preservative out of the three 
examined for maintaining DNA stability. However it must be mentioned that all of the 
preservatives yielded appropriate DNA quantities for molecular analysis. This is 
particularly useful as post-mortem samples are routinely stored in sodium fluoride 
potassium oxalate tubes which yielded the lowest quantity of DNA here. As 
anticoagulants such as sodium fluoride potassium oxalate might inhibit PCR (de Vries 
et al. 2001) it may be that during the washing process EDTA and Lithium Heparin are 
more extensively removed influencing the Quantifiler result. 
 
 
 
Figure 8: Standard curve for Quantification of Promega Samples. 
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Figure 9: Standard curve for Quantification of Qiagen Samples. 
 
 
3.1.2 PCR Amplification of SNP regions of the human OPRM1 gene  
 
Polymerase chain reactions (PCRs) were performed following buccal DNA extraction 
to determine the validity of several primers designed to amplify targeted regions of 
OPRM1. As demonstrated in the methodology this protocol required development in 
order to effectively produce specific primer-template binding. 
 
3.1.2.1 MgCl2 
The aim of this experiment was to demonstrate the effect of MgCl2 on PCR efficiency, 
whilst identifying a concentration range to consider for further work. 
Of the seven MgCl2 volumes only four (1µl, 1.5µl, 2µl and 2.5µl) performed 
efficiently producing adequate DNA banding (Figure 10). The higher MgCl2 volumes 
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resulted no banding (3µl, 3.5µl and 4µl). This is not wholly unexpected, it was 
commented on in the methodology that changes in MgCl2 can affect PCR efficiency 
(Wolff et al. 1993). As demonstrated in Figure 10 the DNA bands for 1.5µl, 2µl and 
3µl are the brightest suggesting an optimal MgCl2 concentration within this 
concentration range. The 1µl band is not as bright possibly reflecting suboptimal 
binding.  
 
 
 
Figure 10: The effect of MgCl2 on PCR success. 
 
Agarose gel (1.6 %), run at 70 volts. MgCl2 volumes >3µl resulted in no DNA banding. 
 
 
3.1.2.2 Temperature 
3.1.2.2.1 Gradient PCR reaction 
The initial stage in testing the effects of temperature as discussed in the methodology 
was to conduct a gradient PCR. The results from this experiment however were poor 
and this was somewhat unexpected (Figure 11). Clear banding is only present for 
60.1ºC PR0554 and 62.2ºC PRO995. Smearing can be identified for 60.7ºC PRO554 
   1µl 1.5µl 2µl 2.5µl 3µl 3.5µl 4µl                     
1kb ladder 
250 bp 
500 bp 
MgCl2 concentration 
1 kb ladder 
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and 60.1ºC PRO995 reflecting non-specific primer annealing. Faint banding can also 
be seen for 61.8ºC and 63.3ºC PRO554. 
 
 
 
 
Figure 11: Gradient PCR reaction for PRO554 and PRO995 primers. 
 
Agarose gel (1.6 %), run at 70 volts. The gel shows non-specific primer annealing. 
 
 
In response to the poor banding demonstrated in Figure 11 a new dNTP stock was 
used together with an increase in MgCl2 amount to 5µl. 
 
3.1.2.2.2 Temperatures selected from the Gradient Reaction 
The effects of three temperatures (60.1ºC, 61.2ºC, and 62.2ºC) selected from the 
previous gradient reaction on PRO554 and PRO995 primer banding are displayed in 
Figure 12. Banding is clear however there is still smearing indicating too much MgCl2 
which correlates with the results demonstrated in Figure 10 where the optimum 
MgCl2 concentration range was between 1.5 and 3µl. 
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Figure 12: Temperature reaction for PRO554 and PRO995 primers. 
 
Agarose gel (1.6 %), run at 70 volts. Smearing indicates a high concentration of MgCl2. 
 
3.1.2.2.3 Temperature optimisation to increase specificity 
Further temperature optimisation was required to produce DNA banding suitable for 
DNA sequencing. As described in Section 2.1.2.3.2 Temperature this involved a 
decrease in temperature for PRO55, PR0995, EX1 and EX2. The annealing 
temperature for EX3 was increased and as Figure 13 demonstrates this greatly 
improved the PCR results. 
 
Clear bands were identified for EX1, EX2 and EX3 allowing the sequencing of these 
samples, the promoter regions did not amplify efficiently with smearing present. As a 
result the temperatures for PRO554 and PRO995 were decreased further (Figures 14 
& 15). 
 
250 bp 
500 bp 
1 kb ladder 
 60.1 61.2 62.2 60.1 61.2 62.2 
 
PRO554   TempºC  PRO995 
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Figure 13: Improved banding efficiency following annealing temperature optimisation. 
 
Agarose gel (1.6 %), run at 70 volts. Clear DNA banding for the PCR amplified exon 1 region. 
 
 
 
 
Figure 14: Improved PRO554 annealing following a decrease in temperature. 
 
Agarose gel (1.6 %), run at 70 volts. Clear DNA banding for the promoter region containing G554A. 
 
 
As demonstrated by Figure 14 a decrease in temperature improved the specificity of 
the reaction producing a band suitable for subsequent DNA processing sequencing of 
the promoter region PRO554 primer set.  
1 kb ladder 
1 kb ladder 
250 bp 
250 bp 
500 bp 
500 bp 
65.1 62.1 61.5 62.1 65.8 65.3 63.2 63.6 64.7 65.3 (ºC) 
PRO554  PRO995      EX1        EX2         EX3 
59.5ºC 
PRO554 
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Figure 15: Improved PR0995 annealing following an increase in temperature. 
 
Agarose gel (1.6 %), run at 70 volts. Clear DNA banding for the promoter region containing C995A. 
 
3.1.2.2.4 SNPs revealed by DNA sequencing results 
Following PCR development the samples were sent for sequencing to validate primer 
efficiency. Each of the primer sets (PRO554, PRO995, EX1, EX2, and EX3) 
amplified the required target regions of OPRM1. From this it can be deduced that the 
primers used during method development are suitable to screen for specific OPRM1 
SNPs. The DNA sample processed for the promoter and exonic regions of OPRM1 
did not demonstrate any variations and can therefore be used as negative controls in 
the real-time genotyping experiments. 
 
In Figure 16 the highlighted base (51) denotes the position of the A118G SNP 
discussed in the literature review earlier. The wild type allele AA is present for this 
sample. The variant allele would be present either as a heterozygous (AG) or as a 
homozygous (GG) allele change. This variation is a functional variation causing an 
amino acid change from asparagine to aspartic acid. As discussed in Section 1.6.3 
Pharmacogenomic influences on methadone-receptor binding and response the 
fundamental role of this mutation is unclear and requires further investigation. 
1 kb ladder 
250 bp 
500 bp 
58.0 ºC       59.5ºC 
Temperature 
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Exon 1 
 
 
Figure 16: DNA sequencing results for EX1_HB primer amplification of OPRM1 A118G 
SNP. 
 
The arrow indicates the base position of the A118G SNP. 
 
 
 
 
 
 
 
 
Figure 17: DNA sequencing results for EX1_HB primer amplification of the OPRM1 C17T 
SNP. 
 
The arrow indicates the base position of the C17T SNP. 
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The highlighted base above (Figure 17) demonstrates the position of the C17T SNP, 
the base seen is the ancestral allele CC, the variant allele would be TT. This missense 
mutation induces an amino acid change from serine to phenylalanine. 
 
Exon 2 
 
 
Figure 18:  DNA sequencing results for EX2_HB primer amplification of OPRM1 C440G 
SNP. 
 
The arrow indicates the base position of the C440G SNP. 
 
The highlighted base above (Figure 18) refers to the OPRM1 C440G SNP, the 
ancestral base C is present. This DNA sample can therefore be used as a negative 
control if SNP genotyping is conducted for this variant. This variant is a non 
synonymous mutation inducing an amino acid change from serine to cysteine. 
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Figure 19: DNA sequencing results for EX2_HB primer amplification of OPRM1 A454G 
SNP. 
 
The arrow indicates the base position of the A454G SNP. 
 
 
The wild type allele AA is shown in Figure 19 by the highlighted A nucleotide base. 
The variant allele GG for this SNP induces an amino acid change from asparagine to 
aspartic acid. The results for the exon 2 SNPs validate the EX2_HB primer set.  
 
 
Exon 3 
 
 
 
Figure 20: DNA sequencing results for EX3_HB primer amplification of OPRM1 G779A 
SNP. 
 
The arrow indicates the base position of the G779A SNP. 
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The highlighted base above (Figure 20) denotes the ancestral allele GG the variant 
would be present as either GA or AA and induces an amino acid change from arginine 
to histidine. 
 
The wild type allele CC for the C793T SNP is present in Figure 21. This is a 
functional non synonymous SNP inducing an amino acid change from arginine to 
cysteine 
 
 
 
Figure 21: DNA sequencing results for EX3_HB primer amplification of OPRM1 C793T 
SNP. 
 
The arrow indicates the base position of the C793T SNP. 
 
 
 
The ancestral allele (GG) was identified for the third SNP examined (Figure 22) 
within the exon 3 region. The variant would be present as either the heterozygous GA 
or the homozygous AA allele inducing an amino acid change from aspartic acid to 
asparagine. 
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Figure 22: DNA sequencing results for EX3_HB primer amplification of OPRM1 G820A 
SNP. 
 
The arrow indicates the base position of the G820A SNP. 
 
 
 
 
Figure 23: DNA sequencing results for EX3_HB primer amplification of OPRM1 G877A 
SNP. 
 
The arrow indicates the base position of the G877A SNP. 
 
 
Figure 23 shows the ancestral allele GG for the G877A SNP screened for. The variant 
would be present as either GA, or AA and would induce an amino acid change from 
valine to isoleucine. 
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Figure 24: DNA sequencing results for EX3_HB primer amplification of OPRM1 G942A 
SNP. 
 
The arrow indicates the base position of the G942A SNP. 
 
 
The final exon 3 SNP screened for was the G942A SNP, as shown in Figure 24 the 
ancestral allele is present GG. This variation is a synonymous or silent mutation 
which does not affect the amino acid sequence. Synonymous variations as discussed 
in the previously have been linked with alterations in gene expression. 
 
 
The OPRM1 Promoter region 
 
 
The PRO554 mutation is located within a cis-element in the OPRM1 promoter region 
and may therefore be involved with gene expression modifications. The wild type 
allele GG is depicted in Figure 25, the variant would be present as either GA or AA. 
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Figure 25: DNA sequencing for PR0554_HB primer amplification. 
 
The arrow indicates the base position of the G554A SNP. 
 
 
The PRO995 variant displayed in Figure 26 similarly to PRO554 is located within a 
cis-element and is therefore likely to be involved in gene expression. The wild type 
allele CC is demonstrated, the variant would be present either as CA or AA. 
 
 
 
Figure 26: DNA sequencing for PRO995_HB primer amplification. 
 
 
The arrow indicates the base position of the C995A SNP. 
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3.1.2.3 A118G identification 
 
Of the OPRM1 SNPs examined thus far only one is a likely candidate for further 
research, the A118G SNP. As discussed in Section 1.6.3 Pharmacogenomic influences 
on methadone-receptor binding and response A118G may be linked with inter-
individual responses to opioids (specifically morphine). However only one study has 
discussed this variation with regards to methadone response and there are no studies 
that have examined this SNP for molecular autopsy. A real-time Taqman® SNP 
genotyping assay will be used to examine allelic discrimination in multiple samples 
(post-mortem and healthy living controls). This method requires both negative (wild 
type allele) and positive variant allele controls. Earlier work demonstrates that the 
EX1_HB primer set correctly amplifies the region surrounding A118G. Therefore this 
primer set was used to screen 20 different subjects to identify an A118G positive 
control for SNP genotyping. Clear DNA amplification for all 20 samples was 
achieved (Figures 27 & 28). This result allowed further DNA processing in the form 
of DNA sequencing to screen for the A118G mutation. 
 
 
Figure 27: Amplification of OPRM1 exon 1 region using EX1_HB primers PCR 1. 
 
Agarose gel (1.6 %), run at 70 volts. The exon 1 region was successfully amplified for 10 subjects. 
1 kb ladder 
250 bp 
500 bp 
DC1 DC2           DC3 DC4 DC5 DC6 DC7 DC8 DC9 DC10             
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Figure 28: Amplification of OPRM1 exon 1 region using EX1_HB primers PCR 2. 
 
Agarose gel (1.6 %), run at 70 volts. The exon 1 region was successfully amplified for 10 subjects 
 
 
 
3.1.2.3.1 A118G sequencing results 
 
PCR amplified DNA for 20 subjects were sequenced to identify a positive control for 
A118G. All of the samples sent for sequencing yielded sufficient sequences for 
analysis. 
 
1 kb ladder 
500 bp 
250 bp 
DC11 DC12           DC13 DC14 DC15 DC16 DC17 DC18 DC19 DC20   NC    PC 
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Figure 29:  A comparison of two SNP genotypes for the A118G SNP ( 118 AA & 
118 AG). 
 
A typical DNA profile for the OPRM1 A118G SNP. The arrows indicate the base position of the 
A118G SNP for the 118 AA and 118 AG genotypes. For the 118 AA genotype there is a single green 
peak denoting the A allele. For the 118 AG genotype there is a black peak denoting the G allele and 
below this there is a green peak denoting the A allele. Therefore this is a heterozygous subject. 
 
 
In total three out of twenty post-mortem samples sequenced were heterozygous for the 
A118G SNP (DC15, DC12, & DC19). 
118 AA 
118 AG 
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3.1.3 PCR Amplification of SNP regions of the human CYP2B6 gene 
 
3.1.3.1 Primer validation 
Polymerase chain reactions (PCRs) were performed to test the validity of the C2B6E4, 
C2B6E5, and C2B6Pr primers which have been designed to amplify targeted regions 
of CYP2B6. 
 
C2B6E4 & C2B6E5 
 
 
 
 
 
 
Figure 30: PCR validation for C2B6E4 & C2B6E5 primers. 
 
Agarose gel (1.6 %), run at 70 volts. Method development for the C2B6E4 and C2B6E5 primer sets. 
 
Figure 30 displays the banding yielded for the C2B6E4 and C2B6E5 primers during 
PCR validation. For the C2B6E5 primer set there is a significant amount of smearing 
and the presence of non specific amplification with more than one DNA band 
identified, suggesting poor PCR selectivity. Faint DNA banding is present for the 
C2B6E4 primer set. This is the initial phase in the method development for C2B6E4 
and C2B6E5 and the presence of DNA bands demonstrates adequate primer design. 
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250 bp 
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C2B6Pr 
Figure 31 displays a gradient reaction conducted to validate the C2B6Pr primer set. 
There is significant DNA smearing beginning at the well and continuing throughout 
the gel suggesting the presence of genomic DNA. In addition multiple DNA bands 
can be seen highlighting non specific amplification. Further optimisation is required 
for this primer set. 
 
 
 
 
Figure 31: PCR validation for C2B6Pr primers. 
 
Agarose gel (1.6 %), run at 70 volts. Method development for C2B6Pr primer set indicating poor 
selectivity. 
 
 
3.1.3.2 T750C PCR validation 
3.1.3.2.1 Temperature 
Poor selectivity is still apparent in this reaction with multiple bands present 
throughout the gel (Figure 32). 
56.0  56.8  57.5  58.2  59.0  59.7 (º C) 
 
           C2B6Pr 
1 kb ladder 
500 bp 
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Figure 32: PCR temperature optimisation for C2B6Pr. 
 
Agarose gel (1.6 %), run at 70 volts. Temperature gradient set at 62 ºC ± 3 ºC. 
 
3.1.3.2.2 MgCl2 
A reduction in MgCl2 reduced some of the smearing and poor selectivity. However 
this result is still not sufficient for further processing. 
 
Figure 33: PCR MgCl2 optimisation for C2B6Pr. 
Agarose gel (1.6 %), run at 70 volts. A decrease from 6 µl to 4 µl MgCl2 did not improve selectivity. 
1 kb ladder 
500 bp 
DC1, DC2, DC3, DC4, DC5, DC6, DC7, DC8, DC9, DC10 
DC1, DC2, DC3, DC4, DC5 
1 kb ladder 
500 bp 
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3.1.3.3 T750C Identification 
As demonstrated in Figure 34 an increase in annealing temperature (65ºC) produced 
banding suitable for DNA sequencing. 
 
 
 
 
Figure 34: Amplification of CYP2B6 promoter region using C2B6PR primers. 
 
Agarose gel (1.6 %), run at 70 volts. An increase in temperature from 62.1 ºC to 65 ºC improved DNA 
banding for the C2B6Pr primer set. 
 
 
3.1.3.3.1 T750C sequencing results 
PCR amplified DNA for 9 subjects were sequenced to identify a positive control for 
T750C. All of the samples sent yielded sufficient sequences for analysis. 
1 kb ladder 
500 bp 
DC1, DC2, DC4, DC5, DC6, DC7, DC9, DC10, DC11, DC12, NC 
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Figure 35:  A comparison of two SNP genotypes for the T750C SNP (750 TC & 750 
CC). 
 
A typical DNA profile for the CYP2B6 T750C SNP. The arrows indicate the base position of the 
T750C SNP for the 750 TC and 750 CC genotypes. For the 750 TC genotype there is a black peak 
denoting the G allele and below this there is a blue peak denoting the C allele. Therefore this is a 
heterozygous subject. For the 750 CC genotype there is a single blue peak denoting the C allele.  
 
 
 
750 TC 
750 CC 
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3.1.3.4 G516T PCR validation 
 
3.1.3.4.1 Temperature 
 
Temperature gradients 
 
A gradient reaction for C2B6E4 was conducted to determine the optimal primer 
annealing temperature. Temperatures 58.0 ºC, 58.8 ºC and 59.5 ºC yielded the clearest 
DNA bands. The higher temperatures tested demonstrated poor selectivity with 
temperatures exceeding 63.0 ºC yielding barely visible DNA bands (Figure 36). 
 
 
Figure 36: Gradient PCR amplification for C2B6E4. 
 
Agarose gel (1.6 %), run at 70 volts. Temperatures > 63 ºC did not produce adequate DNA banding. 
 
 
Temperatures selected from gradient PCR reactions 
 
 
 
 
Figure 37: C2B6E4 banding following a decrease in annealing temperature. 
 
Agarose gel (1.6 %), run at 70 volts. The 59.0 ºC temperature yielded the best DNA banding. 
58.0   58.8   59.5   60.2   61.0   61.7   62.3  63.0   63.8, 64.5, 65.2 (ºC) 
1 kb ladder 
500 bp 
 56.0   56.8   57.5   58.2  59.0  (ºC) 
1 kb ladder 
500 bp 
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A decrease in annealing temperature was tested following the gradient reaction results 
(Figure 37). The best DNA bands were obtained at 58.2 ºC and 59.0 ºC in agreement 
with earlier results (Figure 36). 
 
3.1.3.4.2 MgCl2 
 
 
 
 
 
 
Figure 38: The effect of MgCl2 concentration on C2B6E4 amplification. 
 
Agarose gel (1.6 %), run at 70 volts. DNA extracted from blood yielded clearer DNA banding.  
 
 
 
The effect of differing MgCl2 concentrations on PCR success for C2B6E4 primers 
was tested (Figure 38). The volumes of MgCl2 ranged from 4 to 9µl with 7µl yielding 
the clearest DNA banding. Template source was also tested with DNA extracted from 
blood samples demonstrating much clearer DNA bands than the buccal samples. The 
results from this study recommend further reactions with C2B6E4 using a MgCl2 
volume of 7µl. 
 
 
 
 
 
 
 
 
4µl  5µl  6µl 7µl  8µl   9µl    4µl  5µl  6µl  7µl   8µl  9µl 
(Buccal DNA)     MgCl2 concentration   (Blood DNA) 
1 kb ladder 
500 bp 
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3.1.3.5 G516T Identification 
 
 
 
 
Figure 39: Amplification of CYP2B6 exon 4 region using C2B6E4 primers run 1. 
 
Agarose gel (1.6 %), run at 70 volts. PCR ampliciation of C2B6E4 for ten subjects. 
 
Clear DNA amplification for most of the samples was successfully achieved (Figures 
39 & 40). Poor amplification was noted for DC2, DC3, and DC8 (Figure 39) which 
may be a result of template degradation following repeated freeze and thaw cycles. 
Alternatively the DNA sample may have required further mixing prior to use to 
ensure a homogenous solution and adequate template collection. All of the other 
samples amplified yielded clear bands allowing further DNA processing in the form 
of DNA sequencing to screen for the G516T mutation. 
DC1 DC2 DC3 DC4 DC5 DC6 DC7 DC8 DC9 DC10 
1 kb ladder 
500 bp 
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Figure 40: Amplification of CYP2B6 exon 4 region using C2B6E4 primers run 2. 
 
Agarose gel (1.6 %), run at 70 volts. PCR amplification of C2B6E4 for ten subjects. 
 
 
3.1.3.5.1 G516T sequencing results 
PCR amplified DNA were sequenced to identify a positive control for G516T. All of 
the 10 samples sent off for sequencing yielded sufficient sequences for analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
      DC11 DC12 DC13 DC14 DC15 DC16 DC17 DC18 D1C9 DC20 
1 kb ladder 
500 bp 
250 bp 
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Figure 41:  A comparison of two SNP genotypes for the G516T SNP (516 GG & 516 
GT). 
 
A typical DNA profile for the CYP2B6 G516T SNP. The arrows indicate the base position of the 
G516T SNP for the 516 GG and 516 GT genotypes. For the 516 GG genotype there is a single black 
peak denoting the G allele. For the 516 GT genotype there is a red peak denoting the T allele and below 
this there is a black peak denoting the G allele. Therefore this is a heterozygous subject.  
 
 
 
 
 
 
516 GT 
516 GG 
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3.1.3.6 A785G validation 
 
3.1.3.6.1 Temperature 
 
 
 
Figure 42: C2B6E5 banding following an increase in annealing temperature.  
 
Agarose gel (1.6 %), run at 70 volts. Temperatures between 61.5 ºC and 63.2 ºC yielded suitable bands. 
 
The results from the primer validation run for C2B6E5 (Figure 42) highlighted the 
need for an increase in annealing temperature. Of the three temperatures tested 63.2 
ºC demonstrated the clearest DNA band, with minimal smearing. Therefore this 
annealing temperature will be used for further C2B6E5 amplifications.  
 
3.1.3.7 A785G Identification 
 
 
 
Figure 43: Amplification of CYP2B6 exon 5 region using C2B6E5 primers run 1. 
 
Agarose gel (1.6 %), run at 70 volts. PCR amplification of C2B6E5 for ten subjects. 
Temperature (º)   61.5  62.1  63.2  
 
  
1 kb ladder 
500 bp 
DC1 DC2 DC3 DC4  DC5  DC6 DC7 DC8 DC9 DC10 
1 kb ladder 
500 bp 
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Clear DNA amplifications from all but samples DC3 (Figure 43) and DC14 (Figure 
44) were successfully achieved (Figures 43 & 44). This result allowed further DNA 
processing in the form of DNA sequencing to screen for the A785G polymorphism. 
 
 
 
Figure 44: Amplification of CYP2B6 exon 5 region using C2B6E5 primers run 2. 
 
Agarose gel, run at 70 volts. PCR amplification of C2B6E5 for ten subjects. 
 
 
3.1.3.7.1 A785G sequencing results 
 
PCR amplified DNA were sequenced to identify a positive control for A785G. All of 
the 10 samples sent off for sequencing yielded sufficient sequences for analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
        DC11  DC12 DC13  DC14  DC15  DC16  DC17  DC18 DC19 DC20 
1 kb ladder 
500 bp 
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Figure 45:  A comparison of two SNP genotypes for the A785G SNP (785 AA & 785 
GG). 
 
A typical DNA profile for the CYP2B6 A785G SNP. The arrows indicate the base position of the 
A785G SNP for the 785 AA and 785 AG genotypes. For the 785 AA genotype there is a single green 
peak denoting the A allele. For the 785 AG genotype there is a black peak denoting the G allele and 
below this there is a green peak denoting the A allele. Therefore this is a heterozygous subject.  
 
785 AG 
785 AA 
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3.2 Post-mortem Sample Examination 
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3.2.1 Postmortem sample study 
 
 
This section discusses the summary of toxicological findings reported by the 
Centre of Forensic and Legal Medicine Laboratory, Dundee University for all cases 
that have been used in this work. In total 84 cases were examined (Table 26), of these 
69 were attributed to methadone, determined by the pathologist using case histories 
(which were not always available for use in this study) and post-mortem findings. 
Most toxicologists would generally agree that a methadone blood concentration > 0.4 
mg/L is fatal and that the death can be attributed to methadone, however due to 
unknown case histories and polydrug use the cases reported in this study are reliant on 
the pathologists decision. A preliminary study reported the association between 
OPRM1 and CYP2B6 variations and blood methadone concentrations in 40 post-
mortem subjects (Chapter 4). The study was then increased to include 69 methadone-
attributed deaths as determined by the pathologist (Chapter 5). A further 15 cases 
where methadone was involved in the cause of death (death attributed to polydrug 
use) were then used to examine the difference of OPRM1 and CYP2B6 allele 
frequencies between the post-mortem population and a living control population of 
non-methadone using subjects. The results from the post-mortem study are reported 
below and discussed further in Chapters 4, 5, and 6. 
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Table 26: Drug Toxicology for samples DC1-DC84 where the deaths had been associated 
with methadone. 
 
Case Age Sex Race Methadone 
(mg/l) 
Sample EtOH 
(mg/100ml) 
Drug Toxicology 
(mg/L) 
1 43 M Caucasian 0.13 Sc ND Morphine total 8.3 
2 32 M Caucasian 0.27 Fm ND Diazepam 1.2 
3 57 F Caucasian 0.86 Fm ND Diazepam 1.3 
4 37 F Caucasian 1.16 Fm ND Venlafaxine 3.9 
5 36 M Caucasian 0.30 Fm ND Morphine 0.085 
6 20 M Caucasian 1.1 Fm ND  
7 32 M Caucasian 0.82 Fm 138 Propranolol 4.09 
Mirtazapine 1.2 
8 24 M Caucasian 0.97 Fm ND  
9 26 M Caucasian 0.22 Fm 18 Morphine 0.024 
Diazepam 0.8 
Nordiazepam 1.98 
10 33 M Caucasian trace Fm ND Morphine 0.13 
Diazepam 0.42 
11 28 M Caucasian 0.20 Fm 81 Trazadone 0.18 
12 26 M Caucasian 1.44 Fm ND  
13 31 M Caucasian 0.48 Fm ND Morphine 0.032 
Diazepam 0.84 
14 38 M Caucasian 1.25 Fm 35 Citalopram 0.28 
Quetiapine 1.5 
15 32 F Caucasian 1.08 Fm ND Morphine 0.028 
Diazepam 1.13 
Nordiazepam 2.72 
Dothiepin 1.19 
16 27 M Caucasian 0.44 Fm 78 Morphine 0.04 
Diazepam 1.23 
Nordiazepam 0.76 
17 44 M Caucasian 0.58 Fm ND Morphine 0.03 
Diazepam 0.41 
18 30 M Caucasian 0.44 Sc ND Diazepam 0.26 
Nordiazepam 0.44 
19 20 M Caucasian 0.33 Fm ND Diazepam 2.19 
Nordiazepam 1.6 
Amfetamine 0.59 
20 37 M Caucasian 0.95 Fm 296 Diazepam 0.81 
Nordiazepam 2.72 
Fluoxetine 0.5 
21 32 M Caucasian 0.58 Fm ND  
22 42 M Caucasian 0.65 Fm 299 Dihydrocodeine 
1.8 
23 20 M Caucasian 1.66 Fm ND Morphine 0.05 
Diazepam 0.30 
Nordiazepam 1.10 
24 17 F Caucasian 0.60 Fm ND Morphine 0.02 
25 41 F Caucasian D Ur ND Morphine 0.34 
Diazepam 0.57 
Nordiazepam 0.49 
Citalopram 0.41 
26 23 M Caucasian 1.70 Cd 68  
27 22 M Caucasian 0.54 Fm 86 Diazepam 0.21 
Nordiazepam 0.32 
Citalopram 0.39 
28 60 F Caucasian 0.26 Fm ND  
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Case Age Sex Caucasian Methadone 
(mg/l) 
Sample EtOH 
(mg/100ml) 
Toxicology 
(mg/l) 
29 45 M Caucasian D Ur ND Morphine 0.09 
Diazepam 1.13 
Nordiazepam 3.29 
Mirtazapine 0.17 
30 34 M Caucasian 2.23 Fm ND Morphine 0.09 
31 36 M Caucasian 0.39 Fm 14 Morphine 1.00 
Dihydrocodeine 
0.50 
32 18 M Caucasian 0.25 Fm 51 Diazepam 0.27 
Nordiazepam 0.35 
33 44 M Caucasian 0.15 Cd ND Amitriptyline 2.5 
Venlafaxine 2.3 
34 24 M Caucasian 0.37 Fm ND Morphine 0.02 
Nordiazepam 0.39 
35 21 M Caucasian 0.22 Fm 110 Diazepam 0.68 
Nordiazepam 0.55 
36 22 M Caucasian 0.22 Fm 34 Morphine 0.11 
Diazepam 0.24 
Nordiazepam 0.34 
37 41 M Caucasian 1.3 Fm ND  
38 32 M Caucasian 1.38 Fm ND  
39 20 M Caucasian 0.19 Fm 53 (Ur) Morphine 0.04 
40 23 M Caucasian D Ur ND Morphine 0.06 
MDMA 0.74 
41 40 M Caucasian 0.75 Fm 24 Diazepam 0.45 
Nordiazepam 1.11 
42 18 M Caucasian 0.24 Fm ND  
43 31 M Caucasian 1.53 Fm ND Morphine 0.025 
Diazepam 0.64 
Nordiazepam 1.02 
44 32 M Caucasian Tr Fm ND Morphine 0.09 
45 46 M Caucasian 0.56 Fm 16  
46 21 F Caucasian D Ur ND Morphine 0.41 
47 34 M Caucasian     
48 29 F Caucasian     
49 35 M Caucasian / 
Asian 
0.80 Fm ND Morphine 0.02 
Diazepam 0.59 
Nordiazepam 1.21 
Dothiepin 0.45 
50 33 M Caucasian 0.75 Fm ND Diazepam 0.78 
Nordiazepam 1.64 
51 29 M Caucasian 0.43 Cd ND Diazepam 0.29 
Nordiazepam 0.53 
Dothiepin 0.56 
Lamotrigine 0.4 
52 26 M Caucasian 10.1 Cd ND  
53 44 M Caucasian 0.72 Fm ND Dihydrocodeine 
0.90 
Nordiazepam 0.26 
Chlorodiazepoxide 
0.8 
54 51 M Caucasian D Ur ND Diazepam 0.23 
Nordiazepam 0.36 
Dihydrocodeine 
4.13 
55 22 F Caucasian 0.85 Fm ND Morphine 0.016 
Diazepam 0.62 
Nordiazepam 0.58 
56 30 F Caucasian 0.44 Fm 11  
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Case Age Sex Caucasian Methadone 
(mg/l) 
Sample EtOH 
(mg/100ml) 
Toxicology 
(mg/l) 
57 56 M Caucasian 2.99 Fm ND  
58 44 F Caucasian <0.15 Fm ND Tramadol 0.39 
59 35 M Caucasian 0.31 Fm 13 Morphine 0.08 
60 49 F Caucasian 0.99 Fm 29  
61 27 F Iranian 2.48 Fm ND  
62 26 M Caucasian 0.021 Fm ND Morphine 0.22 
63 22 M Caucasian 0.71 Fm ND  
64 37 F Caucasian 2.1 Fm ND  
65 21 M Caucasian 0.15 Fm 11 Morphine 0.18 
66 32 F Caucasian 2.59 Fm ND Morphine 0.05 
Amitriptyline 2.62 
Nortriptyline 5.89 
67 35 M Caucasian 0.21 Fm ND Amitriptyline 1.58 
68 55 F Caucasian 0.3 Fm ND  
69 32 M Caucasian 1.24 Fm ND Amitriptyline 0.26 
Diazepam 0.78 
Nordiazepam 0.68 
70 37 F Caucasian 1.1 Fm ND Diazepam 1.3 
Nordiazepam 0.98 
Citalopram 0.84 
71 43 F Caucasian 1.9 Fm ND Diazepam 0.95 
Nordiazepam 0.48 
Mirtazapine 0.39 
72 43 M Caucasian 2.63 Fm ND  
73 54 M Caucasian 0.75 Fm 114 Nordiazepam 0.21 
74 20 F Caucasian 0.3 Fm ND Diazepam 0.52 
75 34 M Caucasian / 
Asian 
0.35 Fm ND  
76 40 M Caucasian 1.22 Fm ND  
77 23 M Caucasian 0.42 Fm 22 Diazepam 1.07 
Nordiazepam 0.58 
78 28 M Caucasian 0.66 Fm 11 Diazepam 0.24 
Nordiazepam 0.32 
79 30 F Caucasian 0.58 Fm  Diazepam 2.38 
Nordiazepam 1.67 
80 34 F Caucasian 0.36 Fm 98 Citalopram 0.84 
81 31 M Caucasian 1.17 Fm ND Morphine 1.1 
82 49 F Caucasian 2.11 Fm ND Morphine 0.02 
Diazepam 1.90 
Tramadol 2.95 
Amitriptyline 1.05 
Carbamazapine 
4.05 
83 37 M Caucasian 1.77 Fm ND Morphine 0.05 
Temazepam 1.03 
84 23 M Caucasian 0.22 Fm ND Morphine 0.07 
Diazepam 0.43 
Nordiazepam 0.43 
 
Note: D equals detected, Fm is femoral, Sc is subclavian, Ur is urine, Cd is cardiac and ND equals 
undetermined. 
 
 
 
The drug toxicology results for the 84 methadone involved deaths samples are 
displayed above in Table 26. The mean and median age of the post-mortem subjects 
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was 33.2 and 33 respectively. Sixty two of the subjects were male (74 %) and 98 % 
were Caucasian. Methadone was detected in all 84 cases however in some cases only 
trace amounts were identified. Furthermore, for some case subjects the blood sampled 
was collected from the sub clavian and cardiac regions, not the preferred femoral vein. 
Therefore for the analysis of SNP effects on methadone concentration and response 
only femoral and quantifiable samples were analysed (For results see Chapters 4, 5, & 
6). Polydrug use was identified for most of the case subjects sampled, with 
benzodiazepines found in combination with methadone in 47 % of subjects. 
 
 
3.2.1.1 Quantification of DNA from post-mortem blood 
 
All of the 84 extracted post-mortem samples were successfully quantified using the 
human quantifiler® kit (Table 27).  
 
Table 27: DNA yield for methadone and morphine associated post-mortem whole blood 
extractions. 
 
 
 
 
 
Sample DNA 
yield 
ng/µl 
Sample DNA 
yield 
ng/µl 
Sample DNA 
yield 
ng/µl 
Sample DNA 
yield 
ng/µl 
Sample DNA 
yield 
ng/µl 
DC1  55.98 DC18 36.06 DC35 43.72 DC52 39.67 DC69 28.36 
DC2 11.35 DC19 24.30 DC36 22.87 DC53 89.42 DC70 34.80 
DC3 2.88 DC20 28.51 DC37 10.41 DC54 51.07 DC71 19.74 
DC4 20.19 DC21 20.64 DC38 106.39 DC55 54.02 DC72 15.81 
DC5 48.25 DC22 15.77 DC39 46.13 DC56 59.62 DC73 3.47 
DC6 30.69 DC23 72.13 DC40 45.30 DC57 21.77 DC74 34.20 
DC7 23.85 DC24 60.69 DC41 114.12 DC58 20.50 DC75 0.13 
DC8 4.16 DC25 65.18 DC42 71.24 DC59 20.24 DC76 35.07 
DC9 78.98 DC26 103.36 DC43 8.57 DC60 14.76 DC77 9.12 
DC10 63.93 DC27 75.01 DC44 74.53 DC61 12.39 DC78 0.92 
DC11 60.89 DC28 20.41 DC45 13.06 DC62 20.22 DC79 0.87 
DC12 36.52 DC29 41.11 DC46 81.53 DC63 45.33 DC80 57.35 
DC13 28.72 DC30 38.72 DC47 1.21 DC64 8.58 DC81 23.98 
DC14 16.20 DC31 62.21 DC48 38.84 DC65 21.86 DC82 88.34 
DC15 49.77 DC32 86.29 DC49 59.00 DC66 69.60 DC83 21.37 
DC16 18.29 DC33 30.22 DC50 34.93 DC67 7.55 DC84 68.07 
DC17 78.86 DC34 84.56 DC51 6.08 DC68 37.71   
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3.2.1.2 A118G SNP Genotyping 
 
All 84 subjects of the post-mortem group where methadone was associated with the 
cause of death were successfully genotyped for the OPRM1 A118G variation (Figure 
46; Table 28). 
 
Figure 46: A typical allelic discrimination plot for the A118G SNP. 
 
Where homozygous 1/1 stands for 118 AA subjects, 1/2 stands for 118 AG subjects and homozygous 
2/2 represents 118 GG subjects. As shown in the legend undetermined samples are denoted by a X. No 
post-mortem subjects were undetermined during A118G SNP genotyping. The black square denotes the 
negative control. All samples were run in duplicate together with positive controls.  
 
 
 
 
 
 154 
Table 28: A118G genotypes for the 84 post-mortem samples. 
 
Sample A118G 
genotype 
Sample A118G 
genotype 
Sample A118G 
genotype 
Sample A118G 
genotype 
DC1 AA DC22 AA DC43 AA DC64 AA 
DC2 AA DC23 AA DC44 AA DC65 AA 
DC3 AA DC24 AA DC45 AA DC66 AA 
DC4 AA DC25 AA DC46 AA DC67 AA 
DC5 AA DC26 AA DC47 AA DC68 AA 
DC6 AA DC27 AA DC48 AA DC69 AA 
DC7 AA DC28 AA DC49 AA DC70 AA 
DC8 AA DC29 AG DC50 AA DC71 AA 
DC9 AA DC30 AA DC51 AG DC72 AA 
DC10 AA DC31 AA DC52 AA DC73 AG 
DC11 AA DC32 AA DC53 AG DC74 AA 
DC12 AG DC33 AA DC54 AA DC75 AA 
DC13 AA DC34 AA DC55 AG DC76 AA 
DC14 AA DC34 AA DC56 AA DC77 AA 
DC15 AG DC36 AA DC57 AG DC78 AA 
DC16 AA DC37 AA DC58 AA DC79 AA 
DC17 AA DC38 AA DC59 AA DC80 AA 
DC18 AA DC39 AA DC60 AA DC81 AA 
DC19 AG DC40 AA DC61 AA DC82 AG 
DC20 AA DC41 AA DC62 AA DC83 AG 
DC21 AA DC42 AA DC63 AA DC84 AG 
 
 
In total 12 of the post-mortem subjects were heterozygous for the A118G SNP and 72 
subjects were homozygous for the A allele. No subjects were homozygous for the G 
allele. 
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3.2.1.3 T750C SNP Genotyping 
 
All 84 subjects of the post-mortem group where methadone was associated with the 
cause of death were successfully genotyped for the CYP2B6 T750C variation (Figure 
47, Table 29). 
 
 
 
Figure 47: A typical allelic discrimination plot for the T750C SNP. 
 
Where homozygous 1/1 stands for 750 TT subjects, 1/2 stands for 750 TC subjects and homozygous 
2/2 represents 750 CC subjects. As shown in the legend undetermined samples are denoted by a X. No 
post-mortem subjects were undetermined during T750C SNP genotyping. The black square denotes the 
negative control. All samples were run in duplicate together with positive controls.  
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Table 29: T750C genotypes for the 84 post-mortem samples. 
 
Sample T750C 
genotype 
Sample T750C 
genotype 
Sample T750C 
genotype 
Sample T750C 
genotype 
DC1 TC DC22 CC DC43 TC DC64 TT 
DC2 TT DC23 TT DC44 TC DC65 CC 
DC3 TC DC24 TT DC45 TT DC66 TT 
DC4 TT DC25 TT DC46 TT DC67 CC 
DC5 TT DC26 TT DC47 TT DC68 TT 
DC6 TC DC27 TC DC48 TC DC69 TC 
DC7 TT DC28 TT DC49 TC DC70 TC 
DC8 TC DC29 CC DC50 CC DC71 TT 
DC9 TC DC30 TT DC51 CC DC72 TC 
DC10 TC DC31 TC DC52 TC DC73 TC 
DC11 TT DC32 TC DC53 TC DC74 TT 
DC12 TC DC33 TC DC54 TT DC75 TC 
DC13 CC DC34 CC DC55 TT DC76 TC 
DC14 TC DC34 CC DC56 CC DC77 TC 
DC15 TT DC36 TC DC57 CC DC78 TT 
DC16 CC DC37 TT DC58 TC DC79 TC 
DC17 TC DC38 TT DC59 TC DC80 CC 
DC18 TT DC39 TC DC60 TC DC81 CC 
DC19 TC DC40 TC DC61 TT DC82 TT 
DC20 TC DC41 CC DC62 TT DC83 TC 
DC21 TC DC42 TT DC63 CC DC84 TT 
 
 
In total 37 of the post-mortem subjects were heterozygous for the T750C SNP, 16 
subjects were homozygous for the C allele, and 31 subjects were homozygous for the 
T allele. 
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3.2.1.4 G516T SNP Genotyping 
 
All 84 subjects of the post-mortem group where methadone was associated with the 
cause of death were successfully genotyped for the CYP2B6 G516T variation (Figure 
48, Table 30). 
 
Figure 48: A typical allelic discrimination plot for the G516T SNP. 
 
Where homozygous 1/1 stands for 516 GG subjects, 1/2 stands for 516 GT subjects and homozygous 
2/2 represents 516 TT subjects. As shown in the legend undetermined samples are denoted by a X. No 
post-mortem subjects were undetermined during G516T SNP genotyping. The black square denotes the 
negative control. All samples were run in duplicate together with positive controls.  
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Table 30: G516T genotypes for the 84 post-mortem samples. 
 
Sample G516T 
genotype 
Sample G516T 
genotype 
Sample G516T 
genotype 
Sample G516T 
genotype 
DC1 GT DC22 GG DC43 GG DC64 GG 
DC2 GG DC23 GT DC44 GT DC65 GG 
DC3 GG DC24 GG DC45 GG DC66 GT 
DC4 GT DC25 GT DC46 GT DC67 GG 
DC5 GG DC26 GG DC47 GT DC68 GG 
DC6 GG DC27 GT DC48 GT DC69 GT 
DC7 GT DC28 GT DC49 GG DC70 GG 
DC8 GT DC29 GG DC50 GG DC71 GG 
DC9 GG DC30 GT DC51 GG DC72 GG 
DC10 GT DC31 GG DC52 GT DC73 GT 
DC11 GT DC32 GG DC53 GG DC74 GT 
DC12 GT DC33 GT DC54 GT DC75 GT 
DC13 GG DC34 GG DC55 GT DC76 GT 
DC14 GG DC34 GG DC56 GG DC77 GT 
DC15 GT DC36 GG DC57 GG DC78 GT 
DC16 GG DC37 GT DC58 GG DC79 GT 
DC17 GG DC38 TT DC59 GG DC80 GG 
DC18 GT DC39 GG DC60 GT DC81 GG 
DC19 GT DC40 GG DC61 GG DC82 GT 
DC20 GG DC41 GG DC62 GG DC83 GT 
DC21 GG DC42 GG DC63 TT DC84 GT 
 
 
In total 37 of the post-mortem subjects were heterozygous for the G516T SNP, 2 
subjects were homozygous for the T allele, and 45 subjects were homozygous for the 
G allele. 
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3.2.1.5 A785G SNP Genotyping 
 
All 84 subjects of the post-mortem group where methadone was associated with the 
cause of death were successfully genotyped for the CYP2B6 A785G variation (Figure 
49, Table 31). 
 
 
 
Figure 49: A typical allelic discrimination plot for the A785G SNP. 
 
Where homozygous 1/1 stands for 785 AA subjects, 1/2 stands for 785 AG subjects and homozygous 
2/2 represents 785 GG subjects. As shown in the legend undetermined samples are denoted by a X. No 
post-mortem subjects were undetermined during A785G SNP genotyping. The black square denotes the 
negative control. All samples were run in duplicate together with positive controls.  
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Table 31: A785G genotypes for the 84 post-mortem samples. 
 
Sample A785G 
genotype 
Sample A785G 
genotype 
Sample A785G 
genotype 
Sample A785G 
genotype 
DC1 AG DC22 AA DC43 AG DC64 AA 
DC2 AA DC23 AG DC44 AG DC65 AA 
DC3 AA DC24 AA DC45 AA DC66 AG 
DC4 AG DC25 AG DC46 AG DC67 AA 
DC5 AA DC26 AA DC47 AG DC68 AA 
DC6 AA DC27 AG DC48 AG DC69 AG 
DC7 AG DC28 AG DC49 AA DC70 AA 
DC8 AG DC29 AG DC50 AA DC71 AA 
DC9 AA DC30 AG DC51 AA DC72 AA 
DC10 AG DC31 AA DC52 AG DC73 AG 
DC11 AG DC32 AA DC53 AA DC74 AG 
DC12 AG DC33 AG DC54 AG DC75 AG 
DC13 AA DC34 AA DC55 AG DC76 AG 
DC14 AA DC34 AA DC56 AA DC77 AG 
DC15 AG DC36 AA DC57 AA DC78 AG 
DC16 AA DC37 AG DC58 AA DC79 AG 
DC17 AA DC38 GG DC59 AA DC80 AA 
DC18 AG DC39 AG DC60 AA DC81 AA 
DC19 AG DC40 AA DC61 AG DC82 AG 
DC20 AA DC41 AA DC62 AA DC83 AG 
DC21 AA DC42 AA DC63 GG DC84 AG 
 
In total 40 of the post-mortem subjects were heterozygous for the G516T SNP, 2 
subjects were homozygous for the T allele, and 42 subjects were homozygous for the 
G allele. 
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3.3 Control Sample Examination 
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3.3.1 Control Sample Study 
All of the control samples collected were successfully quantified and genotyped for 
the OPRM1 A118G, and CYP2B6 T750C, G516T and A785G SNPs. The results for 
DNA quantification and SNP genotyping are reported below. 
 
3.3.2 Buccal DNA quantification 
All of the 100 extracted control samples were successfully quantified using the human 
quantifiler® kit (Table 32). 
 
Table 32: DNA yield for control group buccal extractions. 
 
 
 
 
 
 
 
 
Samples DNA yield Samples DNA yield Samples DNA yield Samples DNA yield 
  ng/µl  ng/µl  ng/µl  ng/µl 
CC1 11.32 CC26 6.77 CC51 5.51 CC76 3.98 
CC2 3.86 CC27 8.05 CC52 2.84 CC77 6.98 
CC3 2.88 CC28 5.44 CC53 1.93 CC78 2.40 
CC4 7.05 CC29 2.56 CC54 2.72 CC79 5.26 
CC5 1.18 CC30 10.77 CC55 4.13 CC80 6.26 
CC6 11.32 CC31 1.11 CC56 3.94 CC81 4.58 
CC7 3.86 CC32 5.48 CC57 7.38 CC82 5.26 
CC8 2.88 CC33 6.02 CC58 3.05 CC83 3.97 
CC9 7.05 CC34 6.02 CC59 6.30 CC84 4.45 
CC10 7.33 CC35 5.11 CC60 1.97 CC85 2.25 
CC11 7.84 CC36 6.79 CC61 4.87 CC86 1.79 
CC12 5.67 CC37 4.51 CC62 6.25 CC87 3.39 
CC13 3.47 CC38 4.60 CC63 7.16 CC88 3.42 
CC14 8.67 CC39 4.01 CC64 4.88 CC89 5.80 
CC15 4.22 CC40 5.41 CC65 3.65 CC90 1.0 
CC16 8.63 CC41 3.83 CC66 10.76 CC91 1.96 
CC17 5.16 CC42 6.40 CC67 5.42 CC92 1.0 
CC18 3.59 CC43 9.41 CC68 4.23 CC93 0.34 
CC19 10.61 CC44 5.01 CC69 5.50 CC94 2.30 
CC20 6.18 CC45 6.29 CC70 5.99 CC95 2.79 
CC21 3.39 CC46 4.28 CC71 15.48 CC96 6.96 
CC22 4.38 CC47 6.28 CC72 7.39 CC97 3.36 
CC23 7.19 CC48 5.90 CC73 8.90 CC98 2.08 
CC24 11.33 CC49 9.94 CC74 9.07 CC99 4.02 
CC25 5.88 CC50 4.56 CC75 7.50 CC100 0.77 
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3.3.3 A118G SNP genotyping 
 
Table 33: A118G genotypes for the 100 control samples. 
 
 
In total 30 subjects were heterozygous for the A118G SNP, two were homozygous for 
the G allele (CC5 & CC10) and 68 were homozygous for the A allele. The frequency 
of the A118G variation is statistically higher in the control population than the post-
mortem population sampled (difference of 15.7 %, P = 0.0046). 
  
 
 
 
 
 
Samples A118G 
genotype 
Samples A118G 
genotype 
Samples A118G 
genotype 
Samples A118G 
genotype 
CC1 AA CC26 AA CC51 AA CC76 AG 
CC2 AA CC27 AA CC52 AA CC77 AG 
CC3 AG CC28 AG CC53 AA CC78 AG 
CC4 AA CC29 AA CC54 AG CC79 AA 
CC5 GG CC30 AA CC55 AG CC80 AG 
CC6 AG CC31 AA CC56 AA CC81 AA 
CC7 AA CC32 AG CC57 AA CC82 AA 
CC8 AA CC33 AA CC58 AA CC83 AG 
CC9 AA CC34 AG CC59 AA CC84 AA 
CC10 GG CC35 AG CC60 AA CC85 AA 
CC11 AA CC36 AA CC61 AA CC86 AG 
CC12 AA CC37 AA CC62 AA CC87 AA 
CC13 AG CC38 AA CC63 AA CC88 AA 
CC14 AA CC39 AA CC64 AA CC89 AA 
CC15 AG CC40 AA CC65 AG CC90 AG 
CC16 AG CC41 AA CC66 AA CC91 AA 
CC17 AA CC42 AA CC67 AA CC92 AA 
CC18 AG CC43 AA CC68 AA CC93 AA 
CC19 AG CC44 AG CC69 AA CC94 AA 
CC20 AG CC45 AA CC70 AA CC95 AA 
CC21 AA CC46 AA CC71 AA CC96 AG 
CC22 AG CC47 AA CC72 AG CC97 AA 
CC23 AA CC48 AA CC73 AA CC98 AA 
CC24 AG CC49 AA CC74 AA CC99 AG 
CC25 AA CC50 AG CC75 AG CC100 AA 
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3.3.4 T750C SNP genotyping 
 
Table 34: T750C genotypes for the 100 control samples. 
 
 
In total 49 of the control subjects were heterozygous for the T750C variation, 17 were 
homozygous for the C allele and 34 were homozygous for the T allele. This is a 
similar frequency to the post-mortem population sampled (19 %, 2 % difference 
between populations). 
 
 
 
 
 
 
 
 
 
 
 
Samples T750C 
genotype 
Samples T750C 
genotype 
Samples T750C 
genotype 
Samples T750C 
genotype 
CC1 TC CC26 CC CC51 CC CC76 TT 
CC2 TC CC27 TT CC52 CC CC77 TT 
CC3 TC CC28 CC CC53 TT CC78 TC 
CC4 TT CC29 TC CC54 CC CC79 TC 
CC5 TT CC30 TT CC55 TC CC80 TT 
CC6 CC CC31 TT CC56 TC CC81 TC 
CC7 TT CC32 CC CC57 TC CC82 TC 
CC8 TT CC33 TC CC58 TC CC83 TT 
CC9 TC CC34 TC CC59 TC CC84 TC 
CC10 TC CC35 TC CC60 TC CC85 TT 
CC11 TC CC36 TC CC61 TC CC86 TT 
CC12 TC CC37 TT CC62 TT CC87 TT 
CC13 TC CC38 TT CC63 TC CC88 CC 
CC14 CC CC39 TT CC64 TT CC89 TC 
CC15 CC CC40 CC CC65 TT CC90 TC 
CC16 CC CC41 TT CC66 CC CC91 TC 
CC17 TC CC42 TT CC67 TT CC92 TC 
CC18 TC CC43 TC CC68 CC CC93 TC 
CC19 TC CC44 TT CC69 TC CC94 TC 
CC20 TT CC45 CC CC70 TT CC95 TC 
CC21 CC CC46 TT CC71 TC CC96 TC 
CC22 TC CC47 TC CC72 TT CC97 TC 
CC23 TC CC48 TT CC73 TC CC98 TC 
CC24 TC CC49 TT CC74 CC CC99 TC 
CC25 TC CC50 TT CC75 TT CC100 TT 
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3.3.5 G516T SNP genotyping 
 
Table 35: G156T genotypes for the 100 control samples. 
 
 
 
In total 34 subjects were genotyped as being heterozygous for the G516T variant, 
three were homozygous for the TT genotype and 63 were homozygous for the GG 
genotype. The frequency of G561T variants was higher in the post-mortem population 
however this result was not statistically significant (P = 0.92). 
 
 
 
 
 
 
 
 
 
 
 
Samples G516T 
genotype 
Samples G516T 
genotype 
Samples G516T 
genotype 
Samples G156T 
genotype 
CC1 GG CC26 GG CC51 GG CC76 GT 
CC2 GG CC27 GG CC52 GG CC77 GG 
CC3 GG CC28 GG CC53 GG CC78 GG 
CC4 GT CC29 GT CC54 GG CC79 GG 
CC5 GT CC30 GT CC55 GG CC80 GG 
CC6 GG CC31 GT CC56 GG CC81 GG 
CC7 GG CC32 GG CC57 GG CC82 GG 
CC8 GT CC33 GT CC58 GG CC83 GG 
CC9 GT CC34 GG CC59 GG CC84 GG 
CC10 GG CC35 GT CC60 GT CC85 GT 
CC11 GT CC36 GG CC61 GT CC86 GT 
CC12 GT CC37 GT CC62 GT CC87 GT 
CC13 GG CC38 GT CC63 GG CC88 GG 
CC14 GG CC39 GG CC64 GT CC89 GG 
CC15 GG CC40 GG CC65 GG CC90 GT 
CC16 GG CC41 GT CC66 GG CC91 GG 
CC17 GG CC42 GG CC67 GT CC92 GG 
CC18 GG CC43 GG CC68 GG CC93 GT 
CC19 GG CC44 GG CC69 GG CC94 GG 
CC20 TT CC45 GG CC70 GG CC95 GG 
CC21 GG CC46 GG CC71 GT CC96 GT 
CC22 GT CC47 GG CC72 GT CC97 GT 
CC23 GG CC48 GG CC73 GG CC98 TT 
CC24 GT CC49 GG CC74 GG CC99 GT 
CC25 GT CC50 GG CC75 TT CC100 GT 
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3.3.6 A785G SNP genotyping 
 
Table 36: A785G genotypes for the 100 control samples. 
 
 
 
In total 38 of the control subjects were genotyped as heterozygous carriers of the 
A785G variant, three were homozygous for the GG genotype and 59 were 
homozygous for the AA genotype. The frequency for A785G is lower in the control 
population than the post-mortem population however this result is not statistically 
significant (P = 0.90). 
Samples A785G 
genotype 
Samples A785G 
genotype 
Samples A785G 
genotype 
Samples A785G 
genotype 
CC1 AA CC26 AA CC51 AG CC76 AG 
CC2 AA CC27 AA CC52 AA CC77 AA 
CC3 AG CC28 AA CC53 AA CC78 AA 
CC4 AG CC29 AG CC54 AA CC79 AA 
CC5 AG CC30 AG CC55 AA CC80 AA 
CC6 AA CC31 AG CC56 AA CC81 AA 
CC7 AA CC32 AG CC57 AA CC82 AA 
CC8 AG CC33 AG CC58 AA CC83 AA 
CC9 AG CC34 AA CC59 AA CC84 AA 
CC10 AA CC35 AG CC60 AG CC85 AG 
CC11 AG CC36 AA CC61 AG CC86 AG 
CC12 AG CC37 AG CC62 AG CC87 AG 
CC13 AA CC38 AG CC63 AA CC88 AA 
CC14 AA CC39 AA CC64 AG CC89 AA 
CC15 AA CC40 AA CC65 AA CC90 AA 
CC16 AA CC41 AG CC66 AA CC91 AA 
CC17 AA CC42 AA CC67 AG CC92 AA 
CC18 AA CC43 AA CC68 AG CC93 AG 
CC19 AG CC44 AA CC69 AA CC94 AA 
CC20 GG CC45 AA CC70 AA CC95 AA 
CC21 AA CC46 AA CC71 AG CC96 AG 
CC22 AG CC47 AA CC72 AG CC97 AG 
CC23 AA CC48 AA CC73 AA CC98 GG 
CC24 AG CC49 AA CC74 AA CC99 AG 
CC25 AG CC50 AA CC75 GG CC100 AG 
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3.4 CYP2B6 Cloning 
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3.4.1 Cloning of promoter region of human CYP2B6 gene 
 
3.4.1.1 Examination of the plasmid by HindIII & XbaI Digest 
In preparation for the experimental cloning work a double digest using the restriction 
enzymes HindIII and XbaI was conducted. The results are displayed in Figure 50. 
Banding is clear for both the uncut DNA and the DNA cut with HindIII and XbaI. If 
Figure 4 within section 2.4.1 Primary Cloning Strategy is examined it is possible to 
see that these enzymes were used to cut the relevant sections out of the two vectors 
(hSVCT2 and pYEGFP3) to create specific vectors to examine CYP2B6 expression in 
response to promoter regions variations. 
 
 
 
Figure 50: Double restriction digest using HindIII and XbaI for Cloning method 
development. 
 
Agarose gel (2 %), run at 70 volts. Two DNA bands following the HindIII and XbaI double digest are 
shown for hSVCT2 and pyEGFP3. 
 
1 kb ladder 
250 bp 
500 bp 
Uncut DNA 
hSVCT2                                     pYEGFP3 
 
                              Vectors 
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3.4.1.2 Gel Extraction of pYEGFP3 Gene 
Aliquots of double digested (HindIII, XbaI) pyEGFP DNA were run on a 2% gel in 
order to conduct the gel extraction (Figure 51). After the removal and collection of the 
DNA bands, gel extraction was conducted and confirmed through gel electrophoresis 
(Figure 52). 
 
 
Figure 51: Double restriction digest of pyEGFP using HindIII and XbaI for Gel Extraction. 
 
Agarose gel (2 %), run at 70 volts. The pyEGFP3 DNA fragments (748 bp) are indicated. 
 
 
 
Figure 52: Gel Extracted pyEGFP inserts for cloning strategy. 
Agarose gel (2 %), run at 70 volts. Purified pyEGFP3 fragements following Qiaquick gel extraction. 
1 kb ladder 
pyEGFP insert 
500 bp 
pyEGFP 
1 kb ladder 
Gel Extracted pyEGFP insert 
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3.4.1.3 Gel Extraction of hSVCT2 Vector 
 
Aliquots of triple digested (HindIII, BamHI XbaI) hSVCT2 DNA were run on a 2% 
gel in order to conduct the gel extraction (Figure 53). After the removal and collection 
of the DNA bands, gel extraction was conducted and confirmed through gel 
electrophoresis (Figure 54). 
 
Figure 53: Triple restriction digest of hSVCT2 using HindIII, BamHI and XbaI for Gel 
Extraction. 
 
Agarose gel (2 %), run at 70 volts. The arrows indicate the hSVCT2 vector and the digested hSVCT2 
gene. 
 
 
Figure 54: Gel Extracted hSVCT2 vector for cloning strategy. 
Agarose gel (2 %), run at 70 volts. Purified hSVCT2 vector following QIAquick gel extraction. 
hSVCT2 vector 
1 kb ladder 
Digested sections of 
the hSVCT2 gene 
Gel extracted 
hSVCT2 vector 
1 kb ladder 
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3.4.1.4. Ligation of pyEGFP into hSVCT2 vector 
 
The efficiency of the ligation of pyEGFP into the hSVCT2 vector was tested by a 
Lamda-HindIII ligation. As Figure 55 shows the two Lamda-HindIII ligated controls 
(LDH) had single bands indicating a successful ligation experiment.  
 
 
 
Figure 55: Ligated Lamda-HindIII positive controls. 
Agarose gel (2 %), run at 70 volts. Arrow indicates the unligated Lamda-HindIII control sample. 
 
3.4.1.5. NdeI confirmation of hSVCT2-EGFP vector transformation. 
 
Following transformation, 43 clones were identified: 
B (1:3 vector: insert ratio) – B21, B22, B23, B24, B25, B26, B31. 
C (1:2 vector: insert ratio) – C21, C22, C31. 
D (1:1 vector: insert ratio) – D31, D32, D33, D34, D35, D36. 
E (2:1 vector: insert ratio) – E21, E22, E23, E24, E25, E26, E27, E31, E32, E33, E34,    
                                            E35, E36, E37. 
F (3:1 vector: insert ratio) – F21, F22, F23, F24, F25, F26, F27, F28, F29, F210, F211,   
                                            F31, F32. 
As expected no clones grew in the negative controls (A 0:1; G 1:0). 
1 kb ladder 
 LHD,   LHD, Control 
Unligated  
Lamda-HindIII 
control 
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Clone identity was tested by conducting an NdeI digest on the samples. With the 
successful ligation of EGFP into the hSVCT2 vector, NdeI should cut the clones twice. 
If Figures 56, 57, 58, & 59 are examined there is only a single cut, suggesting that 
instead of ligating EGFP into hSVCT2, the vector had ligated to itself creating an 
empty vector.  
 
 
Figure 56: Single restriction digest of hSVCT2-EGFP clone using NdeI. 
Agarose gel (2 %), run at 70 volts. Arrow indicates single cut following the NdeI digest. 
 
 
 
Figure 57: Single restriction digest of hSVCT2-EGFP clone using NdeI. 
Agarose gel (2 %), run at 70 volts. Arrow indicates single cut following the NdeI digest. 
 
 
  B21, B22, B23, B24, B25, B26, B31, C21, C22, C31, D31, D32 
Single band 
denoting 
empty vectors 
1 kb ladder 
D33, D34, D35, D36, E21, E22, E23, E24, E25, E26, E27, E31 
1 kb ladder 
Single band 
denoting 
empty vectors 
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Figure 58: Single restriction digest of hSVCT2-EGFP clone using NdeI. 
Agarose gel (2 %), run at 70 volts. Arrow indicates single cut following the NdeI digest. 
 
 
Figure 59: Single restriction digest of hSVCT2-EGFP clone using NdeI. 
Agarose gel (2 %), run at 70 volts. Arrow indicates single cut following the NdeI digest. 
 
In order to continue with cloning the CYP2B6 promoter region the Invitrogen TOPO® 
kit was employed and a new cloning strategy constructed (Figure 5). 
 
3.4.1.6. CYP2B6 Promoter Region Primer Validation 
As Figure 60 demonstrates the primary amplification of the CYP2B6 promoter region 
had poor selectivity with lots of smearing visible. Banding for CYP2B6 is visible 
however the bands are faint and require improvement for the TOPO® cloning strategy. 
E32, E33, E34, E35, E36, E37, F21, F22, F23, F24, F25, F26, F27, F28  
   F29,    F210,   F211,    F31,    F32 
Single band 
denoting 
empty vectors 
Single band 
denoting 
empty vectors 
1 kb ladder 
1 kb ladder 
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Figure 60: Amplification of CYP2B6 promoter region for primer optimisation. 
Agarose gel (2 %), run at 70 volts. Arrow indicates amplified CYP2B6 promoter region (2.4 kb). 
 
3.4.1.7 PCR Temperature Development 
The gradient reaction demonstrated that the optimal temperature range for CYP2B6 
promoter region amplification was between 61.0 and 62.3 ºC (Figure 61). However, 
there was still poor selectivity with faint banding for CYP2B6. 
 
 
 
Figure 61: Gradient reaction to improve amplification selectivity for CYP2B6 promoter. 
 
Agarose gel (2 %), run at 70 volts. Arrow indicates amplified CYP2B6 promoter region (2.4 kb). 
 
CYP2B6 promoter 
region 
(2.4 kb) 
1 kb ladder 
ºC   60.2,   60.2,   61.0,   61.0  
ºC 61.0, 61.7, 62.3, 63.0, 63.8 
CYP2B6 promoter 
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3.4.1.8 Amplification of CYP2B6 promoter region 
 
 
 
 
 
 
Figure 62: Amplification of CYP2B6 promoter regions for 750TT, 750TC, & 750CC 
genotypes. 
 
Agarose gel (2 %), run at 70 volts. Amplified CYP2B6 promoter variants to analyse the influence of the 
T750C SNP. 
 
 
As Figure 62 shows the optimal annealing temperature for CYP2B6 promoter 
amplification had been identified at 60.2 ºC. Adequate banding for all three T750C 
genotypes had been yielded to continue with the molecular cloning strategy (Figure 5) 
using the TOPO® Cloning Reaction (Invitrogen, UK). 
 
3.4.1.9 Transformation of CYP2B6 750TT, 750TC, & 750CC into TOPO® vector 
 
 
The ligation and transformation of the amplified CYP2B6 regions for the three T750C 
genotypes was successful and clones for each were isolated. Each of the clones were 
confirmed by conducting a BglII & HindIII double restriction digest to confirm the 
presence of three bands (Figures 63, 64, 65). The orientation of the CYP2B6 promoter 
region was then confirmed by conducting a single BglII digest to identify two bands 
(Figures 63, 64, 65).  
    -750TT -                       -750TC-                      - 750CC- 
CYP2B6 T750C Genotypes 
CYP2B6 promoter 
region 
(2.4 kb) 
1 kb ladder 
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Figure 63: Validation of the CYP2B6 promoter region transformation and orientation for the 
750 TT genotype. 
 
Agarose gel (2 %), run at 70 volts. The arrow indicates the CYP2B6 promoter region visible after the 
HindIII/BglII double digest. The orientation is correct as shown by the two bands for the BglII single 
digest. 
 
 
 
Figure 64: Validation of the CYP2B6 promoter region transformation and orientation for the 
750 TC genotype. 
 
Agarose gel (2 %), run at 70 volts. The arrow indicates the CYP2B6 promoter region visible after the 
HindIII/BglII double digest. The orientation is correct as shown by the two bands for the BglII single 
digest. The reverse CYP2B6 orientation is indicated by *.  
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       BglII   HindIII & BglII 
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Figure 65: Validation of the CYP2B6 promoter region transformation and orientation for the 
750 CC genotype. 
 
Agarose gel (2 %), run at 70 volts. The arrow indicates the CYP2B6 promoter region visible after the 
HindIII/BglII double digest. The orientation of CYP2B6 is reversed as indicated by *. 
 
 
As Figures 63 and 64 show the CYP2B6 promter regions for the 750 TT and TC 
genotypes were successfully ligated into the TOPO® TA vector creating the p2B6-
GFP-HB-750 TT and p2B6-GFP-HB-750 TC clones. However, for the 750 CC 
genotype the CYP2B6 promoter region was successfully ligated into the vector, 
however the orientation was reversed (Figure 65). Therefore, no p2B6-GFP-HB-750 
CC clone was created. 
1 kb ladder 
       HindIII & BglII   BglII        HindIII & BglII   BglII       HindIII & BglII   BglII        HindIII & BglII   BglII 
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3.5 A118G Methadone Binding Study 
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3.5 A118G Methadone Binding Study 
 
The effects of the the A118G SNP on µ opioid receptor internalisation following 
methadone treatment was studied using Human primary CLL cell lines. DNA samples 
extracted from the CLL cells were quantified (Table 37) and genotyped for the 
A118G SNP (Table 38). Then, CLL cell lines for the 118 AA and 118 AG genotypes 
were exposed to varying concentrations of methadone to measure the effect of A118G 
on internalisation. The results from this study are discussed below. 
 
3.5.1 B-cell line DNA Quantification 
 
All of the 44 Human CLL cell lines were extracted and quantified successfully (Table 
37). 
 
Table 37: DNA yield for human CLL cell lines. 
Cell Sample Mean DNA Concentration 
(ng/µl) 
Cell Sample Mean DNA Concentration 
(ng/µl) 
CL1 20.83 CL23 19.85 
CL2 7.87 CL24 21.0 
CL3 5.50 CL25 12.88 
CL4 18.79 CL26 25.36 
CL5 5.71 CL27 528 
CL6 14.05 CL28 15.96 
CL7 20.74 CL29 35.34 
CL8 16.15 CL30 234 
CL9 4.12 CL31 7.88 
CL10 4.54 CL32 13.03 
CL11 20.78 CL33 12.44 
CL12 24.80 CL34 2.74 
CL13 25.00 CL35 38.47 
CL14 7.50 CL36 8.63 
CL15 16.70 CL37 18.91 
CL16 23.0 CL38 17.05 
CL17 5.30 CL39 32.42 
CL18 6.60 CL40 1.05 
CL19 12.38 CL41 2.22 
CL20 8.73 CL42 5.04 
CL21 6.96 CL43 12.64 
CL22 18.87 CL44 19.55 
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3.5.2 A118G SNP Genotyping 
Of the 44 human CLL cell lines genotyped for the OPRM1 A118G variation 28 were 
homozygous for the AA genotype, 15 were heterozygous (AG) and 1 was 
homozygous for the GG genotype (Table 38). 
 
Table 38: A118G SNP Genotypes for CLL Subjects. 
Cell Sample A118G SNP Genotype Cell Sample A118G SNP Genotype 
 
CL1 AG CL23 AG 
CL2 AG CL24 AG 
CL3 AG CL25 AA 
CL4 AA CL26 AA 
CL5 AA CL27 AA 
CL6 AA CL28 AA 
CL7 AG CL29 AA 
CL8 AA CL30 AA 
CL9 AA CL31 AA 
CL10 AA CL32 AA 
CL11 AA CL33 AA 
CL12 AA CL34 AA 
CL13 AG CL35 AG 
CL14 AG CL36 GG 
CL15 AA CL37 AA 
CL16 AA CL38 AA 
CL17 AA CL39 AA 
CL18 AG CL40 AG 
CL19 AG CL41 AG 
CL20 AG CL42 AG 
CL21 AA CL43 AA 
CL22 AA CL44 AA 
 
 
3.5.3 Receptor Internalisation 
3.5.3.1 Primary anti-µ and secondary anti-rabbit IgGFITC validation 
As shown in Table 39 the optimal antibody concentration for visualising cell surface 
µ opioid receptor presence was P 1:20, S 1:10, closely followed by P 1:20, S 1:20.  It 
was observed that the negative control mean fluorescence intensity was higher than 
expected with a geometric mean of 4.7. It was postulated that the goat polyclonal to 
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rabbit IgG-FITC secondary antibody may be binding to other locations, for example 
Fc receptors. 
 
Table 39: The mean fluorescence intensity for antibody bound µ opioid receptors. 
Tube Reaction Geometric Mean Receptor Visualisation 
(% change from S 1:10) 
1 P 1:10 S 0 3.34  
2 P 0 S 1:10 4.70  
3 P1:10 S 1:10 4.72 0.4 % 
4 P1:10 S 1:20 7.65 63 % 
5 P1:10 S 1:50 2.85 - 39 % 
6 P1:20 S 1:10 29.31 524 % 
7 P1:20 S 1:20 19.28 310 % 
8 P1:20 S 1:50 3.85 -18 % 
9 P1:50 S 1:10 9.66 106 % 
10 P1:50 S 1:20 3.44 - 27% 
11 P1:50 S 1:50 3.92 - 17% 
12 Kappa/Lamda control 11.02 134 % 
 
3.5.3.2 Blockage of Fc Receptors to improve Antibody-Receptor Binding 
In order to minimise secondary antibody binding to Fc receptors a blocking 
experiment using human AB (HAB) serum was tested (Table 40). 
 
Table 40: The mean fluorescence intensity for antibody bound µ opioid receptors following 
HAB blocking of Fc receptors. 
 
Tube Reaction Geometric Mean Receptor Visualisation 
(% change from S 1:10) 
1 P 1:20 S 0 1.5  
2 P 0 S 1:20 2.09  
3 P1:20 S 1:10 1.91 -9 % 
4 P1:20 S 1:20 2.12 1.4 % 
5 Kappa/Lamda control 2.45 17 % 
 
 
As shown in Table 40 the addition of HAB serum may have reduced the geometric 
mean result for S 1:20, however, the percentage change from the negative control was 
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minimal. The difference between the sample geometric mean and the S1:20 controls 
were used to identify the effects of methadone concentration and the A118G 
polymorphism on µ opioid receptor internalisation. 
 
3.5.3.3 Primary anti-µ and secondary anti-rabbit IgGPE Optimisation 
Previous works from this study used a goat polyclonal to rabbit IgG-FITC secondary 
antibody and it was postulated that non-specific binding could be interfering with the 
results. No improvement was observed using the HAB blocking agent. An experiment 
was conducted using the mouse monoclonal to rabbit IgG-PE secondary antibody to 
determine whether this improved visualisation of µ receptors. However as shown in 
Table 41 little µ receptor visualisation was observed. It was proposed that the rabbit 
monoclonal [EP1470Y] to µ opioid receptor primary antibody was degraded, possibly 
as a result of freeze/thawing. 
 
Table 41: The mean fluorescence intensity for PE antibody bound µ opioid receptors. 
Tube Reaction Geometric Mean Receptor Visualisation 
(% change from S 1:10) 
1 P 1:10 S 0 1.11  
2 P 0 S 1:10 1.12 0 % 
3 P1:10 S 1:10 1.13 0.9 % 
4 P1:10 S 1:20 1.13 0.9 % 
5 P1:10 S 1:50 1.12 0 % 
6 P1:20 S 1:10 1.13 0.9 % 
7 P1:20 S 1:20 1.13 0.9 % 
8 P1:20 S 1:50 1.12 0 % 
9 P1:50 S 1:10 1.14 1.8 % 
10 P1:50 S 1:20 1.13 0.9 % 
11 P1:50 S 1:50 1.12 0 % 
12 Kappa/Lamda control 1.18 5.4 % 
 
 
 
 183 
3.5.3.4 Primary anti-µ and secondary anti-rabbit IgGFITC Optimisation 
As shown in Table 42 the optimal µ opioid receptor (ab10275) primary antibody 
concentration was 1:10, and the optimal secondary antibody (goat polyclonal to rabbit 
IgG-FITC) was also 1:10. This was then followed by P 1:100, S 1:10, and P 1:1000, S 
1:10. It is also clear from these results that the mouse monoclonal to rabbit IgG-PE 
secondary antibody was not suitable for this experiment. Therefore the primary µ 
opioid primary antibody (ab10275) 1:10 and goat polyclonal to rabbit IgG-FITC 
secondary 1:10 antibody concentrations were used to determine the effects of 
methadone concentration and the A118G polymorphism on µ opioid receptor 
internalisation. 
 
Table 42: The mean fluorescence intensity for FITC and PE antibody bound µ opioid 
receptors. 
 
Tube Reaction Geometric 
Mean 
Receptor Visualisation 
(% change from S 1:10) 
1 P 1:10 S 0 1.39  
2 P 0 S 1:10 FITC 2.21  
3 P0 S 1:10 PE 1.09  
4 P1:10 S 1:10 FITC 9.92 349 % 
5 P1:10 S 1:100 FITC 1.94 -12 % 
6 P1:10 S 1:1000 FITC 1.09 -51 % 
7 P1:100 S 1:10 FITC 2.71 23 % 
8 P1:100 S 1:100 FITC 1.56 -29 % 
9 P1:100 S 1:1000 FITC 1.09 -51 % 
10 P1:1000 S 1:10 FITC 2.4 9 % 
11 P1:1000 S 1:100 FITC 1.6 -28 % 
12 P1:1000 S 1:1000 FITC 1.08 -51 % 
13 P1:10 S 1:10 PE 1.10 -50 % 
14 P1:10 S 1:100 PE 1.10 -50 % 
15 P1:10 S 1:1000 PE 1.09 -51 % 
16 P1:100 S 1:10 PE 1.10 -50 % 
17 P1:100 S 1:100 PE 1.09 -51 % 
18 P1:100 S 1:1000 PE 1.09 -51 % 
19 P1:1000 S 1:10 PE 1.09 -51 % 
20 P1:1000 S 1:100 PE 1.07 -52 % 
21 P1:1000 S 1:1000 PE 1.09 -51 % 
22 Kappa/Lamda control 2.45 11 % 
 
 184 
3.5.4 Racemic Methadone Binding Study 
3.5.4.1 The effects of cell culture incubation interval on cell apoptosis 
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Figure 66: The influence of cell culture incubation time on cell apoptosis following freezing 
and thawing. 
 
There is an increase in % live cells for Samples A and D over the 1.3 and 2 hour time intervals, 
however the increase is not significant. 
 
As Figure 66 shows the difference in cell apoptosis between different incubation 
intervals was not significant. An incubation time of one hour was selected for the 
apoptosis and µ opioid receptor internalisation experiments. This incubation time was 
the same as other works (Keith et al. 1998; Trapaidze et al. 2000). 
 
3.5.4.2 Cell culture of B-lymphocytes in methadone 
3.5.4.2.1 Cell Apoptosis Trial 
The effects of the A118G polymorphism and methadone exposure on cellular 
apoptosis were examined. As shown in Figures 67 and 68, typically there was an 
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increase in the percentage of total cells positive for Annexin V. This trend is clearer in 
Figure 68 and could be a result of the 118 AG genotype. 
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Figure 67: The influence of methadone concentration on early stage cell apoptosis for 118 
AA subjects, determined by the % of Annexin V-FITC positive cells. 
 
For 118 AA subjects there is an increase in apoptosis for the 100µM treatment. 
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Figure 68: The influence of methadone concentration on early stage cell apoptosis for 118 
AG subjects, determined by the % of Annexin V-FITC positive cells. 
 
For 118 AG subjects there is an increase in apoptosis for the 20 and 10µM treatments. 
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Figure 69: The influence of methadone concentration on late stage cell apoptosis for 118 
AA subjects, determined by the % of propidium iodide permeabilised cells. 
 
For 118 AA subjects there is a decrease in apoptosis for the 100µM treatment for all subjects except 
CL34 and CL44. 
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Figure 70: The influence of methadone concentration on late stage cell apoptosis for 118 
AG subjects, determined by the % of propidium iodide permeabilised cells. 
 
For 118 AG subjects there is a decrease increase in apoptosis until the 20 µM treatment. 
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Figure 71: The influence of methadone concentration on late stage cell apoptosis for 118 
AA subjects, determined by the % of propidium iodide fragmented cells. 
 
For 118 AA subjects there is an increase in cell fragementation after the 100µM treatment, which 
decreased for the following methadone treatments. 
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Figure 72: The influence of methadone concentration on late stage cell apoptosis for 118 
AG subjects, determined by the % of propidium iodide fragmented cells. 
 
For 118 AG subjects there is a noticeable increase in cell fragmentation between the 20 µM and 10 µM 
methadone treatments. 
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The propidium iodide results for cell permeabilisation show an increase for the 20 µM 
and 10 µM methadone concentrations (Figures 69 & 70). As shown in Figure 71 an 
increase in cell fragmentation for 118 AA subjects following the 100 µM methadone 
concentration and between 20 and 5 µM methadone was observed. For the 118 AG 
subjects the trend was clearer with the majority of subjects demonstrating an increase 
in cell fragmentation following the 100 µM and 20 µM methadone concentrations 
(Figure 72). These results are discussed in Chapter 8. 
 
3.5.4.2.2 µ Receptor Internalisation 
 
The effect of the A118G polymorphism and methadone exposure on µ-opioid receptor 
internalisation was examined to determine whether alterations to receptor 
internalisation are associated with individual susceptibility to methadone. 
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Figure 73: The influence of methadone concentration on µ opioid receptor internalisation 
for 118 AA subjects.  
 
For 118 AA subjects there is an increase in cell fragementation following methadone treatment for 
CL38.  
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Figure 74: The influence of methadone concentration on µ opioid receptor internalisation 
for 118 AG subjects.  
 
For 118 AG subjects the mean fluorescence intensity is significantly higher than 118 AA subjects 
indicating a higher reduction in µ receptor internalisation for 118 AG subjects compared with 118 AA 
subjects following methadone treatment. 
 
Interestingly the mean fluorescence intensity for 118 AA subjects (Figure 73) was 
lower than that of 118 AG subjects (Figure 74). It was postulated that this might be 
associated with µ opioid receptor accumulation at the cell surface as a result of 
methadone exposure. However it could also be linked with alterations to OPRM1 
gene expression as a result of the A118G polymorphism. There was a significant 
increase in the mean fluorescence intensity for 118 AG subjects compared with 118 
AA subjects (Figure 74). For both 118 AA and AG subjects the mean fluorescence 
intensity increased after the 20 µM and 10 µM methadone treatments (Figure 73 & 
74). For a discussion of these results see Chapter 8. 
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3.6 Statistical Analysis 
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3.6.1 Data Normalisation 
 
Data normality was checked for CYP2B6 T750C, G516T, A785G and OPRM1 
A118G, with a normal distribution for all of the SNPs. 
 
3.6.2 Post-mortem Drug Correlations 
 
3.6.2.1 Post-mortem Drug Concentrations 
The association between post-mortem methadone concentrations and post-mortem 
morphine, benzodiazepine, SSRIs, SNRIs, Ethanol, Tricyclic Antidepressants were 
examined (Figures 75 to 80). It was not possible to examine the association between 
methadone and dihydrocodeine as there were only two cases of methadone and 
dihydrocodeine. There was no significant correlation between methadone 
concentration and other drugs examined (Figures 75 to 80). However, although these 
results do not appear to be significant statistically, as an isolated number from the 
measurements given, the plots for methadone and morphine (Figure 75), methadone 
and ethanol (Figure 79) and methadone and tricyclic antidepressants (Figure 80) do 
show a trend. 
 
 192 
 
Figure 75: The correlation between post-mortem methadone concentrations and post-
morphine concentrations. 
 
 
 
 
Figure 76: The correlation between post-mortem methadone concentrations and post-
mortem benzodiazepine concentrations. 
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Figure 77: The correlation between post-mortem methadone concentrations and post-
mortem SSRI concentrations. 
 
 
 
 
Figure 78: The correlation between post-mortem methadone concentrations and post-
mortem SNRI concentrations. 
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Figure 79: The correlation between post-mortem methadone concentrations and post-
mortem ethanol concentrations. 
 
 
 
 
Figure 80: The correlation between post-mortem methadone concentrations and post-
mortem tricyclic antidepressant concentrations. 
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3.6.3 Independent T test 
Using the Independent T-Test significant associations between the CYP2B6 G516T, 
and A785G gene variations and increased post-mortem methadone concentrations 
were identified (see Chapters 4, 5, 6). There was no association between T750C and 
methadone concentration observed in this study. For the first post-mortem population 
sampled (40 subjects) there was no significant difference in post-mortem methadone 
concentrations for the A118G SNP (Chapter 4). However when this population was 
increased to 69 subjects a statistically significant association was identified (Chapter 
5; P = 0.05). 
 
3.6.4 Hardy Weinberg equilibrium  
3.6.4.1 CYP2B6 
3.6.4.1.1 T750C SNP 
Post-mortem population 
Table 43: Post-mortem expected and observed frequencies for the T750C SNP. 
Genotype Expected Observed 
750 TT 24.11 37 
750 TC 41.79 16 
750 CC 18.11 31 
 
P allele frequency is 0.54; Q allele frequency is 0.46 
 
Table 44: Hardy Weinberg results for the T750C SNP in the post-mortem population. 
 750 TT 750 TC 750 CC p allele freq q allele freq 
750 TT 2.06 16 31 0.21 0.79 
750 TC 37 67.73 31 0.52 0.48 
750 CC 37 16 1.73 0.82 0.18 
 
X2 = 31.99, 1 degree of freedom, P < 0.001. 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
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Control population 
Table 45: Control expected and observed frequencies for the T750C SNP. 
 
Genotype Expected Observed 
750 TT 33.06 49 
750 TC 48.87 17 
750 CC 18.06 34 
 
P allele frequency is 0.57; Q allele frequency is 0.43 
Table 46: Hardy Weinberg results for the T750C SNP in the control population. 
 750 TT 750 TC 750 CC p allele freq q allele freq 
750 TT 2.13 17 34 0.2 0.8 
750 TC 49 81.63 34 0.55 0.45 
750 CC 49 17 1.47 0.85 0.15 
 
X2 = 42.53, 1 degree of freedom, P < 0.001. 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
3.6.4.1.2 G516T SNP 
Post-mortem population 
Table 47: Post-mortem expected and observed frequencies for the G516T SNP. 
 
Genotype Expected Observed 
516 GG 15.43 35 
516 GT 41.14 2 
516 TT 27.43 47 
 
P allele frequency is 0.43; Q allele frequency is 0.57 
Table 48: Hardy Weinberg results for the G516T SNP in the post-mortem population. 
 516 GG 516 GT 516 TT p allele freq q allele freq 
516 GG 0.02 2 47 0.02 0.98 
516 GT 35 81.12 47 0.46 0.54 
516 TT 35 2 0.03 0.97 0.03 
 
X2 = 76.03, 1 degree of freedom, P < 0.001. 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
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Control population 
Table 49: Control expected and observed frequencies for the G516T SNP. 
 
Genotype Expected Observed 
516 GG 11.9 33 
516 GT 45.19 3 
516 TT 42.9 64 
 
P allele frequency is 0.35; Q allele frequency is 0.66 
Table 50: Hardy Weinberg results for the G516T SNP in the control population. 
 516 GG 516 GT 516 TT p allele freq q allele freq 
516 GG 0.04 3 64 0.02 0.98 
516 GT 33 91.91 64 0.42 0.58 
516 TT 33 3 0.07 0.96 0.04 
 
X2 = 87.16, 1 degree of freedom, P < 0.001. 
 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
 
3.6.4.1.3 A785G SNP 
Post-mortem population 
Table 51: Post-mortem expected and observed frequencies for the A785G SNP. 
 
Genotype Expected Observed 
785 AA 16.3 36 
785 AG 41.4 2 
785 GG 26.3 46 
 
P allele frequency is 0.44; Q allele frequency is 0.56 
Table 52: Hardy Weinberg results for the A785G SNP in the post-mortem population. 
 785 AA 785 AG 785 GG p allele freq q allele freq 
785 AA 0.02 2 46 0.02 0.98 
785 AG 36 81.39 46 0.47 0.53 
785 GG 36 2 0.03 0.97 0.03 
 
X2 = 76.08, 1 degree of freedom, P < 0.001. 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
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Control population 
Table 53: Control expected and observed frequencies for the A785G SNP. 
Genotype Expected Observed 
785 AA 15.6 38 
785 AG 47.8 3 
785 GG 36.6 59 
 
P allele frequency is 0.4; Q allele frequency is 0.61 
Table 54: Hardy Weinberg results for the A785G SNP in the control population. 
 785 AA 785 AG 785 GG p allele freq q allele freq 
785 AA 0.04 3 59 0.02 0.98 
785 AG 38 94.7 59 0.45 0.55 
785 GG 38 3 0.06 0.96 0.04 
 
X2 = 87.84, 1 degree of freedom, P < 0.001. 
 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
 
3.6.4.2 OPRM1 
3.6.4.2.1 A118G SNP 
Post-mortem population 
Table 55: Post-mortem expected and observed frequencies for the A118G SNP. 
 
Genotype Expected Observed 
118 AA 5.25 21 
118 AG 31.5 0 
118 GG 47.25 63 
 
P allele frequency is 0.25; Q allele frequency is 0.75 
Table 56: Hardy Weinberg results for the A118G SNP in the post-mortem population. 
 118 AA 118 AG 118 GG p allele freq q allele freq 
118 AA 0 0 63 0 1 
118 AG 21 72.75 63 0.37 0.63 
118 GG 21 0 0 1 0 
 
X2 = 84, 1 degree of freedom, P < 0.001. 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
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Control population 
Table 57: Control expected and observed frequencies for the A118G SNP. 
 
Genotype Expected Observed 
118 AA 9.61 30 
118 AG 42.78 2 
118 GG 47.61 68 
 
P allele frequency is 0.31; Q allele frequency is 0.69 
Table 58: Hardy Weinberg results for the A118G SNP in the control population. 
 118 AA 118 AG 118 GG p allele freq q allele freq 
118 AA 0.01 2 68 0.01 0.99 
118 AG 30 90.33 68 0.4 0.6 
118 GG 30 2 0.03 0.97 0.03 
 
X2 = 90.87, 1 degree of freedom, P < 0.001. 
The null hypothesis that the population is in Hardy-Weinberg equilibrium is rejected. 
 
3.6.5 CYP2B6 and OPRM1 SNP-SNP Correlations 
 
In all cases where the CYP2B6 G516T was identified, A785G was also found. This is 
in agreement with previous reports where it was noted that G516T acts as a marker of 
A785G. Linkage between G516T and A785G presence was identified with a χ2 
(32.471), 1 df, P <0.001. Linkage between the T750C, G516T and A785G gene 
variants was identified in both populations (see Chapter 6). In the post-mortem 
population the T750C, G516T and A785G variants were identified together in 17 
cases (20 %) and in the control population the SNPs were found in 17 % of cases.  
No linkage was found between A118G and T750C, G516T and A785G in the control 
population (P = 0.479, P = 0.572, P = 0.479 respectively). Interestingly linkage was 
identified between A118G and G516T (P < 0.01) and A785G (P < 0.01) in the post-
mortem population. 
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3.6.6 The Influence of Age, Gender and Involvement in Methadone Maintenance 
  
The binary logistic regression model revealed that gender and age were significantly 
associated with population and this is discussed in Chapter 7. 
 
 
 
Table 59: Variables entered into the Binary Logistic Regression Equation to determine the 
effects of Age and Gender on CYP2B6 and OPRM1 SNP prevalence. 
 
 
  B S.E. Wald df Sig. 
Step 
1(a) 
A118G 
    .228 2 .892 
  A118G(1) 19.601 27237.521 .000 1 .999 
  A118G(2) 19.399 27237.521 .000 1 .999 
  G516T     .364 2 .834 
  G516T(1) 21.726 21843.516 .000 1 .999 
  G516T(2) 22.238 21843.516 .000 1 .999 
  A785G     .000 1 .985 
  A785G(1) .015 .817 .000 1 .985 
  T750C     2.306 2 .316 
  T750C(1) -.132 .577 .053 1 .819 
  T750C(2) -.651 .536 1.474 1 .225 
  Gender(1) 1.748 .411 18.104 1 .000 
  Age .145 .026 31.464 1 .000 
  Constant -46.341 34914.348 .000 1 .999 
 
 
Variable(s) entered on step 1: A118G, G516T, A785G, T750C, Gender, and Age. 
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Chapter 4 
Identification of a rapid screening method to differentiate 
methadone susceptible individuals using OPRM1 and 
CYP2B6 gene variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been published and has been presented here in paper format. 
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4.1 ABSTRACT  
 
Methadone is a medication valued for its effectiveness in the treatment of heroin 
addiction, but with many fatal poisonings reported over the years. We have examined 
the association between CYP2B6 and µ-opioid receptor (OPRM1) gene variations and 
apparent susceptibility to methadone poisoning. Genomic DNA was extracted from 
post-mortem whole blood of 40 individuals whose deaths were attributed to 
methadone poisoning. Presence of CYP2B6*4,*9, and *6 alleles and the OPRM1 
A118G variant were determined by SNP genotyping. CYP2B6 *4, *9, and *6 alleles 
were associated with higher post-mortem methadone concentrations (P ≤ 0.05). 
OPRM1 A118G was also associated with higher post-mortem methadone 
concentrations but not at a level of statistical significance (P = 0.39). In these 
methadone deaths OPRM1 118GA was associated with higher post-mortem 
benzodiazepine concentrations (P = 0.04), a finding not seen for morphine. The risk 
of a methadone fatality during treatment may be evaluated in part by screening for 
CYP2B6*6 and A118G. 
 
Keywords: 
 Methadone; Benzodiazepines; µ-opioid receptor; CYP2B6; Fatal; Post-mortem blood 
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4.2 Introduction  
 
Methadone is a µ-receptor agonist valued for its effectiveness in the treatment of 
opioid dependency and pain management. Administered in a racemic mixture, 
methadone has a long plasma elimination half-life (between 13 to 55 hours) and high 
oral bioavailability (70-90%) (Wolff et al. 1997; Foster et al. 1999; Corkery et al. 
2004; Moffat et al. 2004; Nettleton et al. 2007). Extensively metabolised in the liver 
methadone is converted into its primary metabolite 2-ethylidene-1, 5-dimethyl-3, 3-
diphenylpyrrolidine (EDDP) by the cytochrome P450 enzymes CYP3A4, CYP2B6 and 
to a lesser extent CYP2D6 (Crettol et al. 2007). 
Inter-individual variation in blood methadone concentration and toxic drug 
accumulation have been increasingly reported (Osselton et al. 1984; Buster et al. 
2002; Corkery et al. 2004; Maxwell et al. 2005; Eap et al. 2007; Shields et al. 2007) 
and might be explained by pharmacogenomics (Foster et al. 1999; Corkery et al. 
2004; Eap et al. 2007). In drug tolerant individuals blood methadone concentrations 
can reach > 0.84 mg/L, whilst in fatal cases blood methadone concentrations typically 
range between 0.4 mg/L to > 1.8 mg/L. However many fatalities occur with 
concentrations as low as 0.05 mg/L, significantly lower than the average blood 
concentration (Caplehorn & Drummer, 2002). Genetic variations in the cytochrome 
enzymes responsible for methadone metabolism may affect drug pharmacokinetics 
explaining this inter-individual variation. Although a number of CYP3A4 variants 
have been identified and CYP3A4 gene expression levels demonstrate up to 40-fold 
inter-individual differences (Dai et al. 2001; Plant et al. 2007) thus far no significant 
association between CYP3A4 variants and methadone metabolism has been 
documented (Westlind et al. 2001).  
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CYP2B6 is of interest because it is involved in the metabolism of a number of 
drugs including midazolam (Lang et al. 2001), ketamine (Yanagihara et al. 2001), 
bupropion (Faucette et al. 2000), and methadone (Crettol et al. 2007; Eap et al. 2007). 
Although expressed predominantly in the liver CYP2B6 can also be found at lower 
levels in the brain, stomach, lung, kidney and heart (Park et al. 2000). CYP2B6 is 
highly polymorphic and a number of different genotypes have been identified (Lang 
et al. 2001). CYP2B6*4/*4 is associated with allele * 4 (A785G single nucleotide 
polymorphism, SNP) and this genotype produces a fast metaboliser phenotype. When 
allele * 9 (G516T SNP) is found in combination with allele * 4 they form a haplotype 
corresponding to allele * 6. The CYP2B6*6/*6 genotype produces a slow or poor 
metaboliser phenotype and is present at a frequency of about 6% in Caucasian 
populations (Lang et al. 2001; Crettol et al. 2007; Eap et al. 2007). Slow metabolisers 
have reduced enzymatic activity, which can result in drug accumulation and increased 
toxicity. 
Genetic variations within the opioid receptors may also affect drug 
pharmacodynamics impacting the response to methadone. The µ opioid receptor 
(OPRM1) is of particular interest since it is the preferential binding target of 
methadone. A number of OPRM1 variants have been identified and the A118G 
missense SNP in exon 1 has been linked with significant reductions in β-endorphin 
binding (Bond et al. 1998), increased morphine requirements (Klepstad et al. 2005), 
protection from morphine-6-glucuronide (M6G) induced toxicity (Lötsch et al. 2002), 
and susceptibility to drug addiction (Bart et al. 2004). Therefore gene variations such 
as the OPRM1 A118G variation could affect drug binding and drug response. The 
association between A118G and methadone is unclear and requires further 
investigation. 
 205 
Benzodiazepines are often administered to methadone maintenance patients to 
treat anxiety associated with drug addiction and heroin withdrawal (Darke et al. 1995), 
however concomitant use of benzodiazepines and methadone can increase lethal 
respiratory depression (McCormick et al. 1984).  
We explored the possibility that genetic variations in the µ opioid receptor 
OPRM1 and CYP2B6 may be linked with susceptibility to methadone toxicity by 
analysing the prevalence of the OPRM1 A118G variation and CYP2B6*4, *9 and *6 
alleles in 40 fatalities attributed to methadone toxicity. 
 
  4.3 Materials and Methods  
 
Case Selection 
A retrospective review (2007-2008) of methadone-associated deaths from a 
geographically defined area of Scotland (Tayside, Fife and Central regions) was 
conducted. 
 
Toxicological Analyses 
The toxicological analysis for each subject was conducted at the Centre for Forensic 
and Legal Medicine, Dundee University. Following cross-clamping of the femoral 
vein, blood samples were collected by needle and syringe distally. Methadone was 
extracted from post-mortem blood specimens using liquid/liquid extraction followed 
by high pressure liquid chromatography with a diode array detector (HPLC – DAD).  
Post-mortem blood specimens were made alkaline using 0.2M carbonate buffer and 
extracted with 1-chlorobutane.  A Waters Spherisorb 5µm OD/CN HPLC column (4.6 
x 150mm) and a guard column were used with acetonitrile (25% acetonitrile in 
aqueous TEAP buffer) as the mobile phase. 
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DNA Extraction and Quantitation 
Genomic DNA was isolated from leukocytes (sodium fluoride anticoagulated blood) 
by the DNeasy Blood and Tissue Kit (Qiagen, Crawley, UK) and quantified using the 
Human Quantifiler® Kit (Applied Biosystems, Warrington, UK) in accordance with 
the manufacturer‟s instructions.  
 
OPRM1 & CYP2B6 Genotyping by Conventional PCR 
Samples were amplified by PCR to identify homozygous wild type, homozygous 
variant and heterozygous controls. For the A118G SNP in exon 1 of OPRM1 primer 
EX1F_HB (forward: 5‟ ATGCCTTGGCGTACTCAAGTTG) and primer EX1R_HB 
(reverse: 5‟ CTAACTCCCAAGGCTCAATGTTG) were used. G516T in exon 4 was 
amplified using primer C2B6E4F (forward: 5‟ GTACATAATTAGCTGTTACGG) and 
primer C2B6E4R (reverse: 5‟ AAGTCTGGTAGAACAAGTTCA). A785G in exon 5 of 
CYP2B6 was amplified using primer C2B6E5F (forward: 5‟ 
AGGAGATATAGAGTCAGTGAG) and primer C2B6E5R (reverse: 5‟ 
AGTTCCTCCTCCCTATTTTCT). PCRs were performed with a reaction volume of 50 
l, including 27.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 3.0 mM MgCl2, 
1 l of 10 mM deoxynucleoside triphosphates (dNTPs) (final concentration of 0.25 
mM), 1 l Forward and Reverse primers, 10 ng/ l DNA and 0.5 l GoTaq ™ DNA 
polymerase. PCR reactions were performed with a Primus 96 advanced machine 
(Alpha Laboratories, Eastleigh, UK).  The cycling conditions were as follows: initial 
denaturation at 95C for 5 minutes; subsequent denaturation at 95C for 1 minute; 
annealing at 65.3C (118 A>G), 59.5C (516 G>T), and 62.1C (785 A>G) for 30 
seconds; primer extension at 72C for 2 minutes, repeated for 30 cycles, followed by 
final extension at 72C for 5 minutes. PCR products were visualised by 
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electrophoresis with a 2 % Cyber Green-agarose gel on blue light. Samples were 
purified using the QIAquick PCR Purification Kit (Qiagen, Crawley, UK) in 
accordance with the manufacturer‟s instructions. DNA sequencing was conducted by 
COGENICS (COGENICS, Essex, UK). 
 
OPRM1 Genotyping by Real-time PCR 
Samples were genotyped for the A118G variation using the commercialised 
TaqMan® SNP Genotyping assay (Applied Biosystems, Warrington, UK, product no. 
4351379) following the manufacturers instructions.  
 
CYP2B6 Genotyping by Real-time PCR 
Samples were genotyped for the G516T variation using the commercialised 
TaqMan® Drug Metabolism Genotyping assay (Applied Biosystems, Warrington, UK, 
product no. 4362691). A custom designed TaqMan® assay (Applied Biosystems, 
Warrington, UK, product no. 4331349) was used to genotype for A785G. Genotyping 
was performed according to the manufacturer‟s instructions. 
 
Statistical Analysis 
Data are presented as median, means ± SE of the mean. The statistical significance of 
the differences between methadone mean concentrations and the G516T and A785G 
variants and methadone/benzodiazepine mean concentrations and A118G was 
determined using the two-tailed Independent T test. Linkage between gene variants 
was determined using Pearson‟s Chi-square test and Spearman‟s rank correlation. A P 
value of ≤ 0.05 was considered to indicate statistical significance. All analyses were 
performed with SPSS Software (version 14.0). 
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4.4 Results  
 
The 40 post-mortem cases where methadone had been implicated in the cause of 
death included 34 men and 6 women, the majority of whom were Caucasian (97.5%). 
The mean age of the case subjects was 31 ± 1.6 (17 – 60 range). Methadone together 
with benzodiazepines was present in 20 of the 40 subjects. Other drugs detected in the 
post-mortem blood samples are listed in Table 60. 
 
Table 60: Drugs detected at post-mortem in 40 fatalities attributed to methadone as a cause 
of death. 
 
Psychoactive substance Total 
Blood 40   (100%) 
   Ethanol  
     Negative 25  (62.5 %) 
     ≤ 100 mg/100ml 11  (27.5 %) 
      100-200 mg/100ml 2    (5 %) 
      200-300 mg/100ml 2    (5 %) 
   Antidepressants 11  (27.5 %) 
   Benzodiazepines 20  (50 %) 
   Morphine  15  (37.5 %) 
   Dihydrocodeine 2    (5 %) 
   Quetiapine 2    (5 %) 
   Amfetamine 1    (2.5 %) 
   Propanolol 1    (2.5 %) 
Urine  
   Codeine 3    (7.5 %) 
   6-MAM 2    (5 %) 
   Cannabinoids 11  (27.5 %) 
   Cocaine and or metabolites 1    (2.5 %) 
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CYP2B6 alleles and post-mortem methadone blood concentrations 
Of the 40 methadone related fatalities, 14 were genotyped as heterozygous carriers of 
allele * 9, a frequency of 35% and 1 was genotyped as a homozygous carrier, an 
allelic frequency of 2.5%. This result is higher than previous reports (Kircheiner et al. 
2003; Crettol et al. 2005; Crettol et al. 2007) but within the expected range detailed 
on the National Center for Biotechnology Information (NCBI) website for Caucasian 
populations (www.ncbi.nlm.nih.gov/SNP). Heterozygous carriers of allele * 4 were 
identified in 16 cases, a frequency of 40% which is noticeably higher than other 
reports from Caucasian populations (Kircheiner et al. 2003; Jacob et al. 2004; Crettol 
et al. 2005; Crettol et al. 2007). Allele * 6 was identified in 15 cases, an allelic 
frequency of 37.5%, once again an elevated frequency compared with other studies 
(Kircheiner et al. 2003; Jacob et al. 2004; Crettol et al. 2005). As expected the post-
mortem methadone blood concentrations (mean 0.56 mg/L, P < 0.05) for the 
CYP2B6*1/*1 (wild type) genotype were statistically lower than the other genotypes 
identified (Table 61). The frequency of CYP2B6*1/*1 (57.5%) was higher than other 
reports (43%, 22%) conducted on living subjects (Lang et al. 2001; Crettol et al. 
2005), although only 3 alleles were observed from the post-mortem subjects in this 
study.  
All of the CYP2B6 alleles tested (*4, *9 and * 6) were associated with higher mean 
post-mortem methadone blood concentrations (P < 0.05, Independent T-test), 
reflecting poor methadone metabolism (Figures 81 & 82, Table 61).  
In all cases where allele * 9 was identified, allele *4 was also found. This is in 
agreement with previous reports where it was noted that allele * 9 acts as a marker of 
allele *4 (Crettol et al. 2007; Eap et al. 2007). Linkage between allele * 9 and allele * 
4 presence was identified with a χ2 (32.471), 1 df, P <0.001. Only one subject was 
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identified with the CYP2B6*6/*6 genotype, this subject had a post-mortem blood 
methadone concentration of 1.38 mg/L, a concentration 3.45 fold higher than the 
normally recognised fatal threshold, but this result was not statistically significant 
(Table 61). CYP2B6*1/*4 was identified in two cases, a frequency of 5%. By itself 
allele * 4 has been linked with fast metabolism (Lang et al. 2001) however our results 
did not show this trend, with a mean post-mortem concentration of 0.86 mg/L (Table 
61). No CYP2B6*4/*4 genotypes were identified.  
Table 61: CYP2B6*4,*9, and *6 alleles and post-mortem methadone blood concentrations. 
 
 
 
Significance at < 0.05 is denoted by *. 
 Frequency Mean Std. Deviation Std. Error Mean Median 
 
P value 
 
CYP2B6       
A785G 
(allele * 4) 
      
AA 23 0.56 mg/L 0.296 0.062 0.56   
GA & GG 17 0.95 mg/L 0.608 0.148 0.97 0.024* 
G516T 
(allele * 9) 
      
GG 25 0.58 mg/L 0.353 0.071 0.56  
TG & TT 15 0.96 mg/L 0.598 0.154 0.97 0.039* 
Allele * 6 15 0.96 mg/L 0.598 0.154 0.97 0.039
*
 
*1/*1 23 0.56 mg/L 0.296 0.618 0.56 0.024
*
 
*1/*4 2 0.86 mg/L 0.948 0.670 0.86 0.690 
*1/*6 14 0.93mg/L 0.609 0.163 0.91 0.041
*
 
*6/*6 1 1.38 mg/L    0.153 
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Table 62: OPRM1 and CYP2B6 Genotyping Data for the Post-mortem Methadone-attributed 
fatalities. 
 
Case CYP2B6 
G516T 
Genotype 
GG, GT, TT 
 
CYP2B6 
A785G 
Genotype 
AA AG GG 
OPRM1 
A118G 
Genotype 
AA, AG, GG 
Methadone 
(mg/L) 
Sample 
1 GG AA AA 0.27 Fm 
2 GG AA AA 0.86 Fm 
3 GT AG AA 1.16 Fm 
4 GG AA AA 0.30 Fm 
5 GG AA AA 1.1 Fm 
6 GT AG AA 0.82 Fm 
7 GT AG AA 0.97 Fm 
8 GG AA AA 0.22 Fm 
9 GT AG AA 0.20 Fm 
10 GT AG AG 1.44 Fm 
11 GG AA AA 0.48 Fm 
12 GG AA AA 1.25 Fm 
13 GT AG AG 1.08 Fm 
14 GG AA AA 0.44 Fm 
15 GG AA AA 0.58 Fm 
16 GT AG AG 0.33 Fm 
17 GG AA AA 0.95 Fm 
18 GG AA AA 0.58 Fm 
19 GG AA AA 0.65 Fm 
20 GT AG AA 1.66 Fm 
21 GG AA AA 0.60 Fm 
22 GT AG AA 0.54 Fm 
23 GT AG AA 0.26 Fm 
24 GT AG AA 2.23 Fm 
25 GG AA AA 0.39 Fm 
26 GG AA AA 0.25 Fm 
27 GT AG AA 0.15 Cd 
28 GG AA AA 0.37 Fm 
29 GG AA AA 0.22 Fm 
30 GG AA AA 0.22 Fm 
31 GT AG AA 1.3 Fm 
32 TT GG AA 1.38 Fm 
33 GT AG AA 0.19 Fm 
34 GG AA AA 0.75 Fm 
35 GG AA AA 0.24 Fm 
36 GG AA AA 1.53 Fm 
37 GG AA AA 0.56 Fm 
38 GG AA AA 0.80 Fm 
39 GG AA AA 0.75 Fm 
40 GT AG AG 0.85 Fm 
 
Where Fm = femoral. 
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Figure 81: Distribution (median and interquartile range) of post-mortem methadone 
concentrations for the 516GG, 516GT, and 516TT genotypes. 
 
 
 
 
 
 
Figure 82: Distribution (median and interquartile range) of post-mortem methadone 
concentrations for the 785AA, 785AG and 785 GG genotypes. 
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OPRM1 A118G and post-mortem methadone blood concentrations 
The A118G SNP demonstrated an allelic frequency of 10%, a similar result to that 
reported in other studies conducted on living subjects (Bergen et al. 1997; Lotsch et al. 
2002). No significant association was seen between A118G and post-mortem 
methadone blood concentrations (P > 0.05, Table 63). However the median 
methadone concentration for 118 GA carriers is higher than 118 AA carriers at 0.97 
mg/L and 0.58 mg/L respectively (Figure 83). No homozygote for the G allele was 
identified in this study. A significant association was identified in this study between 
118G allele and CYP2B6 * 9 allele, and 118G allele and CYP2B6 * 4 allele by using 
Spearman‟s rank correlation (P < 0.01, P < 0.05 respectively). 
 
 
 
 
 
Figure 83: Distribution (median and interquartile range) of post-mortem methadone 
concentrations for the 118AA, 118GA and 118GG genotypes. 
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OPRM1 A118G and post-mortem benzodiazepine blood concentrations 
Benzodiazepines are concurrently administered with methadone to addicts for the 
treatment of substitute related anxiety. The additive effect of benzodiazepines and 
methadone in causing respiratory depression has been well documented (McCormick 
et al. 1984; Lintzeris et al. 2007). Concomitant use of methadone and 
benzodiazepines was demonstrated in 50% of the subjects (Table 60). There was a 
significant association between the A118G SNP and mean post-mortem 
benzodiazepine concentrations, P < 0.01 (Table 63). Heterozygous individuals 
demonstrated a 2.4 fold higher mean benzodiazepine concentration compared to 
homozygous wild type (Figure 84).  
 
 
 
 
 
Figure 84: Distribution (median and interquartile range) of post-mortem benzodiazepine 
concentrations for the 118AA, 118GA and 118GG genotypes. 
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Table 63: A118G genotypes and post-mortem methadone and benzodiazepine 
concentrations for a population of methadone-attributed fatalities (population 1) and A118G 
genotypes and post-mortem morphine and benzodiazepine concentrations for a population of 
morphine-attributed fatalities (population 2). 
 
Population 1 
A118G genotype Frequency Mean  Std. Deviation Std. Error Mean Median 
Methadone      
AA 36 0.70 mg/L 0.493 0.082 0.58 
GA 4 0.93 mg/L 0.465 0.233 0.97 
2-tailed Sig. 0.391     
Benzodiazepines      
AA 18 0.69 mg/L 0.363 0.086 0.66 
GA 2 1.66 mg/L 0.749 0.530 1.66 
2-tailed Sig. 0.004
*
     
Population 2 
A118G genotype Frequency Mean  Std. Deviation Std. Error Mean Median 
Morphine      
AA 25 0.45 mg/L 0.86 0.172 0.22 
GA 2 0.12 mg/L 0.05 0.035 0.16 
2-tailed Sig. 0.593     
Benzodiazepines      
AA 25 1.62 mg/L 1.57 0.315 0.58 
GA 2 1.05 mg/L 0.10 0.705 0.97 
2-tailed Sig. 0.626     
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4.5 Discussion  
 
Use of methadone in maintenance programmes worldwide (Buster et al. 2002; 
Maxwell et al. 2005) has been associated with methadone-associated fatalities. 
Patients prescribed methadone for heroin withdrawal are reported to be 6.7 times 
more likely to experience an adverse drug reaction during the drugs induction phase 
(Caplehorn & Drummer, 2002), at a time when either drug tolerance may be 
overestimated or other drugs are in use (Corkery et al. 2004). In this study, a 
significant association was revealed between the CYP2B6*4, *9 and *6 alleles and 
high methadone concentrations in post-mortem blood, characteristic of the slow 
metaboliser phenotype. This is the first time such a genetic association has been 
demonstrated in methadone related fatalities (Table 61) i.e. deaths in which 
methadone toxicity was assessed as a probable significant factor by the autopsy 
pathologist. Furthermore, the allelic frequencies of these target alleles were 
considerably higher than those reported in live patients (Crettol et al. 2007; Eap et al. 
2007) supporting the concept that there is linkage between these gene variants and 
methadone toxicity. This observation is in agreement with the results of a study 
examining CYP2D6 SNPs in post-mortem cases and methadone metabolism, where 
the prevalence of poor metabolisers exceeded the reported frequencies in general 
population reports (Wong et al. 2003). Thus the risk of a methadone fatality may be 
predetermined in part by screening for CYP2B6 variants, in particular CYP2B6*6. 
Therefore there is potential value in screening for CYP2B6 variants before prescribing 
methadone for drug addiction, and possibly also in palliative care where methadone 
may be used as an alternative to morphine for analgesia (Ripamonti et al. 1997). It 
would be interesting to examine CYP2B6 allele frequencies in an opioid abusing 
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population to identify whether there are higher frequencies among opioid abusers 
compared with the general population. 
The CYP2B6*4 allele has been linked with increased enzymatic activity (Lang 
et al. 2001; Kircheiner et al. 2003) and fast metaboliser status but the anticipated 
lower drug levels were not observed in the present study. Only two subjects were 
CYP2B6*1/*4 carriers limiting further interpretation (Table 61). Future studies which 
take into account individual drug history, the time period between drug administration 
and death, and post-mortem interval might strengthen our findings, which this far only 
identify a trend. The inevitable post-mortem interval between death and sampling 
could potentially increase blood drug concentrations due to post-mortem 
redistribution (Pounder & Jones et al. 1990). The sampling site and manner of sample 
collection used in this study should ameliorate this. Nevertheless, even femoral 
venous blood samples are subject to post-mortem increase (Moriya & Hashimoto, 
1997).  
A number of studies have examined the association between OPRM1 variants 
and inter-individual variability in morphine metabolism (Lotsch et al. 2002; Klepstad 
et al. 2005), but there is limited information on the relationship between this genotype 
and response to methadone. The OPRM1 A118G SNP has been shown to affect 
opioid efficacy (Klepstad et al. 2005). This SNP, located in exon 1, results in an 
amino acid change from asparagine to aspartic acid causing the loss of a putative N-
linked glycosylation site, which might be associated with changes in receptor 
trafficking to the membrane (George et al. 1999). In vitro expression studies at the 
transcription level examining this SNP also noted significant increases in wild-type 
expression over 118 GA carriers (Zhang et al. 2005). Since OPRM1 118AA receptors 
have ten times more binding sites than that of 118GA (Zhang et al. 2005) it was 
postulated that the residue of 118 may be attributed to a cis-acting factor. Reductions 
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in cell surface µ receptors may limit the availability of drug binding sites. 
Significantly increased post-mortem methadone concentrations were not found in 
association with OPRM1 118 GA (Table 63), however there is a distinct separation 
between the median post-mortem methadone concentrations for 118 AA and 118 GA 
carriers at 0.70 mg/L, 0.93 mg/L respectively (Figure 83), without considering two 
data outliers (1.66 & 1.44 mg/L) which could be falsely elevating the 118 AA mean 
drug concentration. Since A118G reduces receptor binding sites (Zhang et al. 2005) 
this might offer an explanation for the increased drug concentrations observed in this 
study. Therefore the possibility of an association between A118G and methadone 
blood concentration cannot be excluded. An increased sample size would assist in 
exploring this potential relationship.  
When benzodiazepines were found in conjunction with methadone (Table 63, 
Population 1), carriers of OPRM1 118 GA had a 2.4 fold higher post-mortem mean 
blood benzodiazepine concentration (P < 0.01). Although the study has a limited 
sample size it has to be noted that a clear difference was observed. Interestingly this 
was not seen in morphine-associated fatalities (Table 63, Population 2) suggesting a 
specific link between methadone and benzodiazepines. Given that both methadone 
and morphine bind to the mu opioid receptor similarly, this raises the question why 
the interaction varies for different opioids. It may be postulated that this is linked with 
receptor endocytosis which is induced by methadone but not morphine (Keith et al. 
1998). However the reason for this interaction remains unknown and it would be 
interesting to study this further. A potential pharmacokinetic mechanism for 
interactions between methadone and benzodiazepines may take place via a shared 
CYP metabolic pathway. A number of benzodizapines are metabolised by CYP3A4 & 
CYP2B6 including diazepam (Schminder et al. 1996), midazolam (Lang et al. 2001), 
and flunitrazepman, (Hesse et al. 2001). Furthermore, some benzodiazepines have 
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been theorised to act as weak inhibitors of CYP3A4 (Spaulding et al. 1974).  Increased 
methadone concentrations in liver and brain have been reported when diazepam was 
administered following methadone exposure (Shah et al. 1979). It has been reported 
that benzodiazepine inhibition of CYP3A4 is weak and unlikely to be of clinical 
significance (Foster et al. 1999). Other drugs known to inhibit methadone metabolism 
include ketoconazole (Baldwin et al. 1995), nelfinavir (Hesse et al. 2001), paroxetine 
(Walsky et al. 2006), and sertraline (Walsky et al. 2006), therefore concomitant use of 
these drugs may lead to increased methadone concentrations post-mortem. Drug 
interactions cannot therefore be excluded as additional factors in the increased 
methadone concentrations reported in this study. 
 It is well documented that the co-administration of methadone and 
benzodiazepines can result in lethal respiratory depression (McCormick et al. 1984; 
Borron et al. 2002; Lintzeris et al. 2007). Since benzodiazepines bind to GABAA 
receptors and not opioid receptors this does not involve a direct association (Borron et 
al. 2002). However, both receptor systems share common signal transduction 
pathways (Dan‟ura et al. 1988).  Animal models have indicated the occurrence of 
associations between the opioid and GABAA receptor systems, where for example 
benzodiazepines have been shown to potentiate the respiratory effects of fentanyl 
(Bailey et al. 1990). In the rat concomitant use of benzodiazepines with the partial µ-
opioid agonist buprenorphine resulted in the increased recruitment of µ-opioid 
receptors (Poisnel et al. 2009). Consequently it may be postulated that 
benzodiazepines affect µ-opioid receptor regulation through signal transduction and 
regulatory pathways. Our findings suggest that susceptibility to methadone and 
benzodiazepines is associated with the A118G genotype by a presently unknown 
mechanism. 
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A significant association between OPRM1 A118G genotype and CYP2B6 *4, 
9* and 6* alleles was revealed in this study. Both genes are vital to methadone action 
in vivo and this assemblage of gene variants may reflect the nature of coordinated 
action of the enzyme and receptor in contributing to susceptibility to methadone. 
Agonist-occupancy at µ-receptors leads to receptor phosphorylation and rapid 
receptor desensitization (Koch et al. 1998). This in turn facilitates receptor 
internalisation reducing agonist response (Koch et al. 2005), and is thought to be a 
mechanism involved in the acquisition and development of drug tolerance (Koch et al. 
2005). Receptor internalisation should reduce the number of potential drug binding 
sites, protecting against methadone toxicity in the presence of poor drug metabolism. 
However, concomitant use of methadone and benzodiazepines may up-regulate µ 
receptors (Poisnel et al. 2009) neutralising the reduction in available binding sites, 
leading to methadone toxicity. The A118G genotype of OPRM1 has been linked also 
with susceptibility to heroin addiction (Bart et al. 2004).  As demonstrated in our 
study CYP2B6*9 & *6 alleles can be linked with poor drug metabolism as expressed 
by higher post-mortem blood drug concentrations. The combination of OPRM1 
A118G genotype and CYP2B6*9 & *6 variants could lead to predisposition to opioid 
addiction and greater susceptibility to methadone fatality. The sensitivity of the µ-
opioid receptor to methadone will be reduced in 118 GA subjects, therefore these 
subjects may reach higher concentrations before toxic effects appear. 
In this retrospective review of case fatalities, potential confounding factors 
such as the presence and concentrations of all other drugs, mode of drug intake, 
previous opiate use or recent abstinence, and rapid or delayed death cannot be 
excluded. In summary, CYP2B6 variants, specifically the CYP2B6*6 allele are 
associated with higher methadone concentrations in the post-mortem blood of 
fatalities from methadone toxicity, likely as a consequence of “poor” or “slow” drug 
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metabolism. This genotype clearly correlates with higher methadone concentrations; 
we can therefore postulate that for a normal population subjects with this genotype 
will experience higher methadone accumulation and are therefore more at risk of 
methadone toxicity. This suggests that the CYP2B6*6 allele may be a suitable risk 
factor for screening for individual susceptibility to methadone toxicity. The 118 GA 
genotype may have a similar value, which needs to be explored in a larger study. The 
presence of the A118G SNP on the OPRM1 gene may also be of forensic value when 
interpreting the potential toxic relationship between methadone and benzodiazepines. 
Given that methadone maintenance therapy has been effective in reducing heroin 
associated mortalities for many years (Esteban et al. 2003) it would be beneficial to 
reduce methadone-associated mortality by assessing and monitoring its adverse 
effects on individuals with slow-metaboliser genotypes. Genetic screening for 
“susceptibility” variations prior to maintenance therapy could therefore be used to 
identify patients who may be at increased risk, since it is not routine practice for 
patients undergoing methadone maintenance treatment to undergo therapeutic drug 
monitoring (TDM). Typically TDM is employed for substances with a low therapeutic 
index such as cardio-toxic, neuroleptic and immunosuppressive drugs where the 
difference between beneficial therapeutic and toxic blood/plasma concentrations is 
small. Although TDM offers a scientific approach to selecting a drug regime to 
optimise therapy it involves regular clinic visits, can involve costly analysis and in 
many instances clinical response does not correlate with plasma drug concentration. 
Genetic screening of subjects prior to methadone maintenance treatment would 
involve a single rapid diagnostic test. Specific screening to identify CYP2B6*6 and 
OPRM1 A118G carriers prior to addiction treatment could therefore be valuable as 
part of a cost-effective risk management strategy. 
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Chapter 5 
Validation of a screening method to differentiate methadone 
susceptible individuals using OPRM1 and CYP2B6 gene 
variants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been drafted for publication and has been presented here in 
paper format. 
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5.1 ABSTRACT  
 
 The last chapter examined the association between CYP2B6 and µ-opioid receptor 
(OPRM1) gene variations and apparent susceptibility to methadone poisoning. In this 
chapter the effect of CYP2B6 and OPRM1 variations will be studied for a larger 
population of subjects whose deaths were attributed to methadone. Genomic DNA 
was extracted from post-mortem whole blood of 69 individuals whose deaths were 
attributed to methadone poisoning. Presence of CYP2B6*4,*9, and *6 alleles and the 
OPRM1 A118G variant were determined by SNP genotyping. CYP2B6 *4, *9, and *6 
alleles were associated with higher post-mortem methadone concentrations (P ≤ 0.05). 
OPRM1 A118G was also associated with higher post-mortem methadone 
concentrations at a level of statistical significance (P = 0.05). This confirms that the 
risk of a methadone fatality may be evaluated in part, by screening for CYP2B6*6 
and A118G. 
 
 
Keywords: 
 Methadone deaths; µ-opioid receptor; CYP2B6; MMT; Gene promoters 
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5.2 Introduction  
 
Methadone is used in the treatment of opioid dependence, resulting in the decrease 
and often suspension of illicit opioid abuse (Shields et al. 2007). However, methadone 
has a long and unpredictable half life which can result in drug accumulation and 
delayed overdose (Sawe, 1986; Kreek et al. 1996; Foster et al. 2000; Manfredi et al. 
2001). This can be complicated further by gene variations resulting in considerable 
inter-and intra-individual pharmacokinetic and pharmacodynamic variability 
(Kharasch et al. 2009).  
Methadone action in vivo is largely mediated through CYP2B6 metabolism 
and drug-receptor interactions at the µ opioid receptor (Chapter 4; Bunten et al. 2010). 
The primary metabolic route for methadone metabolism is N-demethylation and 
spontaneous decyclisation converting the drug into EDDP (Kobek et al. 2009). Earlier 
work revealed a significant association between the cytochrome P450 CYP2B6*4, *9 
and *6 alleles and high methadone concentrations in post-mortem blood, 
characteristic of the slow metaboliser phenotype (Chapter 4; Bunten et al. 2010). 
However, despite, an established genotype-phenotype relationship, the molecular 
basis of the *6 allele remains unclear with effects at the transcription, splicing, protein 
stability and substrate specificity levels (Hofmann et al. 2008). Clarification of the 
molecular role of CYP2B6 could assist in explaining inter-individual variability in 
blood methadone concentrations and drug toxicity (Chapter 4; Bunten et al. 2010). 
This has particular significance for the interpretation of post-mortem 
methadone concentrations which can be complex due to a significant overlap between 
therapeutic and lethal concentrations, for example, therapeutic plasma methadone 
concentrations range between 0.075 and 1.1 mg/L, toxic concentrations between 0.2 
and 2.0 mg/L and lethal concentrations between 0.4 and 2.8 mg/L (Moffat et al. 2004; 
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Schulz & Schmoldt, 2003). The interpretation of post-mortem results is further 
complicated by the fact that in a significant number of opioid-related deaths, several 
hours may elapse between the time the drug enters the body and the time of death, 
during which extensive metabolism may take place. The identification of gene 
variations responsible for inter-individual variability in blood methadone 
concentrations, such as CYP2B6*6 could aid toxicological interpretation identifying 
poor metabolisers at autopsy. 
 cis-Acting functional polymorphisms that affect transcription, mRNA 
processing, mRNA stability, and protein translation may also represent a cause of 
human phenotypic variability (Zhang et al. 2005). The CYP2B6 T750C promoter 
region single nucleotide polymorphism (SNP) could also be of importance in 
individual methadone susceptibility. T750C is one of the most frequently identified 
SNPs in the CYP2B6 promoter region (Zukunft et al. 2005), and has been reported to 
decrease CYP2B6 expression which would result in alterations to methadone 
metabolism. (Lang et al. 2001; Lamba et al. 2003). 
The µ opioid receptor is a critical factor in methadone response that could 
influence the post-mortem concentration. The work presented in Chapter 4 identified 
a trend between higher methadone concentrations and the µ opioid receptor (OPRM1) 
A118G variation (Chapter 4; Bunten et al. 2010). This result was not statistically 
significant (P = 0.39) however, and could be a consequence of a limiting sample size. 
In vitro expression studies on A118G report significant increases in wild-type 
expression over 118 GA carriers (Zhang et al. 2005). Since A118G reduces receptor 
binding sites (Zhang et al. 2005) this might offer an explanation for increased post-
mortem blood methadone concentrations and should be further explored with a larger 
sample size.  
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µ opioid receptor OPRM1 and CYP2B6 gene variations were examined in a post-
mortem population where the deaths had been attributed to methadone to confirm the 
role of CYP2B6*6 in methadone susceptibility. Whilst trying to clarify the role of the 
OPRM1 A118G variation to methadone toxicity. 
   
5.3 Materials and Methods  
 
Case Selection 
A retrospective review (2007-2010) of methadone-associated deaths from a 
geographically defined area of Scotland (Tayside, Fife and Central regions) was 
conducted. 
 
Toxicological Analyses 
The toxicological analysis for each subject was conducted at the Centre for Forensic 
and Legal Medicine, Dundee University. Following cross-clamping of the femoral 
vein, blood samples were collected by needle and syringe distally. Methadone was 
extracted from post-mortem blood specimens using liquid/liquid extraction followed 
by high pressure liquid chromatography with a diode array detector (HPLC – DAD).  
Post-mortem blood specimens were made alkaline using 0.2M carbonate buffer and 
extracted with 1-chlorobutane.  A Waters Spherisorb 5µm OD/CN HPLC column (4.6 
x 150mm) and a guard column were used with acetonitrile (25% acetonitrile in 
aqueous TEAP buffer) as the mobile phase. 
 
DNA Extraction and Quantitation 
Genomic DNA was isolated from leukocytes (sodium fluoride anticoagulated blood) 
by the DNeasy Blood and Tissue Kit (Qiagen, Crawley, UK) and quantified using the 
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Human Quantifiler® Kit (Applied Biosystems, Warrington, UK) in accordance with 
the manufacturer‟s instructions.  
 
OPRM1 & CYP2B6 Genotyping  
The procedure for OPRM1 A118G, CYP2B6*4, *9, and *6 genotyping was described 
previously (Chapter 4; Bunten et al. 2010). For the CYP2B6 T750C promoter SNP 
samples were amplified by PCR to identify homozygous wild type and heterozygous 
controls using primer C2B6PrF (forward: 5‟ CAGGTTCAAGTGATTCTCTTG) and 
primer C2B6PrR (reverse: 5‟ CATGTTCAAAACTGAGAGGCT). PCRs were performed 
with a reaction volume of 50 l, including 27.5 l PCR grade water, 10 l of 5x 
GoTaq ™ buffer, 3.0 mM MgCl2, 1 l of 10 mM deoxynucleoside triphosphates 
(dNTPs) (final concentration of 0.25 mM), 1 l Forward and Reverse primers, 10 ng/ 
l DNA and 0.5 l GoTaq ™ DNA polymerase. PCR reactions were performed with 
a Primus 96 advanced machine (Alpha Laboratories, UK).  The cycling conditions 
were as follows: initial denaturation at 95C for 5 minutes; subsequent denaturation at 
95C for 1 minute; annealing at 65ºC for 30 seconds; primer extension at 72C for 2 
minutes, repeated for 30 cycles, followed by final extension at 72C for 5 minutes. 
PCR products were visualised by electrophoresis with a 2 % Cyber Green-agarose gel 
on blue light. Samples were purified using the QIAquick PCR Purification Kit 
(Qiagen, UK) in accordance with the manufacturer‟s instructions. DNA sequencing 
was conducted by COGENICS (The Sequencing Company, Essex, United Kingdom 
Corporation). Samples were then genotyped for the T750C SNP using the validated 
TaqMan® SNP Genotyping assay (4362691) 
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Statistical Analysis 
Data are presented as median, means ± SE of the mean. The statistical significance of 
the differences between methadone mean concentrations and the CYP2B6 T750C, 
G516T, A785G variants and the OPRM1 A118G was determined using the two-tailed 
Independent T test. Linkage between gene variants was determined using Pearson‟s 
Chi-square test and Spearman‟s rank correlation. The effect of subject participation in 
methadone maintenance on post-mortem methadone concentration was explored using 
the Independent T-test. The association between participation in methadone 
maintenance and SNP presence was examined using Pearson‟s Chi-square test. A P 
value of ≤ 0.05 was considered to indicate statistical significance. All analyses were 
performed with SPSS Software (version 14.0). 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
5.4 Results  
 
The 69 post-mortem cases where methadone had been implicated in the cause of 
death included 50 men and 19 women, the majority of whom were Caucasian 
(99.94%). The mean age of the case subjects was 33 ± 1.38 (17 – 60 range).  
CYP2B6 alleles and post-mortem methadone blood concentrations 
Of the 69 methadone related fatalities, 27 were genotyped as heterozygous carriers of 
allele * 9, a frequency of 39 % and 2 were genotyped as homozygous carriers, an 
allelic frequency of 2.9 %. This result is in accordance with the work presented in 
Chapter 4 (Bunten et al. 2010). Heterozygous carriers of allele * 4 were identified in 
29 cases, a frequency of 42 %. Allele * 6 was identified in 29 cases, an allelic 
frequency of 42 %, an elevated frequency compared with other studies (Kircheiner et 
al. 2003; Jacob et al. 2004; Crettol et al. 2005). For the T750C promoter region SNP 
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30 individuals were heterozygous, a frequency of 43.5 % and 14 were genotyped as 
homozygous for the CC genotype (20.1 %). This is in accordance with other reports 
from Caucasian populations (Zukunft et al. 2005). 
All of the CYP2B6 alleles tested (*4, *9 and * 6) were associated with higher mean 
post-mortem methadone blood concentrations (P < 0.05, Independent T-test), 
indicative of poor methadone metabolism (Table 64). 
Two subjects were identified with the CYP2B6*6/*6 genotype, with post-mortem 
blood methadone concentrations of 1.38 mg/L, and 2.10 mg/L (mean 1.74 mg/L). 
CYP2B6*1/*4 was identified in two cases, a frequency of 2.9 %. By itself allele * 4 
has been linked with fast metabolism (Lang et al. 2001) however our results did not 
show this trend, with a mean post-mortem concentration of 0.86 mg/L (Table 65). No 
CYP2B6*4/*4 genotypes were identified.  
There was no significant difference in mean blood concentration for the T750C 
variation (P = 0.302), with a mean methadone blood concentration of 0.79 mg/L for 
heterozygous carriers, 0.69 mg/L for subjects homozygous for the CC genotype and 
1.02 mg/L for homozygous TT subjects. Interestingly the mean post-mortem 
methadone concentration is lower in subjects with the T750C allele than wild type 
subjects. 
OPRM1 A118G and post-mortem methadone blood concentrations 
The A118G SNP demonstrated an allelic frequency of 13 %, higher than a previous 
study (Bunten et al. 2010) but within the range reported in other studies (Bergen et al. 
1997; Lötsch et al. 2002). With an increased post-mortem sample size of 69 subjects a 
significant association was observed between A118G and post-mortem methadone 
blood concentrations (P = 0.05, Table 64). The median methadone concentration for 
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118 GA carriers was 0.58 mg/L and for 118 AA carriers 1.08 mg/L respectively. No 
homozygote for the G allele was identified in this study.  
 
Table 64: CYP2B6*4,*9, and *6 alleles and OPRM1 A118G post-mortem methadone blood 
concentrations. 
 
Significance at < 0.05 is denoted by *. 
 
CYP2B6 and OPRM1 Correlations 
A significant association was identified in this study between 118G allele and 
CYP2B6 * 9 allele, and 118G allele and CYP2B6 * 4 allele using Pearson‟s Chi 
 Frequency Mean Std. Deviation Std. Error Mean Median 
 
P value 
 
CYP2B6       
A785G 
(allele * 4) 
      
AA 38 0.69 0.638 0.104 0.52  
GA & GG 31 1.06 0.729 0.131 0.97 0.028* 
G516T 
(allele * 9) 
      
GG 40 0.70 0.640 0.101 0.52  
TG & TT 29 1.07 0.730 0.136 0.97 0.027* 
OPRM1       
A118G       
AA 60 0.79 0.651 0.084 0.58  
AG 9 1.28 0.895 0.298 1.08 0.050* 
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Square Test (P = 0.004, P = 0.002 respectively). Furthermore, T750C presence 
correlated with CYP2B6*4, *9, & *6 alleles (P < 0.01), this result is in accordance 
with other reports (Zukunft et al. 2005). 
 
Methadone Maintenance 
The association between post-mortem methadone concentration and subject 
participation in methadone maintenance was explored for 32 of the 69 subjects 
sampled in this study. A significant association was identified between higher post-
mortem methadone concentrations and subject enrolment in methadone treatment 
programmes (P = 0.001, 0.54 mg/L mean concentration for subjects not in methadone 
treatment, 1.44 mg/L mean concentration for subjects in methadone treatment) using 
the Independent T-test. Furthermore, post-mortem methadone concentration 
significantly correlated with methadone maintenance daily dosage (Figure 85) using 
Pearson‟s two-tailed correlation coefficient. There was no association between subject 
participation in methadone maintenance and the CYP2B6 and OPRM1 SNPs (Table 
65). Furthermore, there was no significant association between methadone treatment 
daily dosage and the CYP2B6 and OPRM1 SNPs (Table 65).  
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Figure 85: The association between post-mortem methadone concentration (mg/L) and 
methadone maintenance daily dosage (mg/L). 
 
 
 
Table 65: The effect of CYP2B6 T750C, G516T, A785G, OPRM1 A118G, Gender and Age 
on subject participation in maintenance and daily methadone dosage. 
 
Gene variants 
 
R
2
 value P value 
Subject participation in methadone maintenance 
 
T750C  0.049 0.792 
A785G -0.122 0.507 
G516T -0.22 0.507 
A118G -0.030 0.870 
Age 0.299 0.096 
Gender -0.181 0.320 
Methadone Maintenance Daily Dosage 
 
T750C  -0.267 0.140 
A785G 0.166 0.363 
G516T 0.166 0.363 
A118G -0.108 0.557 
Age 0.209 0.250 
Gender 0.218 0.231 
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5.5 Discussion  
 
Polymorphisms in metabolizing enzymes and transporters can be valuable biomarkers 
for variable pharmacokinetics, pharmacodynamics and adverse drug reactions. The 
human cytochrome P450 enzyme CYP2B6 is highly polymorphic playing a key role in 
the biotransformation of drugs (Hofmann et al. 2007). Previous works have reported 
that heterozygous and homozygous carriers of the CYP2B6*6 allele express up to 4-
fold less protein with resulting changes in enzymatic activity (Desta et al. 2007). In 
this study the CYP2B6 *9 (G516T), CYP2B6*4 (A785G), and CYP2B6*6 (G516T & 
A785G) alleles all associated with statistically higher blood methadone concentrations 
(Table 64), this is in agreement with previous results indicating that CYP2B6*6 
(G516T, A785G) can be used to determine poor methadone metabolism (Chapter 4, 
Bunten et al. 2010). A study examining CYP2B6*6 expression and function in human 
liver samples reported that the G516T SNP is the casual mutation leading to poor drug 
metabolism (Hofmann et al. 2008). Interestingly the study also reported that G516T is 
responsible for aberrant splicing leading to a major splice variant that lacks the region 
between exons 4 and 6 (Hofmann et al. 2008). This results in reduced levels of 
functional mRNA transcripts, protein and enzymatic activity (Hofmann et al. 2008). It 
was theorised that the CYP2B6*6 allele might be a result of a pretranslational 
mechanism involving the T750C promoter variation, however, the study did not 
identify any such association (Hofmann et al. 2008).  
In this study T750C was not associated with higher drug concentrations, with 
wild type carriers having higher blood methadone concentrations than heterozygous 
or wild type subjects. As T750C has been linked with decreased receptor expression 
(Lang et al. 2001; Lamba et al. 2003), higher methadone concentrations were 
expected due to a reduced ability to metabolise the drug. Additionally, T750C 
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associated with CYP2B6*6, which is in accordance with earlier studies where T750C 
is part of the CYP2B6*6B haplotype with the G516T and A785G variations (Lamba 
et al. 2003; Hesse et al. 2004; Zukunft et al. 2005). This assemblage of gene variants 
would result in reduced expression of a poorly functioning gene and could be 
expected to result in higher post-mortem methadone concentrations. However, there 
have also been contrasting reports documenting that the T750C SNP is not involved 
with reduced CYP2B6 expression (Zukunft et al. 2005; Hofmann et al. 2008).  T750C 
is also part of the CYP2B6*22 allele together with C1848A, G801T, and T82C which 
has been linked with high CYP2B6 expression as a result of the T82C SNP (Faucette 
et al. 2000; Zukunft et al. 2005). A study examining human liver expression reported 
that the T82C variation significantly impacted CYP2B6 mRNA expression (P <0.01), 
with heterozygous carriers of T82C demonstrating 2.1 fold higher expression than 
subjects homozygous for the 82 TT genotype (Zukunft et al. 2005). Despite the 
significance of T82C for CYP2B6 expression, there is considerable variability within 
the TT and TC groups indicating the involvement of additional unknown factors 
(Zukunft et al. 2005). The significance of CYP2B6*22 has not been explored in this 
study however examination of this allele would be interesting to determine the 
relevance of CYP2B6*22 for methadone susceptibility as it may result in an ultrarapid 
metaboliser phenotype (Zukunft et al. 2005). It is logical to suggest that the increased 
methadone concentrations identified for 750 TT subjects in this study may be linked 
with increased CYP2B6 expression due to the CYP2B6*22 allele. 
Opioid receptors belong to the family of seven trans-membrane protein 
coupled receptors and are involved in the modulation of numerous endogenous 
physiological and neurobiological systems (Binyaminy et al. 2008). µ receptors are 
located in brain and spinal regions, in addition to various circulating immune cells 
(Bidlack, 2000; Ross et al. 2005; Toskulkao et al. 2009). Methadone deaths are 
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primarily due to respiratory depression following the activation of the opioid system 
at the respiratory control centre within the brain resulting in reduced sensitivity to 
carbon dioxide (CO2). A study on the post-mortem brain of heroin abusers reported 
exaggerated impairments to the opioid neuropeptide system in the presence of A118G 
carriers (Drakenberg et al. 2006). Such changes are likely to be associated with 
A118G affects on OPRM1 expression and could impact respiratory function. A major 
effect of µ receptor activity in the brain is the decrease of neuronal membrane 
excitability, due to an increase in K
+
 conductance and hyperpolarization of the cell 
membrane (Chavkin, 1988; Mestek et al. 1995).  Agonist binding at µ alters receptor 
confirmation, facilitating coupling to heterotrimeric guanine nucleotide binding 
proteins (G proteins) inducing a variety of downstream effectors including the 
inhibition of adenylyl cyclase and intracellular cyclic AMP (cAMP) (Beyer et al. 
2004; Kroslak et al. 2007). Chronic receptor activation results in a reduction of 
receptor responsiveness limiting the physiological response of the cell to external 
signals (Binyaminy et al. 2008). The exon 1 A118G variation has the highest overall 
frequency of any missense OPRM1 variant reported and has been linked with a higher 
potency for activation of G protein-coupled potassium channels increasing receptor 
functionality (Bond et al. 1998). A previous study reported higher post-mortem 
methadone concentrations in the presence of the A118G variation (Bunten et al. 2010) 
however this result was not statistically significant (P = 0.391). In this study we 
examined an increased post-mortem sample size and revealed that the A118G 
variation significantly associated with higher blood methadone concentrations (Table 
64, P = 0.05). As a clear functional role for A118G regulation of receptor expression 
has been documented  (Zhang et al. 2005; Kroslak et al. 2007), it is theorised that the 
higher methadone concentrations observed are a result of A118G affecting receptor 
expression, resulting in a reduction of surface receptors (Chapter 4; Bunten et al. 
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2010). The attenuation of activated cell surface receptors could lead to increased 
methadone in vivo, with subsequent drug accumulation and a lack of sensitivity to the 
toxic effects of methadone (Chapter 4; Bunten et al. 2010). The A118G variation has 
also been linked with lower levels of forskolin-induced cAMP accumulation and 
differences in agonist-mediated cAMP signalling for methadone (Kroslak et al. 2007). 
A study using animal models reported that the adenylyl cyclase and cAMP pathways 
are involved in opioid analgesia, tolerance, and withdrawal (Kim et al. 2006). A118G 
induced disruptions to these signal transduction pathways could have subsequent 
effects on methadone response and susceptibility.  
Methadone maintenance programmes have been shown to reduce the illicit use 
of opiates, and the risks of acquiring the human immunodeficiency virus (HIV) 
(Milroy & Forrest, 2000). Nevertheless, there continues to be concerns regarding the 
use of methadone (Lintzeris et al. 2007). The work in this study and the work 
described in Chapter 4 revealed that CYP2B6 and OPRM1 gene variations may 
contribute to individual susceptibility to methadone fatality (Chapter 4; Bunten et al. 
2010). Information regarding subject participation in methadone maintenance was 
available for 32 subjects for this work. A total of 17 (53 %) of these post-mortem 
subjects were involved in methadone maintenance programmes with an average daily 
methadone prescription of 76.3 mg/L. Therefore, 47 % of the methadone toxicity 
deaths examined here were in people not in methadone treatment. This result is in 
accordance with other studies examining methadone toxicity and death (Sunjic & 
Zador, 1999; Heinemann et al. 2000; Bell et al. 2009). Fatal blood methadone 
concentrations have been reported to be almost two-fold higher in subjects involved in 
a methadone maintenance programme (Worm et al. 1993). A study on methadone 
maintenance treatment in Hamburg, Germany, reported higher post-mortem blood 
methadone concentrations (0.62 mg/L mean concentration) for subjects in treatment 
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compared with those not enrolled (0.43 mg/L mean concentration) in maintenance 
programmes (Heinemann et al. 2000). Furthermore, blood concentrations below the 
generally accepted fatal 0.4 mg/L concentration were identified in 48 % of subjects 
within methadone treatment and 68 % of subjects not in treatment, indicating that 
susceptibility to methadone overdose is higher in subjects not enrolled in methadone 
maintenance (Heinemann et al. 2000). In agreement with the work presented in 
Chapter 4, this study revealed statistically higher post-mortem methadone 
concentrations in subjects engaged in methadone maintenance at the time of death (P 
<0.01). As expected, the post-mortem methadone concentrations were higher in 
subjects on high daily doses of methadone treatment (Figure 85). However, there was 
no significant association between methadone maintenance participation and the 
CYP2B6*6 allele and A118G. It is logical to assume that the association between 
high post-mortem methadone concentrations and enrolment in methadone 
maintenance is due to chronic methadone accumulation and the development of 
tolerance. A fatal dose for a methadone naïve/novice subject will be lower than an 
individual undergoing maintenance due to the acquisition of drug tolerance (Corkery 
et al. 2004). As there was no association between maintenance enrolment and SNP 
presence it can be postulated that tolerance as a result of chronic methadone treatment 
may result in higher post-mortem methadone concentrations. However, this does not 
alter the association identified between the CYP2B6*6 allele and A118G and post-
mortem methadone concentration in this study. 
Given the potential for such serious adverse events from methadone use, it is 
necessary to understand the molecular mechanisms responsible for methadone action 
in vivo. Earlier works documented the importance of pharmacogenomic research for 
certifying methadone mortality (Wong et al. 2003). The results described here will 
have important consequences for pharmacogenomic research. In addition to 
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identifying drug susceptible individuals (Chapter 4; Bunten et al. 2010), the 
CYP2B6*6 allele could also be used as a tool for the interpretation of forensic 
toxicological results. Forensic toxicology often contributes to the determination of 
cause and manner of death (Druid et al. 1999). Many fatal intoxications concern 
suicidal overdoses, however chronic administration of drugs such as methadone can 
complicate interpretation as it is difficult to differentiate between an acute overdose 
and chronic toxicity due to drug tolerance (Druid et al. 1999). CYP2B6 genotyping 
could be used in cases where the toxicological results are unclear, confirming whether 
the cause of death was through overdose or as a result of poor methadone metabolism. 
Additionally the OPRM1 A118G variation has also been demonstrated to correlate 
with higher post-mortem methadone concentrations indicating that this variation 
could also be of use for methadone pharmacogenomics.  
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Chapter 6 
Inter-individual variability in the prevalence of OPRM1 and 
CYP2B6 gene variations identify drug susceptible 
populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been drafted for publication and has been presented here in 
paper format. 
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6.1 ABSTRACT  
 
Methadone is used worldwide for the treatment of heroin addiction; however fatal 
poisonings are increasingly reported. The prevalence of CYP2B6 and µ-opioid 
receptor (OPRM1) gene variations were examined between a post-mortem population 
where the deaths were associated with methadone and a live non-drug using control 
population using Taqman™ SNP Genotyping assays. The CYP2B6*6 allele was 
higher in the post-mortem population however the difference was not significant (P = 
0.92). The CYP2B6 T750C promoter variation was similar in frequency for both 
populations. Linkage between T750C, and CYP2B6*6 was identified for both 
populations (P < 0.01). The prevalence of the OPRM1 A118G variation was 
significantly higher in the control population (P = 0.0046) which might indicate a 
protective mechanism against opioid toxicity. Individual susceptibility to methadone 
may be determined by screening for CYP2B6*6.  
 
 
 
Keywords: Forensic Science, Pharmacogenomics, OPRM1, A118G, Methadone 
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6.2 Introduction  
 
The application of pharmacogenomics for the interpretation of drug toxicity and 
individual drug susceptibility is steadily increasing and several studies indicate that 
the genotyping of single nucleotide polymorphisms (SNPs) may be a useful forensic 
tool (Wong et al. 2001; Janneto et al. 2002; Bunten et al. 2010). Most functionally 
important SNPs are located within genetic coding regions (exonic domains) and are 
ideal candidates to examine inter-individual drug responses (Giacomini et al. 2007). 
Gene variations in the Cytochrome P450 (CYP) enzymes can alter individual drug 
metaboliser status (Wong et al. 2003; Gerber et al. 2004, Eap et al. 2007; Bunten et al. 
2010). Similarly linkage between receptor variations and drug response has been 
reported, with the µ opioid receptor gene (OPRM1) recognised as a key variable in 
individual sensitivity to opioids (Lötsch et al. 2002). A number of significant SNPs 
have also been identified within critical non-coding regions i.e. gene promoter regions 
(Mills et al. 2006). 
Screening for SNPs involved in methadone action in vivo could identify 
individuals susceptible to methadone toxicity in addition to improving toxicological 
interpretation. CYP2B6 is one of the cytochrome P450 enzymes responsible for 
methadone metabolism. The T750C variant is located in the proximal promoter region 
and has been linked with decreased gene expression. The influence of T750C on 
methadone susceptibility is currently unknown. The CYP2B6*6/*6 genotype results 
from the combination of the G516T and A785G SNPs and has been associated with 
poor metabolism. CYP2B6*6/*6 is present at a frequency of about 6% in Caucasian 
populations (Lang et al. 2001; Crettol et al. 2007; Eap et al. 2007). In living subjects 
the frequency of CYP2B6*1/*6 has previously been reported at 24-26% (Kircheiner 
et al. 2003; Crettol et al. 2005) with CYP2B6*1/*4 at 26% (Kircheiner et al. 2003). 
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However, the work conducted in Chapter 4 reported higher frequencies in post-
mortem subjects whose deaths were attributed to methadone at 40 % and 37.5% 
respectively (Chapter 4, Bunten et al. 2010). This may be indicative of CYP2B6 
involvement in methadone toxicity. The work in Chapter 4 also documented a 
significant association between CYP2B6 variants and increased post-mortem 
methadone concentrations (Chapter 4, Bunten et al. 2010).  
OPRM1 is of special interest as it is the preferential binding target of 
methadone. The association between SNP frequencies in the OPRM1 gene and drug 
response have been examined in Hispanic (Bond et al. 1998), African-American 
(Gerlernter et al. 1999), Caucasian (Klepstad et al. 2005), and Japanese populations 
(Ide et al. 2006). The A118G SNP has been reported at frequencies ranging between 2 
and 48.5% across different populations (Bond et al. 1998; Gerlernter et al. 1999; Li et 
al. 2000; Ross et al. 2005).  
The purpose of this study was to explore the joint effects of OPRM1 and 
CYP2B6 genes in predicting individual susceptibility to methadone. Using SNP 
genotyping the prevalence of the OPRM1 A118G variation, the CYP2B6 T750C 
promoter variation and CYP2B6*4, *9 and *6 alleles were studied in 84 methadone 
associated fatalities comparing the gene frequencies against a non methadone using 
control population. 
 
6.3 Materials and Methods  
 
Case Subjects and Controls 
A population of 84 subjects whose deaths were associated with methadone in the East 
of Scotland was selected. The control population consisted of 100 healthy non-
 243 
methadone using volunteers from Bournemouth University. This study was approved 
by the Bournemouth University Ethics Committee. 
 
DNA Extraction and Quantitation 
Genomic DNA for the post-mortem subjects was isolated from leukocytes (sodium 
fluoride anticoagulated blood) using the DNeasy Blood and Tissue Kit (Qiagen, 
Crawley, UK). For the control group buccal cells were collected using the Epicentre 
Catch-All Swab and extracted in 150µl of MasterAmp™ buccal extraction fluid 
(Epicentre Biotechnologies, Madison, USA). All DNA samples were quantified using 
the Human Quantifiler® Kit (Applied Biosystems, Warrington, USA) in accordance 
with the manufacturer‟s instructions.  
 
Genotyping 
The procedure for OPRM1 A118G, CYP2B6*4, *9, and *6 genotyping was described 
previously (Bunten et al. 2010). For the CYP2B6 T750 promoter SNP samples were 
amplified by PCR to identify homozygous wild type and heterozygous controls using 
primer C2B6PrF (forward: 5‟ CAGGTTCAAGTGATTCTCTTG) and primer C2B6PrR 
(reverse: 5‟ CATGTTCAAAACTGAGAGGCT). PCRs were performed with a reaction 
volume of 50 l, including 27.5 l PCR grade water, 10 l of 5x GoTaq ™ buffer, 3.0 
mM MgCl2, 1 l of 10 mM deoxynucleoside triphosphates (dNTPs) (final 
concentration of 0.25 mM), 1 l Forward and Reverse primers, 10 ng/ l DNA and 
0.5 l GoTaq ™ DNA polymerase. PCR reactions were performed with a Primus 96 
advanced machine (Alpha Laboratories, Eastleigh, UK).  The cycling conditions were 
as follows: initial denaturation at 95C for 5 minutes; subsequent denaturation at 95C 
for 1 minute; annealing at 65ºC for 30 seconds; primer extension at 72C for 2 
minutes, repeated for 30 cycles, followed by final extension at 72C for 5 minutes. 
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PCR products were visualised by electrophoresis with a 2 % Cyber Green-agarose gel 
on blue light. Samples were purified using the QIAquick PCR Purification Kit 
(Qiagen, Crawley, UK) in accordance with the manufacturer‟s instructions. DNA 
sequencing was conducted by COGENICS (COGENICS, Essex, UK). Samples were 
then genotyped for the T750C SNP using the validated TaqMan® SNP Genotyping 
assay (Applied Biosystems, Warrington, UK, product no. 4362691) 
 
Statistical Analysis 
Data are presented as means ± SE of the mean. A Binary Logistic Regression model 
was used to examine the effects of OPRM1 A118G, CYP2B6*4, *9, *6, age, gender 
and race variables between the control and post-mortem population (95% confidence 
intervals). T-Test and Fisher‟s exact test were used to examine the difference between 
genotype frequencies for the control and post-mortem populations.  Binary 
correlations were used to examine the association between the CYP2B6 and OPRM1 
SNPs. A P value of ≤ 0.05 was considered to indicate statistical significance. All 
analyses were performed with SPSS Software (version 14.0). 
  
6.4 Results 
 
 
 
The 84 post-mortem cases where methadone had been implicated in the cause of 
death included 62 men and 22 women, the majority of whom were Caucasian (98 %). 
The mean age of the case subjects was 33.2 ± 1.12 (17 – 60 range). The 100 control 
subjects included 45 men and 55 women, the majority of whom were Caucasian 
(97%). The mean age of the control subjects was 24 ± 0.72 (18-55 range). 
 CYP2B6 G516T, A785G and T750C frequency data   
Of the 84 post-mortem samples screened, 37 were genotyped as heterozygous carriers 
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of G516T (allele * 9), a frequency of 44 % and 2 were genotyped as homozygous 
carriers, an allelic frequency of 2.4 %. For the control group 34 % were genotyped as 
being heterozygous for allele * 9 (a difference of 10 %) and 3 % were homozygous 
for the variant allele (Figures 86 and 87). This difference was not statistically 
significant with a P value of 0.92 (Fishers exact test). Heterozygous carriers of 
A785G (allele * 4) for the post-mortem group were identified in 40 cases, a frequency 
of 47.6 % and 2.4 % were homozygous for the variant allele, which is noticeably 
higher than other reports from Caucasian populations (Kircheiner et al. 2003; Jacob et 
al. 2004; Crettol et al. 2005; Crettol et al. 2007). For the control group 38% of 
subjects were heterozygous for A785G. The difference between the post-mortem and 
control frequencies was 9.6 %, this result was not statistically significant (P = 0.90). 
For the methadone-attributed deaths allele * 6 was identified in 39 subjects, an allelic 
frequency of 46.4 %, which was higher than the control group where allele *6 was 
identified in 36% of subjects (P = 0.92).  
 
The T750C promoter region SNP has been linked with alterations in gene expression 
(Lang et al. 2001). In the post-mortem population 37 subjects were heterozygous for 
T750C, a frequency of 44 %, a similar frequency to that identified in the control 
population (49%). 16 post-mortem subjects were homozygous for the CC genotype 
( 19 %) again a similar frequency to the control population (17%) (Figure 87). 
 
Linkage between the T750C, G516T and A785G gene variants was identified in both 
populations (Table 66). In the post-mortem population the T750C, G516T and A785G 
variants were identified together in 17 cases (20 %) and in the control population the 
SNPs were found in 17 % of cases. Interestingly wherever the variant homozygote for 
T750C was identified the G516T variant was not present. For the post-mortem 
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population the variant T750C homozygote was found in 16 subjects and for the 
control population in 17 subjects. Only one of the 9 post-mortem subjects also had the 
A785G variant and for the control group only 3 subjects also had the A785G variant. 
Table 66: Genotype prevalence between the healthy control population and the post-mortem 
population whose deaths have been associated with methadone. 
 
Gene variants R
2
 value P value 
Post-mortem population 
T750C & G516T -0.442** 0.001 
T750C & A785G -0.389** 0.001 
T750C & A118G -0.123 0.265 
A118G & G516T 0.485** 0.001 
A118G & A785G 0.495** 0.001 
A785G & G516T 0.931** 0.001 
Control population 
T750C & G516T -0.365** 0.001 
T750C & A785G -0.274** 0.006 
T750C & A118G 0.072 0.479 
A118G & G516T 0.058 0.572 
A118G & A785G 0.072 0.479 
A785G & G516T 0.903** 0.001 
 
** Correlation is significant at the < 0.01 level (two-tailed). 
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Figure 86: Heterozygous frequencies for OPRM1 A118G & CYP2B6 G516T, A785G & 
T750C genotypes. 
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Figure 87: Homozygous variant frequencies for OPRM1 A118G & CYP2B6 G516T, A785G 
& T750C genotypes.  
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 OPRM1 A118G frequency data 
In the post-mortem group the A118G SNP was found in 12 subjects a frequency of 
14.3 % (Figure 86) which is a similar result to previous studies (Bergen et al. 1997; 
Lotsch et al. 2002; Bunten et al. 2010). No homozygote for the G allele was identified. 
In the control group 30 subjects had the AG genotype and 2 subjects were 
homozygous for the G allele. The difference in frequency between the groups 
(15.7 %) was statistically significant with a P value of 0.0046. 
 
No linkage was found between A118G and T750C, G516T and A785G in the control 
population. Interestingly linkage was identified between A118G and G516T and 
A785G in the post-mortem population (Table 66). 
 
Age, gender and race effects 
The logistic regression model demonstrated the importance of gender and age for the 
SNP associations reported in this study. 
 
Gender correlated significantly with T750C in the post-mortem population (-0.301 R
2
, 
P value = 0.005). This was not repeated in the control population (0.039 R
2
, P value = 
0.699). No SNP correlation with age were observed in the post-mortem population, 
however both G516T and A785G were associated with age in the control population 
(0.256 R
2
, P value = 0.010; 0.293 R
2
, P value = 0.003 respectively). 
Age and gender were also significantly correlated with population (0.395 R
2
, P value 
= 0.001; -0.375 R
2
, P value = 0.001 respectively). 
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6.5 Discussion 
 
The importance of CYP2B6 and OPRM1 variations for individual susceptibility to 
methadone was reported in Chapters 4 and 5. Identification of methadone risk factors 
will improve the toxicological interpretation of methadone-related deaths at autopsy 
whilst assisting in the prevention of methadone toxicity particularly during the drug 
induction phase.  
The present study examined the prevalence of CYP2B6 and OPRM1 SNPs in a 
post-mortem population where the deaths had been associated with methadone 
compared with a healthy control population of non-methadone using living subjects. 
The work presented in Chapters 4 and 5 noted higher incidences of the CYP2B6 
G516T and A785G variations in post-mortem subjects (Bunten et al. 2010) when 
compared with previous studies sampling live subjects (Crettol et al. 2007; Crettol et 
al. 2005; Kircheiner et al. 2003). Similarly the results from this study report higher 
frequencies of G516T and A785G in the post-mortem population than the control 
group (Figure 86). However, this difference was not statistically significant (P = 0.92, 
P = 0.90, respectively) and may be indicative of a trend that has been limited by 
sample size. A larger number of post-mortem subjects would elucidate the association 
between G516T and A785G prevalence and methadone susceptibility. 
The T750C variant had a similar distribution across both populations sampled 
suggesting that the presence of this variant is not a suitable risk factor for methadone 
susceptibility. However, when examining linkage between T750C and G516T and 
T750C and A785G a significant association was discovered (Table 66). T750C has 
been reported to decrease CYP2B6 expression (Lang et al. 2001). The work discussed 
in Chapter 4 revealed the importance of the G516T and A785G variants for 
methadone susceptibility with the CYP2B6*6 allele correlating with poor methadone 
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metabolism (Crettol et al. 2007; Eap et al. 2007; Bunten et al. 2010). Subjects with all 
three CYP2B6 variants would therefore experience reduced expression of an already 
poorly functioning gene. The resulting effect on metabolism would likely involve 
methadone accumulation and toxicity. The association between T750C, G516T and 
A785G was significant for both the post-mortem population and the control 
population suggesting the possibility of a haplotype between these three CYP2B6 
SNPs. 
Identification of genetic mutations that alter the functional activity of OPRM1 
may also explain inter-individual responses to methadone (Befort et al. 2001). A118G 
is located in the N-terminal region of the receptor resulting in the loss of a putative N-
glycosylation site which could result in alterations to OPRM1 expression (Zhang et al. 
2005). The frequency of the A118G SNP was significantly higher in the control group, 
with a 15.7 % difference between populations for heterozygous subjects (P = 0.0046). 
Several studies have reported that A118G may confer protection from opioid toxicity 
(Bond et al. 1998; Town et al. 1999; Lötsch et al. 2002). A118G has been associated 
with reductions in cell surface receptors limiting the availability of drug binding sites 
and as a result drug response (Zhang et al. 2005). However, it was reported in Chapter 
4 that the A118G SNP may be associated with the lethal interaction between 
methadone and benzodiazepines, although this may be a consequence of 
benzodiazepine induced µ-receptor up-regulation (Bunten et al. 2010). A118G effects 
on gene expression have been well documented (Zhang et al. 2005; Mague et al. 
2009). A Study on mRNA expression in post-mortem brain tissue reported a ten-fold 
reduction in protein levels for subjects with the G allele (Zhang et al. 2005). 
Furthermore, lower surface receptor expression and decreased forskolin-induced 
receptor activation has been identified in cell systems expressing the G allele (Kroslak 
et al. 2007). It seems logical therefore that receptor function will be reduced in 
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subjects with the G allele. This may confer protection from opioid toxicity at 
therapeutic levels. However these subjects will have a reduced sensitivity of the µ-
receptor which could lead to higher methadone concentrations in vivo before toxic 
effects appear. As methadone has a long mean elimination half life of approximately 
55 hours (Moffat et al. 2004 ) this could be especially pronounced in drug abusing 
subjects, limiting any possible protective function rendered by the G allele. 
No linkage between the OPRM1 A118G genotype and CYP2B6 T750C, 
G516T and A785G genotypes was observed for the control population in this study 
(Table 66). However linkage was identified between A118G and G516T and A118G 
and A785G in the post-mortem population, this result is in agreement with Chapters 4 
and 5 which documented a significant association between A118G and G516T and 
A118G and A785G in post-mortem subjects. In this study G516T, A785G, and 
A118G were found together in 8 of the post-mortem cases (66%) and 11% of the 
control population. An association between A118G, G516T and A785G would have 
significant impacts on methadone response. As discussed in Chapter 4 the CYP2B6*6 
allele associates with increased susceptibility to methadone fatality and A118G has 
been linked with increased heroin addiction (Bart et al. 2004). Therefore this 
combination of gene variants could lead to subjects with increased tendancy to drug 
addiction and a reduced ability to metabolise methadone.  
The logistic regression model detected statistically significant age and gender 
interactions. Furthermore, gender significantly correlated with CYP2B6 T750C in the 
post-mortem population (P < 0.01). As the frequency of this SNP remained constant 
across both the post-mortem and control population it is proposed that T750C has an 
unknown influence on methadone susceptibility that requires further investigation. In 
the control population CYP2B6 G516T and A785G significantly correlated with age. 
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However, as the control group was made up of a student population this may have 
influenced this result. 
Both age and sex influences on the opioid system have previously been 
described (Gabilondo et al. 1995; Zubieta et al.1999). Increased µ-opioid receptor 
densities have previously been found to correlate with age, with older subjects having 
significantly more receptors (Gabilondo et al. 1995). Gender influences could be 
linked with hormonal factors which can influence drug absorption, disposition, 
metabolism and pharmacodynamics (Lukas & Wetherington, 2005). This could 
contribute to differences in both drug action and response between males and females.  
It has been well documented that estrogen is involved in the enhancement of psycho-
stimulants in females (Becker, 1990; Peris et al. 1991; Justice & de Wit, 1999, 2000. 
Conversely, it has also been reported that estrogen may confer protection against 
opioid toxicity as inter-individual variation in morphine potency is higher in males 
(Zubieta et al. 1999). A118G sex-specific associations (Munafo et al. 2006) have 
been reported previously however the functional significance of this is unclear 
(Mague et al. 2009). 
Alternatively gender trends in drug abuse could be an influential factor in the 
significance reported in this study. It has been well documented that drug abuse and 
mortalities from drug overdose occur more frequently in males than females (Roth et 
al. 2004; Becker & Hu, 2008). With reports of men being between two and three 
times more likely to have a drug abuse/dependence disorder (Becker & Hu, 2008). 
Furthermore, studies using animal models indicate that sex differences in drug 
dependence may be a result of sexually dimorphic development of the brain (Peris et 
al. 1991). Socio-cultural and economic parameters can also not be excluded as years 
of education, employment status, medical health status and incidence of physical and 
sexual abuse are all underlying factors contributing to the development of drug abuse 
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and dependence (Lex, 1991; Brady & Randall, 1999; Lukas & Wetherington, 2005). 
The post-mortem population examined in this study only reported 9 females (16%), 
which could explain the significance identified in this study for gender. 
In summary the CYP2B6*6 allele may be linked with increased susceptibility 
to methadone particularly when in combination with the CYP2B6 T750C promoter 
variation. The association between the prevalence of T750C, G516T and A785G 
remained constant across both the post-mortem and control population. The role of 
the OPRM1 A118G variation for methadone susceptibility remains unclear. The 
higher prevalence of A118G in the control population is in support of the theory that 
A118G is protective against opioid toxicity (Bond et al. 1998; Town et al. 1999; 
Lötsch et al. 2002). However, whilst, this protective function may work effectively 
with opioids such as morphine with a relatively short elimination half life (Moffat et 
al. 2004), for methadone, which has a significantly longer elimination half life, this 
could result in high concentrations accumulating in vivo, leading to methadone 
toxicity and in extreme cases death. Furthermore, no linkage was identified in this 
study between A118G and the CYP2B6 G516T and A785G variations. It is suggested 
that a larger post-mortem sample size is required to effectively determine the role of 
A118G for methadone response. Genotyping CYP2B6*6 homozygotes and 
heterozygotes may therefore, assist in reducing adverse reactions to methadone during 
the drug induction phase whilst serving as a useful tool for certifying methadone 
toxicity at autopsy. 
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Chapter 7 
The T750C single nucleotide polymorphism may be 
associated with CYP2B6 gene expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been drafted for publication and has been presented here in 
paper format. 
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7.1 ABSTRACT 
 
 
  
There is significant inter-individual variability in hepatic CYP2B6 expression and this 
has been associated with gene variations within the promoter region. The results from 
Chapters 5 and 6 revealed a significant association between the CYP2B6*6 allele and 
the CYP2B6 T750C promoter region polymorphism. However, the role of T750C for 
methadone action in vivo is unclear. In order to explore the effects of T750C on inter-
individual susceptibility to methadone, subcloning of the proximal CYP2B6 promoter 
region into an EGFP reporter system was employed. Using the TOPO® TA 
Expression kit and OneShot® chemically competent E. coli cells three clones for the 
750 TT, 750 TC and 750 CC genotypes were created, to assess the promoter activity 
of CYP2B6, as a result of the T750C polymorphism.  
 
Keywords: CYP2B6, T750C, Cloning, Expression, Methadone. 
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7.2 Introduction 
 
 
CYP2B6 has long been thought to play a minor role in drug metabolism (Pascussi et 
al. 2003; Lemaire et al. 2004), however its role in methadone metabolism is still 
under investigation. Significant inter-individual differences in gene expression 
patterns are common and result from either environmental factors or cis- or trans-
mediated genetic effects (Johnson et al. 2005). CYP2B6 activity has been documented 
to vary more than 100-fold among different individuals (Ekins et al. 1998). In vitro 
studies have documented inter-individual variability in hepatic CYP2B6 expression at 
the mRNA, protein and catalytic level, with male subjects demonstrating noticeably 
lower levels than females (Code et al. 1997; Ekins et al. 1998; Lang et al. 2001; 
Lamba et al. 2003).  Understanding the molecular pathways leading to CYP2B6 
induction and regulation will lead to better models for the screening and prediction of 
drug interactions (Pascussi et al. 2003). 
Many CYP2B6 alleles have been reported, however there is an inherent bias 
towards sequencing and genotyping of coding regions (Johnson et al. 2005). A 
number of significant SNPs can also be found within critical non-coding regions i.e. 
gene promoter regions (Mills et al. 2006) and these include C1848A, G801T, T750C, 
and T82C (Zukunft et al. 2005). The T750C SNP (CYP2B6*1G) located within the 
proximal promoter region correlated with lower levels of gene expression (Lang et al. 
2004) and could therefore have cascade effects on both drug pharmacokinetics and 
pharmacodynamics. T750C forms part of the CYP2B6*6B allele together with G516T 
and A785G. The work reported in Chapters 4 and 5 demonstrated the importance of 
G516T and A785G for methadone metabolism and individual susceptibility to 
methadone mortality (Bunten et al. 2010). Since, T750C has been linked with lower 
CYP2B6 expression (Lang et al. 2004), it is logical to assume that the combination of 
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T750C together with the CYP2B6*6 allele could result in reduced expression of a 
gene associated with methadone accumulation. Interestingly, the work described in 
Chapter 5 showed that T750C was not associated with significantly higher post-
mortem methadone concentrations despite correlating with the CYP2B6*6 allele. 
Furthermore, 750 TT subjects had higher post-mortem methadone concentrations 
(0.79 mg/L) than 750 TC and 750 CC subjects (0.69 mg/L, Chapter 5). It was 
postulated that this may also be due to T750C involvement in the CYP2B6*22 allele, 
which has been linked with higher CYP2B6 expression as a result of the T82C 
polymorphism (Zukunft et al. 2005; Li et al. 2010).  
Currently, the influence of T750C on CYP2B6 expression and its subsequent 
association with methadone toxicity remains unclear. Linkage between SNPs located 
within the CYP2B6 promoter region and exons such as the G516T SNP (Hoffman et 
al. 2008), requires further investigation, specifically with respect to their potential 
impact on gene transcription.  A stable reporter construct was developed to study the 
effect of the CYP2B6 T750C promoter variation on gene expression. To achieve this 
OneShot®TOP10 Chemically Competent E. coli cells were transfected with the entire 
CYP2B6 proximal promoter region plus the EGFP reporter gene. 
 
7.3 Materials and Method 
 
 
CYP2B6 Cloning Strategy 
A strategy was designed to clone the CYP2B6 promoter region containing the 750 TT, 
750 TC, and 750 CC genotypes into an Enhanced Green Fluorescence Protein (EGFP) 
reporter construct (Figure 4). A second strategy was then created to clone the CYP2B6 
promoter region into the pcDNA3.1/CT-GFP-TOPO® vector (Figure 5). 
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EGFP transformation into hSVCT2 plasmid  
The EGFP gene was excised from pyEGFP (invitrogen) as a 0.7kb XbaI/HindIII 
fragment and recloned into HindIII/XbaI cut hSVCT2 vector (Liang et al. 2001).  
Transformation was carried out using plasmid cDNA prepared by purification on   
Qiaquick™ spin columns (Qiagen, Crawley, UK). PyEGFP expressing plasmid was 
introduced into E. coli JM109 according to the manufacturer‟s instructions. 
Transformants were verified by NdeI enzyme digestions of extracted plasmid DNA in 
gel electrophoresis.  
 
CYP2B6 promoter region amplification 
The CYP2B6 promoter region for the 750 TT, 750 TC and 750 CC genotypes was 
amplified using primer C2B6F1 BglI (forward: 5‟ ataAGATCTTTCTGGTTTTACGGCTCAG) 
and primer C2B6R1 HindIII (reverse: 5‟ attAAGCTTCATCATCCAGGAGCATTAGCTT), 
which introduced BglI and HindIII restriction sites respectively. Promoter region 
amplifications were verified by agarose gel electrophoresis and the Sybergreen 
stained DNA fragments were visualised under blue light. 
 
Cloning the CYP2B6 promoter variants into pcDNA3.1/CT-GFP-TOPO® 
The CYP2B6 promoter variants were extracted and purified using the Qiagen Gel 
Extraction Kit™ (Qiagen, UK) from the Agarose gel (1.6 %) after electrophoresis, 
and cloned into the pcDNA3.1/CT-GFP-TOPO® vector.  The recombinant p2B6-
GFP-HB DNA samples were introduced into OneShot® TOP10 Chemically 
Competent E. coli according to the manufacturer‟s protocol. Transformants bearing 
CYP2B6 promoter variants in the correct orientation were verified by BglII/HindIII 
and BglII enzyme digestions followed by DNA electrophoresis in agarose gel. The 
genotypes of the 750 TT, 750TC, and 750 CC clones were confirmed by DNA 
sequencing (sense strand).  
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7.4 Results 
 
Restriction Site Cloning Strategy 
Subcloning of EGFP into hSVCT2 plasmid 
In total 43 transformants were obtained after the ligation of the EGFP gene into the 
hSVCT2 plasmid. But there have been no correct clones obtained. The NdeI enzyme 
digestions revealed that the 43 clones were all empty vectors. It was anticipated that 
the cheaper/conventional strategy would be less efficient. Under the pressure in 
obtaining the clones for further studies on the promoter activity a more efficient but 
expensive strategy (Figure 5) was formulated using the TOPO® TA Expression Kit. 
 
CYP2B6 promoter region amplification 
The promoter regions for the CYP2B6 750 TT, 750 TC and 750 CC genotypes were 
successfully amplified using the C2B6F1 BglI and C2B6R1 HindIII primers (Section 
3.4 CYP2B6 Cloning, Figure 62). 
 
Subcloning CYP2B6 promoter variants into pcDNA3.1/CT-GFP-TOPO® 
p2B6-GFP-HB transformation into the OneShot® E. coli cells was successfully 
verified through the BglII/HindIII restriction digest. In total 40 transformants for 
p2B6-GFP-HB-750 TT were obtained, of these ten were analysed further with one 
correct CYP2B6 transformant verified (Figure 88). For p2B6-GFP-HB-750 TC 50 
transformations were obtained of the ten transformants analysed two were CYP2B6 
clones (Figure 88), however only one had the correct orientation (Figure 88). For 
p2B6-GFP-HB-750 CC five transformations were obtained, of these three were 
CYP2B6 clones, however, all three clones were in the wrong orientation (Figure 88). 
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Figure 88: Total number of CYP2B6 transformants obtained for T750C variants. 
Agarose gel (2 %) and run at 70 volts. Arrows indicate CYP2B6 promoter transformants. 
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7.5 Discussion 
 
The molecular mechanisms responsible for methadone action in vivo are unclear. The 
hepatic expression of CYP2B6 is highly variable and could be affected by a variety of 
factors including drug exposure, age, gender, diet, hormone production and genetics 
(Lamba et al. 2003; Lang et al. 2004; Lukas & Wetherington, 2005; Eap et al. 2008; 
Li et al. 2010). There is growing evidence that polymorphisms within gene promoter 
regions significantly influence gene expression by changing the level of RNA 
transcription (Day & Tuite, 1998; Rockman & Wray, 2002, Johnson et al. 2005). 
T750C is located in the putative HNF1-binding site and has been reported to be 
associated with alterations to CYP2B6 protein levels (Lamba et al. 2003; Lang et al. 
2004). However, the statistical significance of this association is unclear. A study 
examining variants within the CYP2B6 promoter region and hepatic CYP2B6 
expression reported modest T750C effects, with 750 TC and 750 CC subjects having 
1.42 and 1.81 fold less protein than 750 TT subjects (Lamba et al. 2003). Another 
study reported significant reductions in CYP2B6 expression as a result of the T750C 
polymorphism (Lang et al. 2004).  
The work described in Chaper 5 revealed a significant correlation between 
T750C and the CYP2B6*6 allele (G516T & A785G) which could affect individual 
susceptibility to methadone. However there was no association between high post-
mortem methadone concentrations and T750C, which was an unexpected result. 
Currently, the role of T750C for hepatic CYP2B6 expression requires clarification to 
determine whether the polymorphism could be involved in individual susceptibility to 
methadone. It is postulated that p2B6-GFP-HB-750 TT and p2B6-GFP-HB-750 TC 
introduction into mammalian Chinese Hamster Ovary (CHO) cells may identify 
T750C effects on gene expression following methadone exposure in a controlled 
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system. The GFP protein is stable, species independent and can be observed non-
invasively in living cells, therefore, monitoring GFP fluorescence is a suitable method 
for the reliable estimation of GFP expression levels (Nocarova & Fisher, 2009) and 
CYP2B6 promoter activity for the T750C polymorphism.  
The primary cloning strategy designed for the study (Chapter 2, Figure 4) 
involved the insertion of the EGFP gene into the hSVCT2 vector, to act as a marker of 
CYP2B6 promoter activity, and to explore the effects of the T750C polymorphism on 
gene expression. However, the subcloning of EGFP into hSVCT2 was unsuccessful 
and no positive clone was identified as the EGFP-hSVCT2 clone. Ligation reaction 
was successful as tested by conducting a Lamda/HindIII control and was therefore not 
the factor responsible for cloning difficulties. However, the method used to prepare 
the hSVCT2 vector for ligation involved a HindIII/XbaI restriction digest to remove 
the hSVCT2 gene fragment followed by a further digest with BamHI to prevent re-
ciculization of the original expression vector. It was then postulated that either the 
hSVCT2 gene was re-ligated back into the vector or the restriction double digest with 
HindIII/XbaI was not efficient enough such that only one site was digested leading to 
original vector self ligation back. An alternative CYP2B6 cloning strategy was then 
designed using the CT-GFP TOPO® TA expression kit. This was chosen since 
TOPO® cloning involves a rapid and simple strategy allowing the direct fusion of the 
polymerase amplified CYP2B6 promoter variants to a GFP reporter system. The 
amplification of the entire proximal CYP2B6 promoter regions by C2B6F1 BglI and 
C2B6R1 HindIII was successful (Figure 62). The CYP2B6 promoter variants were 
ligated into the pcDNA3.1/CT-GFP-TOPO vector taking advantage of the intensive 
Topisomerases within the kit. The transformations of p2B6-GFP-HB-750 TT, and 
p2B6-GFP-HB-750 TC into the competent E. coli cells were successful, and two 
CYP2B6 promoter variant constructs have been selected to explore T750C effects on 
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gene expression of GFP in the further studies on their association with methadone 
metabolism susceptibility. 
The 84 post-mortem samples genotyped for the T750C polymorphism in 
Chapter 6 revealed a significant association between T750C and gender (P < 0.01). As 
discussed in Chapter 6, gender influences have been linked with hormonal factors 
influencing drug absorption, disposition, metabolism and pharmacodynamics (Lukas 
& Wetherington, 2005) and this requires further investigation. Lamba et al. (2003) 
reported significant differences in CYP2B6 expression in liver between male and 
female subjects, with CYP2B6 activity below quantifiable limits in 7.1 % of females 
and in 20 % of males. In the present study the male gender significantly correlated 
with T750C presence, with only 6 females subjects heterozygous for the T750C 
polymorphism and 2 homozygous for the C allele. As higher reductions in CYP2B6 
activity had been reported in males (Lamba et al. 2003) and T750C has been linked 
with reduced CYP2B6 expression, it is postulated that the association between gender 
and T750C reported here is due to T750C alterations to CYP2B6 activity. Further 
investigation is required to establish whether there are gender differences in CYP2B6 
expression as a result of T750C. Therefore, functionality trials using p2B6-GFP-HB-
750 TT, p2B6-GFP-HB-750 TC, and p2B6-GFP-HB-750 CC clones following 
methadone exposure may determine the influence of T750C on CYP2B6 expression 
and therefore the role of T750C for methadone susceptibility. 
However, identifying the genetic alleles that are accounted for inter-individual 
differences in drug response is complex. The genetic components of complex inter-
individual variations may require resolution of multiple gene variations which 
collectively yield recognizable phenotypes such as drug susceptibility (Li et al. 2010). 
For CYP2B6 the studies described in Chapter 4 and 5 revealed that the presence of 
functional variations in exons 4 and 5 known to alter drug metabolism may interact 
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with T750C. Therefore, the association between methadone metabolism susceptibility 
and CYP2B6 promoter variants will be explored further using p2B6-GFP-HB-750 TT 
and p2B6-GFP-HB-750 TC. However, it must be noted that inter-individual 
variability in CYP2B6 expression may also be attributed to chemical-mediated 
induction through the activation of constitutive androstane receptor and/or the 
pregnane X receptor (Li et al. 2010). As CYP2B6 transcription is correlated with 
constitutive androstane receptor (CAR) expression (Li et al. 2010), it is possible that 
polymorphisms in the CAR gene may also be responsible for altering the CYP2B6 
expression. Studies conducted in recent years have provided evidence that part of the 
human CYP2B6 variability is caused by its drug-inducible regulation via proximal and 
distal response elements termed Phenobarbital-responsive enhancer module at -1.7kb 
(Sueyoshi et al. 1999; Goodwin et al. 2001; Wang et al. 2003) and xenobiotic-
responsive enhancer module at -8.5 kb (Lamba et al. 2003; Wang et al. 2003B). 
Furthermore, it has been revealed that the relative levels of CAR mRNA are higher in 
female subjects than that in male subjects (Wei et al. 2000; Wang et al. 2003; Fery et 
al. 2010). Since, CAR influences CYP2B6 expression, it seems likely that the 
association between T750C and gender reported in this study may also be due to an 
interaction between CYP2B6 and CAR. The human pregnane X receptor induces 
CYP2B6 transcription (Goodwin et al. 2001) forming a heterodimer with the retinoid 
X (RXR) receptor Lemaire et al. 2004). As the hPXR-RXR complex is thought to act 
as a drug-responsive transcription factor to regulate CYP2B6 activity (Geick et al. 
2001) it is also possible that this interaction is influential in the association between 
T750C and gender reported in this study.  
In conclusion the role of the CYP2B6 T750C polymorphism for methadone 
susceptibility is unclear and requiring further investigation. Reductions in hepatic 
CYP2B6 activity as a consequence of T750C have been revealed (Lamba et al. 2003; 
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Lang et al. 2004), therefore, it seems likely that the gene expression level is 
associated with individual susceptibility to methadone toxicity and death. The present 
study has designed and created two CYP2B6 promoter variant clones for the 750 TT, 
and 750 TC genotypes. These clones could now be used to determine the effect of 
CYP2B6 promoter variants on GFP gene expression, to measure the effects of the 
T750C polymorphism on CYP2B6 activity. 
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Chapter 8 
The effects of the OPRM1 A118G variation on cellular 
apoptosis and µ-receptor internalisation following 
methadone treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter has been drafted for publication and has been presented here in 
paper format. 
 267 
8.1 ABSTRACT 
 
 
Earlier work of this research project identified an association between the OPRM1 
A118G polymorphism and increased susceptibility to methadone and methadone and 
benzodiazepine fatality. It is know that methadone binding to µ-opioid receptors 
induces receptor internalisation and it was postulated that this might be linked with 
individual susceptibility to methadone. This study explored the association between 
the A118G polymorphism and methadone concentration on µ opioid receptor 
internalisation and cellular apoptosis in chronic lymphocytic leukaemia (CLL) cells 
using flow cytometry. It was observed in this study that the A118G polymorphism is 
associated with higher levels of cellular apoptosis as demonstrated by Annexin V and 
propidium iodide binding. Furthermore, the G allele is associated with significant 
reductions in receptor internalisation. The A118G polymorphism might be involved in 
receptor accumulation at the cell membrane as a result of poor receptor internalisation, 
which could induce methadone toxicity. 
 
Keywords: A118G, Apoptosis, Internalisation, Methadone, OPRM1. 
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8.2 Introduction  
 
The work presented in Chapters 5 and 6 of this research project demonstrated that the 
µ-opioid receptor is involved in individual susceptibility to methadone toxicity and 
death. However, the molecular mechanisms responsible for this remain unclear. The 
receptor-mediated activation of µ-opioid receptors is a complex process involving a 
number of downstream actions, including the regulation of adenylyl cyclase, mitogen-
activated protein kinase (MAPK), G-protein-gated, inwardly rectifying K
+
 channels 
and voltage-dependent calcium channels (Toskulkao et al. 2010). Agonist exposure at 
the µ-opioid receptor rapidly results in receptor internalisation modulating the number 
of active receptors at the plasma membrane (Trapaidze et al. 2000). The process of 
receptor internalisation occurs within minutes after opioid receptor activation and has 
been observed in opioid receptor transfected cells, neuroblastoma cells and native 
neurons (Koch & Hollt, 2008). Since, receptor internalisation is differentially 
regulated by distinct peptide agonists and alkaloid drugs it has been proposed that 
receptor internalisation plays an important role in individual response to opioids 
(Trapaidze et al. 2000).  
A disruption to receptor internalisation as a result of gene variations could 
have significant effects on signal transduction and individual response to methadone 
(Trapaidze et al. 2000). The OPRM1 A118G single nucleotide polymorphism codes 
for the N40D protein which is located within the second extracellular loop of the 
receptor, which is an important domain for the initial binding of opioids (Ferrer-Alćon 
et al. 2004). The A118G variation is responsible for the loss of an N-glycosylation 
site significantly affecting β-endorphin binding (Bond et al. 1998). The effect of 
A118G on receptor internalisation following methadone exposure is unclear, and 
recent work postulated that the A118G SNP reduces receptor internalisation resulting 
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in an accumulation of desensitised receptors at the membrane surface (Chapters 4 & 
5). To study this further the present study used an in vitro methodology to investigate 
methadone induced receptor internalisation in primary chronic lymphocytic leukaemia 
(CLL) cells. CLL cell samples were selected because µ-opioid receptor presence on 
lymphocytes had been well reported (Mehrishi & Mills, 1983; Wu & Li, 1999; 
Toskulkao et al. 2009 and CLL subjects possess high numbers of B-lymphocytes.  
In addition to determining the effects of methadone on receptor internalisation, 
the effect of methadone concentration on cellular apoptosis was also investigated in 
this work, to determine whether methadone exposure induces cellular stress initiating 
intracellular apoptotic signalling and cell suicide. Studies have reported that morphine 
induces apoptosis in immunocytes and that this is directly associated with opioid 
tolerance and receptor desensitisation (Fecho et al. 1994; Wu et al. 1999; Mao et al. 
2002; Tegeder & Geisslinger, 2004). Furthermore, due to the association between 
apoptosis and receptor desensitisation it has been postulated that receptor 
internalisation is a key event involved in the initiation of opioid-induced cell death 
(Tegeder & Geisslinger, 2004). Therefore the association between apoptosis and 
receptor internalisation requires further study, as this association may be involved in 
individual susceptibility to methadone. 
 
8.3 Materials and Methods 
 
DNA Extraction 
Genomic DNA was isolated from 13 human cell lines using the DNeasy Blood and 
Tissue Kit (Qiagen). All DNA samples were quantified using the Human Quantifiler® 
Kit (Applied Biosystems) in accordance with the manufacturer‟s instructions. 
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OPRM1 A118G SNP Genotyping 
A total of 44 chronic lymphocytic leukaemia (CLL) samples were genotyped for the 
A118G variation using the commercialised TaqMan® SNP Genotyping assay 
(Applied Biosystems, Warrington, UK, product no. 4351379) to identify A118G 
subjects. 
 
Cell Culture and Ligand Binding Assay 
Twelve human B-CLL cell lines (6 homozygous for the AA genotype, 5 heterozygous 
for the G allele and 1 homozygous for the GG genotype) were cultured in GIBCO® 
RPMI Media 1640 (supplemented with Penicillin, Streptomycin, L-Glutamine, and 
10 % Fetal Calf Serum) and incubated with concentrations of 1 µM, 5 µM, 10 µM, 20 
µM, and 100 µM methadone hydrochloride solutions for 1 hour at 37ºC.  
 
Annexin V FITC and propidium Iodide Staining of Apoptosing Cells 
Cell surface staining was performed by washing 500µl of cultured cells with 
phosphate-buffered saline (PBS). Following this 1 x 10
6
 cells for each treatment were 
incubated with 1µl of Annexin V FITC conjugate and 2µl of propidium iodide 
solution for 10 minutes at room temperature protected from the light. After cell 
staining flow cytometric analysis was performed. 
µ-Opioid Receptor Internalisation 
Receptor internalisation was performed by washing 500µl of cultured cells with 
FACSFlow. After this 1 x 10
6
 cells for each treatment were incubated with 2µl of the 
rabbit polyclonal to µ opioid receptor (ab10272) for 30 minutes at 4ºC. The cells were 
washed twice before being incubated with 2µl of Goat polyclonal to Rabbit IgG-FITC 
for 30 minutes at 4ºC. The cells were then washed. After antibody binding flow 
cytometric analysis was performed. 
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Flow cytometric analysis 
Flow cytometric analysis was performed using a Becton Dickinson FACS Analyser 
flow cytometer with argon ion laser excitation at (488) nm, with 10,000 events of 
each sample measured. Data were acquired using forward scatter, side scatter, µ 
antibody to Rabbit IgG FITC, Annexin V FITC and propidium iodide. Medians of 
fluorescent intensities (MFI) of antibody-stained µ-opioid receptors as a measure of 
receptor internalisation were determined. 
 
Statistical Analysis 
Data are presented as median, means ± SE of the mean. The association between 
Annexin V and propidium iodide staining for the subjects was determined using the 
two tailed Spearman‟s rank test. The data was split using treatment grouping and 
genotype grouping to determine the effects of A118G and methadone treatment on 
cellular apoptosis. Spearman‟s rank testing was conducted to explore A118G effects 
on the apoptosis pathway using the following parameters: % live cells, % 
permeabilised cells, and % fragmented cells following methadone treatment. The 
independent T-test was used to determine the association between receptor 
internalisation for 118AA, and 118AG subjects, and the effect of A118G on cell 
apoptosis. The association between apoptosis and receptor internalisation was 
determined using Spearman‟s rank correlation. A P value of ≤ 0.05 was considered to 
indicate statistical significance. All analyses were performed with SPSS Software 
(version 14.0). 
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8.4 Results 
 
OPRM1 A118G SNP Genotyping 
In total 15 subjects were identified as heterozygous for the 118 G allele, a frequency 
of 34 %, one subject as homozygous for the 118 GG genotype (2 %) and 28 subjects 
as homozygous for the 118 AA genotype (64 %). This result is in agreement with 
early work (Chapter 6). 
 
Annexin V FITC staining as a marker of cellular apoptosis 
Annexin V binds to phosphatidylserine on the surface of the cell membrane of cells in 
the early stages of apoptosis. Following flow cytometry the Annexin V cells were 
divided into two separate groups (dead cells and live cells) using cell gating. The cells 
were then further sub-divided into % Annexin V positive, and % Annexin V negative. 
When examining the total cells (dead cells and live cells) there was a significant 
correlation between the % of Annexin V negative cells and the 118 AG genotype 
regardless of methadone treatment (Table 67). For the Annexin V dead cell group, 
the % of Annexin V negative cells was significantly associated with the control (0 
µM), 100 µM, and 5 µM methadone treatments in the presence of the 118 AG 
genotype (P ≤ 0.05). This trend continued with the live cell group with the 100 µM, 
20 µM, and 5 µM methadone treatments associating with % of Annexin V negative 
cells for the 118 AG subjects. Interestingly there was no association between the % of 
cells positive for Annexin V and methadone treatment or subject genotype.  
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Table 67: The effect of the A118G variation on the total % of Annexin V negative cells. 
 
Methadone 
Treatment 
118 AA Genotype 118 AG & GG Genotypes 
 R
2
 P value R
2
 P value 
0 µM 0.086 0.872 0.886 0.019* 
100 µM 0.143 0.787 0.943 0.005** 
20 µM 0.314 0.544 0.943 0.005** 
10 µM 0.314 0.544 0.829 0.042* 
5 µM 0.314 0.544 0.943 0.05* 
1 µM 0.314 0.544 -0.257 0.623 
 
* Denotes ≤ 0.05, ** denotes ≤ 0.01. 
 
The association between genotype and apoptosis was further examined using 
the Independent T-test.  For the total cell group the 118 AG genotype was associated 
with significantly higher levels of Annexin V positive cells (19.92) compared with 
118 AA subjects (5.83; P = 0.001). This trend continued for the % of Annexin 
positive cells within the live cell group (P = 0.037; 118 AA, 0.346; 118 AG, 0.603). 
As expected the A118G variation significantly associated with lower total % of 
Annexin V negative cells (P = 0.002; 118 AA 90.57; 118 AG 76.87). 
 
Propidium Iodide staining as a marker of cellular apoptosis 
Propidium iodide targets and binds to cells in the later stages of cellular apoptosis. 
After flow cytometry the cells were divided into % dead cells and the % live cells. 
Within these groupings three stages of cell apoptosis were designated: % live cells, % 
permeabilised cells, % fragmented cells. There was no association observed when 
examining the total number of cells (dead and live cells). In the dead cell group the % 
of live cells significantly correlated with the 118 AG genotype for the 20 µM and the 
10 µM methadone treatments (P = 0.019, P = 0.019). Within the live cell group the % 
of permeabilised cells were significantly correlated with methadone treatment. 
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Furthermore, the 10 µM and 1 µM methadone treatments were associated with 
apoptosis for 118 AG subjects. 
The association between genotype and propidium iodide for the total cells was 
further explored with the Independent T-test. The A118G variation associated with 
significantly lower live cells (P = 0.007; 84.09, 69.84 respectively), and significantly 
higher fragmented cells (P = 0.006; 9.22, 21.26 respectively). For the permeabilised 
cell group the 118 AG genotype associated with higher levels of cells 
permeabilisation however this result was not statistically significant (P= 0.076; 6.62, 
8.75). This trend continued for the live cell group with significantly lower live cells 
for 118 AG subjects (P = 0.022), higher levels of fragmentation however this result 
was not statistically significant (P = 0.096) and significantly higher levels of 
permeabilisation (P = 0.019).  
 
Annexin V and propidium Iodide joint effects 
Interestingly there was a positive correlation between the total % of Annexin V 
positive cells and the total % of propidium iodide fragmented cells. Furthermore, this 
was associated with both treatment and genotype (Table 68). 
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Table 68: The association between the Total % of Annexin V positive cells and the Total % 
of propidium Iodide Live, Fragmented and Permeabilised Cells. 
 
118 AA Genotype 
Treatment PI % Live Cells PI % Fragmented Cells PI % Permeabilised Cells 
 R
2
 P value R
2
 P value R
2
 P value 
0 µM -0.771 0.072 0.600 0.208 0.771 0.072 
100 µM -0.886 0.019* 0.886 0.019* 0.943 0.005** 
20 µM -0.600 0.208 0.371 0.468 0.771 0.072 
10 µM -0.600 0.208 0.371 0.468 0.600 0.208 
5 µM -0.600 0.208 0.143 0.787 0.657 0.156 
1 µM -0.600 0.208 0.314 0.544 0.886 0.019 
118 AG/GG Genotype 
Treatment PI % Live Cells PI % Fragmented Cells PI % Permeabilised Cells 
 R
2
 P value R
2
 P value R
2
 P value 
0 µM -0.943 0.005** 0.943 0.005** 0.943 0.005** 
100 µM -0.829 0.042* 0.829 0.042* 0.771 0.072 
20 µM -0.829 0.042* 0.829 0.042* 0.429 0.397 
10 µM -0.829 0.042* 0.771 0.072 0.714 0.111 
5 µM -0.943 0.005** 0.886 0.019* 0.771 0.072 
1 µM -0.657 0.156 0.657 0.156 0.829 0.042* 
 
* Denotes ≤ 0.05, ** denotes ≤ 0.01. 
 
µ-Opioid Receptor Internalisation 
Internalisation of the µ-opioid receptor was measured through µ-opioid receptor – anti 
rabbit IgG - FITC fluorescence. The effect of methadone treatment and A118G was 
tested by examining changes in the geometric mean. The average geometric mean for 
118 AA subjects (5.17 mean fluorescence intensity, MFI) was significantly lower than 
118 AG/GG subjects (8.13 MFI, P = 0.002). Furthermore, the mean fluorescence for 
both 118 AA and 118 AG/GG subjects increased from control levels when treated 
with the 20 µM to 5 µM methadone treatments (Figure 89). 
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Figure 89: Mean receptor fluorescence for 118 AA and 118 AG/GG subjects following 
methadone treatment. 
 
The Association between µ-Opioid Receptor Internalisation and Cellular Apoptosis 
There was a significant correlation for 118 AG subjects between the geometric mean 
for µ-opioid receptor internalisation and the % of live Annexin V positive cells, for 
the 20 µM methadone treatment (R
2
 0.829, P = 0.042). 
 
8.5 Discussion 
 
The interaction between the µ-opioid receptor and methadone is complex. In vitro 
analysis of µ may assist in elucidating the molecular mechansisms responsible for 
inter-individual susceptibility to methadone toxicity and death. In the present study 
two indicators of cellular apoptosis were used, Annexin V which detects the early 
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stages of apoptosis and propidium iodide which identifies the later stages of cellular 
apoptosis. Annexin V is a calcium dependent phosholipid binding protein that has a 
high affinity for negatively charged phospolipids (phospatidylserine) on the cell 
surface. One of the earliest features of cellular apoptosis is the translocation of 
phosphatidylserine from the inner to the outer leaftlet of the plasma membrane, 
thereby exposing phosphatidylserine to the external environment and Annexin V. 
Propidium iodide is a membrane impermeant dye and is therefore excluded from 
viable cells. In the later stages of apoptosis the cellular membrane becomes 
compromised allowing propidium iodide to enter the cells and stain the nucleus 
(Riccardi & Nicoletti, 2006). It was identified here that apoptosis correlated with the 
A118G polymorphism (Table 67), furthermore, this was associated with the 20 and 10 
µM methadone treatments (P < 0.05). When the association between the A118G 
genotype and apoptosis was examined further it was revealed that subjects with the 
118 G allele had significantly higher levels of Annexin V positive cells (P < 0.01) and 
higher levels of cellular fragmentation (P <0.01). Therefore it is postulated here that 
the A118G variation is linked with increased cellular apoptosis. Previous works have 
documented that methadone is a potent inducer of apoptosis (Maneckjee & Minna, 
1994; Heusch & Maneckjee, 1998; Maneckjee & Heusch, 1999; Friesen et al. 2008). 
However, it was reported that this may be mediated through a non-opioid mechanism 
involving the autocrine growth-stimulatory factor bombesin (Maneckjee & Heusch, 
1999). Friesen et al. (2008) reported that methadone is a potent inducer of cell death 
in leukaemia cells, and that this was due to the activation of apoptosis pathways  by 
caspase -9 and caspase-3.  Interestingly, the study also reported that there was no 
association between methadone induced apoptosis and nonleukemic cells (Friesen et 
al. 2008). However, the results from the present study indicate an association between 
cellular apotosis and the µ-opioid receptor. Since, an association was reported 
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between the OPRM1 A118G variation and methadone accumulation in Chapter 5 it is 
logical to postulate that this is linked with methadone-induced apoptosis in leukemic 
cells. It is clear that further investigation is required into the association between 
methadone-induced apoptosis and the µ-opioid receptor. However, the results from 
the work reported in this study indicate the OPRM1 gene as a target for future work. 
There was a statistically significant correlation between Annexin V positive 
cells and propidium iodide permeabilisation and fragmentation (Table 68). This is an 
expected result as both Annexin V and propidium iodide are markers of cellular 
apoptosis. It was observed during FACS analysis that no cells were positive for 
Annexin V and negative for propidium iodide (i.e. in early stages of cell apoptosis). 
Earlier works examining different methadone incubation times (Chapter 2, Figure 66) 
did not reveal a change in the % of Annexin V positive cells and propidium iodide 
negative cells. Therefore methadone may induce rapid cell apoptosis. 
Opioid exposure has been postulated to induce changes in the number of 
opioid receptors present on lymphocytes in a similar manner to which opiates induce 
drug tolerance (Toskulkao et al. 2009). Following agonist-receptor activation, opioid 
receptors promote guanine nucleotide exchange of heterotrimeric G-protein 
(Toskulkao et al. 2009). This triggers a downstream signal transduction pathway 
involving adenylyl cyclase, mitogen-activated protein kinase (MAPK), K
+
 channels 
and Ca channels (Zhang et al. 1998; Whistler et al. 1999; Trapideze et al, 2000; 
Toskulkao et al. 2009), leading to receptor phosphorylation and internalisation. This 
results in a depletion of cell surface µ-opioid receptors. Previous work has reported 
significant reductions in µ receptors located on T-lymphocytes in chronic heroin 
abusers, which could be indicative of OPRM1 down regulation (Ferrer-Alcon et al. 
2004). Furthermore, chronic methadone exposure has been documented to affect 
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OPRM1 transcription resulting in the attenuation of µ receptor mRNAs leading to a 
reduction of receptors at the cell surface (Toskulkao et al. 2009). However, in the 
present study an association was revealed between the OPRM1 A118G variation and 
increased receptor levels following methadone treatment. Furthermore, the work 
presented in Chapters 4 and 5 identified an association between A118G and increased 
blood methadone concentrations in post-mortem subjects. This was postulated to be 
representative of a reduction in receptor internalisation resulting in an accumulation 
of desensitised receptors at the membrane surface. Since, a significant association was 
identified here between the 118 AG genotype and increased MFI values it is logical to 
assume that the A118G polymorphism is responsible for reductions in receptor 
internalisation, and may be influential in inter-individual methadone susceptibility. 
However the A118G polymorphism had previously been associated with reductions in 
receptor binding sites, with 118 AA carriers possessing ten times more binding sites 
(Zhang et al. 2005). It would be interesting to explore this further with an increased 
sample size to determine the role of A118G for receptor internalisation and 
methadone susceptibility.  
An agonist-receptor association was observed between the 20 and 10 µM 
methadone concentration range (Figure 89). Since, the MFI for both 118 AG and to a 
lesser extent 118 AA subjects is increased between these methadone treatments, it is 
postulated that this is where methadone is detrimental to µ-receptor internalisation. 
Furthermore, for 118 AG subjects we identified an association between increased µ 
receptor fluorescence and increased Annexin V and propidium iodide apoptosis for 
this concentration range (P < 0.01, P < 0.05 respectively). Several studies indicate that 
opioids are involved in a variety of biological effects independent to analgesia that 
could effect cell survival (Pak et al. 1999; Yin et al. 1997; Yin et al. 1999; Tegeder et 
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al. 2003). It has been observed that opioid receptors can promote apoptosis through 
Fas regulation (Yin et al. 1999). Additionally, it has been documented that opioid 
involvement in apoptosis could be kinase dependent, with pertussis toxin (PTX) 
antagonising the pro-apoptotic effects of morphine in some cells (Yin et al. 1997), but 
not in others (Tegeder et al. 2003) in response to the kinase involved in receptor 
internalisation. Furthermore, as, heterodimerisation between opioid receptors and 
somatostatin (SSTRs) has been observed (Pfeiffer et al. 2002) it had also been 
postulated that cross-talk between these systems can activate apoptosis signalling 
pathways following opioid treatment. However, this was not identified in human 
U266 multiple myeloma cells (Kerros et al. 2009). Therefore it is likely that multiple 
systems are involved in the association between µ opioid receptor internalisation and 
cellular apoptosis following methadone treatment. However, it is clear from the 
results reported here that the OPRM1 A118G variation is involved in both reductions 
in µ receptor internalisation and cellular apoptosis and that this is concentration 
dependent. 
In summary, the OPRM1 A118G variation is involved with higher levels of 
apoptosis in CLL cells, which could have beneficial implications for cancer therapy 
and research, in addition to elucidating the role of A118G for methadone 
susceptibility. An association between A118G and receptor accumulation at the cell 
membrane indicative of reduced receptor internalisation has also been reported in 
Chapter 5. This is in agreement with the earlier theory that A118G is associated with 
increased post-mortem methadone concentrations due to a reduced ability to 
internalise µ receptors (Chapters 4 & 5), resulting in an accumulation of de-sensitised 
receptors at the membrane. Finally an association between µ receptor internalisation 
and cellular apoptosis was established for the 118 AG genotype, however the 
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molecular mechanisms responsible for this remain unclear and require future 
investigation. Further research into the role of A118G for receptor internalisation and 
apoptosis following methadone treatment is required, nevertheless, it is clear from 
these results that A118G is involved in individual susceptibility to methadone at a 
cellular level. 
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Chapter 9 
 
Thesis Conclusions, Limitations & Future Work 
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9.1 Thesis Conclusions 
 
This thesis has presented a wide review on the application of forensic 
pharmacogenomics for methadone toxicity, focusing on the influence of gene 
variations on individual susceptibility to methadone toxicity and death. The early 
chapters have given a thorough description of methadone and its involvement in drug-
related deaths and have included a review of the gene systems pertinent to the project. 
The current problems faced by forensic toxicologists for methadone-attributed deaths 
have been described. The safety profile of methadone has been reviewed and the 
genes vital to methadone action in vivo have been described with particular emphasis 
on CYP2B6 and OPRM1. 
 
This chapter summarises the work carried out for this project at each stage of its 
development. Section 9.2 discusses the main findings and the limitations of the work 
conducted. In section 9.3 the possibilities for further work are detailed, with attention 
to ultimate forensic application. 
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9.2 Results Summary 
 
The application of clinical and forensic pharmacogenomics has been subject to 
considerable research over the last decade. However, the association between gene 
variations and methadone action in vivo has remained a difficult and rather neglected 
problem. The work described in this thesis has focused on the association between 
single nucleotide polymorphisms (SNPs) and individual susceptibility to methadone. 
Specifically, SNPs located within the CYP2B6 gene and that of the µ-opioid receptor 
(OPRM1). Several contributions to this field have been made as part of this work and 
these include: 
 
1: The CYP2B6*6 allele and OPRM1 A118G variation can be used to identify 
methadone susceptible individuals post-mortem. 
 
2: The OPRM1 A118G variation may be linked with the lethal association between 
methadone and benzodiazepines. 
 
3: The development of two recombinant DNA clones for the 750 TT and 750 TC 
variants to study the association between the CYP2B6 T750C promoter variant and 
methadone susceptibility. 
 
4: The OPRM1 A118G variation is involved in receptor accumulation at the cell 
membrane following methadone treatment as a result of poor receptor internalisation. 
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9.2.1 Conclusions 
 
The use of methadone in maintenance programmes worldwide has been associated 
with methadone-attributed deaths. SNPs on the genes encoding the cytochrome P450 
enzyme CYP2B6 and that for the µ opioid receptor (OPRM1) have been explored in 
this study, to determine the association between the CYP2B6 T750C, G516T, A785G, 
and OPRM1 A118G polymorphisms and individual susceptibility to methadone. In 
Chapters 4 and 5 the applications of CYP2B6 and OPRM1 gene variants for the 
toxicological interpretation of deaths attributed to methadone are described. The gene 
encoding the human cytochrome P450 enzyme CYP2B6 is highly polymorphic 
playing a key role in the biotransformation of many drugs (Hofmann et al. 2008). As 
described in Chapter 4, a significant association was identified between the 
CYP2B6*4, *9, & *6 alleles and higher methadone concentrations (P < 0.05), 
characteristic of poor methadone metabolism. The CYP2B6*6 allele had previously 
been associated with slow or poor drug metabolism, with heterozygous and 
homozygous carriers of the CYP2B6*6 allele expressing up to 4-fold less protein than 
wild type individuals (Eap et al. 2005; Desta et al. 2007). However, this current work 
is the first study to report an association between CYP2B6*6 and increased post-
mortem methadone concentrations (Chapter 4; Bunten et al. 2010). Furthermore, the 
association between the CYP2B6*6 allele and mean post-mortem methadone 
concentrations continued with an increased sample size of 69 subjects (Chapter 5; P < 
0.05). A study examining CYP2B6*6 expression in human liver samples reported that 
it is the G516T (allele *9) polymorphism that is primarily responsible for poor 
metabolism (Hoffman et al. 2008). In agreement with this, in all cases where G516T 
was identified, the A785G (allele *4) polymorphism was also found in this work. 
G516T has been linked with aberrant splicing resulting in a major splice variant 
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(SV1) between exons four and five (Hofmann et al. 2008). It has been postulated that 
SV1 may be associated with reductions in functional mRNA transcription, and 
enzymatic activity. Therefore, it would be interesting to determine whether SV1 is 
associated with individual methadone susceptibility. 
It was observed in Chapter 6, that the allele frequencies for G516T and A785G 
were higher in the post-mortem population than the control population (G516T, 44 %, 
34 %; A785G 47.6 %, 38 % respectively). However, this result was not statistically 
significant (P = 0.23, P = 0.5 respectively). It was postulated that this may be 
indicative of a trend that had been limited by sample size, and a larger number of 
post-mortem subjects may elucidate the association between G516T and A785G 
prevalence and methadone susceptibility. It would also be interesting to examine 
CYP2B6*6 allele frequencies in an opioid abusing population, to assist in the 
interpretation of the results, which is discussed further in Section 9.3. 
There is growing evidence that polymorphisms within gene promoter regions 
significantly effect gene expression (Day & Tuite, 1998; Rockman & Wray, 2002; 
Johnson et al. 2005). The role of the CYP2B6 promoter region variation T750C for 
methadone susceptibility is currently unclear and requires further investigation. In this 
study a significant association was identified between T750C and the CYP2B6*6 
allele (Chapters 5 and 6). As described in Chapter 5, T750C correlated with both 
G516T (P < 0.01) and A785G (P < 0.01) in 69 post-mortem subjects. This association 
was also evidenced in 84 post-mortem subjects as described in Chapter 6 (P < 0.01, P 
< 0.01), respectively). This result is in agreement with other earlier studies, with 
T750C forming part of the CYP2B6*6B allele with G516T, and A785G (Lamba et al. 
2003; Hesse et al. 2004; Zukunft et al. 2005). Unexpectedly, in the work presented in 
Chapter 6, T750C was not associated with higher post-mortem methadone 
concentrations, with 750 TT subjects having a higher post-mortem mean methadone 
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concentration (0.79 mg/L) than 750 TC and CC subjects (0.69 mg/L). Since, T750C 
associated with the CYP2B6*6 poor metabolism allele, higher post-mortem 
methadone concentrations were expected. Furthermore, T750C had been reported to 
be associated with reductions in hepatic CYP2B6 expression (Lamba et al. 2003; Lang 
et al. 2004). Therefore the assemblage of T750C, G516T and A785G reported in 
Chapter 5 and 6 could result in a potentially lethal combination where a subject would 
experience poor methadone metabolism as a result of both reduced CYP2B6 
expression and the CYP2B6*6 allele. However, since, T750C was not associated with 
statistically higher post-mortem methadone concentrations in this study, the 
significance of the association between T750C, G516T and A785G is unclear 
(Chapter 5). Furthermore, T750C is also part of the CYP2B6*22 allele together with 
T82C, which has been linked with increased CYP2B6 expression (Faucette et al. 
2000; Zukunft et al. 2005; Li et al. 2010). As the significance of the CYP2B6*22 
allele has not been studied in this study it cannot be excluded that the increased post-
mortem methadone concentrations identified for the 750 TT genotype are a result of 
the CYP2B6*22 allele and the T82C polymorphism. It would therefore be interesting 
to investigate the CYP2B6*22 allele further to identify whether the T82C 
polymorphism results in an ultra-rapid metaboliser phenotype impacting methadone 
metabolism.  
 There was no significant difference in allele frequency observed in Chapter 6 
for the T750C polymorphism between the post-mortem (44 %) and control 
populations (49 %), indicating that this polymorphism may not be a suitable risk 
factor for determining methadone susceptibility. However, it was also reported that 
the T750C variation was significantly correlated with gender in the post-mortem 
population. Earlier works have consistently reported that gender differences are 
associated with in vivo hormone levels affecting drug absorption, disposition, 
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metabolism and pharmacodynamics (Becker et al. 1990; Peris et al. 1991; Justice & 
de Wit, 2000; Lamba et al. 2003; Roth et al. 2004; Lukas & Wetherington, 2005; 
Becker & Hu, 2008). Significant differences in CYP2B6 expression have been 
reported between male and female subjects, with higher reductions in CYP2B6 
activity in male subjects (Lamba et al. 2003). The results from this study were in 
agreement with this, with male subjects significantly correlating with the T750C 
polymorphism. Therefore, it is postulated that the association observed between 
T750C and gender here, is due to T750C alterations to CYP2B6 activity. In order to 
study this further, two recombinant DNA clones (p2B6-GFP-HB-750 TT, and p2B6-
GFP-HB-750 TC) were designed and created to determine the role of T750C for 
CYP2B6 activity, and as a result susceptibility to methadone toxicity (Chapter 7).  
Functionality trials modelling the effects of T750C as a measure of green fluorescence 
protein (GFP) activity following methadone exposure would be a logical progression 
and this is discussed further in Section 9.3 Further Work. 
The association between the human µ-opioid receptor and inter-individual 
variability in drug response had been well studied; however there is limited 
information on the association between the A118G polymorphism and response to 
methadone. The OPRM1 A118G polymorphism has been shown to affect drug 
efficiacy and response (Bond et al. 1998). As described in Chapter 4 no significant 
difference was observed between the A118G genotype and post-mortem methadone 
concentration. However, it was observed that subjects heterozygous for the 118G 
allele had higher post-mortem methadone concentrations (0.93 mg/L) than 
homozygous wild-type subjects (0.70 mg/L) which was thought to be indicative of a 
trend. It was postulated that the trend for higher post-mortem methadone 
concentrations in 118 AG subjects could be explained by µ receptor internalisation 
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following agonist binding, resulting in a reduction in the number of available 
receptors for methadone binding at the cell membrane. Interestingly it was observed 
that the OPRM1 A118G polymorphism significantly associated with decreased 
receptor internalisation, with 118 AG subjects demonstrating less receptor 
internalisation (8.13 MFI) than 118 AA subjects (5.17 MFI, in Chapter 8). Earlier 
works reported that  the OPRM1 receptor in 118 AG subjects have ten times less 
binding sites than that with the 118 AA genotype (Zhang et al. 2005). In this study, 
higher MFI values were observed for 118 AG subjects indicative of an increase in µ-
receptors at the cell surface. It is logical to propose however, that this is due to 
receptor accumulation due to an inability to internalise and not an effect of A118G on 
increased gene expression. It was also revealed that subjects heterozygous for the 
A118G polymorphism had significantly higher levels of early and late stage apoptosis, 
and this correlated with receptor internalisation and methadone concentration 
(Chapter 8, P = 0.042).  A number of studies have examined the association between 
OPRM1 and cell apoptosis (Pak et al. 1999; Yin et al. 1997; Yin et al. 1999; Pfeiffer 
et al. 2002; Tegeder et al. 2003; Kerros et al. 2009), with associations reported 
between OPRM1 and Fas regulation (Yin et al. 1999), protein kinases (Tegeder et al. 
2003) and somatostatin (Pfeiffer et al. 2002). Therefore, it is likely that multiple 
systems are involved in the association between µ opioid receptor internalisation and 
cellular apoptosis following methadone treatment. However, it is clear from these 
results that the OPRM1 A118G variation is involved in both reductions in µ receptor 
internalisation and cellular apoptosis and that this is concentration dependent (Chapter 
8).  
The results from the in vitro methadone internalisation study could therefore 
explain the association between the A118G polymorphism and increased post-mortem 
methadone concentrations. Interestingly, when the sample size was increased from 40 
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subjects to 69 subjects the mean post-mortem methadone concentration for A118G 
heterozygous subjects was significantly higher than wild-type subjects (Chapter 5; 
1.28 mg/L, 0.79 mg/L respectively, P = 0.05). Therefore it is postulated that the 
A118G variation is an important factor in methadone toxicity and fatality.  
It was also observed that there was a significant association between the 
A118G polymorphism and accumulation of benzodiazepines (Chapter 4). It is well 
documented that the co-administration of methadone and benzodiazepines can result 
in lethal respiratory depression (McCormick et al. 1984; Borron et al. 2002; Lintzeris 
et al. 2007). When benzodiazepines were found in conjunction with methadone, 118 
AG subjects had a 2.4 fold higher post-mortem mean blood benzodiazepine 
concentration (Chapter 4, P <0.01). Interestingly, this association was not observed in 
morphine-related fatalities (P = 0.626) and is postulated to be linked with µ-receptor 
internalisation (Keith et al. 1998). Since animal studies have reported that the co-
administration of opioids together with benzodiazepines induces increased µ-opioid 
receptor recruitment (Poisnel et al. 2009), the interaction between methadone and 
benzodiazepines observed in the work is postulated to involve signal transduction 
with benzodiazepines up-regulating µ-opioid receptors. The findings from the work 
described here indicate that the A118G polymorphism is involved in individual 
susceptibility to fatality from methadone and benzodiazepines, and requires further 
investigation with a larger sample size. 
A significant association was observed for the A118G allele frequencies 
between the control and post-mortem populations, with a 15.7 % difference between 
populations for heterozygous subjects (Chapter 6, P = 0.0046). The works presented 
in Chapters 4 and 5 indicated that 118 AG subjects will have reduced receptor 
function, which could confer protection from opioid toxicity at therapeutic levels 
(Lötsch et al. 2002). However, these subjects would have reduced sensitivity to 
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methadone at µ-receptors resulting in higher methadone concentrations in vivo before 
toxic effects appear (Chapters 4 & 5). Since methadone has a long mean elimination 
half life (Moffat et al. 2004) drug accumulation in 118 AG subjects could be 
especially pronounced, limiting any possible protective effect of the G allele. 
Finally, a significant association was revealed between the OPRM1 A118G 
genotype and the CYP2B6* 4, *9, and *6 alleles in subjects whose deaths had been 
attributed to methadone (Chapter 4, 5, & 6). As, both genes are essential to methadone 
action in vivo, this assemblage could indicate the coordinated action of the enzyme 
and receptor in contributing to individual susceptibility to methadone. Interestingly, 
no linkage between the A118G genotype and CYP2B6*4, *9, & *6 alleles was 
observed for the control population studied (Chapter 6). Therefore the combination of 
the OPRM1 A118G genotype and CYP2B6*6 could lead to greater susceptibility to 
methadone fatality. 
In summary it is suggested that the CYP2B6*6 allele and the OPRM1 A118G 
variation can be utilised in part to determine individual susceptibility to methadone. 
Both the CYP2B6*6 allele and the OPRM1 A118G variation were associated with 
higher post-mortem methadone concentrations in subjects whose deaths were 
attributed to methadone. Furthermore, the A118G variation associated with higher 
post-mortem benzodiazepine concentrations indicating the possibility of cross-talk 
between the opioid and GABAA systems. When in vitro models were used to explore 
the effects of CYP2B6 and OPRM1 variations, it was observed that the A118G 
polymorphism is associated with reductions in receptor internalisation and higher 
levels of cellular apoptosis following methadone treatment. This result suggests that 
A118G effects on µ internalisation could be responsible for the higher concentrations 
of post-mortem methadone revealed in 118 AG subjects. Therefore, genetic screening 
for the G516T, A785G, and A118G variations has potential value for risk 
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management before prescribing methadone for addiction treatment, in addition to 
assisting in the toxicological interpretation of deaths involving methadone. Further 
study is required for the CYP2B6 T750C promoter region polymorphism to determine 
the role of this SNP for methadone susceptibility. 
 
9.2.2 Limitations of this Study 
 
This study had a number of limitations which restricted the manner in which the work 
was conducted and this will now be discussed. The first study limitation was sample 
size and this was discussed in Chapters 4, 5, 6, and 7. Access to methadone-attributed 
deaths was a limiting factor.The study examined post-mortem subjects to investigate 
the association between individual genotype (CYP2B6 & OPRM1) and post-mortem 
methadone concentration. The CYP2B6*4 allele had previously been linked with 
increased enzymatic activity (Lang et al. 2001; Kircheiner et al. 2007) and rapid 
metaboliser status however the anticipated lower methadone levels were not observed 
in this study (Chapters 4 & 5). Since, only two subjects were CYP2B6*1/*4 carriers, 
further interpretation of this result was limited. Additionally, no 118 GG genotype 
was identified amongst the post-mortem population (Chapters 4 & 5) therefore it was 
not possible to distinguish any difference in post-mortem methadone concentration 
between 118 AG and 118 GG subjects. When exploring the association between 
A118G and post-mortem benzodiazepine concentration in methadone-attributed 
fatalities only two 118 AG subjects were identified. This limited the validity of the 
association identified between A118G and higher post-mortem benzodiazepine 
concentrations. During the study design period, power calculations were conducted to 
determine the optimal number of post-mortem subjects required to meet the study aim 
and objectives. It was determined that 100 post-mortem samples would be the optimal 
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requirement for statistical significance. Unfortunately, however, sampling 100 post-
mortem subjects whose deaths had been attributed to methadone was not possible. 
Therefore this study analysed all post-mortem subjects available and acknowledge 
here that sample size may have been a limiting factor on the accuracy of the statistic 
results reported here, particularly for those reported in Chapters 4, 5 and 6. However, 
this limited sample size did not restrict the observation of the significant associations 
for both CYP2B6 and OPRM1 polymorphisms and post-mortem methadone 
concentrations, and this was the first study to report such an association (Chapters 4 & 
5; Bunten et al. 2010). 
It would also have been interesting to examine the prevalence of CYP2B6 and 
OPRM1 polymorphisms in a current opioid using population (i.e. subjects enrolled in 
methadone maintenance therapy). However, access to such subjects required 
significant ethical approval, a clinic willing to participate in the study, and an 
incentive to subjects for study participation (typically monetary). Furthermore, before 
this could be pursued a significant association between CYP2B6 and OPRM1 
polymorphisms and individual susceptibility to methadone had to firstly be identified. 
It should however be mentioned, that since higher post-mortem methadone 
concentrations in subjects with the CYP2B6*6 allele and the A118G polymorphism 
were revealed, future collaboration with a methadone maintenance clinic has been 
agreed. 
A select number of polymorphisms were examined in this study CYP2B6 T750C, 
G516T, A785G, and OPRM1 A118G. These SNPs were selected after an extensive 
literature search indicated that there was likely to be an association between 
methadone susceptibility and CYP2B6 and OPRM1 polymorphisms. It would have 
been interesting to explore a larger number of SNPs such as the CYP2B6 T82C 
promoter region polymorphism. As observed in Chapter 5, 750 TC subjects were 
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associated with lower post-mortem methadone concentrations compared with 750 TT 
subjects. This was an unexpected result, and postulated to be a result of the T82C 
polymorphism resulting in the increased CYP2B6 expression. However due to a 
restricted financial bursary the association of T82C for individual methadone 
susceptibility could not be explored further.  
In vitro functionality trials to explore the effects of the T750C polymorphism on 
CYP2B6 expression and individual susceptibility to methadone would have been 
interesting. However due to both time and financial constraints this aspect of the in 
vitro study could not be conducted. Nevertheless, two recombinant DNA clones 
(p2B6-GFP-HB-750 TT, and p2B6-GFP-HB-750 TC) harbouring the promoter region 
of CYP2B6 with SNPs was achived. This was due to complications with the initial 
cloning strategy which involved the insertion of the EGFP gene into the hSVCT2 
vector to act as a marker of CYP2B6 promoter activity. However, despite extended 
efforts the transformation of EGFP into hSVCT2 was unsuccessful, which reflected 
the challenging nature of molecular cloning within a short period of time. It was 
determined that the method used to prepare the hSVCT2 vector for ligation was 
responsible. In response to these difficulties a second cloning strategy was designed 
using the CT-GFP TOPO® TA expression kit. This system was selected as TOPO® 
cloning is a one-step cloning strategy involving the direct fusion of polymerase 
amplified products to a GFP reporter. Using the TOPO® cloning system clones for 
the 750 TT, and 750 TC genotypes were created.  
Finally, the µ-opioid receptor internalisation study was limited by both time and 
financial constraints. As a result, we used methadone concentrations and incubation 
time intervals comparable to other studies. An experiment was conducted to examine 
five different methadone incubation treatments (Chapter 2, Figure 66). It would be 
better to conduct an extensive series of pilot experiments examining the effects of 
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methadone concentration, and different incubation times. It was discussed in Chapter 
8 that none of the cell samples treated with methadone were found to be in the early 
stages of cellular apoptosis, which might be due to insufficient cell recovery from 
thawing stress. Therefore, further investigations are needed to to confirm the findings 
from this work.  
 
9.3 Further Work 
 
This thesis has presented a number of studies that contribute towards the development 
of CYP2B6 and OPRM1 as markers of individual susceptibility to methadone. During 
each investigation, particular areas were identified which required further work, and 
these are now presented. As discussed in Section 9.2.2 Study Limitations, post-
mortem sample size was a limiting factor in this study. An increased post-mortem 
sample size is therefore required to fully investigate the role of CYP2B6 and OPRM1 
polymorphisms for individual susceptibility to methadone. Currently the CYP2B6*6 
allele and the OPRM1 A118G variation have been identified as susceptibility 
variations in 69 subjects whose deaths had been attributed to methadone. It would be 
interesting to establish whether this association continued in a much larger post-
mortem sample population. Furthermore, it would be useful to explore the prevalence 
of the CYP2B6*6 allele and the OPRM1 A118G polymorphism in an opioid abusing 
population, and future collaboration with a methadone maintenance clinic has been 
agreed. The current study examined these variations in a post-mortem population 
where the deaths had been attributed to methadone and a control population of non-
methadone using subjects. To futher determine the role of CYP2B6 and OPRM1 SNPs 
for methadone susceptibility it is also necessary to identify the association between 
drug concentration and SNP prevalence in opioid users in vivo as it is logical to think 
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that these subjects are less susceptible to methadone toxicity. Alternatively the 
examination of an opioid using population could reveal a SNP interaction associated 
with adverse methadone responses in tolerant individuals repeatedly exposed to 
methadone. It might be that this could involve SNPs affecting OPRM1 expression. 
Therefore it would also be beneficial to examine different OPRM1 SNPs likely to 
influence gene expression. The G172T polymorphism is located in the OPRM1 
promoter region and could be involved in gene regulation (Ross et al. 2005). Ide et al. 
(2006) examined the association between OPRM1 polymorphisms and 
methamphetamine (MAP) dependence in a Japanese population. Significant linkage 
disequilibrium in the 3‟region of the OPRM1 gene was identified indicating that 
polymorphisms within this region could be linked with gene expression. Furthermore, 
a significant association was identified between the intron 2 IVS2+G691C 
polymorphism and MAP dependence (Ide et al. 2006). Therefore, it would be 
interesting to explore the G172T and IVS2+G691C polymorphisms for methadone 
susceptibility in a Caucasian population.  
 In Chapter 7 two clones were created to explore the effect of the 750 TT and 
750 TC genotypes on CYP2B6 expression. Earlier works indicate that this SNP is 
associated with reductions in CYP2B6 expression (Lamba et al. 2003; Lang et al. 
2004). However, the role of the T750C polymorphism for methadone susceptibility is 
unclear and functionality trials exploring the effect of T750C on CYP2B6 expression 
could elucidate this. The transformation of the CYP2B6 750CC promoter region into 
the TOPO® TA vector was confirmed with a HindIII / BglII digest (Figure 88). 
However, when a single BglII digest was conducted it was observed that the CYP2B6 
promoter region orientation was reversed (Figure 88). Therefore further work is 
required to create a p2B6-GFP-HB-750 CC clone. The p2B6-GFP-HB-750 TT, p2B6-
GFP-HB-750 TC clones contain the GFP reporter gene, which is an important 
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reporter molecule for monitoring gene expression and protein localization in vivo, in 
situ and in real-time observation (Chalfie et al. 1994; Inouye & Tsuji, 1994; Cheng et 
al. 1996; Chishima et al. 1997; Nocarova & Fisher, 2009). It is proposed that p2B6-
GFP-HB-750 TT and p2B6-GFP-HB-750 TC transformation into mammalian Chinese 
Hamster Ovary (CHO) cells may identify T750C effects on gene expression following 
methadone exposure. As GFP protein is stable, species independent and can be 
observed non-invasively in living cells, monitoring GFP fluorescence can be regarded 
as a suitable method for the reliable estimation of GFP expression levels (Nocarova & 
Fisher, 2009). Earlier works have utilised flow cytometry (Bi et al. 2001; Paparella et 
al. 2002), fluorometry (Pérez-Arellano & Pérez-Martínez, 2003; Denis-Quanquin et al. 
2007) and confocal microscopy (Nocarova & Fisher, 2009) to assess GFP 
fluorescence. Further p2B6-GFP-HB-750 TT and p2B6-GFP-HB-750 TC for the 
purposes of this study would be conducted using flow cytometry.  
 As discussed in Chapter 4 an association between the A118G polymorphism 
and post-mortem benzodiazepine concentration for methadone attributed fatalities was 
identified. Interestingly this was not seen in morphine-associated fatalities suggesting 
a specific link between methadone and benzodiazepines. Since, methadone and 
morphine both preferentially bind to the µ opioid receptor, this raised the question 
why the interaction varies for different opioids (Bunten et al. 2010). It is postulated 
that this is linked with receptor internalisation which is induced by methadone but not 
morphine (Keith et al. 1998). The association between the A118G polymorphism and 
receptor internalisation following methadone exposure was investigated, and it was 
observed that 118 AG subjects had reduced internalisation compared with 118 AA 
subjects (Chapter 8). It would be interesting to explore the interaction between 
methadone and benzodiazepines using an in vitro model similar to that described in 
Chapter 8. CLL cells cultured in different concentrations of methadone and diazepam 
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will reveal whether differences in receptor internalisation are responsible for the lethal 
association between methadone and benzodiazepines. Early works reported that 
benzodiazepine binding to GABAA receptors results in the increased recruitment of µ 
opioid receptors (Poisnel et al. 2007). Furthermore, animal models demonstrated that 
benzodiazepines can potentiate the respiratory effects of fentanyl (Bailey et al. 1990). 
Therefore, it would also be beneficial to design an A118G cloning strategy using the 
CT-GFP TOPO® TA expression kit to explore OPRM1 expression following 
methadone and diazepam exposure. This would assist in determining the roles of the 
A118G polymorphism for individual methadone susceptibility. 
Methadone has an asymmetric carbon atom, forming two enantiomers, (- R)- 
methadone and (+ S)-methadone (Chapter 1, Figure 2) and is primarily administered 
as an equal racemic mixture (Pham-Huy et al. 1997; Rudaz & Veuthey, 1999; 
Rodriguez Rosas et al. 2003; Gerber et al. 2004; Lehotay et al. 2005). 
Pharmacological activity at the µ opioid receptor is mostly due to (R)-methadone, 
which has a 10-fold higher affinity at µ and is up to 50 times more potent than the (S)-
enantiomer (Rudaz & Veuthey, 1996; Foster et al. 1999; Liang et al. 2004). 
Activation of the µ receptor by methadone is associated with lethal respiratory 
depression (Chevillard et al. 2010), therefore it is logical to assume that (R)-
methadone is responsible for any adverse effects on the respiratory system. Animal 
models support this conclusion, with (R)-methadone inducing significantly more 
respiratory depression in the neonatal guinea pig than racemic methadone (Silverman 
et al. 2009).  
While (S)-methadone has limited pharmacological activity there have been 
reports of cardio-toxicity as a result of (S)-methadone exposure.  In recent years, 
increases in cardiac episodes have been reported in individuals prescribed methadone 
for maintenance treatment (Eap et al. 2007). Methadone blocks the hERG (human 
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ether-à-gogo related gene) voltage-gated potassium channel prolonging the QT 
interval affecting cardiac repolarisation, which can lead to torsades de pointes and 
sudden death. Furthermore, blockage of hERG by methadone is stereoselective with 
the (S)-enantiomer being significantly more potent than (R)-methadone (Eap et al. 
2007). 
This work has identified a significant association between the CYP2B6*6 
allele and increased post-mortem methadone concentrations in subjects where the 
cause of deaths was attributed to methadone (Bunten et al. 2010). Both in vitro and in 
vivo studies have documented CYP2B6 stereoselectivity for the (S)-methadone 
enantiomer (Gerber et al. 2004; Eap et al. 2007), with the CYP2B6*6/*6 genotype 
correlating with higher (S)-but not (R)-methadone concentrations (Crettol et al. 2005; 
Eap et al. 2007). Furthermore, it has been reported that CYP2B6 metaboliser status 
also influenced individual QTc intervals, with poor metabolisers having a mean QTc 
interval 18 ms longer than extensive metabolisers (Eap et al. 2007).  
Methadone deaths are primarily linked with respiratory depression ((R)-
methadone) or torsades de pointes (tdp) and sudden death ((S)-methadone). However, 
most post-mortem investigations do not allow differentiation between these two 
causes of death. As the CYP2B6*6/*6 genotype is associated with a potentially higher 
risk of cardiac arrythmias and sudden death by (S)-methadone and respiratory 
depression is linked with (R)-methadone, it seems logical that in cases where death 
has been caused by methadone it would be possible to determine whether this was 
respiratory or cardiotoxic in nature through the presence of specific gene variants. It 
would be interesting to explore the association between the CYP2B6*6 allele and the 
OPRM1 A118G polymorphism for (R)-methadone and (S)-methadone to determine 
whether these SNPs demonstrate steroeselectivity. 
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Finally there are a number of genes that could be influential in methadone action 
and response and these include GABAA (Bailey et al. 1990; Cox & Collins, 2001), 
DRD1 (Lalley et al. 2004; Lalley et al. 2005; Crettol et al. 2008), DRD2 (Barratt et al. 
2006), hERG (Eap et al. 2007), ABCB1 (Hoffmeyer, et al. 2000; Crettol et al. 2007), 
and the human pregnane X-receptor hPXR (Bauer et al. 2006). Therefore, building a 
causal relationship between CYP2B6 and OPRM1 variants and phenotypic responses 
is not a simple task and this in part relates to the interconnectivity between different 
genes (Figure 90). Methadone is a substrate for the efflux transporter P-glycoprotein 
(P-gp) where it influences methadone absorption, distribution, brain penetration, 
pharmacodynamics and analgesia (Thompson et al. 2000; Bauer et al. 2006; Kharasch 
et al. 2009). The gene that codes for P-gp is the ABCB1 gene, ABCB1 has a number of 
SNPs that influence P-gp, including C3435T which has been reported to lower gene 
expression (Hoffmeyer et al. 2000). This SNP alone, or a haplotype that includes this 
SNP and the G2677T SNP have been reported to decrease transporter function, which 
could lead to increased plasma concentrations or, if the outward transporter at the 
blood-brain barrier is decreased, to increased brain concentrations of methadone 
(Lötsch et al. 2006). In addition, the xenobiotic activation of the hPXR is involved in 
P-gp up-regulation reducing the efficacy of methadone (Dussault & Forman, 2002; 
Bauer et al. 2006). Therefore, functional hPXR polymorphisms are also likely to 
influence methadone action in vivo (Zhang et al. 2001). 
The dopamine receptors DRD1 and DRD2 play significant roles in the rewarding 
effects of drugs of abuse (Kreek et al. 2005). An earlier work reported an association 
between the DRD2 TaqI A SNP and opioid dependence (Lawford et al. 2000). In 
vitro analysis of the DRD2 C957T polymorphism suggested that this variation may be 
associated with altered mRNA folding and stability affecting DRD2 expression (Duan 
et al. 2003). Blockade of the DRD1 receptor revealed the enhancement of the µ-
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opioid receptor respiratory network, increasing the depressant effects of fentanyl on 
respiration in addition to increasing the duration of action (Lally et al. 2005). In a 
study on 238 methadone maintenance patients a significant association was revealed 
between the DRD2 C957T polymorphism and patient non-response (Crettol et al. 
2008). Furthermore, animal models have reported significant down-regulation of the 
µ opioid receptor in DRD2 knockout mice (Léna at al. 2008). Therefore, analysis of 
the interaction between the dopamine DRD1 and DRD2 receptors and OPRM1 may 
further elucidate the molecular pathways involved in individual methadone 
susceptibility. 
In summary this thesis has presented a number of studies that contribute towards 
the development of CYP2B6 and OPRM1 as markers for identifying individual 
susceptibility to methadone. Furthermore, this work has demonstrated some of the 
important constraints and limitations of the method used in this study, and suggested a 
number of corrections and new techniques for overcoming such obstacles. Particular 
aspects that need further studies have been addressed, and these include the 
acquisition of a larger post-mortem sample size and analysis of a current opioid using 
population. The progression of in vitro analysis on the activities of the CYP2B6 
promoter variants can be conducted by using the p2B6-GFP-HB-750 TT and p2B6-
GFP-HB-750 TC clones. Such study will advance current knowledge of the molecular 
pathways involved in methadone susceptibility. As methadone is a chiral drug further 
research focusing on the association between CYP2B6 and OPRM1 SNPs for both 
enantiomers, ((R)-methadone and (S)-methadone) is required. Finally the network of 
genes in response to methadone action in vivo is complex and identifying the 
molecular pathway for methadone susceptibility will involve not only extensive 
examination of each individual gene but also the cross-talk between genes.  
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Appendix 
 
OPRM1 Sequence information 
 
The sequence information demonstrating SNP and primer location is shown below. 
 
>PROTEIN SEQUENCE FOR OPRM1 
 
MDSSAAPTNASNCTDALAYSSCSPAPSPGSWVNLSHLDGNLSDPCGPNRTDLGGRDS
LCPPTGSPSMITAITIMALYSIVCVVGLFGNFLVMYVIVRYTKMKTATNIYIFNLAL
ADALATSTLPFQSVNYLMGTWPFGTILCKIVISIDYYNMFTSIFTLCTMSVDRYIAV
CHPVKALDFRTPRNAKIINVCNWILSSAIGLPVMFMATTKYRQGSIDCTLTFSHPTW
YWENLLKICVFIFAFIMPVLIITVCYGLMILRLKSVRMLSGSKEKDRNLRRITRMVL
VVVAVFIVCWTPIHIYVIIKALVTIPETTFQTVSWHFCIALGYTNSCLNPVLYAFLD
ENFKRCFREFCIPTSSNIEQQNSTRIRQNTRDHPSTANTVDRTNHQPPLAVSMAQIF
TRYPPPTHREKTCNDYMKR 
 
AJ000341 
> 5’UTR for OPRM1 
and 
>NC_000006 OPRM1 (480 amino acids) 
 
 
aaaaaatcacccagattgttttatttttattttatattatttatcacccagattgca
tatattttatgccattatctgggtataatggcataaaatatatgctaatcatttttt
caactgaattcaaatattatgcacattaatattcatatatgtttaatatagaaagaa
acacagagagtgagggagggagtccactatgtattaagtactgtgttagtgagcaga
cctcccttaggaaccttattacggagtacaaagctaggagagtaaataaagtatatt
aaaaaatgcatacaaaagatgacagaatcaccattccaaaagatcttggtggataag
aatcatgaattggatctaacaagatgtaacttaaaagtgaaaaaatctatagtgttg
tactgagctccctccaaagcaactataaatttataggagatgaaacatatgattcac
caggcataagaagaaagtttccgtaatcaaacactattgtatccatctttttaaact
ccagctcctatcacagcacctggtccaaagcagatctttagtatttgtggaactggc
ttggattgtgtttaggaaattttgtcattggtaaacctaaggagagtcaagagaaca
acgtgaccaaaaaataaaactaaaaaaaaaaaaaagggactttcattgtactggtag
aaagacaaagtttataatctggcttagtttctttttttgttgttgtttgttttttgg
tcagggcaaatttaggtcattatttttaacactggaactgtagtttcagagcagata
gacaaactatcaatgagaatagatgaacagcaaggccactgaaaggactcagaacta
catcttataagaaacaactgaatgatgctaatgtttaacttgcaaaagagaaaactc
agttgatttcaaatatatgaaatatagtggtaaggagttatcacttattaagcaatt
actattgcaatgtatactcatttaatcctgctaacagacatatgaggtgaatattat
tagcctaccctcgccttttttaagtaatgagaagactgtcatcctgtagggtaaagt
aacatgtccaaactcatacagctacaaagttacaaagctgatttataaaatgattga
ctccaaggtcaggaattattatactgtgtcttgtcttccacatgaactaagcacaaa
ggaactgaatgcaggcagacagatttcagctcaatataagagaattgttacattagt
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tcatggaagaatatgttttaaggtatttttgttagtctctaggaaatctctgtaaca
ttttattgtgtaaattatatgctttaatgtaagaggataaaaataatagtgaacatt
ggcaaaatagcctatgattaatagagtttacctatgagttatctgtttctaagataa
atgccaaaaaataatattggaattaaatgttcctttcaagatcttccctccctgctc
cctgaaattgcagtgaatttttcaagaccaactgaggacatgtattttcaatgttta
tggttaaaagatatgtacatgcacagatatatacatgtacagaaatgagaattactt
cagaattggtgttaactttagaaaaaaaaagaccaagaacttactcttggtatttac
aaatttatttctaaaatagaagcactcatggacttagaagtaaggtataaaattcaa
aaacgtatccatgtttctcaaggatcttgttgtaggccactctaattccatatatta
tgtggcttttcctagaatttttacactagaaaacagactgaatgcaaattttgtttt
gttttaacaaccttcttctcagaagcatatgtctatcgaggaagtcttcagataaaa
aagataaacaattccaaacaggtctatgagatttaagatgtgaaagatcaacattat
ctttagttgactttactggatgccacaaccttctgatttctgtaaccacttcttatg
cctcctacccactgaaacaaaatcagaggcaaacagagcttcaccctagaaattggg
gaaaatgaggaacaggttttctgcacaaaagtttatttgtttctcatttctttttca
gaaaataaaggatcgctgttgttcccaacaggtttgtagggaagaaaattggagaaa
cattattaccttttcttagatgttggcaacggaggcaacaaggactgcaaaagaaaa
ttgtgtgtcccccattcctaaataatcaaaattggcagtagggatggaagagcattg
gggttttagggctgttagggtttcatcaagccaatgtattccctgccagattttaag
gagaaaaaggcgctggaaaattgagtgatgttagccccctttcttatttttgcactg
ctaccaaagactaactctatctctctccccaacccttctctccatctccctccttta
gatgtgtttgcacagaagagtgcccagtgaagagacctactccttggatcgctttgc
gcaaaatccaccccttttccctcctccctcccttccagcctccgaatcccgcatggc
ccacgctcccctcctgcagcggtgcggggcaggtgatgagcctctgtgaactactaa
ggtgggagggggctatacgcagaggagaatgtcagatgctcagctcggtcccctccg
cctgacgctcctctctgtctcagccaggactggtttctgtaagaaacagcaggagct
gtggcagcggcgaaaggaagcggctgaggcgcttggaacccgaaaagtctcggtgct
cctggctacctcgcacagcggtgcccgcccggccgtcagtaccatggacagcagcgc
tgcccccacgaacgccagcaattgcactgatgccttggcgtactcaagttgctcccc
agcacccagccccggttcctgggtcaacttgtcccacttagatggcaacctgtccga
cccatgcggtccgaaccgcaccgacctgggcgggagagacagcctgtgccctccgac
cggcagtccctccatgatcacggccatcacgatcatggccctctactccatcgtgtg
cgtggtggggctcttcggaaacttcctggtcatgtatgtgattgtcaggtaaggaaa
gcgccagggctccgagcggagggttcagcggcttaagggggtacaaagagacaccta
actcccaaggctcaatgttgggcgggaggatgaaagaggggaggtaaactgggggga
ctctggaggagaccacggacagtgattgttatttctatgagaaaacctacttttctg
ttttttcttcaactgataaagaaagaattcaaaatttcaggagcagagaagttgctt
tggtaaaagctacaaatgtctaggggtggggggcggagggaagctatagcatagact
tggagcgcttccttatactgagcaaagagggctcttggcagagtcctacactcagtc
cctctgcaggagctatggaaagagtaagttgtgaataatgg 
 
 
 
ccctacaaaagttttttaaaattaacagggtatggtggcatgcacctgggatcccag
ttattcaggaggtgaggcaagaggatctcttgagtccaggaggttaaagctgtagtg
agctctgttcataccattacactccagcctgggtaacagggcaagatcctatccaaa
aaaaaaaaaaaaggaagaaactcaacaaagcagcatcgttgctattattgcagctat
ttagccaataggtacatcattgacatcattgtaaatagccaagctgatactggaaaa
caattctatatctaatctcaaaaaagctttctactaattcatgcaaatttattattg
gaagcttacctatattttacactagtgtcttttactgattctcactcttcttccttt
atctcctagatacaccaagatgaagactgccaccaacatctacattttcaaccttgc
tctggcagatgccttagccaccagtaccctgcccttccagagtgtgaattacctaat
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gggaacatggccatttggaaccatcctttgcaagatagtgatctccatagattacta
taacatgttcaccagcatattcaccctctgcaccatgagtgttgatcgatacattgc
agtctgccaccctgtcaaggccttagatttccgtactccccgaaatgccaaaattat
caatgtctgcaactggatcctctcttcagccattggtcttcctgtaatgttcatggc
tacaacaaaatacaggcaaggtgagtgatgttaccagcctgagggaaggagggttca
cagcctgatatgttggtgatgtcataagcaaagcagtatttatggagtgccccattg
tcttagtcacattgtaattttaattattcttcctagcaaaaaaagcctttgaatact
taaaaataggaattttcctcataattttaggcctattaaatcctttaaagagaatgt
aatctatttatttctgatttctctgtatttacttcataaaaatggtgtgtaaattag
tacatagctctcccaagagtaattggagcttaaacccaaagagtattacactgaggc
ttgtttaaaattatcaagtggctgactacatggcaaatgtatctttctacacctaat
atcagaatattgaacaatccatcaaaaaatgaagtgaaaacatccattacctggagc
cgcctagagactttggacaattattacattttttatatcaatatagacctcatggag
gatctagctcatgttgagaggttcatttttgttccctgaacgaaagcttaatgtgat
cgaagtggactgcaaaatgggaaatttagaaaaaaacaaaaaacattagaagtaaaa
ctttctttgaaaagtaacaaacaactgagtttcttccacaatttctttatagcctta
agttagctctggtcaaggctaaaaatgaatgagcaaaatggcagtattaacacctta
tgacataattaaatgttgctgctaatttttcctttaaattcctttcttctaggttcc
atagattgtacactaacattctctcatccaacctggtactgggaaaacctgctgaag
atctgtgttttcatcttcgccttcattatgccagtgctcatcattaccgtgtgctat
ggactgatgatcttgcgcctcaagagtgtccgcatgctctctggctccaaagaaaag
gacaggaatcttcgaaggatcaccaggatggtgctggtggtggtggctgtgttcatc
gtctgctggactcccattcacatttacgtcatcattaaagccttggttacaatccca
gaaactacgttccagactgtttcttggcacttctgcattgctctaggttacacaaac
agctgcctcaacccagtcctttatgcatttctggatgaaaacttcaaacgatgcttc
agagagttctgtatcccaacctcttccaacattgagcaacaaaactccactcgaatt
cgtcagaacactagagaccacccctccacggccaatacagtggatagaactaatcat
caggtacgcagtctctagaattaggtatatctactggggatgacataaaaattataa
ggctttgtgctaaactaggagtttaatccattatagaggatgagaatggagggaaga
ggggaagcaaattgtggttctagtgttagagaagaggtttgttatataaactgtgtt
ctttatatttgactgtacatattcatttaggtataaagatacaccaatgagaaatcc
atgaaactattcaaaataactatttttatggcctttacttctatgcaaaatttatga 
 
CYP2B6 Sequence information 
 
The sequence information for CYP2B6 demonstrating SNP and primer locations is 
shown below. 
 
ttctggttttacggctcagggggcatcatggaacctgccgacatgtgatgtctcccc
cggacccccagctttaaaatttctctcttttgtgctctgtccctttatttctcaggc
tggccgacacttagggagaacagaaaagaacctacgtggaatattgggggtgaattt
tgcccgatatctggctgaatttcccctgataatgccactctctatgtccatgtgtac
acattgtttagcacccacttatgaatgagaacatgtgatattcactttctgtgcctg
gcttgtttcacttaagataatcccctccagttgtatccatgttgctataaaagacat
tattttattcctttttatggctaaatagtattcaatggtgtatatataccacatttt
atttaaccattcatctgttgattccctatttttgctattgtaaatagcatttggacc
acatttcaagtacttaattagtggccacatgcagcaagtgactatcacattggacaa
tgtagccccaacccactgtatgaccttgggtaagacttgcaaactgtcattgcttca
atatctccatctataaaatggggatggcaacaatacctcactaagagtgtaaagact
 333 
gagttactgtgtgtaaagcacttcacgcctccccatcggtgcttcaccctggggctg
caatgagcacccaatcttagtgtcagatgacacagcacagcaagaccgaggcccttg
gttcaggaaagtccatgctgccacctcttcagggtcaggaaagtacagtttccacct
cttacaaataggactgtttgtctgctcctcctgggtcaaagtaacttcgggttcagg
tcctggatccagcaaagggtttgcttaacattgcaagaaagatgttgcctcatggtc
aaaagtcaggcgtaggatgagacaggcagacacgcacacattcacacccacgttttg
caaagatggactgaccctgtcagaggatgtgtgggtgaaggtgcacagtgaggatag
agacatatgggagtccagtagacatcaatcaaactggactcagtttgcacacacctg
gagctcaagagtctccagggggaaaacagagacacaaagtcagacagagagagagcc
agagaaatttcctgcaccgtgaagatagtcagaggcagggaagaaactccttagcac
tagttagagtgatcagaaaccaagaggacctgatcgctgtacctgccaggtctcagt
ttctgtctccttccaactgaccacctcttcctctgagactcaccagttctgcatctc
ttgctcctccttctgtttctccgaccacttccacctgtggctgtcacagaagggcgg
atgaaggaggggacactggagatagactcagcatctgcaggcttccaaagagagggg
ctaggagatccaccaacacaccagcacaaatacaccagcacacacagatacacacaa
ttggttcatgtattgctaggttacagtttgctatgctacaaaggcagtaggccaaat
ttgattgaattgaataattccttattttcatcagcttctcctttttttttttttttt
tttttttttgagatggagtattgctgtgtcacccaggctggagtgcagtggtgtaat
cttggctcactgcagcctccacctcccaggttcaagtgattctcttgcctcagcctc
ccgagtagctgggattaaaagtacccaccatcacgcccggttaatttttgtgttttt
agtacagatggggttttgccatgtgggccaggatggtctcgaactcttgacctcaat
tgatctgcccccctcagcttcccaacgtgctgggattacaggtgtgagccaccgcac
ccagccagcctctcagttttgaacatgcactaccaccacctccacaacacacaaatg
taaatgcactttcgtatataaaactgtataaatacaaggaagctcatacacatgcaa
ggatacacacataagcacccccagattcaaccacagaaatatacgccagtacatttg
cataaattcaaacacccctttacatgtaaaaatcatataagcacatacagggatgca
agcaggcatggacaaatgcatgcaagcacagacaaacagacaaagctaagtaaaaaa
gtgcaagctcacctatgcttacaaaaatagacatacatatacccacaaacccacaca
cccacacattcacttgctcacctggactttgatatctctaccactgtatccctgcca
atatctacagagtgggtaaagggataggcatcaggtcactgggttgcccaagcagga
agtctgggttccctaacaactttttctaagctaatgctcctggatgatgatgaaaaa
ggaggtggggaatggatgaaattttataacagggtgcagaggcagggtcaggataaa 
 
gactctatagctgtgttgcctgggtctaaatcctggcctcagtaatgagtagctgtg
caactttggtcaaattactcagcctctcggtctgcccatctataaactggagctaat
aatcaaattgcatctgcctcacattgttgtagtgagagttcaatggaattacgcgtg
acgtgctggtacataattagctgttacggttattctcatgtttaccattactgagtg
atggcagacaatcacacagagataggtgacagcctgatgttccccaggcacttcagt
ctgtgtccttgacctgctgcttcttcctaggggccctcatggaccccaccttcctct
tccagtccattaccgccaacatcatctgctccatcgtctttggaaaacgattccact
accaagatcaagagttcctgaagatgctgaacttgttctaccagactttttcactca
tcagctctgtattcggccaggtcagggagacggagagggacagggggtgtgggggtg
aggtgaacacccagaacacacgagaaaaggatgacctgtcttgggggctcagaaatg
cagcttatccttggaagaaacgcagacatgtgaagaatcagggacatggagacctgg
agggaggagagacggtgagacagggatagagacactgagagagagaatgaggcgtga
tggggaggcagaaatagagtcagagagagactgagagaaggaagatgagcaaaaaca
agacaaagaagagcagaaatcaagagattctgagagacagagttgatgagaatgagt
gtgaaagagagggagagagagagaacgaataaggctttgggcttcatgtctattctg
ctcctggatgtcatttctgttttattttttttagacggagtctcgctgtttcattcc 
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aagaggtaaatgtgagatagatcaaaggagatatagagtcagtgagtgaggggttca
gaggcagaggggagtggggaagtggggttcccatggagggattggggcccaggaggc
gctctctccctgtgacctgctagctcagccctaggcaaacctcaccaccccttcttt
cttgcagctgtttgagctcttctctggcttcttgaaatactttcctggggcacacag
gcaagtttacaaaaacctgcaggaaatcaatgcttacattggccacagtgtggagaa
gcaccgtgaaaccctggaccccagcgcccccaaggacctcatcgacacctacctgct
ccacatggaaaaagtggggtctgggagaggaaaaagggaagggaggggagggagggc
aagatggagaggtgagaagagggagggaaaaggggtagggaaggggaagatggggag
ggaagaagaaagactagggaggggagaatagggaaagggaggagagaacatgaggaa
ggaaagaaagatgaggtgaaaggagggagaaaatagggaggaggaactgagacaggg
agagaggggaggtgggaagacagaatgaaagacagagggagagagagagaagactgg
ctgaggaaggaattcggggcaagggacaaaaatacagcaacaagagaaaaaactcac 
 
 
 
pcDNA3.1/CT-GFP-TOPO® Vector Sequence 
 
gacggatcgggagatctcccgatcccctatggtcgactctcagtacaatctgctctg
atgccgcatagttaagccagtatctgctccctgcttgtgtgttggaggtcgctgagt
agtgcgcgagcaaaatttaagctacaacaaggcaaggcttgaccgacaattgcatga
agaatctgcttagggttaggcgttttgcgctgcttcgcgatgtacgggccagatata
cgcgttgacattgattattgactagttattaatagtaatcaattacggggtcatttc 
Atagcccatatatggagttccgcgttacataacttacggtaaatggcccgcctggca
ccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacg
ccaatagggactttccattgacgtcaatgggtggactatttacggtaaactgcccac
ttggcagtacatcaagtgtatcatatgccaagtacgccccctattgacgtcaatgac
ggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctact
tggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcag
tacatcaatgggcgtggatagcggtttgactcacggggatttccaagtctccacccc
attgacgtcaatgggagtttgttttggcaccaaaatcaacgggactttccaaaatgt
cgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtc
tatataagcagagctctctggctaactagagaacccactgcttactggcttatcgaa
attaatacgactcactatagggagacccaagctggctagttaagcttggtaccgagc
tcggatccactagtccagtgtggtggaattctgcagatatccagcacagtggcggcc
gctcgagtctagaatggctagcaaaggagaagaacttttcactggagttgtcccaat
tcttgttgaattagatggtgatgttaatgggcacaaattttctgtcagtggagaggg
tgaaggtgatgctacatacggaaagcttacccttaaatttatttgcactactggaaa
actacctgttccatggccaacacttgtcactactttctcttatggtgttcaatgctt
ttcccgttatccggatcatatgaaacggcatgactttttcaagagtgccatgcccga
aggttatgtacaggaacgcactatatctttcaaagatgacgggaactacaagacgcg
tgctgaagtcaagtttgaaggtgatacccttgttaatcgtatcgagttaaaaggtat
tgattttaaagaagatggaaacattctcggacacaaactcgagtacaactataactc
acacaatgtatacatcacggcagacaaacaaaagaatggaatcaaagctaacttcaa
aattcgccacaacattgaagatggatccgttcaactagcagaccattatcaacaaaa
tactccaattggcgatggccctgtccttttaccagacaaccattacctgtcgacaca
atctgccctttcgaaagatcccaacgaaaagcgtgaccacatggtccttcttgagtt
tgtaactgctgctgggattacacatggcatggatgagctctacaaataatgaattaa
acccgctgatcagcctcgactgtgccttctagttgccagccatctgttgtttgcccc
tcccccgtgccttccttgaccctggaaggtgccactcccactgtcctttcctaataa
aatgaggaaattgcatcgcattgtctgagtaggtgtcattctattctggggggtggg
gtggggcaggacagcaagggggaggattgggaagacaatagcaggcatgctggggat
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gcggtgggctctatggcttctgaggcggaaagaaccagctggggctctagggggtat
ccccacgcgccctgtagcggcgcattaagcgcggcgggtgtggtggttacgcgcagc
gtgaccgctacacttgccagcgccctagcgcccgctcctttcgctttcttcccttcc
tttctcgccacgttcgccggctttccccgtcaagctctaaatcggggcatcccttta
gggttccgatttagtgctttacggcacctcgaccccaaaaaacttgattagggtgat
ggttcacgtagtgggccatcgccctgatagacggtttttcgccctttgacgttggag
tccacgttctttaatagtggactcttgttccaaactggaacaacactcaaccctatc
tcggtctattcttttgatttataagggattttggggatttcggcctattggttaaaa
aatgagctgatttaacaaaaatttaacgcgaattaattctgtggaatgtgtgtcagt
tagggtgtggaaagtccccaggctccccaggcaggcagaagtatgcaaagcatgcat
ctcaattagtcagcaaccaggtgtggaaagtccccaggctccccagcaggcagaagt
atgcaaagcatgcatctcaattagtcagcaaccatagtcccgcccctaactccgccc
atcccgcccctaactccgcccagttccgcccattctccgccccatggctgactaatt
ttttttatttatgcagaggccgaggccgcctctgcctctgagctattccagaagtag
tgaggaggcttttttggaggcctaggcttttgcaaaaagctcccgggagcttgtata
tccattttcggatctgatcaagagacaggatgaggatcgtttcgcatgattgaacaa
gatggattgcacgcaggttctccggccgcttgggtggagaggctattcggctatgac
tgggcacaacagacaatcggctgctctgatgccgccgtgttccggctgtcagcgcag
gggcgcccggttctttttgtcaagaccgacctgtccggtgccctgaatgaactgcag
gacgaggcagcgcggctatcgtggctggccacgacgggcgttccttgcgcagctgtg
ctcgacgttgtcactgaagcgggaagggactggctgctattgggcgaagtgccgggg
caggatctcctgtcatctcaccttgctcctgccgagaaagtatccatcatggctgat
gcaatgcggcggctgcatacgcttgatccggctacctgcccattcgaccaccaagcg
aaacatcgcatcgagcgagcacgtactcggatggaagccggtcttgtcgatcaggat
gatctggacgaagagcatcaggggctcgcgccagccgaactgttcgccaggctcaag
gcgcgcatgcccgacggcgaggatctcgtcgtgacccatggcgatgcctgcttgccg
aatatcatggtggaaaatggccgcttttctggattcatcgactgtggccggctgggt
gtggcggaccgctatcaggacatagcgttggctacccgtgatattgctgaagagctt
ggcggcgaatgggctgaccgcttcctcgtgctttacggtatcgccgctcccgattcg
cagcgcatcgccttctatcgccttcttgacgagttcttctgagcgggactctggggt
tcgcgaaatgaccgaccaagcgacgcccaacctgccatcacgagatttcgattccac
cgccgccttctatgaaaggttgggcttcggaatcgttttccgggacgccggctggat
gatcctccagcgcggggatctcatgctggagttcttcgcccaccccaacttgtttat
tgcagcttataatggttacaaataaagcaatagcatcacaaatttcacaaataaagc
atttttttcactgcattctagttgtggtttgtccaaactcatcaatgtatcttatca
tgtctgtataccgtcgacctctagctagagcttggcgtaatcatggtcatagctgtt
tcctgtgtgaaattgttatccgctcacaattccacacaacatacgagccggaagcat
aaagtgtaaagcctggggtgcctaatgagtgagctaactcacattaattgcgttgcg
ctcactgcccgctttccagtcgggaaacctgtcgtgccagctgcattaatgaatcgg
ccaacgcgcggggagaggcggtttgcgtattgggcgctcttccgcttcctcgctcac
tgactcgctgcgctcggtcgttcggctgcggcgagcggtatcagctcactcaaaggc
ggtaatacggttatccacagaatcaggggataacgcaggaaagaacatgtgagcaaa
aggccagcaaaaggccaggaaccgtaaaaaggccgcgttgctggcgtttttccatag
gctccgcccccctgacgagcatcacaaaaatcgacgctcaagtcagaggtggcgaaa
cccgacaggactataaagataccaggcgtttccccctggaagctccctcgtgcgctc
tcctgttccgaccctgccgcttaccggatacctgtccgcctttctcccttcgggaag
cgtggcgctttctcaatgctcacgctgtaggtatctcagttcggtgtaggtcgttcg
ctccaagctgggctgtgtgcacgaaccccccgttcagcccgaccgctgcgccttatc
cggtaactatcgtcttgagtccaacccggtaagacacgacttatcgccactggcagc
agccactggtaacaggattagcagagcgaggtatgtaggcggtgctacagagttctt
gaagtggtggcctaactacggctacactagaaggacagtatttggtatctgcgctct
gctgaagccagttaccttcggaaaaagagttggtagctcttgatccggcaaacaaac
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caccgctggtagcggtggtttttttgtttgcaagcagcagattacgcgcagaaaaaa
aggatctcaagaagatcctttgatcttttctacggggtctgacgctcagtggaacga
aaactcacgttaagggattttggtcatgagattatcaaaaaggatcttcacctagat
ccttttaaattaaaaatgaagttttaaatcaatctaaagtatatatgagtaaacttg
gtctgacagttaccaatgcttaatcagtgaggcacctatctcagcgatctgtctatt
tcgttcatccatagttgcctgactccccgtcgtgtagataactacgatacgggaggg
cttaccatctggccccagtgctgcaatgataccgcgagacccacgctcaccggctcc
agatttatcagcaataaaccagccagccggaagggccgagcgcagaagtggtcctgc
aactttatccgcctccatccagtctattaattgttgccgggaagctagagtaagtag
ttcgccagttaatagtttgcgcaacgttgttgccattgctacaggcatcgtggtgtc
acgctcgtcgtttggtatggcttcattcagctccggttcccaacgatcaaggcgagt
tacatgatcccccatgttgtgcaaaaaagcggttagctccttcggtcctccgatcgt
tgtcagaagtaagttggccgcagtgttatcactcatggttatggcagcactgcataa
ttctcttactgtcatgccatccgtaagatgcttttctgtgactggtgagtactcaac
caagtcattctgagaatagtgtatgcggcgaccgagttgctcttgcccggcgtcaat
acgggataataccgcgccacatagcagaactttaaaagtgctcatcattggaaaacg
ttcttcggggcgaaaactctcaaggatcttaccgctgttgagatccagttcgatgta
acccactcgtgcacccaactgatcttcagcatcttttactttcaccagcgtttctgg
gtgagcaaaaacaggaaggcaaaatgccgcaaaaaagggaataagggcgacacggaa
atgttgaatactcatactcttcctttttcaatattattgaagcatttatcagggtta
ttgtctcatgagcggatacatatttgaatgtatttagaaaaataaacaaataggggt
tccgcgcacatttccccgaaaagtgccacctgacgtc 
 
 
 
DNA Extraction and Purification Protocols 
 
 
MasterAmp™ Buccal Swab DNA Extraction Kit, Cambio 
 
Protocol 
 
1. Thaw the appropriate number of tubes containing the DNA Extraction 
Solution. 
 
2. Divide the Extraction mixture into aliquots of 150 µl, using fresh labelled 
tubes. 
 
3. Collect tissue (buccal cells) by rolling the buccal brush firmly on the inside of 
the cheek, approximately 20 times on each side making sure to move the brush 
over the entire cheek. 
 
4. Air dry the brush for 10-15 minutes at room temperature at this point you can 
either continue straight to extraction or alternatively you can store the brush in 
its original packaging at 22-37ºC for up to one month before extraction. For 
longer term storage, keep the dry brushes at -20ºC for up to 6 months.  
 
5. For extraction place the buccal brush into a tube containing the required 
amount of extraction fluid and rotate the brush a minimum of 5 times within 
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the fluid. Press the brush against the side of the tube, rotating slightly whilst 
removing if from the tube to ensure maximum DNA yield. 
 
6. Cap the tube and vortex for 15 seconds. 
 
7. Incubate the tube at 65ºC for 2 minutes. 
 
8. Repeat step 6.  
 
9. Transfer the tube to 98ºC and incubate for 3 minutes. 
 
10. Repeat step 6. 
 
11. Leave to cool at room temperature before storing at -20ºC.  
 
 
 
Promega Wizard® Genomic DNA purification Kit 
 
Protocol 
 
Use Table 5 to calculate the appropriate volume to perform the DNA extraction. 
 
1. Combine the appropriate volumes of cell lysis solution and blood in a sterile  
eppendorf. Then mix by inversion. 
 
2. Incubate at room temperature for ten minutes. 
 
3. Centrifuge the sample as follows: 
  
For samples ≤ 300µl spin at maximum speed (13,000 – 16,000 x g) for 20 
seconds. For samples 1-10ml spin at 2,000 x g for 10 minutes. 
 
4. Discard the supernatant and vortex the pellet. 
 
5. Using the above table to calculate the required amount of Nuclei lysis solution, 
add to the tube and mix by inversion. 
 
6. Add the protein precipitation solution, vortex for 20 seconds. 
 
7. Centrifuge the sample as follows: 
  
For samples ≤ 300µl spin at maximum speed (13,000 – 16,000 x g) for 3 
minutes. For samples 1-10ml spin at 2,000 x g for 10 minutes. 
 
8. Transfer the supernatant to a new tube containing isopropanol (use table for 
correct volume to add) and mix. 
 
9. Centrifuge the sample as follows: 
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For samples ≤ 300µl spin at maximum speed (13,000 – 16,000 x g) for 1 
minute. For samples 1-10ml spin at 2,000 x g for 1 minute. 
 
10. Discard the supernatant. Add 70% ethanol (at the same volume as the 
isopropanol). 
 
11. Repeat step 9. 
 
12. Aspirate the ethanol and air-dry the pellet for 10-15 minutes. 
 
13. Rehydrate the DNA in the appropriate volume of DNA rehydration solution 
for 1 hour at 65°C or overnight at 4°C. 
 
 
Qiagen DNeasy Blood and Tissue Kit 
 
Protocol 
 
 
1. Pipet 20µl proteinase K into a 1.5ml or 2ml microcentrifuge tube.  
 
2. Add 50-100 µl anticoagulatd blood. Adjust the volume to 220µl with PBS. 
 
3. Add 200µl Buffer AL and mix thoroughly by vortexing (to ensure a 
homogenous solution) and incubate at 56ºC for ten minutes. 
4. Add 200µl ethanol (96-100% to the sample and vortex. 
5. Pipet the solution into a DNeasy mini spin column (placed in the 2ml 
collection tube) and centrifuge at ≥6000 x g (8000 rpm) for 1 minute. Discard 
flow-through and collection tube. 
6. Place the spin column into a new 2ml collection tube and add 500µl Buffer 
AW1, and centrifuge for 1 minute at ≥6000 x g (8000 rpm). Discard the flow-
through and colledtion tube. 
7. Place the spin column in a new 2ml collection tube and add 500µl Buffer 
AW2, and centrifuge for 3 minutes at 20,000 x g (14,000 rpm) to dry the 
DNeasy membrane. Discard the flow-through and collection tube. 
8. Place the DNeasy mini spin column in a clean 1.5ml or 2 ml collection tube 
and pipet 200µl Buffer AE directly onto the DNeasy membrane. Incubate at 
room temperature for 1 minute and then centrifuge for 1 minute at ≥6000 x g 
(8000 rpm) to elute. 
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QIAquick PCR Purification Kit 
Protocol 
 
 
1. Add 200µl of PBI buffer to 40µl of the PCR product being purified. Mix 
thoroughly using a pipette. 
 
2. Add the mixture carefully to a QIAGEN Quickspin Column. 
 
3. Centrifuge at 13,000 rpm for 1 minute. 
  
4. Discard the waste. 
 
5. Add 750µl of PBE Buffer to wash the column. 
 
6. Repeat step 3. 
 
7. Discard the waste. 
 
8. Repeat step 3 to ensure all the waste is removed. 
 
9. Transfer the Quickspin column to a clean, labelled tube and leave to air dry for 
5 minutes. 
 
10. Add 40µl of EB Buffer to the centre of the Quickspin Column to elute the 
DNA. 
 
11. Leave to air dry for 5 minutes. 
 
12. Centrifuge at 13,000 rpm for 1 minute. 
 
13. Eluted DNA can now be sent off for sequencing. 
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Data Normality 
 
Data normality was examined with SPSS 14.0 software using the Shapiro-Wilks test, 
where a P value above 0.05 indicated a normal data distribution. 
 
OPRM1 A118G SNP 
 
A118G Genotype 
 
Statistic df Significance 
118 AA 0.937 31 0.069 
118 AG 0.989 4 0.953 
 
 
 
118 AA Genotype 
 
 
Normality plot for the 118 AA genotype, with post-mortem methadone concentration 
as the dependent variable and A118G as the factor, where P > 0.05. 
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118 AG Genotype 
 
 
Normality plot for the 118 AG genotype, with post-mortem methadone concentration 
as the dependent variable and A118G as the factor, where P > 0.05. 
 
 
 
 
 
 
 
 
 
CYP2B6 T750C SNP 
 
 
T750C Genotype 
 
Statistic df Significance 
750 TT 0.912 15 0.145 
750 TC 0.919 18 0.127 
750 CC 0.928 7 0.535 
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750 TT Genotype 
 
 
 
Normality plot for the 750 TT genotype, with post-mortem methadone concentration 
as the dependent variable and T750C as the factor, where P > 0.05. 
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750 TC Genotype 
 
Normality plot for the 750 TC genotype, with post-mortem methadone concentration 
as the dependent variable and T750C as the factor, where P > 0.05. 
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750 CC Genotype 
 
 
Normality plot for the 750 TC genotype, with post-mortem methadone concentration 
as the dependent variable and T750C as the factor, where P > 0.05. 
 
 
 
 
 
 
 
 
CYP2B6 G516T SNP 
 
 
G516T Genotype 
 
Statistic df Significance 
516 GG 0.921 24 0.062 
516 GT 0.932 15 0.295 
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516 GG Genotype 
 
 
Normality plot for the 516 GG genotype, with post-mortem methadone concentration 
as the dependent variable and G516T as the factor, where P > 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 346 
516 GT Genotype 
 
 
Normality plot for the 516 GT genotype, with post-mortem methadone concentration 
as the dependent variable and G516T as the factor, where P > 0.05. 
 
 
 
 
 
 
 
 
 
CYP2B6 A785G SNP 
 
 
A785G Genotype 
 
Statistic df Significance 
785 AA 0.923 23 0.077 
785 AG 0.940 16 0.352 
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785 AA Genotype 
 
 
Normality plot for the 785 AA genotype, with post-mortem methadone concentration 
as the dependent variable and A785G as the factor, where P > 0.05. 
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785 AG Genotype 
 
 
Normality plot for the 785 AG genotype, with post-mortem methadone concentration 
as the dependent variable and A785G as the factor, where P > 0.05. 
 
 
 
 
Post-mortem Methadone Concentration 
 
 
In order to examine the data distribution of the post-mortem methadone 
concentrations normality testing using the Shapiro Wilks test and SPSS 14.0 software 
was conducted. With methadone concentration as the dependent variable, no factor 
was selected. 
 
 
 
Statistic df Significance 
Methadone (mg/L) 0.937 30 0.075 
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Normality plot for post-mortem methadone concentration, where P > 0.05. 
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Glossary  
 
5‟…………………………… Five prime end of a DNA/RNA single strand 
3‟…………………………… Three primer end of a DNA/RNA single strand 
ABCB1……………………… Gene that encodes the p-glycoprotein transporter 
Allele………………………. Any of the forms of the same gene that differ in base sequence 
Apoptosis…………………… Is the process of programmed cell death. 
Annexin V………………….. Is a cellular protein that detects the early stages of apoptosis. 
Arrythmia…………………. Irregular heartbeat, loss of rhythm 
AV-12 cells……………….... Mammalian cell line used for in vitro expression studies 
β-endorphin………………… An endogenous opioid peptide that binds to the mu (µ) opioid receptor. 
CAR………………………… Constitutive androstane expression , a gene transcription factor 
Cardiomyopathy……………. A disease of the heart muscle. 
CCAAT…………………….. Sequence to signal the binding site for RNA transcription factor 
Chiral……………………….. A molecule that is non-superimposable on its mirror image. 
Cis-element………………… DNA sequences that regulate via transcription factors gene expression 
CLL………………………… Chronic Lymphocytic Leukemia 
COMT……………………… Catechol-O-methyl transferase, an enzyme involved in dopamine, 
epinephrine, and norepinephrine degradation. 
COS-1 cells………………… Mammalian cell line used for in vitro expression studies 
Cytochrome P450…………... A large and diverse family of enzymes involved in drug metabolism. 
CYP2A6…………………….. Cytochrome P450 member involved in phase I metabolism 
CYP2B6…………………….. Cytochrome P450 member involved in phase I metabolism 
CYP2C9…………………….. Cytochrome P450 member involved in phase I metabolism 
CYP2C19…………………… Cytochrome P450 member involved in phase I metabolism 
CYP2D6……………………. Cytochrome P450 member involved in phase I metabolism 
CYP3A4…………………….. Cytochrome P450 member involved in phase I metabolism 
DIS-III-R…………………… Diagnostic interview schedule 3 revised, measures symptoms of drug 
abuse 
DNA……………………….. Deoxyribonucleic acid 
Enantiomer…………………. Either of a pair of stereoisomers 
Endocytosis………………… The process by which cells absorb molecules. 
Exon………………………... Coding regions of a DNA sequence that will be expressed by mRNA 
Fc Receptor………………… A protein found on the surface of specific cells including: natural killer 
cells, neutrophils, macrophages and mast cells. 
FITC………………………... Fluorescein isothiocyanate (FITC), a commonly used fluorecent dye 
for flow cytometry analysis.  
Genotype…………………… The total genetic constitution of an organism 
GPCR……………………..... G-protein Coupled Receptor, involved in cellular signalling. 
HAB serum…………………. Human AB serum used to minimse non-selective antibody binding. 
Haplotype………………….. Set of SNPs on a single chromatid that are statistically associated  
Hardy Weinberg Equilibrium. Relationship between gene and genotype frequencies in a population 
HEK293 cells………………. Human embryonic kidney 293 cell line for use in in vitro studies 
hERG……………………….. Human Ether-à-go-go gene coding for a potassium ion channel 
Heterodimer………………… A protein composed of two polypeptide chains differing in 
composition in the order, number, or kind of their amino acid. 
Heterozygous………………. A cell or organism with two different alleles for  the same gene  
Homozygous……………….. A cell or organism with two identical alleles for the same gene 
Huh-7 cells…………………. Human hepatoma cell line for in vitro studies 
IhERG........................................ Measurement of ionic current 
Immunoglobulin (IgG)…….. Proteins produced by the immune system to fight infection. 
Induction Phase…………….. The beginning of methadone maintenance treatment, adverse responses 
to methadone are often reported in the induction phase (2 weeks). 
Intron……………………….. Non coding regions of DNA that will not be expressed by mRNA 
In vitro……………………… Occurring outside of the body 
In vivo………………………. Occurring inside of the body 
Isomer………………………. Compounds with the same molecular formula but different structural 
formulas (Chiral). 
KCNH2……………………... The gene name for hERG 
Ki value…………………….. Denotes the disassociation constant between a ligand and a protein 
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Ligand……………………… A substance that is able to bind to and form a comples with a receptor 
to serve a biological purpose, e.g. methadone. 
Linkage disequilibrium…….. Preferential association of linked genes/DNA markers in a population 
Luciferase …………………. Monooxygenase enzyme that catalyses bioluminescent reactions 
Medulla…………………….. Lower portion of the brainstem, involved in respiration. 
Mean Fluorescence Intensity 
(MFI)……………………….. 
A measure of fluorescence intensity for flow cytometry to measure 
changes at the cellular level e.g. receptor internalisation. 
mRNA……………………… Messenger RNA, involved in DNA translation 
Mu (µ) opioid receptor ……. The preferential binding target for many opioids including morphine 
Myocardial Fibrosis………... A type of heart disease where healthy heart muscle is replaced with 
fibrous tissues. 
Myocarditis………………… Inflammation of the heart muscle. 
Np-SAD……………………. National Programme on substance abuse deaths report 
OPRM1…………………….. The gene name for the µ opioid receptor 
Pharmacodynamics………… Biochemical and biophysical effects of a drug on the body 
Pharmacokinetics………….. Biochemical and biophysical effects of the body on a drug 
Phenotype………………….. An observable characteristic or trait determined by the genotype 
Phosphorylation……………. The addition of a phosphate group to a protein, involved in the 
activation or deactivation of manty protein enzymes. 
PE…………………………... Phycoerythrin, a commonly used fluorecent dye for flow cytometry 
analysis. 
pKa…………………………. An acid dissociation constant, which measures the strength of an acid 
in a solution and can be used to determine the extent to which a drug 
will enter the blood stream. 
Polymorphism……………… Multiple alleles of a gene within a population, usually expressing 
different phenotypes. 
Pre-Botzinger Complex…….. An important region of the medulla for respiration. 
Pregnane X Receptor……….. A nuclear factor involved in the upregulation of detoxification and 
clearance proteins in the presence of xenobiotics. 
Promoter Region…………… A regulatory DNA region found upstream of a gene that controls gene 
expression. 
Propidium Iodide…………… A dye used to measure apoptosis as it can only cross the membrane of 
non-viable cells. 
Pulmonary Oedema………… Fluid accumulation in the lungs. 
QT interval…………………. Measurement of the hearts electrical cycle between the Q and T waves 
Racemic……………………. A mixture that has has equal amounts of left and right-handed 
enantiomers of a chiral molecule e.g. methadone. 
Respiratory depression…….. Inadequate ventilation which can lead to death 
RNA………………………... Ribonucleic acid 
RT-PCR…………………….. Real-time PCR used to amplify and simultaneously quantify a target 
SNRIs………………………. Serotonin–norepinephrine reuptake inhibitors – antidepressant drug. 
SNP………………………… Single nucleotide polymorphism 
Splice variant………………. Variation from the original DNA sequence due to alternative splicing 
SSRIs……………………….. Selective serotonin reuptake inhibitors- antidepressant drug. 
Stereoselectivity……………. Preferential formation or targeting of one of a pair of enantiomers 
TATA………………………. The core promoter sequence involved in the initiation of transcription 
TDM………………………... Therapeutic Drug Monitoring, involves the measurement of medication 
in blood levels to avoid toxicity. 
Torsades de pointes………… A rare ventricular arrhythmia characterised by a long QT interval 
UGT2B7……………………. Gene for UDP-glucuronosyltransferase 2B7, phase II metabolism 
Wild type…………………… The typical or normal form of an organism, gene or characteristic 
 
